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Abstract
The aim of this research was to explore the potential of routinely collected primary
care data to support the identification of individuals for cardiovascular risk reduction.
The work involved a systematic literature review of reminder interventions operating
at the point of care; a randomised controlled trial of a novel software tool to facilitate
the targeting of individuals at risk of cardiovascular disease; and an exploration of
qualitative issues relevant to the challenge of cardiovascular risk reduction in current
practice.
The Systematic review resulted in a narrative synthesis and a meta-analysis.
It concluded that reminder interventions are generally effective at changing
practitioner behaviour, but the effect is inconsistent, probably dependent on
organisational context, and difficult to predict.
The e-Nudge trial involved 19 practices in Coventry and Warwickshire, who
used the e-Nudge software tool for two years. This tool was programmed for the
project by the clinical software company EMIS. Whilst the primary outcome
(cardiovascular event rate) was not significantly reduced in this timescale, a
beneficial effect was demonstrated on the adequacy of data to support risk estimation
and on the visibility of the at risk population. A new means of addressing the problem
of undiagnosed and late-diagnosed diabetes was also discovered.
Qualitative aspects of this area of care are presented through a discussion of
ethical issues, a limited series of interviews with members of the public included in
the appendix, and extensive field notes taken throughout the research. These provide
some context in support of the e-Nudge trial.
Routinely collected data of UK general practice provide a potentially rich
resource to support primary cardiovascular disease prevention, but practical, ethical
and conceptual issues must all be addressed to optimise their impact. This conclusion
forms the thesis to be explored and justified through this dissertation.
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Chapter 1: Background and scope of the thesis
______________________________________________________________________
1.1 Historical background
The development of National Health Service (NHS) software infrastructure during the
last two decades of the 20th Century created new opportunities to exploit the
availability of health information. This applied particularly to primary care through the
creation of electronic health records in the late 1980s. Standardisation of coding (i.e.
the shared use of a defined set of electronic codes for clinical and administrative data),
and the requirement that independent clinical software companies adhere to
interoperability standards defined by Health Level 7 (1) allowed this infrastructure to
develop in a cohesive way. The research described in this thesis made use of, and
required this standardised infrastructure.
An ambitious agenda for NHS integration was proposed in 1998 by the
National Programme for IT (NPfIT) and is summarised in the document Information
for Health (2). This provided a vision for NHS software development with three major
components: electronic prescribing, on-line transmission of records from practice to
practice and, perhaps most significantly, the NHS Care Records Service (CRS),
through which individual records could be accessed from outside the practice. The
subsequent failure of this vision to meet its own expected deadlines is beyond the scope
of this work, and the concept of a fully integrated NHS software environment still faces
seemingly insurmountable barriers. However, standardisation of data coding and the
integration of previously unconnected domains (such as those of hospital laboratories
and primary care records) succeeded in achieving the necessary interoperability to
support the Quality and Outcomes Framework of the new General Medical Services
Contract of 2004 (3). This required QMAS (Quality Management and Analysis
System) (4) software that extracts relevant data anonymously from practices to monitor
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performance remotely against QOF targets. This development moved chronic disease
management away from individual patient care at the practice level, and closer to a
nationally distributed public health endeavour.
From a research perspective, routinely collected primary care data were a
potentially rich but problematic resource from an early stage (5). Data began to be
extracted from multiple sites into the General Practice Research Database (GPRD) as
early as 1987 (6), and this usage increased during the following two decades.
Information on clinical data, including health variables, events, prescribing, referrals,
and demographic profiles were pooled and made available to the research community.
This led on to a range of data repositories and integrated data collection systems
summarised by Gnani and Majeed (7). In addition to GPRD and QMAS, they include
MIQUEST (Morbidity Information Query and Export Syntax) (8), Prescribing Analysis
and Cost (PACT) data (9), the RCGP Weekly Returns Service (10), the Primary Care
Information Service (PRIMIS) (11), and QRESEARCH, a large database hosted at the
University of Nottingham (12). But at the outset of GPRD in the late 1980s, such health
data were still recorded inconsistently. Standardisation of data coding came later,
during the 1990s and 2000s, for a number of identifiable reasons.
Electronic data recording was, at the start of the 1990s largely designed to
support individual care. It then expanded to meet the needs of clinical audit, later
becoming a tool for monitoring adequacy of care at the practice level and of comparing
different practices by primary care organisations. These included Health Authorities,
Health Boards, Primary Care Groups and later Primary Care Trusts who were able not
only to extract anonymised data remotely (as GPRD already could) but also to feed the
results back to practices on a regular basis. This process required a certain level of code
standardisation that was unnecessary for the requirements of the decade before. A
further early incentive for standardisation of electronic coding was in the area of
prescribing. Electronic coding facilitated the monitoring of drug usage and expenditure,
compliance, identification of adverse reactions, and the monitoring of prescribing
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behaviour of clinicians and practices. As a significant minority of practices also
function as dispensing pharmacies managed as businesses by general practitioners, the
benefits of electronic coding became increasingly evident, and even more likely to spill
over into clinical care.
The use of electronic databases for quality assurance provided an
unprecedented opportunity to identify adverse drug reactions and other safety issues,
areas exploited early on by GPRD, attracting investment from the pharmaceutical
industry.
Another major trigger was the introduction of clinical audit, a requirement of
all NHS clinicians identified in the 1989 White Paper ‘Working for Patients’ (13) and
in the subsequent General Medical Services Contract of 1990. Whilst addressed to the
NHS as a whole, this move was designed to increase the accountability of general
practitioners as the key ‘gatekeepers’ of NHS expenditure (14). This set the scene for
Fundholding, a contractual system that controlled referral and prescribing behaviour as
well as secondary care commissioning during the mid-1990s (15). Although response
to the introduction of audit was mixed (16), the early 1990s saw a proliferation of audit
activities at the practice level, through which a clinical area (such as hypertension)
would be examined and subjected to the clinical audit cycle. A list of patients whose
most recent blood pressure was out of a predefined target range could be produced only
if the data were coded consistently. This provided an incentive for the recording of
blood pressure measurements using electronic codes rather than as free hand entries.
Clinical software providers facilitated this process through automated screen templates,
which rapidly developed for all the chronic diseases that were increasingly managed in
primary care during this time.
Central to this process was the concept of a ‘disease register.’ Outside the
primary care environment, the benefits of disease registers are less evident. But where
(in principle) each resident in the population is identifiable through a unique identifier
(the NHS number) and registered with one (and only one) general practice, the disease
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register provides the means of attributing responsibility of care to named clinicians or
practices. Cross-referencing above the practice level using NHS numbers developed
during the 1990s. At the start of this decade, it was common for practice lists to include
‘ghost’ patients – individuals who were still registered after they had left the area and
re-registered with a new practice elsewhere. Capitation payments could be made
concurrently to more than one practice for the same patient. The cross-checking made
possible by centralised data on NHS numbers has reduced this duplication, with the
result (in principle) that each practice now has sole responsibility for all their registered
patients (even if they commission care from elsewhere). Disease registers have become
the focus of structured, systematic chronic disease management in primary care. More
recent moves to diversify primary care provision are justified on various bases
including the need to reduce health inequalities (17), but might in principle undermine
this achievement.
Electronic recording of diagnoses combined with clinical software search
engines together facilitated the automated creation of disease registers. Before the
advent of electronic records, such registers (if they existed at all) were created using
‘hard copy’ systems that required an active initiative on the part of clinician or
administrative staff to record and maintain the information on card files. This also
applied to Age/Sex registers, regarded until quite recently a minimum standard of
demographic record keeping in general practice. Following the introduction of
electronic records and recognised codes for disease and other categories, registers were
created automatically as soon as practice staff recorded such information in searchable
form. Producing a ‘register’ of patients with a certain condition became almost trivially
easy using a simple search on the appropriate codes, although the maintenance of
disease registers for conditions (unlike cardiovascular disease) that may resolve and
become a past problem is a non-trivial issue relevant to this work to be discussed in
Chapter 6.
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In many important clinical areas (e.g. autism, osteoporosis, peripheral vascular
disease, learning difficulties, HIV infection, psoriasis) the ‘register’ may be a poor
reflection of the true prevalence of the condition in the community, whilst for others
(such as stroke or coronary heart disease) it has become increasingly adequate as a
result of the developments described above. The standardised coding of such
information has become important in the establishment of meaningful primary care
disease registers and following on from this the development of well organised,
proactive care.
1.2 Relevance to current UK practice
Integrated software infrastructure is still a fairly recent development, but in addition to
the potential benefits discussed above (e.g. monitoring of prescribing, safety, quality
assurance, and contracting), the availability of integrated information provides for a
more efficient system of targeting interventions towards the neediest individuals. This
approach potentially benefits recipients, providers and commissioners. Identifying at
risk individuals or groups using health data, including practice based data collected
during routine care, increases the efficiency of this process, because the effectiveness
of preventive interventions is generally greatest when aimed at those at highest risk.
This specific issue is the focus of this thesis, applied to the areas of cardiovascular and
diabetes risk reduction.
From the advent of electronic records, cardiovascular disease data were
generally well supported by the Read coding system discussed in the next chapter. For
each risk factor, an appropriate Read code is usually available and there is often a
selection of alternative codes with similar meanings. For other conditions, where
relevant Read codes did not exist, the facility was available for practices to create their
own electronic codes. This enabled primary care teams to undertake audits of practice
specific activities for which no relevant Read code existed. During the latter half of the
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1990s this practice began to be discouraged as the NHS prepared for integration above
the practice level. Such ‘home-grown’ codes might be meaningless when retrieved
outside the original practice context and so were seen as a barrier to standardisation and
data integration. The most recent development in this process has been the Directed
Enhanced Service (DES) for Information Management and Technology of 2008,
through which practices rationalised their use of such codes. In 2002, a new
international coding system SNOMED CT (Systematised Nomenclature of Medicine
Clinical Terms) was created through a merger of the Clinical Terms Version 3 (a
subgroup of Read codes used in the NHS) with the SNOMED RT (Reference
Terminology) system (18), the latter already in use by the College of American
Pathologists (19). This expanded system is becoming increasingly adopted into the
NHS and is the basis for the new EMIS-Web electronic record system to be discussed
at the end of this thesis. It is designed to support the integration of health data at an
international level.
Practice based audit activity led on later in the 1990s to Primary Care
Organisations (PCOs) carrying out audits remotely and providing comparisons with
similar practices in the region, adjusted for demographic confounders such as age and
deprivation distributions. This was only possible if appropriate data were standardised
across practices in the region under study. Before long, this concept applied to the NHS
as a whole.
The focus on cardiovascular disease contrasts with that of other medical
conditions including malignancy, whose risk factors or symptom profiles (particularly
with regard to electronically coded data) are often still poorly defined at least in such a
way that would facilitate early detection (20). Social health variables are poorly
recorded in primary care. Even a factor as important for cardiovascular outcomes as
ethnicity has only very recently started to be recorded systematically by practices. Risk
factor information is often incomplete, and its adequacy for cardiovascular disease will
be explored later in this thesis. There are many problems in health care that require
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identification and targeting of those at greatest risk, as suggested above. Of these,
cardiovascular disease has several advantages as a topic for primary care research.
Firstly, cardiovascular risk variables have benefited above all others in the data
standardisation process described above. Prior to the Quality and Outcomes
Framework, other initiatives provided incentives (including financial) for the collection
of cardiovascular risk factor information. This particularly applied to the ‘Banding’
system of the early 1990s, through which practices would collect data on such variables
as smoking status, blood pressure, and cholesterol levels. Different levels of activity
(‘Bands’) would attract different levels of payment. This system was later dissolved,
but the resulting electronic data were saved in the practice systems, available for future
access. The result of this was that by the end of this decade a tradition had become
established to promote cardiovascular risk factor recording in coded, standardised form.
Secondly, cardiovascular risk is a well researched area and the relative
importance of the various risk factors is known quite well, as a result of several large
cohort studies and epidemiological surveys to be discussed in Chapter 2. The result of
this is that risk algorithms that weight the main independent factors and produce risk
estimates, are widely available and in common use among primary care practitioners all
over the UK. Targeting patients at raised cardiovascular risk has become an area of
intense interest over the past few years, because of the availability of these algorithms
and of the opportunity to modify risk through a variety of interventions.
Finally, the study of cardiovascular risk benefits from the fact that the outcomes
(cardiovascular events) are to a large extent recorded electronically in the same
databases as the risk factor data. The same is not true of outcomes such as hospital
admission, which may occur without any coded entry into the practice based record, or
of fall risk, where the fall itself might (occasionally) be recorded in primary care but
the risk data (such as whether there are stairs at home, whether the patient uses a
walking aid) are, if recorded at all, more likely to be found in a database at social
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services, at a local occupational therapy provider, or in housing data of the local
council.
The importance of cardiovascular risk reduction to current UK practice is
reflected in its inclusion in a number of recent guidelines and recommendations by
expert bodies. These include the National Framework for Coronary Heart Disease of
2000 (21), the Fourth report of the British Hypertension Society of 2004 (22), the
Second report of the Joint British Societies on prevention of cardiovascular disease in
clinical practice of 2005 (23), the NICE Technology Appraisal 24: Statins for
prevention of cardiovascular events of 2006 (24), the SIGN Clinical Guideline 97: Risk
estimation and the prevention of cardiovascular disease of 2007 (25) and the NICE
Clinical Guideline 67: Lipid Modification of 2008 (26). All of these documents
recommend the identification of individuals for preventive interventions based on
estimated cardiovascular risk, generally drawing on the availability of standardised risk
factor data in UK general practice.
1.3 What will be included and excluded
This research concerns the use of general practice data for identifying ‘at risk’
individuals for cardiovascular disease. Whilst not explicitly stated in the title, in the
current environment this effectively means electronic, rather than paper based data. The
work is exclusively NHS based, and draws on a collaborative relationship with EMIS,
one of the UK’s suppliers of clinical software to general practice, and (to a much
smaller degree) Newchurch, a private company providing information technology
solutions under contract with the NHS. EMIS is one of a number of clinical software
suppliers in the UK, so throughout the thesis I will take care to focus on issues that are
common to all systems rather than ‘EMIS-specific.’
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1.4 Existing evidence for reminder interventions
The major issues to be investigated through this research involved the adequacy of
electronic data to support a targeted programme of CVD risk reduction in primary care,
and the role of automated reminders to influence clinical practice. At the outset, I
looked for evidence that this work had already been done or was in process. As well as
a number of completed published reviews, a listed Cochrane protocol was entitled ‘On-
screen computer reminders: effects on professional practice and health care outcomes’
by Richard Gordon, Jeremy Grimshaw, Martin Eccles, Rachel Rowe and Jeremy Wyatt
(27). I contacted Jeremy Grimshaw at the University of Ottowa and Martin Eccles at
the University of Newcastle, who advised me that publication was expected fairly soon.
I was told that the lead author was now Kaveh Shojania, whom I then also contacted.
He gave me an update and again suggested an early publication date. He also sent me
38 relevant citations that his group were considering. I expected that this review would
overlap significantly with my area, but when I studied the protocol I realised that there
were some significant differences. Most importantly, I was interested in reminders
generated by patient specific data, rather than computerised decision support or other
guidelines that were only condition or medication specific.
1.4.1 Existing systematic reviews
In addition to this protocol (and the completed review that followed discussed in
Chapter 4), I found 18 published reviews. Some of these were conducted systematically
and others less formally. As they were not contributing original data they were not
included in my own review (conducted in collaboration with my supervisors and
described in Chapter 4), but were nevertheless useful sources of information for the
thesis. None were sufficiently recent or relevant to my work to make our review
unnecessary. Some included a range of process interventions that targeted patients as
well as providers, and in many of them computerised reminders were just one
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intervention among several included in the review. The following paragraphs describe
some key insights arising from these papers.
Balas et al (1996) (28) reviewed 98 randomised controlled trials of clinical
information systems. This was a comprehensive review, but only 64% of the
interventions targeted the health care provider and this review is no longer very recent.
Provider reminders were generally found to make a significant difference to process
outcomes.
Balas et al (2004) (29) described forty studies of computerised knowledge
management interventions to support diabetes care. These included eight studies of the
effects on guideline compliance of computerised prompting, reporting significantly
improved compliance in six of them.
Bennett, Glasziou and Sim (30) reviewed articles specifically related to
medication management, concluding that computerised reminders and feedback were
generally valuable in this situation.
Berlin, Sorani and Sim (31) used a previously developed taxonomy of
computer-based clinical decision support systems (CDSSs) to describe the current
literature. Seventy-four CDSSs were reported in fifty-eight studies, and two distinct
subsets were identified: those aimed at patients (via mail or telephone) and online
systems directed at physicians in inpatient contexts. These studies were generally not
relevant to my current work, but an important conclusion was derived: that CDSSs are
heterogenous and dependent on the clinical or workflow setting, limiting their
generalisability.
Garg et al (32) reviewed 100 controlled trials of CDSSs both to investigate their
effectiveness and to identify features predicting success. They found that the quality of
the trials improved over time, and that improvements in practitioner performance were
more evident than patient outcomes. Out of 21 trials of reminder systems, 16 produced
positive benefits in terms of performance. Automatic prompts were generally more
effective than those requiring the user to activate them.
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Hasman, Safran and Takeda (33) concluded that reminder systems linked to
physician order entry systems were generally beneficial but their use for diagnostic
support was more limited.
Kawamoto et al (34) studied 70 articles describing CDSSs and undertook
regression analyses to determine the influence of up to fifteen characteristics of the
intervention predictive of success in terms of improved clinical practice. Four features
produced independent predictors. These were:
 Automatic provision of decision support as part of clinical workflow
 Provisions of recommendations rather than just assessments
 Provision of decision support at the time and location of decision making
 Computer based decision support
Thirty out of 32 papers that included all four features significantly improved
clinical practice. This suggests the need to embed such interventions into the working
environment at the point of care.
A review by Kupets and Covens from 1966 to 2000 (35) identified papers
related specifically to improving breast and cervical cancer screening using a variety of
techniques. They identified three categories of intervention: physician based,
physician/patient based, and patient based. The physician based strategies such as
manual and computer generated reminders proved the most effective at improving
screening rates. They described the concept of a ‘Number Needed to Intervene’ (NNI),
and estimated that in the case of reminder notices 3 physicians need to be exposed to
the intervention for one of them to order a screening test. This number was lower (i.e.
more effective) than for other types of intervention.
McPhee and Detmer (36) also reviewed approaches to the problem of cancer
screening using office based interventions. This review was published in 1993 and so is
now rather out of date when considering the computerised examples. Of relevance to
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my own review described below, the authors drew a distinction not only between
physician and patient directed interventions (and both), but also between ‘in-reach’ and
‘out-reach’ activities. In-reach approaches include the consultation based reminders
that are of particular relevance to the e-Nudge trial, although other examples included
practice based audit which was excluded from our own review. The conclusion of this
review was generally positive regarding the effectiveness of office based interventions
for cancer prevention.
Mitchell and Sullivan (37) considered more generally the impact of computers
in primary care consultations. They identified ‘a descriptive feast but an evaluative
famine,’ highlighting the relative lack of high quality, controlled trials of computerised
interventions, in contrast to the volume of papers describing interventions, their
development, use and acceptability. Out of 89 papers included, 61 reported the effect of
computers on practitioner performance, 17 used patient outcomes, and 20 were
qualitative studies of practitioner and patient attitudes. This review identified negative
aspects related to process measures (including lengthening consultations) but not to
patient outcomes. The phenomenon through which effectiveness may fall after
withdrawal of the intervention was also identified.
Montgomery and Fahey’s review (38) included 7 randomised controlled trials
investigating the use of computers specifically in the area of hypertension management.
These studies included 11962 patients and were combined using a narrative rather than
meta-analytical approach due to heterogeneity of patient populations, interventions and
outcomes, although their methodological quality was similar. A beneficial effect was
seen on processes of care such as follow up, but once again the effects on patient
outcomes (such as control of blood pressure) were less conclusive.
A meta-analytical approach was, however possible in a review of general
practitioner based reminders to support cervical cancer screening reported by Pirkis,
Jolley and Dunt (39). Ten studies were identified and a positive effect demonstrated on
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a woman’s chance of having a Pap smear if the GP had been reminded. A strong
recommendation over the use of such reminders was made.
Shea, DuMouchel and Bahamonde (40) conducted a meta-analysis of 16
randomised controlled trials reporting the impact of computerised reminders in six
areas of preventive care (vaccinations, breast cancer screening, colorectal cancer
screening, cardiovascular risk reduction, cervical cancer screening, and ‘other
preventive care.’) The first four of these areas were associated with benefits of the
reminders but not the final two. Ten out of the sixteen interventions evaluated were
directed at physicians, the remainder at patients or family. Cardiovascular preventive
activities included measurement of blood pressure; follow up of hypertension;
cholesterol screening; and dietary assessment and counselling. The overall odds ratio
(ratio of odds of completing the target behaviour in intervention and comparator arms)
was 1.77 [95% CI 1.38-2.27], and for the cardiovascular risk reduction subgroup 2.01
[95% CI 1.55-2.61].
Shiffman, Liaw, Brandt and Corb (41) reviewed studies of computer based
interventions including clinical guideline implementation systems and their impact on
clinician behaviour and patient outcomes. Quantitative meta-analysis was impossible
due to study heterogeneity. A narrative synthesis concluded that better control of
confounding factors would be needed to derive firm conclusions over the effectiveness
of such systems at influencing clinician behaviour Seventeen out of twenty systems
described used paper based reminders, albeit computer generated. The authors
remarked that ‘the paperless office remains a vision of the future.’
Shojania 2006 (42) (note different from Shojania 2009 discussed in Chapter 4)
considered only interventions related to diabetes care and using glycosylated
haemoglobin level as the outcome, but included any type of quality improvement
strategy. Studies using before/after designs were included as well as randomised and
quasi-randomised trials. Out of eleven strategies, team changes and case management
interventions produced the clearest benefits. Publication bias (suggested through the
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finding of more clearly positive outcomes in the smaller studies) was an issue, and the
authors also commented on the difficulties in classifying the complex interventions
involved in quality improvement when assessing effectiveness.
Tu and Davis (43) reviewed the evidence for educational interventions in the
management of hypertension. Reminder systems were only one of a number of
interventions that were generally not relevant to my research, including academic
detailing, but were apparently the most promising in terms of changing clinician
behaviour. However, once again it was the processes of care (such as follow up) rather
than clinical outcomes (such as blood pressure levels) that benefited.
van der Sijs et al (44) identified 17 papers describing trials of drug safety alert
systems used during computerised order entry. This review was concerned largely with
the reasons why physicians over-ride such alerts (in 49%-96% of cases) rather than
their effectiveness. Problems include low specificity or sensitivity, unclear information
content, and incorrect handling of the alerts. This review is important because it
emphasises the need to embed a new intervention such as an alert system in the
workflow context if it is to be useful rather than disruptive.
Finally, Dexheimer et al (45) updated a previous review by Balas et al (2000)
(46) of both paper-based and computerised prompts related to preventive measures.
Reporting nine years later than Shiffman et al (discussed above), they also found a
preponderance of paper based rather than fully computerised systems, the latter
involved in just 8 out the total of 61 studies. They found an increase in preventive care
measures of between 12% and 14% averaged over all studies. Cardiac care and
smoking reminders were the most effective.
1.4.2 Summary of existing evidence
In summary, the existing systematic reviews discussed above provided a range of
insights that influenced my own research, and can be distilled under the following
headings:
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 Reminder systems are complex interventions that may influence more than one
component of the health care environment: practitioners, patients, administrative staff,
and workflow.
 Reminder systems lend themselves well to computerisation, but this does not
automatically result in changes in clinician behaviour, and the over-riding of electronic
alerts is common.
 On the whole, reminder systems are beneficial, but these benefits are very context-
dependent and there are many examples of no benefit.
 The benefits of reminder systems may fall off quite rapidly when the intervention is
withdrawn.
 Examples of reminders improving processes of care are much commoner than those
influencing clinical outcomes.
 Reminders can have detrimental effects on workflow such as lengthening
consultations.
This ‘review of reviews’ was helpful in planning my research. Whilst the articles
provided some key insights, they also reassured me that my major research questions
were not already answered. The benefits of reminder systems are generally evident, but
their impact is inconsistent and context-dependent. They are not proven in the specific
setting of CVD risk assessment and reduction in current UK primary care.
1.5 Chronology of the research
This thesis describes research undertaken over a period of five years 2004-2009. I
commenced my current post in March 2004 and registered for the degree in October of
that year. At the same time I began working as a part time general practitioner in a
practice in Warwickshire. Just prior to moving to the area I co-authored a ‘concept’
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paper in the British Journal of General Practice (47). During 2004-2005 I undertook
much of the preparatory work described in Chapter 5. This involved collaborative work
with the private firm Newchurch, at that time contracted to provide an integrated
electronic care record resource to the NHS across South Warwickshire. A series of
systematic literature searches was undertaken to identify trials of reminder interventions
and also papers describing the development of such tools including qualitative
evaluations of their use in practice. This was carried out with advice from Warwick
Medical School’s librarian Diane Clay, and used to support the e-Nudge trial design. A
number of the identified papers (48-75) were cited in the trial protocol approved by
Warwickshire Local Research Ethics Committee in August 2005 and published in the
journal Trials in April 2006 (76) (see Appendix).
In early 2006 I collaborated with the company EMIS to develop the e-Nudge
software, as it had become evident that the Newchurch platform could not support the
trial, and in May 2006 I piloted it in a test practice in Coventry. Reasons for the change
from Newchurch to EMIS are discussed in Chapter 5. Minor amendments to the
protocol were necessary partly as a result of changes in UK practice, including the
introduction of screen reminder messages to support the quality and outcomes
framework. These changes are described in detail in Section 8.6 of Chapter 8.
The trial commenced in June 2006 and ran until September 2008. During this
time the baseline data following installation of the software were published as a cross-
sectional survey (77), and a separate project resulting from the baseline data was
undertaken using the QRESEARCH database. This resulted in two further publications
(78, 79).
The formal systematic literature review of reminder interventions commenced
in September 2007 and was completed in 2009 prior to thesis submission, although it
has not yet been submitted for publication. This was a piece of original research
separate from the initial literature searches, and resulted in a quantitative meta-analysis
described in detail in Chapter 4. Most of the articles identified in the initial searches
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were not included in the systematic review as this only included controlled trials
operating in the consultation environment. It therefore excluded qualitative and
descriptive papers that were nevertheless useful to me in developing the e-Nudge
intervention. The formal systematic review was an important part of my training as it
gave me the opportunity to develop skills in meta-analysis. Developing these skills was
a less urgent priority than commencing the e-Nudge trial as the data that it would
generate were required within the 5 year PhD timescale. For this reason, I depended for
the design of the trial on the preliminary literature searches that were much broader
methodologically.
After the completion of the trial the data collection and analysis took from
September 2008 to March 2009. It was submitted to the British Journal of General
Practice in May 2009, accepted in September 2009 and is due for publication in April
2010 (80).
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Chapter 2: Cardiovascular risk prediction
______________________________________________________________________
2.1 Introduction
This research examines the use of electronic data for the identification and targeting of
individuals at risk of cardiovascular disease in primary care. A central focus is the
process by which such data are used by practice teams. A related issue is the definition
of cardiovascular risk itself. In this chapter I will discuss the usage and definition of
cardiovascular disease and cardiovascular risk, the factors used to identify those at risk,
and how the coding of electronic information in primary care might influence them.
Historically the development of cardiovascular risk algorithms, and in particular the
selection of putative risk factors to support them, has been influenced by the
availability of objective information, and not only by their relevance to cardiovascular
outcomes. This issue has implications for the study of cardiovascular disease in the
current primary care environment.
2.2 Definitions and usage of ‘cardiovascular disease’ and
‘cardiovascular risk’
The term ‘cardiovascular disease,’ when used in the context of cardiovascular risk,
implies coronary artery, cerebrovascular, and peripheral vascular disease.
Atherosclerosis, thrombo-embolism, or haemorrhage affecting the arterial circulation
are the underlying pathological processes or complications. Venous thrombo-embolism
is an important cause of vascular mortality and morbidity but its risk factor distribution
is sufficiently different from arterial disease that it is considered separately when
cardiovascular risk is estimated. The venous circulation is prone to thrombosis, but
venous thrombo-embolism is not influenced appreciably by arterial hypertension and
much less so by lipid abnormalities than is the arterial circulation. Haemorrhage occurs
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in veins but is less often catastrophic and fatal than haemorrhagic events occurring in
arteries. Valvular heart disease (congenital or acquired), vasculitic disorders (e.g.
temporal arteritis), those involving abnormal vasomotor function (e.g. Raynaud’s
syndrome, vibration white finger) and congenital abnormalities of the blood vessels
(unless causing haemorrhagic stroke) are also excluded from the concept of
‘cardiovascular risk’ used in primary care.
Atrial fibrillation is an important cause of cardiovascular events that falls outside
(or perhaps between) the arterial/venous distinction. The atria are on the venous side of
the circulation, but in the case of the left atrium and the pulmonary veins that feed into
it, thrombosis my produce emboli directly into the arterial tree. Venous emboli arising
anywhere else in the body are prevented from doing so by the need to pass through the
pulmonary circulation. Left atrial thrombosis commonly results from atrial fibrillation
(AF), in which disorderly contractions produce turbulence and relative stasis,
facilitating thrombosis. AF is therefore a very significant risk factor for thrombo-
embolic stroke, but (perhaps because of the difference between the risk factor profiles
for arterial and venous disease) is absent from most of the standard CVD risk
algorithms, and is considered separately. An exception to this is the recently developed
QRISK2 (1), which combines AF with other CVD risk factors within the same
algorithm. This is discussed later.
2.2.1 ICD-10 Classification
The definition of CVD is influenced by the particular context in which it is used. e.g.
clinical care or research. The World Health Organisation (WHO) developed the
International Classification of Diseases (ICD) to standardise definitions for all
diagnostic categories. This system originated in the 1850s and was last updated in 1990
as the ICD-10 (http://www.who.int/classifications/icd/en/). Relevant diagnostic
categories for cardiovascular disease are:
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I20-I25 Ischaemic heart diseases
I60-I69 Cerebrovascular diseases
I70-I79 Diseases of the arteries, arterioles and capillaries
These classifications largely involve atheromatous, haemorrhagic, or thrombo-
embolic disorders, but there are exceptions, e.g. cerebral arteritis, hereditary
haemorrhagic telangiectasia, and others, which would not have the same implication
for vascular prevention in clinical practice.
2.2.2 Read codes and SNOMED CT
More importantly for this research, the Read coding system used in current NHS
primary care involves a similar classification to ICD-10 with regard to cardiovascular
diseases. Arterial disorders are taxonomically separate from venous disorders even
though either may involve thrombosis. For the majority of conditions the Read code
groups G3… and G6… refer to disorders involving arterial thromboembolism or
haemorrhage. These share a broadly common pathophysiology and range of risk
factors, in contrast with venous disorders as discussed above.
SNOMED CT (Systematised Nomenclature of Medicine Clinical Terms),
discussed in the previous chapter, was developed in 2002 through a merger of NHS
Clinical Terms Version 3 (CTV3) Read codes and the SNOMED RT (Reference
Terminology) system in use in the United States. In the process the relationships
between different disease states and other medical terms was revised. The four basic
elements of SNOMED CT are concepts, hierarchies, relationships, and descriptions.
The details are beyond the scope of this thesis, except that the term ‘concept’ has a
specific meaning in SNOMED CT. It is the most basic ‘unit of thought’ used for
specific entities at the lowest taxonomic level (2). The creation of SNOMED CT
involved an extensive mapping exercise validated by independent US- based and UK-
based data editors. The initial mapping of concepts was followed by a review of the
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hierarchical structures defining taxonomic relationships (3). Fortunately for my
research the Read codes that are still in use in current general practice provide an
adequate taxonomy for cardiovascular disease.
However there are exceptions, in addition to the issue discussed above
concerning atrial fibrillation. An important example is the inclusion of ‘Vertebrobasilar
Insufficiency’ in the same Read code group as ‘Stroke’. Use of this term, when coded
in an electronic record, automatically includes the patient in the Stroke disease register,
even though it is not included as such in ICD-10. However, the diagnosis does not
necessarily imply cerebrovascular atheroma, or the need to control vascular risk
factors. Vertebrobasilar perfusion may typically be impaired by degenerative disease of
the cervical spine to which the vertebral artery is intimately related anatomically.
Practices have had to rationalise their use of this Read code to avoid this misplacement,
if inappropriate to the individual. Similarly, this specific issue had to be accounted for
in the measurement of outcomes in the e-Nudge trial described later in this thesis.
2.2.3 Research study outcomes
Research contexts may require alternative definitions to those used in clinical care.
Observational or intervention studies require clearly defined outcomes or endpoints. At
one extreme, this might be limited to hard outcomes e.g. myocardial infarction, stroke,
or coronary death, where it is relatively easy to determine to which category an
individual belongs at the end of the study. It would be more difficult to categorise
whether a person has a significant aortic aneurysm (a potentially serious arterial
complication) unless it ruptured, as aortic aneurysms develop gradually and expand in
size over a period of years. Detection on a routine ultrasound scan or during a clinical
examination could not easily be included as an outcome event in such a study, unless
the entire study population were screened and a minimum diameter defined as a
diagnostic threshold. For larger studies, this is not a practical option. Study design
therefore also determines the usage and concept of cardiovascular risk.
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This issue also applies to some of the commoner cardiovascular outcomes,
including angina pectoris, transient ischaemic attack (TIA), and heart failure. Until the
mid- or late-1990s, the diagnosis of angina was largely a clinical one, based on history
taking. Since then, most patients with suggestive symptoms have been referred for
investigations to confirm the diagnosis prior to their entry on Coronary Heart Disease
registers. A diagnosis of angina has become a much more objective outcome. Transient
ischaemic attacks are largely a clinical diagnosis, as by definition the neurological
deficit resolves within 24 hours of onset (without associated infarction detectable on
brain imaging), but they are now usually followed up by investigation. ‘Fast-track’
neurovascular clinics are now widespread and have streamlined referral pathways,
improving the quality of this diagnosis as an indication of significant cerebrovascular
disease over the past ten years. This in turn has improved the quality of the general
practice registers, to which a patient will be added when the diagnosis is confirmed. In
practice this simply requires the entry of the relevant Read code into the record with the
date of onset, as discussed in the previous chapter. Feigin and Hoorn recommend the
inclusion of general practice registers for case ascertainment in stroke/TIA incidence
surveys (4), based on the success of this technique in the OXVASC study (5).
However, in general practices not participating in research studies the diagnosis might
be less reliable. Heart failure is a further example. The Quality and Outcomes
Framework (QOF) of the new General Medical Services contract now requires this
diagnosis to be confirmed by echocardiography, improving considerably the quality of
practice based heart failure registers.
These clinical diagnoses are now much more likely to be supported by
investigations. The question then arises over how the modern diagnosis compares with
the outcome definition used in classical research studies such as the Framingham Heart
Study. The Framingham investigators studied cohorts that were followed up
intensively, but used outcome assessments that only required questionnaires, physical
examination, office measurements, electrocardiographs (ECGs), and death certificates
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(6). All the patients they diagnosed with coronary artery disease had symptomatic
angina, a history of myocardial infarction, or evidence of silent myocardial infarction
on ECG. Even for ‘hard’ events, technology may affect detection rates significantly.
For instance, the OXVASC investigators commented on the effect of introducing
sensitive biomarkers including troponins on the rates of diagnosis of myocardial
infarction (7). The ICD classification discussed above was used as a basis for
diagnostic definitions of CVD events in the OXVASC study, even though the primary
source of their data (general practice records) utilises the Read code classification
system. As discussed above, both of these systems (ICD and Read coding) make a
distinction between arterial and venous events, and between coronary, cerebral, and
peripheral arterial events.
The Framingham Heart Study is still the most frequently used data source for the
identification of cardiovascular risk. It used a number of different outcomes and has
alternative algorithms (using different co-efficient values) for the following (8):
 Myocardial infarction (MI) including silent and unrecognised MI
 Coronary Heart Disease (CHD) death (sudden or non-sudden)
 CHD (including MI, CHD death, angina pectoris and coronary insufficiency)
 Stroke (including transient ischaemia)
 Cardiovascular disease (all of the above plus peripheral vascular disease and
heart failure)
 Cardiovascular death
Here, ‘cardiovascular disease’ includes all of CHD, stroke, transient ischaemic
attacks (TIA), peripheral vascular disease and heart failure. These outcomes are
included in the Framingham CVD algorithm. However, the Joint British Societies (9),
also using the Framingham data, have a different definition of ‘cardiovascular disease’
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that is a simple summation of the risks calculated from the CHD and Stroke/TIA
algorithms (i.e. not including peripheral vascular disease or heart failure). The same
approach is used in the subsequent QRISK algorithm described later (1, 10). The
justification for this is firstly that peripheral vascular disease (PVD) is much more
difficult to define, for the reasons discussed above. Many older patients have a degree
of it, often without obvious symptoms. Most patients reporting symptoms will have the
diagnosis made only on clinical grounds (not confirmed through investigations), and
practices are not currently required to have PVD registers, so diagnosis and recording
(particularly electronic) is less consistent. Secondly, heart failure is not always due to
coronary artery disease, but may be found in patients with cardiomyopathies, valvular
disorders (congenital and acquired), as a complication of hypertension, or associated
with other pathogenic mechanisms. It does not necessarily imply ischaemic vascular
disease associated with atheroma.
2.2.4 Sudden death from cardiovascular disease
Unless due to trauma, sudden death is usually caused by a vascular event. An exception
to the above distinction between venous and arterial disorders therefore arises when an
individual dies suddenly from pulmonary embolism. In this case, the event would only
be included as a relevant outcome if death was ‘sudden’. This in itself requires a
definition. In the MONICA study discussed below, death within 24 hours of hospital
admission was suspected to be vascular and required monitoring (11). Later in this
thesis the issue of sudden cardiovascular death is discussed again as it represents a
‘vulnerable’ area of data quality in primary care (Chapters 6 and 7).
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2.3 Risk factors and their independence
As well as the outcome measures, the selection of risk factors as inputs to the
algorithms may be biased towards those that are independent, objective and easily
measurable. For instance, in the Framingham Heart Study:
“The components of the profile were selected because they are objective and
strongly and independently related to CHD and because they can be measured
through simple office procedures and laboratory results.” (12)
2.3.1 Framingham risk factors
The risk factors used in the Framingham algorithm were:
Age
Gender
Smoking status
Blood pressure (usually based on systolic)
Total serum cholesterol
Serum high density lipoprotein (HDL) cholesterol
Diabetes status
Presence or absence of Left Ventricular Hypertrophy on ECG
Other factors were measured, but these are the ‘classical’ factors that have
become the inputs for the most commonly used algorithms derived from this study’s
data.
2.3.2 Definitions used by Framingham investigators and issues arising
Age and gender were uncontroversal. Smoking status was considered positive in any
participant reporting tobacco use in the past 12 months, i.e. those quitting for a longer
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interval become non-smokers. (More recently, the CHD National Service Framework
(13) and JBS2 (9) recommend that smoking status should be based on lifetime
exposure, and that an ex-smoker should be considered a ‘current smoker’ until 5 years
have passed since quitting for the purposes of a Framingham risk estimation. However
the original definition was based on 12 months). Systolic blood pressure was based on
the average of two office readings taken on the same day. Cholesterol levels were
measured using laboratory techniques that are equivalent to modern practices. Diabetes
status was based either on use of hypo-glycaemic drugs or insulin, or a single raised
blood glucose measurement. In the recruitment of 1968-1975 this level was 150mg/dl
(8.3mmol/L approx) on a casual (random) measurement. In the later ‘Framingham
Offspring Cohort’ recruitment phase, the definition was altered to include all those with
a fasting plasma glucose level of >140mg/dl (or >7.8mmol/L). The modern diagnostic
threshold based on a fasting plasma glucose is now >7.0 mmol/L following revision to
the World Health Organisation criteria in 1999 (14). (Discussions are currently
underway likely to revise the diagnostic definition for diabetes to one based on
glycosylated haemoglobin rather than blood glucose values, a technique developed
during the 1980s and therefore unavailable to the original Framingham investigators.)
This change has significantly altered the proportion of the population considered to
have diabetes and contributes to the rise in recorded prevalence over the past ten years.
The Framingham investigators treated diabetes status as a binary input (diabetes
present or absent). In recent years, people with diagnosed diabetes have not been risk
assessed using the Framingham algorithm, and have been considered to be generally at
raised risk. However there is increasing recognition of the continuous rather than
binary nature of hyperglycaemia as a CVD risk factor and this is reflected in the
UKPDS risk algorithm which takes account of both the level of glycosylated
haemoglobin and duration of diabetes in the individual (15). For those without
diagnosed diabetes there is a grey area of impaired glucose regulation below the
diagnostic threshold for diabetes, particularly in association with central obesity and
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other risk factors as the ‘metabolic syndrome’ (16). The Joint British Societies suggest
that patients with impaired glucose tolerance (but not diabetes) are at about 1.5 times
the risk estimated using the standard Framingham equation (9). There is some
evidence that recognising the metabolic syndrome in clinical practice improves the
assessment of cardiovascular risk (17). However, its value for clinical care continues to
be debated (18, 19).
Whilst other risk factors were recorded during the Framingham Heart Study, the
Framingham algorithms include the factors believed to be independently related to the
development of cardiovascular disease. Other variables may influence risk through the
‘classical’ factors. For instance, body mass index (BMI) is related to diet and exercise,
both of which are reflected to some extent in the serum cholesterol profile and through
the blood pressure input. Adding BMI to the Framingham algorithm does not
significantly improve its predictive performance (12). Diastolic blood pressure is
similarly omitted because it is so strongly correlated with systolic blood pressure that to
include both would create statistical redundancy, making interpretation more difficult
(12). A separate algorithm is available using diastolic instead of systolic blood
pressure, with slightly different co-efficient values, but is rarely used in practice.
Family history exerts its effects partly through the lipid profile and blood pressure
inputs, which include heritable components. So whilst family history is extremely
significant as a risk factor, much (but importantly not all) of its influence is conveyed
though the cholesterol profile and blood pressure level. The independent relevance of
family history is recognised by the Joint British Societies, who recommend that it be
taken into account in assessing the risk of an individual, and more recently by NICE
CG67: Lipid modification (20). Family history partly ‘covers’ some of the risk
attributable to ethnicity (21).
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2.3.3 More recent approaches
Since the original Framingham study, new factors have been identified, but in most
cases their influence is already at least partially represented. This explains the
‘diminishing returns’ phenomenon (21) through which the addition of further variables
beyond the classical factors adds less and less to the algorithm’s performance as a
predictive tool. This preference for minimalism in the algorithm restates the desire of
the original Framingham investigators (as quoted above) for strong, independent
factors. The Framingham Heart Study led on to intervention studies that demonstrated
the impact of risk factor control on cardiovascular events, particularly blood pressure
reduction (22) and lipid lowering (23). Only by modifying causative factors will risk be
reduced and outcomes improved. However, current policies on lipid lowering and
blood pressure reduction advise the targeting of individuals based on overall risk, and
not simply on lipid or blood pressure values respectively. Modification of causative
factors is most effective in those whose overall risk is highest. This is the basis for the
current policy on statin therapy, which recommends treatment in all people at high risk
of CVD irrespective of pre-treatment values (20). More recently, the case has been
made for blood pressure reduction in those at risk of CVD even when the pre-treatment
level is normal (24, 25). Jackson et al made this case particularly clearly in a review
paper in which they highlighted the interactive nature of risk factors and the rationale
for basing treatment decisions on absolute risk and not on individual risk factor levels
(26). However, current policy on treating blood pressure still requires the pre-treatment
level to be at least elevated to 140-159mmHg systolic or 90-99mmHg diastolic for the
general population, combined with raised CVD risk.
The need to identify those at highest overall CVD risk sets an important task for
primary care and has become the focus of this thesis. Improvements to the ‘classical’
risk algorithms (most of which are derived from the Framingham Heart Study data)
might take advantage of risk variables that have become available since this study took
place, including currently available electronic data. An example of this is the inclusion
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of deprivation scores in the ASSIGN algorithm published in 2007 (21). Deprivation
affects cardiovascular risk in a number of ways, some of which are conveyed through
the ‘classical’ risk factors. Unemployment, for instance, is known to be associated with
adverse values of the classical risk factors (27). But when classical algorithms are used
to predict cardiovascular outcomes in areas of high deprivation, they tend to under-
estimate risk (21). This contrasts with their tendency to over-predict among the general
population (28). This suggests that the association of deprivation with cardiovascular
risk is not simply due to the confounding effects of the classical factors. It suggests
either that other factors associated with deprivation are independently involved or that
the algorithm that weights and combines the known risk factors needs to be adjusted for
use in these populations. This has implications for the targeting of interventions, as it
means that reduction of blood pressure and cholesterol may be more worthwhile in a
deprived inner city environment than in a more affluent situation, all other things being
equal.
2.4 Absolute and relative risk
The current approach towards risk factor management for CVD prevention is based on
the principle that control of risk factors is most justifiable in those at highest short or
medium term (10 year) absolute risk. Such patients have a need for drug therapies
whose safety and effectiveness have been demonstrated over timescales of years rather
than decades. However, this approach may neglect younger patients whose estimated
absolute risk will generally be low (because age is such an important factor) but whose
relative risk compared to age matched peers may be high, and whose life time risk is
high. Such people are likely to benefit in the longer term from risk factor control in
terms of added life years. Recognising this problem, the Joint British Societies in their
first report of 1998 recommended basing treatment on the individual’s projected risk to
age 60 years (29). In the subsequent second report, this strategy was replaced through
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the development of a new algorithm introducing a more complicated age adjusting
factor (9). In this approach, patients who are less than 50 years are all assumed to be 49
for the purposes of calculating risk (which is only recommended in people under 40
years in special circumstances). Those between 50 and 59 years are assumed to be 59,
and those who are 60 years and over are all assumed to be 69. This approach therefore
leads to an over-estimation of risk in people who are less than 49, between 50 and 58,
and between 60 and 68, with an under-estimation in people over 70 years. This
manoeuvre is designed to offset the tendency of the Framingham algorithm to focus
attention excessively on the elderly population in primary prevention.
2.5 Missing data
Whether in a clinical or in a research context, the issue of missing data commonly
arises. For Framingham risk estimates, profiles not uncommonly have either the HDL
cholesterol level missing, or the LVH status unknown. A number of risk assessment
tools have been designed to take account of these potential data inadequacies (e.g.
(30)). Very commonly, assumed values are imputed where data are missing. This
approach may fail to recognise that missing data are not necessarily distributed in the
same way as recorded data, a problem discussed by Sterne et al as applied to research
and epidemiological contexts (31). This is not just an issue for current primary care, but
was also a problem for the Framingham investigators. In the equations developed prior
to the 1968-1975 cohort, HDL cholesterol was not included. From 1968 onwards it was
recorded, as the improved predictions resulting from its inclusion had become evident
(12). In some individuals, information on either LVH or diabetes status was
unavailable, and if so was assumed to be negative. Modern approaches using the
Framingham algorithms also need to account for missing data. This issue will be
discussed in detail later in this thesis.
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2.6 Pre-treatment and modified risk factor values
For the years that followed the 1968-1975 Framingham cohort recruitment, at least
until the 1980s, effective treatment of risk factors using drug therapies was relatively
uncommon, although antihypertensive drugs were used increasingly in subsequent
years. Lipid lowering therapy did not become commonplace until the 1990s. A
reduction in smoking occurred in men (although not in most female populations, where
it tended to rise), and blood pressure and cholesterol values tended to decline,
contributing to the global improvement in coronary heart disease mortality since the
1980s (32).
The Framingham study therefore took place in an environment relatively free of
the effects of risk factor modification on outcomes. This raises a further issue, as the
estimation of cardiovascular risk using the Framingham algorithms is required for
modern populations whose future risk may be affected by drug therapy, and whose risk
estimation should theoretically be carried out using ‘pre-treatment’ values of blood
pressure and cholesterol. In modern practice, such values are often unavailable if the
patient is already on treatment, particularly when the drug therapy preceded the
introduction of electronic medical records. In the UK, this began in the late 1980s or
early 1990s. By the end of the latter decade the majority of UK practices were
computerised to varying degrees. Nevertheless, as discussed above a significant
proportion of modern patients have treated risk factors whose pre-treatment values are
either not recorded or recorded in a form not accessible to electronic retrieval.
Lack of availability of ‘pre-treatment’ values for blood pressure and cholesterol
creates a practical difficulty, and an obstacle to the estimation of risk in treated
individuals. Such individuals include the majority of those on the hypertension register,
which was recommended in the Coronary Heart Disease National Service Framework
(13) as the most likely place to begin case finding for those at high coronary heart
disease risk. A systematic attempt to identify the practice’s ‘at risk’ population will
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therefore miss these patients if it is confined to those who are not currently taking anti-
hypertensive or lipid lowering drug therapy, although this approach has been advocated
(33). A similar approach was recommended by JBS2, in which patients off treatment
were to be risk assessed opportunistically.
Other solutions have included:
 Recognising the problem but still using the modified values as inputs,
accepting that cardiovascular risk will be under-estimated. This is the approach used in
the ‘e-Nudge’ case-finding tool to be described in detail later in this dissertation. It is
also suggested in the 2008 NICE guidance on Lipid Modification (20).
 Using ‘treatment for blood pressure’ status as an input to the algorithm. This
is used in the Pocock algorithm (34) and in the later QRISK and QRISK2 algorithms
(1, 10).
 Introducing an interaction term between systolic blood pressure and anti-
hypertensive treatment (35).
 Entering an ‘assumed value’ for the pre-treatment levels of blood pressure or
cholesterol. JBS2 (9) suggests a systolic blood pressure of 160 mmol/L and a total to
HDL cholesterol ratio of 6.0 as the assumed values.
 In a new Framingham based risk algorithm designed for use in primary care,
D’Agostino et al provide alternative regression co-efficients for systolic blood pressure
depending on whether it is a treated value or not (36).
The Framingham study has become the most frequently used data source for
estimating cardiovascular risk, partly because of the relative freedom from the effects
of treatment on outcomes. Because of the global improvement in cardiovascular
mortality since the original study was completed, the CHD algorithm has been found to
over-predict risk in the general population of the UK (28), in Germany (37), and in
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Belfast and France (38). In the UK, over-estimation is particularly evident in the low
risk populations as discussed above (21).
The Framingham algorithms themselves have experienced numerous revisions
over the years. An early risk scoring system was published in 1967 (39) and drew on
the data collected from the original recruitment cohorts that commenced in 1948. A
widely cited paper from 1976 (6) describes a new logistic regression algorithm to
combine the risk factors but at this point high density lipoprotein (HDL) cholesterol
was not included. The algorithm in current common use is that published in 1991 (8)
and includes HDL cholesterol. This was further modified in 2000 to enable it to predict
cardiovascular events in patients with established cardiovascular disease such as a
history of myocardial infarction, i.e. in the secondary prevention scenario (35) although
this algorithm has not entered routine practice in the UK.
The contrast between ‘pre-treatment’ and ‘modified’ risk is particularly relevant
if one is attempting to create practice based ‘At risk of CVD’ registers. This was first
proposed by the CHD NSF of 2000 (although this document was concerned more
specifically with CHD rather than CVD risk). Such registers would include people
whose risk had been identified on the basis of pre-treatment risk factor measurements
(e.g blood pressure and serum cholesterol) but who had subsequently undergone
treatment of these factors to the point where the estimated risk based on treated values
would be lower than that required to justify inclusion on the register. This raises the
important issue for identifying potentially at risk individuals based on current
electronic data: are we interested in identifying those that are still at risk when assessed
using treated factors values, or are we interested in controlling risk in those whose
‘original’ (unmodified) risk was high? The CHD NSF of 2000 clearly preferred the
latter, whilst more recent guidelines (such as NICE CG67) that recognise the
difficulties (increasingly evident since 2000) in identifying pre-treatment levels in
general practice tend to favour the former, with appropriate adjustment in risk
estimation to account for this difference.
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2.7 Cardiovascular risk algorithms using alternative data to
Framingham
Other important studies contributing to what is known about cardiovascular risk
include MONICA (40), PROCAM (41), SCORE (42) ASSIGN (21) and QRISK (1,
10).
2.7.1 MONICA
MONICA (Monitoring trends and determinants in cardiovascular disease) was a large
prospective observational survey of cardiovascular risk factor patterns and event rates
organised by the World Health Organisation, involving 41 collaborating centres in 21
countries, and a total study population of approximately 15 million people aged 25-64
years. It was designed to investigate the relationships between trends in CVD risk
factors and CVD mortality rates (43). The original Framingham study included 5573
individuals, a small enough number to allow an intensive follow up strategy. MONICA
involved much larger numbers and required alternative approaches. Designed
prospectively and conducted using protocols standardised across collaborating centres,
MONICA is an early example of epidemiological surveillance of cardiovascular
disease patterns using routinely collected health data on an international scale. This
source created quality issues in event monitoring (11). Differences in ascertainment
occurred between collaborating centres. Some used the ‘hot pursuit’ method, in which
patients admitted to hospital following an event would be interviewed whilst still an
inpatient. Others used the ‘cold pursuit’ approach, in which event monitoring relied on
searches on hospital records following discharge (44). Hense et al suggested that blood
pressure measurement quality in MONICA should be assessed not simply by visits and
inspections of the collaborating sites, but by examining the actual blood pressure
measurements themselves (45). Two techniques, the ‘last digit preference’ and the
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‘proportion of identical duplicate measurements’ were shown to improve the
comparability of quality standards between centres. In the two Belgian collaborating
centres, misclassification of CHD cases was found to be partly due to coding problems
(46). This issue is likely to affect any research relying on diagnostic coding, and will be
discussed further later in this dissertation.
MONICA was designed primarily as a longitudinal survey of diverse
multinational populations rather than a cohort study with individual follow up
(although this did also occur). It did not therefore result in a risk algorithm, other than
through its contribution to the SCORE project, which included MONICA cohort data
from Scotland and Germany (42).
2.7.2 PROCAM
PROCAM (Prospective Cardiovascular Munster study) was a cohort study based at
Munster in Germany, commencing in 1986 (41). The study confirmed the relevance of
the classical risk factors, and suggested that serum triglycerides, apolipoprotein b, and
coagulation factors were also relevant to CHD risk and might be used to improve risk
estimations. The main outcomes in this study were myocardial infarction and sudden
cardiac death. Cerebrovasular disease outcomes were recorded, but the upper limit of
the age range was 65 years, above which stroke incidence rises steeply (7).
Interestingly, this study raised the question of a ‘J-shaped curve’ relating total and LDL
cholesterol levels to all cause mortality, due to an apparent increase in cancer deaths in
smokers with low levels of these factors (47).
2.7.3 SCORE
The SCORE (Systematic Coronary Risk Evaluation) algorithm is based on examination
of 12 different cohort studies from 11 European countries (42). The outcomes only
include fatal cardiovascular events. Whilst these data are from European rather than
North American populations, the SCORE algorithm was not considered superior to
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Framingham for the UK population in the JBS2 report or in the 2006 NICE guidelines
on statin prescribing (48). One of the reasons for this was the need to include non-fatal
as well as fatal CVD outcomes.
SCORE does not include diabetes status as an input risk variable, recognising
that patients with diabetes should generally be considered at high CVD risk. This
became the recommended approach supported by the British Hypertension Society
(49), the Diabetes National Service Framework (50, 51) and JBS2 (9). However, risk
algorithms have been derived for patients with diabetes from the United Kingdom
Prospective Diabetes Study for both CHD (15) and stroke (52). The CHD algorithm has
been compared with the Framingham CHD function in a study of patients with newly
diagnosed type 2 diabetes but free of CHD (53). Both algorithms were found to be
poorly calibrated to the study population’s outcomes, although discrimination was
moderately effective. However the most recent NICE guideline on type 2 diabetes
recognises that not all patients are at sufficient cardiovascular risk to justify lipid
lowering therapy and that in such cases a risk assessment should be undertaken on an
annual basis using the UKPDS risk engine (15).
2.7.4 QRISK and QRISK2
More recently, a new risk algorithm based on UK data was derived using the
QRESEARCH database at the University of Nottingham (54). This algorithm was
named QRISK (10) and was later improved to produce QRISK2 (1). Based exclusively
on data held in EMIS practices, the algorithm was later validated using the THIN
database (which involve VISION (In Practice Systems) data) and found to out-perform
Framingham as a predictive tool for CVD events in the UK population (55). However,
as discussed above (and very clearly stated by Liew and Glasziou (56)), it may be more
appropriate to address the concept of underlying, untreated risk rather than the risk
based upon outcomes of populations whose CVD risk factors are being actively
managed.
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2.7.5 Comparisons between Framingham and alternatives
The Framingham risk function has been compared with European algorithms including
Dundee, British Regional Heart Study (BRHS), and PROCAM (57). The algorithms
were applied to a sample of 206 consecutive male patients attending a hypertension
clinic. Apart from the BRHS data (in which systematically lower risk estimates were
produced), Framingham made comparable predictions to the other algorithms and was
considered adequate for use in Northern European male populations.
Framingham algorithms have also been applied to different ethnic groups to test
external validity, as the Framingham study population was predominantly composed of
white Americans. The multiple ethnic groups investigation (58) examined data from six
prospective cohort studies in ethnically diverse populations. The algorithm performed
well among white and black men and women, but required recalibration for Japanese
American and Hispanic men, and Native American women.
The validity of the Framingham algorithm in the modern UK population remains
a concern, particularly in Asian men, whose observed risk tends to be higher than the
predicted risk using Framingham. To estimate the diverse risk levels of different
minority groups, the ETHRISK algorithm was developed, based on survey data from
UK populations (59). However, this has not yet been validated through a cohort study
within these populations.
2.8 Alternative models for risk prediction
This section describes the background and justification behind the development of past
and current statistical models for CVD risk estimation, and the options for future
models based on primary care data. I will describe the basic structure of the logistic
regression model originally used by the Framingham investigators, explain how this
model was later developed, and end with a discussion over the advantages and
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disadvantages of newer approaches. The purpose of this is to consider whether more
complex models offer advantages over existing options, as this was an original research
question motivating the thesis (60).
2.8.1 Basis for original and subsequent Framingham CVD risk equations
Logistic regression is typically used for classification or regression problems involving
multiple categorical, binary or continuous predictor variables and a binary outcome
(dependent variable) such as development of a disease. This is the model used for the
original Framingham risk function presented in 1976 by Kannel, McGee and Gordon
(6). In such cases, the outcome (e.g. development of CVD) is not continuous and
Normally distributed, a requirement of linear regression analysis.
In logistic regression, a logarithmic transformation of the odds ratio (the ‘logit’)
is used instead of the probability of a positive outcome. This avoids deriving
meaningless probability values greater than 1.0 or less than zero (61). The other
advantage of the transform is that the logit takes values from -∞ to +∞, allowing 
confidence intervals to be derived around an estimated value within this range. The
logistic regression equation can then take a form similar to a multiple linear regression
function, with the dependent variable (the logit) equal to the sum of an intercept
(constant) and a number of predictor variables, each multiplied by its regression co-
efficient:
Log (odds ratio) = β0 + β1X1 + β2X2 + β3X3…… [Equation 1]
where β0 is a constant and β1, β2, β3….. are the regression co-efficients for each
risk factor X1, X2, X3….etc.
Fitting the equation to the data involves maximum likelihood techniques to
derive the optimal intercept and co-efficient values.
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The relationship between risk factor values and the outcome is non-linear, but
the log (odds ratio) is a linear function of the co-efficient values (Equation 1). Each risk
factor (X1, X2, X3 etc) makes an independent contribution to the outcome. The
proportion of overall risk attributable to each risk factor is estimable. The logit can be
transformed back to produce a probability value p for a positive outcome:
p = 1/1 + exp(-(β0 + β1X1 + β2X2 + β3X3……)) [Equation 2]
In survival analysis (where the outcome of interest is the time to death or
development of some other end point) the Cox proportional hazards model is
appropriate. This uses the hazard ratio (HR) in place of the odds ratio. The HR is the
ratio of the hazard of developing the disease in the presence of one or more risk factors
to the hazard in a comparator population with zero or baseline risk factor values (61).
The outcome of the risk function is the log of the hazard ratio (rather than the log of the
odds ratio).
Whilst Cox regression introduces a continuous dimension (the timescale at
which the hazard ratio may be measured), the hazard still relates to binary outcome
events. The Cox model includes an assumption that the hazard ratio itself is constant
over time, even though the hazard itself may be rising or falling with time. An
individual who is twice as likely to develop the disease as another individual after (say)
five years remains twice as likely after ten years, even though the hazard for both may
have increased. The probability distribution of the baseline survival function does not
need to be specified if the constant hazard ratio assumption is valid. Cox proportional
hazards was brought in to Framingham risk modelling subsequent to the original
logistic regression model, to recognise the importance of the time dimension in CVD
risk, and is used by Anderson et al in paper published in Circulation in 1991 (12).
A subsequent paper led by Anderson in the same year (8) introduced an
assumption that the time T to an event follows a Weibull distribution. This distribution
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is appropriate for degenerative processes (both in medicine and engineering) where
functioning components of a system tend to ‘wear out’ over time. For those at risk of a
cardiovascular event, the hazard increases over time (although the hazard ratio may still
in principle remain constant). Anderson et al in this later paper claimed superiority of
the new algorithm over both the logistic regression and Cox proportional hazards
precursors, and this model became the basis for the most widely used Framingham
algorithm. The co-efficients from this paper were used in the programming of the e-
Nudge algorithm described later in this thesis.
In the regression models described so far, interactions between risk factors
are assumed to have a relatively minor influence on outcomes, but can be built in if
expected to be important. For instance, in the Anderson equation (8), interactions
between age and female gender, and between left ventricular hypertrophy and male
gender, were built in to improve the statistical fit. These authors also introduced a
quadratic term, the (log (age))2, as an additional risk variable, and also built in an
interaction between this and female gender. These were found to improve the
performance of the standard equations.
This discussion is intended simply to illustrate that traditional CVD risk
equations, whether based on logistic regression, Cox proportional hazards, or a Weibull
model, are designed to identify the independent influence of the explanatory variables
and include a limited range of interaction terms. The interaction terms (and the
quadratic term mentioned above used by Anderson et al) have the same status as the
other weighted risk variables in the function linking predictors to outcomes (e.g.
Equation 1 for logistic regression). This approach is designed to identify the most
important risk factors and to measure their relative contributions to overall risk.
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2.8.2 Structure of more recent risk algorithms
During the 1990s and 2000s other risk algorithms were developed, as discussed above.
The most important of these were PROCAM, SCORE, ASSIGN, QRISK, and
D’Agostino 2008.
PROCAM (41) used a standard Cox proportional hazard model as the basic
multivariate risk algorithm.
The SCORE (42) project, involving the synthesis of data from cohort studies in
12 European countries, used the Weibull proportional hazards model as discussed
above. A separate hazard function was derived for men and for women in each
contributing study, and the results were collated to produce an overall risk function. An
assumption was made that risk factors have similar effects in both men and women and
across different countries. The authors compared the performance of the Weibull model
with a Cox proportional hazards model to test the validity of their estimate of the
baseline survival curve.
The ASSIGN project (21) used a Cox proportional hazards model. This was the
first algorithm to demonstrate improvement in CVD risk estimation through the
inclusion of family history and social deprivation (measured by the Scottish Index of
Multiple Deprivation, SIMD). A different function was developed for men and women
as it was evident that in women (but not men) a significant interaction was present
between sex and deprivation. Risk factors were only included in the final model if they
were significantly and independently related to cardiovascular outcomes in both sexes.
The QRISK and QRISK2 projects (1, 10) also utilised Cox proportional
hazards models and again derived co-efficients for men and women separately. QRISK
included, in addition to the ‘classical’ Framingham risk factors: deprivation linked to
Townsend scores (based on Postcode output areas of about 125 households); body mass
index; existing treatment for hypertension; and family history of premature coronary
heart disease. The QRISK2 algorithm also added self-assigned ethnicity, type2
diabetes, renal disease, atrial fibrillation and rheumatoid arthritis to this list. In the
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QRISK projects, interactions between various factors were tested and quadratic terms
inserted (as described above for Anderson Framingham).
In 2008, D’Agostino et al produced a new algorithm specifically tailored to the
primary care environment and based on Framingham data. It used data from the later
offspring cohort (unavailable to the original investigators of the 1968-1975 algorithm),
and therefore included more CVD events. It included (as mentioned above) a means of
taking account of blood pressure treatment. This algorithm also used Cox proportional
hazards as the basic regression model.
2.8.3 Other possible risk models
The algorithms described so far have certain characteristics in common. The underlying
model structure and risk factors were generally selected a priori and the studies are
termed prospective, although the cohort populations used for QRISK and QRISK2
were identified retrospectively. Potential interactions between risk factors have been
built in and tested to varying extents.
An alternative approach involves more complex data mining models including
artificial neural networks (ANNs). The following section will give some background to
this general approach and then discuss examples applied to the area of CVD risk.
2.8.4 Background to artificial neural networks
ANNs have become widely used in engineering and industry, where there is frequently
a need to recognise patterns in datasets for classification or outcome prediction. The
superiority of this over traditional approaches is greatest when a large number of
interactive factors are present. The potential for introducing neural networks into
medical care was discussed in a series of articles dedicated to this topic in the Lancet
during late 1995 (62-71). More recent articles have continued to make this area
conceptually accessible to clinicians and the range of applications within medicine has
increased. A PubMed search that I conducted on 16.8.09 for review articles on Neural
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networks (MeSH) limited to core clinical journals with no date range returned 28
citations. I found the most informative of these, in addition to the Lancet series, to be a
paper by Ohno-Machado and Rowlands (72) and one by Drew and Monson (73).
Ohno-Machado and Rowlands describe the basic structure of ANNs and compare
them with simpler models such as logistic regression. Describing their structure in
detail is beyond the scope of this thesis, but the following characteristics distinguish
ANN models from less complex approaches:
 The influence of individual input risk variables on outcomes may be very
context dependent (i.e. dependent of the values and patterns of other factors), and may
be less clearly significant in isolation (i.e. independently, as discussed above).
 Interactions between inputs are much more important in determining
outcomes than in traditional regression models.
 ‘Training’ of the network (i.e. optimisation of the internal weight values)
occurs automatically through exposure of the model to the dataset. The weights are
usually set with random initial values and these are then adjusted iteratively through a
process of ‘learning’ in which the input data and the actual outcome for each subject
(e.g. patient) in the training dataset is presented to the network. The most frequently
used training technique is based on the principle of ‘back propagation’, in which the
error detected between observed and expected outcomes automatically adjusts the
weight values until the error is minimised.
 This machine learning occurs with minimal supervision by the human
investigator. The ANN ‘discovers’ its own interaction patterns without preconceived
assumptions being built in a priori.
2.8.5 Published uses of ANNs for future CVD prediction
The ANN approach has been used to address the issue of cardiovascular risk in at least
two separate scenarios: the first using a dataset from a small study of lipid fractions by
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Lapuerta et al (74); the second utilising a large dataset from the PROCAM study (75).
In the latter study Voss et al compared the standard logistic regression (LR) approach
with two types of ANN in their ability to identify high risk groups for coronary events
in the PROCAM dataset. One of the ANNs, a multi-layer perceptron, outperformed the
LR model, producing a significantly higher area under the receiver operating
characteristic curve (AUROC). The LR identified 8.4% of the men as ‘high risk,’ of
which 36.7% suffered a coronary event over 10 years. The multi-layer perceptron
identified 7.9% of the men as high risk, and 64% suffered an event. In a commentary
on this article Margaret May drew attention to the considerable potential for this
approach to improve identification of the highest risk groups. However, she also
emphasised the need to ensure generalisability of the model to alternative data sources
(76).
Despite this apparent success, complex modelling of cardiovascular risk has not
so far seriously challenged more traditional approaches in clinical settings. Reasons for
this may include:
1. As above, a preference for minimalism that inevitably places the emphasis on
independent factors and downplays the interactions between them, as already
discussed.
2. The ‘black box’ anxiety (71): models derived from neural networks may
function well in terms of predictive performance but we may not understand in detail
what is actually happening computationally inside the algorithm.
3. A preference among most statisticians for frequentist rather than Bayesian
analysis (77).
Any attempt to utilise more complex models will need to address these issues and
demonstrate superiority over traditional approaches in terms of consistent predictive
performance when tested in new environments.
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2.8.6 Advantages and disadvantages of ANNs
A summary of the potential role of the ANN approach is given by Drew and Morton
(73):
"In general, a neural network may be superior to a standard statistical
analysis in nonlinear relationships when the importance of a given prognostic
variable is expressed as a complex unknown function of the value of the variable,
when the prognostic impact of a variable is influenced by other prognostic
variables, or when the prognostic impact of a variable varies over time."
The advantages and disadvantages of ANNs and other complex models may be
compared with those of more standard approaches.
In standard approaches, the problems include the models’ inability to identify
useful interactions between inputs without the foresight of an investigator, who needs
to actively build such interactions into the model and then test their influence. The
range of possible interactions is inevitably limited and may be biased by preconceived
expectations. Opportunities may be lost to include useful non-independent factors due
to concerns over statistical redundancy. In addition, the logistic regression algorithm
structure cannot easily accommodate ‘linearly inseparable’ classes. These include ‘J-
shaped curves,’ where the outcome does not change continuously with the predictor,
but instead experiences a reversal of direction. In the setting of CVD risk, this is known
to occur both with alcohol consumption (78) and with body mass index (79). In the
PROCAM study, another example mentioned above was suggested between mortality
and serum total and LDL cholesterol, although the excess risk at low levels was found
to be due to an excess of lung cancer deaths in smokers with low cholesterol levels
(47). As lung cancer mortality is a different outcome to CVD mortality, it could be
argued that this example is invalid. Nevertheless, complex risk factor profiles including
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J-shaped relationships might well require more complex pattern recognition techniques
than those of standard regression models.
Finally, the neural network model has the theoretical advantage that it can
recognise correlations between risk factor inputs more flexibly than conventional
regression models and so potentially offers greater robustness to missing data. This
problem is a significant issue in the development of modern CVD risk algorithms
derived from primary care data, including QRISK and QRISK2.
For ANNs, in addition to the anxieties listed 1-3 above, problems include:
1. Over-fitting. Any dataset containing predictor variable and outcome values
inevitably includes a component of random variation that is not attributable to the
predictor-outcome relationship, and should be ignored when fitting a model to the data.
The fitting of a traditional (e.g. logistic) regression algorithm involves identifying the
function that minimises these residuals, as discussed above. But neural networks are
sufficiently flexible to fit the function to the random noise also. If measures are not
taken to prevent this, the ANN will perform less than optimally when applied to a new
dataset.
2. Getting stuck on local maxima. The training of a neural network involves
an exploration of a large space of possible internal weight values in search of the
optimum weight set. For large datasets, an exhaustive exploration of all possibilities is
in practice an intractable problem. The network attempts to reduce the dimension of the
classification task, but there remains a risk that a set of weight values will be
discovered that is adequate but inferior to the optimum weight set in terms of predictive
performance. Rather like a rambler attempting to find a high spot on a landscape, there
is a risk of getting stuck on a foothill and never reaching the summit if the strategy is
always to follow the upward gradient locally.
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2.9 Summary
The definition of cardiovascular risk has a long history that spans the introduction of
electronic coding into routine health care. The availability of relevant information has
been important throughout this time both in conceptualising and actually estimating
cardiovascular risk. These issues affect both risk factors and outcomes, and must be
accounted for in any initiative aiming to systematically reduce cardiovascular disease
in the population. This is particularly the case in primary care, where recorded data
may be less ‘tidy’ (in terms of quality and completeness) than those generated by a
prospectively designed research study.
Since the original development of CVD risk algorithms based on the
Framingham Heart Study, new approaches have been developed to improve the
targeting of the ‘at risk’ population for effective interventions. These approaches have
also been guided to some extent by the availability of relevant data. More recent cohort
studies such as PROCAM have utilised a broader range of risk predictors than the
‘classical’ factors identified by the Framingham investigators, and in the case of
ASSIGN, included for the first time a measure of social deprivation. However these
more recent studies were less able than Framingham to measure the natural history of
CVD in populations unaffected by drug therapy, a situation that may never arise again.
New resources have been established including large health care databases,
allowing ‘prospective’ cohort studies to be conducted based on the follow up of
retrospectively identified historical populations, including QRISK and QRISK2.
The range of statistical methods has also expanded, including meta-analytical
techniques that allowed the SCORE investigators to combine results from 12 different
cohort studies. This process is ongoing, and has included the development of new
models of pattern recognition including artificial neural networks. Such models might
become more relevant in situations where targeting of therapies is based on a broader,
context-dependent definition of CVD risk, and not purely upon independent risk
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factors. Trends in health care policy defined in the guidelines of the past decade are
moving in this direction, compared with the original aims of the Framingham
investigators. We now know the relative importance of the modifiable CVD risk factors
(blood pressure, serum cholesterol, tobacco smoking and other lifestyle factors), and
effective interventions have been developed to reduce them. The current priority is to
target such interventions efficiently towards those at greatest overall risk.
Despite progress in risk estimation, cardiovascular risk reduction is a more
challenging area that includes not only quantitative measures but also qualitative and
ethical aspects to be discussed in the next chapter.
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Chapter 3: Ethics of cardiovascular risk
reduction
3.1 Introduction
This chapter explores the ethical issues related to cardiovascular disease prevention: the
use of NHS resources to prevent rather than treat disease; the identification and
‘labelling’ of individuals at risk; the issue of personal responsibility for health; and the
use of personal information to identify risk. Some of these are specific to
cardiovascular disease. Others apply more generally in health care.
3.2 Ethics of disease prevention: ‘turning people into patients’
The first issue concerns the basic principle of disease prevention: can this activity
justifiably be resourced in a world where established, manifest disease is still
commonplace? Is there an ethical basis for preferring or prioritising a preventive
approach over an approach based on treatment of symptomatic disease, or vice versa?
The apparently self-evident wisdom of ‘prevention rather than cure’ is
identified as a theme in the in-depth interviews with members of the public discussed in
Chapter 8 and reported in the Appendix. However this view is not universally accepted.
Iona Heath argues that the National Health Service’s first priority should be to treat
those who are suffering before those who may suffer in the future. She defends the
notion of a ‘National Sickness Service’ (1) and has suggested a levy on preventive drug
therapies in industrialised countries to alleviate established health problems in the
developing world (2). Her objection to preventive medicine is primarily based on the
moral imperative to treat those who are actually suffering now before those who may
(or may very well not) suffer in the future. But she also argues that people living in the
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developed world would actually feel better if less money were spent on their preventive
health care.
This position aims to protect healthy individuals from the potentially
detrimental effects of the disease label, i.e. from ‘turning people into patients’(3).
However UK policy since 2000 moved in the opposite direction. People ‘at risk’ of
cardiovascular disease were to be treated with the same priority (in terms of
identification, monitoring and follow up) as those with established, symptomatic
disease (4, 5). From a medical perspective this is justified because people are
identifiable on the basis of risk factors whose risk of serious cardiovascular events is
comparable to those who already have clinical manifestations of the disease. The
underlying pathophysiology supports this. Coronary atheroma may predate the onset of
an acute event by years, as the development of atheroma is a different process
occurring over a much longer timescale than the acute thrombosis that produces a
myocardial infarction. People identified as ‘at risk’ of cardiovascular disease may
already have established atheroma and from a biomedical perspective have an
established pathological disorder that is not yet manifest clinically. This is conceptually
distinct from the situation in which risk factors are identifiable but not associated with
abnormal pathophysiology, such as those at risk of accidents due to risk taking
behaviours. A similar distinction might be made between those at risk of prevalent
undiagnosed diabetes, a situation that is known to be associated with occult diabetes
specific complications and those at risk of future, incident diabetes, which is not. Acute
cardiovascular events include potentially lethal myocardial infarction and stroke (from
which recovery may be only partial), and sudden death. However a preventive
approach involves the treatment (typically with drugs) of people with no symptoms,
requiring monitoring and follow up. Heath may be untypical in the strength of her
dislike of preventive care, but a concern over the medicalisation of healthy people
attracts wider support (3). This is discussed in detail by John-Arne Skolbekken in a
book chapter entitled Unlimited medicalisation? Risk and the pathologisation of
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normality (6). Whilst there may be well-recognised detrimental effects of preventive
medicine (including the side effects of drugs, the risks associated with screening
procedures, and the anxiety created through screening or monitoring processes), a
further potential detriment is the wider effect on both individuals and society of a
prevention oriented culture. “Turning people into patients” may not only affect self-
image but also the perception of others, with (for instance) implications for life
insurance premiums. In addition to these issues, Getz et al discuss the impact on the
treatment of established disease from pressure on clinicians to address preventive
issues opportunistically during consultations, and question the ethics of this approach
(7). Interestingly, these authors specifically mention the use of reminders designed to
identify preventive health needs in this environment and their potentially detrimental
effect on patient autonomy. This area of care is to be explored in depth in the next
chapter. But the next question concerns the implications of successfully identifying risk
for clinical behaviour and health service priorities.
3.3 The ‘Rule of Rescue’
The ‘Rule of Rescue’ (RR) is the principle that it is justifiable to spend more per
quality adjusted life year (QALY) on treating identifiable individuals at high risk of
avoidable death or serious illness than on smaller reductions in risk among a larger
number of non-identifiable individuals in a population (8). We may be confident that a
programme of preventive care, such as statin therapy to an at-risk population for
cardiovascular events will save lives and reduce morbidity, and we may be able to
quantify this utility gain with reasonable accuracy. But we cannot identify which
individuals’ lives will benefit, i.e. those who would die or have a cardiovascular event
without the treatment. The ethical dilemma arises because the RR conflicts with
traditional cost effectiveness analysis (CEA), through which decisions should always
optimise overall utility measured in QALYs. Meeting the immediate needs of a high
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risk, identifiable individual may be less cost effective than treating or preventing illness
in a larger number of less identifiable individuals, but may in practice be justified
through the RR. The term RR was originally coined in 1986 by Jonsen (9), and tends to
be used when the situation is urgent (preventing carefully balanced decisions over the
pros and cons of rescue), distressing (eg the ‘buried miner’ scenario), well publicised
(eg appearing in the mass media), and critical to life or death so that rescue might make
all the difference to the outcome (eg the child dying of liver failure needing a liver
transplant).
The RR suggests that rescue is attempted even when the overall utility gain will
probably be less than if resources were committed in other directions (where the
beneficiaries are not identifiable), and even if the risk of death of the rescuers
outweighs the survival prospects of the victim. The RR may also influence decision
making in less extreme scenarios. The ‘rescue’ may involve a treatment whose denial
would seem unethical even though the cost is difficult to justify on the basis of CEA.
The RR is said to have operated in the Oregon priority setting exercise described
by Hadorn (10) and discussed by McKie and Richardson (8). Based on the expected
impacts of various treatments for a range of medical and surgical conditions, a priority
list was drawn up broadly based on CEA. In several cases life saving emergency
treatments (eg for ectopic pregnancy or appendicitis) received a lower priority to more
mundane interventions (dental caps for pulp exposure and splints for temporo-
mandibular joint disorder respectively). The situation was resolved by considering and
prioritising emergency situations separately. This is suggested by Hadorn to be an
example of the Rule of Rescue in practice. The RR in this situation was applied to
resolve an otherwise ethically untenable position: the out-prioritising of life threatening
emergency treatments by treatments for much less serious and certainly not life
threatening conditions.
Hope considered six potential arguments in favour of the RR, and concluded that
none were sufficiently powerful to justify its use in rationing health care. However his
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discussion does not include the less measurable effect of people believing they belong
to a sufficiently compassionate society that their own rescue would be attempted in
such circumstances. This aspect of the RR is discussed in detail by McKie and
Richardson (8), who also conclude that the RR conflicts with CEA, and is difficult to
justify ethically. However, whilst recognising that being ‘identifiable’ is not a morally
relevant ground for discrimination, they suggest that:
‘…the evaluation of health services is not simply a technical matter but a
quintessentially ethical endeavour, and that in complex societies with
divergent values there may be a range of considerations that may
“trump” the utilitarian rationality that is implicit in cost effectiveness
analysis.’
Such considerations perhaps include the detrimental effects of ‘labelling’ in
people treated with preventive therapies discussed earlier (6), an issue that does not
apply to ‘rescue’ scenarios. Many if not most people accepting preventive treatments
will not benefit in terms of hard outcomes, whilst a proportion may suffer the negative
consequences. But Hope suggests that a society that neglected opportunities to prevent
future anonymous deaths would be at least equally uncaring as one that refused
treatment to an identifiable individual at high risk of immediate death.
3.4 Individual choice versus population benefits
In addition to the issue of labelling individuals who may or may not benefit from
preventive care, the necessary resource commitment has implications for the viability
of the health service itself, which may risk overload through the need to identify,
assess, treat and follow up a substantial proportion of the population. Getz et al (11)
demonstrate the high proportion of the Norwegian population whose cardiovascular
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risk profile was adverse in some way according to European guidelines (76% of those
over 20 years). Some of this adverse risk is attributable to lifestyle factors that are not
necessarily within the remit of clinical health care, but they discuss the likely effect on
the adherence of clinicians to such guidelines given this high prevalence.
In a review article in the journal Nature Zimmet, Alberti and Shaw claim that
“One of the myths of the modern world is that health is determined largely by
individual choice” (12). They consider sedentary lifestyle, overly rich diet, and obesity
to be to a large degree the consequences of the modern environment. They make a
particularly clear appeal for internationally co-ordinated preventive measures to curtail
the rising prevalence of ‘diabesity’ and associated vascular disease in the developing
world. This contrasts sharply with Heath’s emphasis on treating ‘the sick’ not just in
preference to but almost to the exclusion of disease prevention discussed earlier (1, 2).
However, the need to address lifestyle factors at a public health level may be a common
ground. The question then becomes: to what extent should individuals be targeted for
more personally tailored risk assessment and reduction interventions?
Targeting on the basis of absolute cardiovascular risk, discussed in Chapter 2
may lead to the prioritisation of individuals who are unwilling to change their lifestyle
above those who have succeeded in doing so. This effect applies particularly to
smoking, the most important modifiable cardiovascular risk factor, but also to serum
cholesterol and blood pressure, which are also affected by lifestyle choices. Current
policy generally leads to targeting of smokers for lipid lowering therapy in preference
to those who have succeeded in quitting, as their estimated risk is higher. Some find
this approach questionable (13). However, as smoking (and other adverse lifestyle
issues) is more prevalent among disadvantaged groups, health inequalities are likely to
be amplified should this policy be reversed.
Marteau and Kinmonth discuss the implications of an ‘informed choice’
approach towards cardiovascular risk screening (14). Such an approach is
recommended by the National Screening Committee but is different from the
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traditional public health approach described in their paper, in which less information is
provided to the person screened, and the needs and opinions of individuals are not
considered in offering the screening test. Screening programmes may be beneficial at
the population level, but only a few individuals will benefit, whilst some may actually
be harmed. An informed choice approach, in which the possible adverse outcomes as
well as the possible benefits were discussed prior to the individual consenting to
participate might filter out many of the poorly motivated, including those with adverse
lifestyle factors. The authors make the case that whilst this approach may not achieve
the maximum public health benefits, it should make the interventions more effective
among those consenting. However they also recognise the potentially adverse effects
on health inequalities.
3.5 Patient decision making and informed consent
Whether better-informed patients choose the lifestyle options recommended by the
medical profession has been questioned (15). If not, more emphasis on informed choice
might in fact backfire as a means of achieving public health gains. In primary care
consultations (an environment where decisions about screening and risk frequently take
place), Ford et al found in an observational study that the ability of doctors to meet
patients’ preferences for involvement was very variable (16).
Kinmonth, Woodcock, Griffin et al (17) undertook a randomised controlled
trial of patient centred care in newly diagnosed type 2 diabetes (trialling an intervention
that trained general practitioners and practice nurses in patient centred consulting
techniques). After 12 months, they reported improved treatment satisfaction, wellbeing,
and communication with the doctor for those in the intervention arm. However there
were detrimental effects on some outcome measures (including body mass index and
triglycerides concentrations), and no effect on Hba1c levels. It appeared that an
emphasis on patient centred care risked losing focus on risk factor control. We can not
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perhaps assume that increasing patient involvement in decision making will achieve the
outcomes we might desire as health professionals.
The process of reducing cardiovascular risk may depend on an understanding of
the concept of 'risk' that is not necessarily shared between individuals, health
professionals, and others, raising further ethical issues. Patients may be unaware that
information collected during routine care may at a later date be used to make
judgements about their risk of different conditions. This might then affect not only
individuals’ self image but also their life or health insurance payments. Those without
known CVD may currently have no ‘disease label’ although many who are found to be
at risk will have a diagnosis of hypertension, and be on medication for it. A further
issue has recently been highlighted by Mangin et al (18), specifically related to the
extension of cardiovascular risk reduction to the elderly population. By reducing
cardiovascular mortality in elderly people we may be increasing their risk of dying of
something they might consider less preferable eg cancer. The PROSPER trial (19)
tested the effects of pravastatin on cardiovascular outcomes in people without
cardiovascular disease aged 70-82 years followed for an average of 3.2 years. The
primary endpoint was reduced significantly (Hazard Ratio 0.85, 95% CI 0.74-0.97) and
this was interpreted as a success for the use of statins to prevent CVD in older people.
However, the reduction in cardiovascular mortality was offset by an increase in cancer
diagnoses in the intervention arm. This effect is unlikely to be a toxic effect of the
statin (as it was not evident in a meta-analysis of statin trials conducted by the
PROSPER authors). It appears to represent, as Mangin et al suggest, a case of changing
the cause of death without reducing overall mortality. Patients might expect to be
informed of this effect before starting a statin at this age.
These issues also have implications for clinicians. Good practice in primary
care is to record the diagnosis or the clinical indication for each prescription. This
therefore requires the application of an electronic code in some form indicating that the
person is at raised risk of cardiovascular disease. Without such an entry the clinician is
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risking criticism if there is a problem such as an adverse reaction to the medication, as
the justification for its use may not be clearly supported in the medical record.
3.6 Absolute or relative cardiovascular risk?
In the case of cardiovascular disease, a policy of targeting people on the basis of raised
absolute risk will tend to result in a focus on older people whose major risk factors (eg
age itself) may be un-modifiable (13). However, this issue relates to that discussed in
the previous chapter over whether modifiable (and particularly causative) factors
should be allowed to dictate policy over cardiovascular risk reduction.
Those at higher absolute risk are generally likely to benefit more in terms of
absolute risk reduction, although their risk factors may be less modifiable. An
alternative policy of targeting people on the basis of raised relative risk (relative to age-
and sex-matched peers) offsets this problem, but it is then more difficult to justify any
adverse consequences of being identified (labelling, side effects of medication) as the
reduction in absolute risk may, in the short to medium term, be very small, producing a
very high number needed to treat for one prevented cardiovascular event. In
cardiovascular disease prevention, where disease risk may accrue over decades, the
lifetime risk of a serious event may only be reduced by a treatment schedule carried out
over a similar timescale, and there is a risk of ‘missing the boat’ if preventive
treatments are withheld until the absolute risk is raised to the usual threshold.
3.7 Ageism and the Fair Innings Argument (FIA)
The ethics of extending cardiovascular prevention to older age groups is worth
examining further. The 2005 JBS2 guideline (5) advocated no upper age limit for
primary prevention, and suggested “a comprehensive cardiovascular risk assessment in
all adults aged 40-80 years who attend their general practitioner, or other member of
the primary care team, for whatever reason.” Apart from the issues discussed earlier in
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this chapter, removing the upper age limit may result in treatment that is less robustly
supported by research evidence than in younger groups, so that problems such as
reactions to medication (or drug interactions that are commoner in older people)
become more difficult to justify. More recently, the NICE CG67 guideline on Lipid
Modification (20) reinstated the 40-74 year age group for targeted CVD prevention
originally recommended in the 2000 CHD National Service Framework (4). However
people starting preventive drug therapies before the age of 75 will continue on them
indefinitely according to all of these guidelines. Behind this debate lies the issue of
whether people who have lived to average life expectancy should be offered life-
prolonging therapies at the public’s expense, i.e. do the have a right to this investment,
or should they simply accept that they’ve had ‘a fair innings’?
The Fair Innings Argument (FIA) has been used to defend the preferential
allocation of treatments to younger rather than older people when resources are limited
and other factors are equal. According to the FIA, elderly people have had their ‘fair
share’ of life and have less right to access finite resources to extend what time they
have left compared with younger people. The FIA is supported by the Judeo-Christian
‘three score years and ten’ as the natural human lifespan [Psalms 90:10, King James
Version]:
The days of our years are threescore years and ten;
and if by reason of strength they be fourscore years,
yet is their strength labour and sorrow;
for it is soon cut off, and we fly away.
In 1973 the epidemiologist Sir Richard Doll argued that instead of attempting to
increase the span of life we should “aim to reduce mortality at young ages and to
relieve disability at old.” (21). Monitoring the success of the health service should
focus on “the trend in age-specific mortality under 65 years of age and the trend in
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prevalence of physical dependence thereafter.” He appears to identify 65years as a
threshold in health care policy.
Martin Rivlin (22) argues against the FIA, but his case largely concerns age-
based rationing in the context of treatment rather than prevention of illness. Doll’s
distinction between reducing mortality and relieving disability is less clear now than in
the early 1970s due to the development of new preventive interventions. These include
not only effective drug therapies for raised cholesterol and blood pressure, but also
surgical treatments. Fairhead and Rothwell draw attention to the systematic under
investigation and under treatment of elderly candidates for carotid artery interventions
(23). Such interventions aim to prevent stroke, a major cause of disability (and not just
mortality) in the older population. Increased life expectancy since the early 1970s may
have also influenced policy development over cardiovascular risk reduction, leading to
an extension to the 65 year threshold identified by Doll (21).
Despite the generally increasing tendency to extend preventive interventions to
older people, the FIA still draws support. Lilford highlighted the need for pragmatism
particularly in acute situations where decisions have to be made quickly over finite
resources (24). Mangin et al (18) do not use the term explicitly, but hint at the same
principle, arguing against the active prevention of cardiovascular disease in those ‘who
have already exceeded an average lifespan.’ However, as discussed above their
concerns are not about ‘fairness’ per se but surround the issues of individual labelling,
altering causes of death without reducing overall mortality, and the broader societal
effects resulting from the pathologisation of ageing.
3.8 Clinicians’ duty of care
A final ethical issue to discuss surrounds the clinician’s awareness of raised risk
(perhaps facilitated by patient-specific electronic data and/or risk algorithms) and his or
her duty of care both to make the patient aware of this raised risk and to address it. This
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issue is relevant both to the lack of a shared understanding of the ‘risk’ concept and to
that of the varying abilities of clinicians to match patients’ needs for involvement in
decision making, both discussed above. This problem is explored further in Chapter 8
as it arose during the initial recruitment for the e-Nudge trial. One general practitioner
raised the issue of whether the identification of people at risk of cardiovascular disease
would entail a duty of care to address the risk that the clinician might not have time to
execute at that particular time. Indeed, the e-Nudge software tested through this
research identifies in each practice a parallel ‘control’ population that are at equally
raised risk but whose potential need for treatment or advice is not flagged up to the
practice team. The Warwickshire Research Ethics Committee considered that as this
control arm would receive the ‘usual care’ available in the practice (which included
recommended primary prevention strategies) the situation was acceptable. The general
practitioner concerned was reassured on a similar basis. However, the increasing
availability of risk factor data for various conditions is likely to raise further, similar
dilemmas for clinicians in the future, as the identification of risk improves both through
better data and better algorithms. The quality of the algorithms used to identify risk is
also an issue, as some would claim that the Framingham algorithm that is still the
current convention is simply not well enough tailored to the modern UK population to
be used to inform decision making for cardiovascular prevention (25).
3.9 Summary of ethical issues
The prevention of cardiovascular disease and type 2 diabetes has become a major
priority for health care services throughout the world. This has occurred because of
rising prevalence (linked in some situations to increasing life expectancy, in others to
lifestyle issues), the availability of effective, affordable preventive treatments, and
improvements in the quality of health care records, facilitating the targeting of
interventions towards those most likely to benefit. However, what might appear to be
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an obvious ethical imperative (the offering of evidence based, potentially life saving
treatments to an increasingly receptive population) raises a number of ethical problems.
The first ‘group’ of issues includes patient awareness, the patient’s concept of
‘risk’, the lack of concordance between patients’ choices and health professionals’
advice, and the patient’s personal responsibility for health. This is particularly relevant
in cardiovascular disease prevention, as the most effective (but most difficult to
maintain) interventions involve personal lifestyle changes such as smoking cessation
and weight reduction.
The second group includes the rationing of preventive treatments and our ability
as clinicians to adhere to the conventional logic of cost effectiveness analysis. As
discussed above, traditional CEA based on the maximisation of overall utility gain is a
poor model for instinctive human decision making. It may be ‘trumped’ by the Rule of
Rescue and Fair Innings Arguments whose intuitive appeal to the public, the media,
and to many clinicians may override a more rational policy.
Thirdly, a group of issues surrounds the pathologisation of ageing and the
potentially detrimental effects of ‘turning people into patients,’ including its
implications for self image and life insurance risk. This is arguably the most important
group, particularly where patient awareness of the issues is insufficient to inform
individual decision making, and where reducing cardiovascular risk might potentially
lead to increased suffering due to the alternative development of even more disabling
conditions such as cancer. However, this specific area is not well researched, and whilst
touched on in the patient interviews described in Chapter 8, is beyond the scope of this
thesis.
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Chapter 4: Systematic literature review:
Changing clinical practice through patient
specific electronic reminders available in the
consultation
______________________________________________________________________
4.1 Introduction
I have drawn on a number of areas of literature to support this thesis. The most
important area concerns the effects of electronically generated reminders on the
behaviour of clinicians in the consultation environment. Literature searches were
initially undertaken non-systematically to support the e-Nudge trial protocol. Most of
the citations identified were not included in the formal review described in detail in this
chapter, which includes a number of new papers that had not originally been found.
This systematic review was carried out in collaboration with Margaret Thorogood and
Frances Griffiths. I will first of all explore the background to this piece of work and
then describe the methods in detail. The preliminary and final results will then be
reported. At the end of the chapter I will also discuss the influence of excluded papers
on the overall thesis.
4.2 Changing professional practice through electronic
reminders
Automated electronic screen reminders are now a standard component of practice
based software in the UK. Their use increased following the introduction of the Quality
and Outcomes Framework (QOF) of April 2004. Optional screen message functionality
was established in most UK practices from 2005. A later chapter will describe how this
impacted on the e-Nudge trial, on the one hand increasing practices’ receptiveness to
the testing of an alert-generating tool, but also requiring that one of the original six
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subgroups of the trial was withdrawn. This was due to the introduction of identical
QOF alerts as standard practice in UK primary care. A further subgroup was also later
withdrawn due to national developments resulting partly from the e-Nudge trial itself
and described in Chapters 8 and 10. But despite their widespread use, screen alert
messages and electronic reminders have a mixed evidence base as tools to support
health care. This became a very relevant and also topical area of study.
4.2.1 The Shojania 2009 review
An unpublished Cochrane review protocol (1) that I originally identified (and
mentioned in Chapter 1) was replaced by a new review by Shojania et al published in
July 2009 (2), by which time our own review was almost completed. Shojania 2009
covered areas that were similar but not identical to our review. The authors commented
that previous reviews failed to distinguish between reminders delivered to the clinician
at the point of care from those delivered in other settings (e.g. by email outside the
consultation). This was indeed an important issue that we had identified in designing
our own review method. Entitled The effects of on-screen, point of care computer
reminders on processes and outcomes of care, Shojania 2009 differed from ours in two
major respects. Firstly, we chose to include computer generated paper reminders
provided that they were displayed at the point of care. Shojania 2009 recognised that
such reminders may be as relevant as on-screen reminders and that the matter of
greatest importance is whether the intervention is delivered ‘at the point of care’.
However, their review title still included the term ‘on-screen’ and a number of articles
were excluded on the basis that they were not on-screen reminders (but in fact were
paper based). Secondly, we required the computer responsible for generating the
reminders to draw on patient specific information in the record rather than simply
providing ‘best practice’ recommendations for a particular disease condition or
prescribed medication. A reminder to monitor full blood count in response to a
prescription for methotrexate for instance, would only be included in our review if the
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intervention examined the individual patient’s electronic record and only generated the
reminder if a full blood count had not been recorded within the required time interval.
The conclusions of the Shojania 2009 review were that on-screen, point of care
reminders are generally beneficial, but that their effect on provider behaviour is small
to modest in the majority of cases. The review was unable to identify specific features
of either the reminder or the context that predicted the effect size (2).
Shojania 2009 and Kawamoto 2005 were examined in detail as part of a
process (discussed below) through which additional references were identified for our
review.
4.3 Method for our systematic literature review
4.3.1 Protocol statement
In designing this review, we (TH, MT, FG) considered the essential characteristics of
the e-Nudge intervention that were of particular interest and which had not been
covered in previous published reviews. This included the use of patient-specific
information held in an electronic record as the basis for electronic reminders, and their
availability within the consultation environment. The protocol statement was:
Can clinical practice be changed by patient specific computer generated reminders
available in the consultation?
4.3.2 Search strategies
The search strategy was designed prospectively but developed iteratively. An initial
PubMed search was conducted on 7.9.07 using the following parameters:
Reminder systems [MeSH] AND (Computer* [text word] OR Electronic* [text word])
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Limits: Date of publication 1st January 1970 to present
Human
English
Major Topic
Randomised controlled trial OR Controlled clinical trial
This returned 87 articles. I combined these with the 38 citations originally mentioned
by Kaveh Shojania with 12 duplicates excluded, to produce a list of 113 references.
This list appeared rather short. We considered it likely that other relevant
literature would be available and that this original search was too restrictive. The fact
that Shojania’s papers were only duplicated in 12 instances reinforced this. Whilst
controlled trials were likely to provide the most robust evidence of effectiveness, the
exclusion of non-controlled trials might have missed potentially important references
describing evidence for reminder interventions. (This decision was in fact later reversed
as discussed below, but in the process much more literature was examined and this
benefitted the review as well as the thesis.) It was also necessary to apply the search to
a broader range of databases including social science literature. Following discussion
with Samantha Johnson of University of Warwick Library, the following adjustments
were made:
1. Remove the ‘RCT/Controlled clinical trials’ limit
2. Change the search terms to:
Reminder systems [MeSH] AND (Health OR Medic* OR Clinical) AND (Computer*
[text word] OR Electronic* [text word])
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(Not all of these databases use MeSH terms, in which case Reminder systems was
included as a text word or key word).
3. Repeat on the following databases:
 ISI Web of Knowledge (using Science Citation Index Expanded and Social Sciences
Citation Index but not the Arts and Humanities Citation Index)
 PubMed
 Medline
 ASSIA
 DARE
 EMBASE
 CINAHL
 HMIC
Continue the limits: Humans, English language, and Publication date 1970-present.
Where possible, ‘Health’ was an exploded Key word as well as a Text word. ‘Clinical’
was included both as the Key word ‘Clinical Medicine’ (exploded) and the text word
clinical*. This search protocol was saved in OVID so that it could be regularly
repeated, and email alerts of new entries were set up in ISI Web of Knowledge.
4.4 Initial results
The searches were conducted on 4.12.07 and the following results obtained (Table 4.1):
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Source Identified Duplicates Running total
ISI Web of
Knowledge 85 N/A 85
PubMed 353 32 406
Medline No new references not already included in PubMed
HMIC 6 2 410
Embase 61 28 443
CRD/DARE 5 0 448
CINAHL 108 43 513
Table 4.1: Numbers of papers identified, and cumulative total from different source
databases.
The citations were imported into EndNote libraries and then merged as a final
combined library. A further manual trawl for duplicates identified 33 more, leaving a
running total of 480. Finally, the 113 references from the original search were
imported. Of these, 88 were already present, and 25 were included.
New total: 505 references
The abstracts of these 505 references were examined using the following
decision rules derived from the protocol statement: Can clinical practice be changed by
patient specific computer generated reminders available in the consultation?
4.4.1 Decision rules
1.Clinical practice. This meant the professional behaviour of clinicians. Clinicians
may be doctors, nurses, health visitors, midwives, chiropodists, or other health
professionals but we did not include reminder interventions that only influence
administrative or other non-clinical aspects of care. On this basis we excluded articles
about reminders that generate recall letters to patients regarding overdue screening
interventions or vaccinations.
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2.Patient specific. The reminders needed to be patient-specific rather than simply
providing advice on good practice in a specific clinical area. We therefore excluded
decision support systems that were not using patient data, or those whose content
related simply to a diagnosis but were not otherwise patient-specific. We also excluded
reports of interventions that were specific to a diagnostic test (or vaccination) rather
than being specific to the patient.
3.Computer generated. The ‘reminders’ may be paper-based but must have been
generated using a computer. They do not have to be visible on the screen but must be
readily visible within the consultation environment. A computer generated printed
reminder attached to paper notes for use during a consultation would be included
provided the other criteria were met.
4.Available in the consultation. A clinician must be able to readily access the
reminders during a consultation, with little effort. We included reminders that do not
appear on the screen automatically, provided they are sufficiently available to
(potentially) influence clinical practice in this environment. If the clinician has to
actively seek the reminder (eg by opening a new software module) then we excluded
the paper.
We continued to specify that only papers published after 1970 would be included. This
generally predates the use of electronic reminders in the consultation environment
anywhere in the world.
4.4.2 Initial examination of abstracts
Abstracts of the 505 references were all examined by TH and were distributed between
MT and FG (50% each) to identify articles clearly irrelevant to the review.
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This process created 4 different categories (Table 4.2):
Number
Both agreed the reference should be excluded 235
One reviewer wished to exclude but the other to include 83
One reviewer felt unsure but the other wished to include 49
Both agreed the reference should go through to the next stage 138
Table 4.2: Initial categories of decisions.
4.4.3 Casting votes
During the next stage a third opinion was obtained on the 132 abstracts where there
was disagreement or uncertainty. This process resulted in the following decisions
(Table 4.3):
Number
Excluded from review after casting vote 95
Included in the next stage after casting vote 37
Number already identified in first stage 138
Total included in the next stage 175
Table 4.3: Casting vote outcomes
The next stage was to obtain full text pdfs of these 175 articles (all of the original 505
not considered irrelevant by at least two reviewers on the basis of the abstract) and
where a paper was excluded, determine the reason for exclusion.
4.4.4 Exclusions based on examining the full texts and exclusion of non-
controlled studies
I examined each of the original 175 full text articles, and each was also examined by
either MT or FG. During this process the decision to include non-controlled studies was
revised. As described above, the initial search had included only controlled trials of
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interventions. For the benefit of the thesis I decided to broaden this search and include
all types of study, to gain insights into the use and design of similar interventions to the
e-Nudge in different organisational contexts. Some of the papers so identified describe
the design and development (but not trialling) of such interventions and were therefore
of interest. Others test the effects of the intervention using before-after designs so that
there is an historical comparator. However during the data extraction process described
below we examined a number of such papers that were of poor methodological quality
and appeared to have been carried out in an opportunistic, unplanned or even
retrospective way. We therefore decided to exclude all uncontrolled trials from the
systematic review. This had a considerable impact on the numbers included.
For each excluded paper, a reason was given based on the following categories:
1.Not related to clinical practice. This included studies of reminder interventions
aimed at patients rather than clinician behaviour, such as letters to patients about
overdue vaccination or screening.
2.Not patient specific. This group included interventions that simply reminded
clinicians about best practice but did not draw on patient specific data in the record,
other than perhaps a major diagnosis.
3.Not computer generated. One study tested a reminder that required no electronic
data. This was excluded under this heading.
4.Not available during the consultation. A number of studies tested systems that drew
on electronic data but then sent a reminder either to the patient or to a non-clinical
professional outside the consultation environment.
5.Inappropriate type of study. This exclusion group was a large one, and included all
studies that did not have a contemporaneous control group, and also papers describing
the development of interventions or providing qualitative analyses, e.g. of acceptability
or usability.
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6.Other reason for exclusion. These included studies where it was not possible to
distinguish a patient directed component from a clinician directed component of an
intervention. In a few cases, it was not possible to extract the outcome data as no
denominator was given (only the proportions), and attempts to obtain the raw data from
the article authors failed.
In some cases, a paper could be excluded on the basis of more than one category.
4.5 Re-run of the original searches
I originally ran the searches on 4.12.07. At the same time, I created an alert in ISI Web
of Knowledge to identify subsequent citations and these were sent to me by email on a
weekly basis. On 11.2.09 I examined all of these emails and altogether 12 new articles
were identified. Of these, one was possibly relevant (Mold JW), and one was a
systematic review (Dexheimer (3)) that I also kept and have described above. Both of
these were transferred to a new EndNote library.
I was concerned that only one possible study had been identified (as I expected
that the number of trials in this area would be increasing over the last decade) and
decided to make the other repeat searches more inclusive.
A further search was carried out on 11.2.09 using OVID including MEDLINE,
EMBASE and HMIC. It used the following terms:
Key words: Reminder$
AND Health
AND Electronic
Limits: Years 2007-2009
Human
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English language
This produced 34 papers and included the systematic review by Dexheimer, but not the
Mold reference. This was therefore added to make 35 references in total.
A further search was then carried out on MEDLINE, EMBASE and HMIC
databases via OVID using the original search term:
Reminder systems AND (Health OR Medic* OR Clinical) AND (Computer* OR
Electronic*) (Limited to publication years 2007-2009)
in the Textword field. This yielded just nine references, three of which were duplicates
when uploaded to the EndNote library i.e. a further six references were identified using
this apparently less inclusive strategy (but most of the original 34 above were not).
After discarding these three duplicates there were 41 references.
For the CINAHL repeat search I simply used:
MW Reminder AND MW electronic
and then MW Reminder AND MW computer
(where MW means that the word is in the subject heading)
This returned 13 and then 8 = 21 articles. Six of these were duplicates, giving 56
citations so far.
The DARE database was then searched but produced no relevant reviews. At
this point we had decided anyway to exclude reviews from our own review although
they might still be useful for the thesis if related to electronic reminders. None of the
nine returned was relevant.
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ASSIA was next searched and produced no new citations.
Finally, a more inclusive search was carried out on PubMed using the search
term:
Reminder systems [MeSH] (Limited to 1.11.07-12.2.09, Humans, English language)
This returned 125 citations. When combined with the 62 above there were 15
duplicates, giving a final list of 166 references for the updated search.
I then examined all of these 166 abstracts, removing obviously irrelevant
articles to find 58 papers of potential interest, from the following sources (Table 4.4):
Number
PubMed 45
Ovid: Medline/Embase/HMIC 10
CINAHL 11
Duplicates 8
Total 58
Table 4.4: Initial results of the re-run searches.
These abstracts were then distributed between Frances Griffiths (FG) and Margaret
Thorogood (MT). Disagreements in 14 cases were resolved by the third reviewer, and 8
papers required full text assessment and if appropriate, data extraction. These full texts
were then distributed equally between MT and FG and I also examined them. Further
rejections occurred and at the end of this process, only three new studies resulting from
the re-run searches were identified that were included in the review. These were Lo
2009, Matheny 2008, and Tamblyn 2008.
4.6 Results before final additions
As a result of the original searches of November 2007 and the updated searches of
February 2009, a total of 175+58=233 abstracts were identified (out of 505+166=671)
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and, following full text examination where necessary, 204 were rejected. The following
table gives the numbers of abstracts excluded for the 202 papers for each of six
exclusion criteria. In some cases more than one reason was present.
Not related to clinical practice 14
Not patient specific 13
Not computer generated 1
Not available in the
consultation 37
Inappropriate type of study 141
Other reason for exclusion 9
Table 4.5: Reasons for exclusion of 202 initial full papers examined.
4.7 Additions based on other systematic reviews
I examined the reference lists of other systematic reviews, particularly the two most
recent ones: Shojania 2009 and Kawamoto 2005 (2, 4). I was looking for papers
relevant to our review that had not been identified so far.
4.7.1 Comparison with Shojania 2009
Of the 29 papers included in the Shojania 2009 review, five were not initially identified
in our original 505 papers resulting from the first searches. This was presumably due to
the wider search protocol used by these authors, which included search terms such as
‘Prompt’ as well as ‘Reminder’. In all other cases, lack of overlap between this review
and ours was the result of inclusion/exclusion decisions. Twelve of the 29 papers in
Shojania 2009 were at that point already included in our review. We re-examined nine
papers included in this review that we had previously rejected, as well as the five that
we had not identified in our 505 originally identified papers. As a result, ten new
papers were included (Dexter 2001, Frank 2004, Hicks 2007, Judge 2006, Kralj 2003,
Rothschild 2007, Tamblyn 2003, Tierney 2003, Tierney 2005, and van Wijk 2008).
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4.7.2 Comparison with Kawamoto 2005
I looked closely at this review as it was published quite recently and overlapped
significantly with ours. However this group had included a wider range of CDSS
systems and the majority of their papers were not in fact relevant for us. Their review
identified a total of 88 papers, but aimed primarily to identify factors predicting the
effect of CDSS interventions rather than actually measuring the effect size itself. As a
result, seven new papers were included in our review (Burack 1996, Burack 1998,
Chambers 1991, McDonald 1980, McDonald 1976, McDonald 1984, McDowell 1998).
4.8 Final results
A number of papers included descriptions of interventions, or of analyses that were not
clear enough to the three reviewers to enable data extraction. In twelve cases I
contacted the original authors by email for clarification. Eight of these resulted in
responses but in 4 cases the paper was withdrawn as it became apparent that it no
longer met the inclusion criteria.
The result of this final stage was that 41 studies were included in our final list
(5-45). These studies included a range of significantly different analytical approaches
affecting the interpretation of outcomes.
4.8.1 Issues affecting interpretation
Some studies included more than one type of intervention e.g. clinician directed and
patient directed, or consultation based and telephone reminders. In these cases we only
included data related to the intervention relevant to our review. Studies had been
excluded where it was not possible to separate the clinician-directed effect from a
patient directed effect on the outcome, as we were only interested in the former. Other
studies involved multiple reminders (e.g. vaccination, screening tests, etc) and it was
straightforward to combine the results into aggregate figures. This was a similar
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process to that actually provided in the reports of other papers, where the overall
response to multiple reminders was given. In two cases (Tamblyn 2003, and van Wijk
2008), the study results needed to be subdivided into two sub-studies as aggregation
would have been inappropriate. In the case of Dexter 1998, there were three slightly
different interventions that were all relevant to our review, with one control arm.
Following advice from Dr Simon Gates, we divided the control data in this study by
three (both numerator and denominator, giving effectively the same control odds) and
entered each intervention as if it were a separate study. This avoided overweighting of
these studies in the meta-analysis. One study (Eccles 2002) was not included in the
meta-analysis for reasons discussed below.
Based on this interpretation we identified a final list of 44 comparisons from
the 41 papers. A list of the included studies is given in Table 4.6 along with some
descriptive details and comments.
4.9 Data extraction
To extract the necessary data from these papers, a template form was developed
iteratively through trialling on the first few papers followed by review. The third draft
became the version used and is given in the Appendix. Whilst this form includes a row
for ‘Baseline numerator and denominator,’ we used odds ratios based on the outcomes
alone rather than the change from baseline. As recommended by the Cochrane
Handbook for Systematic Reviews of Interventions (46), this form was completed by
two reviewers for each paper. This enabled us to identify errors of interpretation.
Where these occurred a consensus was obtained through discussion or by referring to
the third reviewer.
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Study Country Setting Area of care/target behaviour Comments
Bates 1999(6) USA Tertiary care hospital
inpatients
Diagnostic tests – identifying redundant tests Randomised by internal identification
number (as in e-Nudge)
Burack 1996(7) USA Large Health Maintenance
Organisation in Detroit
Mammography screening in women overdue
a mammogram
For the physician directed intervention
only women who actually visited were
included in the analysis
Burack 1998 (8) USA Large Health Maintenance
Organisation in Detroit
Cervical cancer screening in women due a
Pap smear
As above, eligible women who did not
attend the clinic were not included in the
analysis
Chambers 1991
(9)
USA University based family
practice centre
Completion of influenza vaccination in
eligible people
Positive evidence that reminders were not
contaminating the control arm
Dexter 1998 (10) USA Academic primary care
practice affiliated to an
urban teaching hospital
Discussions about advanced directives Divided into three comparisons in our
RevMan analysis, so the control data
divided into three for each comparison to
avoid over-weighting
Dexter 2001 (11) USA Inpatient wards of teaching
hospital
Preventive care: pneumococcal and influenza
vaccinaton, subcutaneous heparin, aspirin
28% were hospitalised more than once
during the study
Eccles 2002 (12) UK General practice in UK Multiple process of care outcomes related to
management of angina and asthma
Unable to extract data as no primary
outcome identified
Fillipi 2003 (13) Italy Italian general practice Anti-platelet prescribing for patients with
diabetes over 30 years with one other CVD
risk factor
Optional intervention, general practitioner
had to activate it
Frank 2004 (14) Australia Australian general practice Multiple reminders for preventive activities Data from all reminders aggregated in our
analysis
Hicks 2007 (15) USA Primary care practices Management of hypertension Clinical outcome, not significant.
Judge 2006 (16) Canada Academically affiliated long
term care facility
Prescribing safety issues Example of analysis by reminder
opportunity
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Kenealy 2005 (17) New
Zealand
Primary care practices Screening for diabetes in people over 50
years with no blood glucose in the past 3 yrs
Contacted the author for accurate
denominator data
Kralj 2003 (18) USA Community oncology
practices
Prescription for erythropoietin to patients
with cancer and Haemoglobin <12g/dL.
Significant difference between control
and intervention arm at baseline
Krall 2004 (19) USA Kaiser Permanante
Northwest
Prescription of aspirin in eligible patients Single off-line data analysis after a month
to detect patients still eligible for an alert
Kucher 2005 (20) USA Inpatients on medical and
surgical wards
Identification of patients at risk of deep vein
thrombosis or pulmonary embolism
Positive result from a clinical outcome
study (only example in this review)
Litzelman 1993
(21)
USA Academic primary care
internal medicine practice
Cancer screening investigations (Pap smear,
mammography, faecal occult blood)
Reminders need a response to indicate
intended actions
Lo 2009 (22) USA Academic teaching
hospitals, community
hospitals and outpatient
clinics
Recommendations for baseline test when
prescribing new medication
Similar to Matheny 2008 but relates to
baseline rather than ongoing monitoring
tests
Matheny 2008
(5)
USA Academic teaching
hospitals, community
hospitals and outpatient
clinics
Reminders for arranging monitoring tests for
ongoing medication prescriptions
As above – very similar to Lo 2009
McCowan 2001
(23)
UK UK general practice Asthma guidelines with reminders including
the need for asthma review
Primary care consultations identifiable as
the primary outcome, but there were
many outcomes
McDonald 1976
(24)
USA Hospital diabetes clinic Reminders to order tests or change therapy The two reminder types were combined in
our analysis.
McDonald 1980
(25)
USA Hospital General Medicine
clinic
Computerised management rules
predominantly related to prescribing
The two active interventions (which were
very similar) were aggregated in our
analysis as suggested was appropriate in
the paper
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McDowell 1989a
(26)
Canada Family Medicine Centre at
civic hospital
Blood pressure measurement Two other arms included in this study
were excluded from this review
McDowell 1989b
(27)
Canada Family Medicine Centre at
civic hospital
Screening for cervical cancer by Pap smear Used the intention to treat data in our
analysis
Murray 2004 (28) USA Academic primary care
Internal medicine practice
Treatment suggestions for management of
uncomplicated hypertension
Also included a Health related quality of
life secondary outcome
Overhage 1996
(29)
USA Inpatient general medical
ward
Related to multiple preventive interventions Reminders were both paper and on-screen
Overhage 1997
(30)
USA Inpatient general medical
ward
Prescribing reminders Immediate compliance rather than 24
hour outcome used in our analysis
Rosser 1991 (31) Canada Family Medicine Centre at a
civic hospital
Multiple preventive interventions (screening,
vaccination, assessment)
Two other interventions arms (letter and
telephone reminders) not relevant to our
review
Rosser 1992 (32) Canada Family Medicine Centre at a
civic hospital
Tetanus vaccination reminders Thirty-eight consultations monitored to
detect unrecorded vaccinations
Rossi 1997 (33) USA Primary care providers Reminders to change patients with
hypertension taking calcium channel blockers
to alternative drug
Quality assured through pharmacy check
and check on patient records
Rothschild 2007
(34)
USA Academic medical centre
with emergency department
and inpatient beds
Reminders concerning inappropriate orders
for transfusion products
All orders independently checked for
appropriateness and inter-rater agreement
measured
Safran 1995 (35) USA Hospital based outpatient
clinic
Guidelines on management of HIV infection Analysis include binary and continuous
measures of the same outcome
Sequist 2005 (36) USA Network of outpatient
clinics, community and
Management of diabetes and of coronary
heart disease
Aggregated data extracted for RevMan
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teaching hospitals
Shea 1995 (37) USA Large urban hospital Screen messages giving estimated discharge
date for diagnostic groups
The only continuous outcome study
(length of stay) in our review
Tamblyn 2003
(38)
Canada Canadian primary care Prescribing issues
Data extracted and added to RevMan
separately for prescribing and
discontinuation outcomes
Tamblyn 2008
(39)
Canada Canadian primary care Reminders to identify prescribing problems One arm required the clinician to actively
view the alert when they considered it
relevant. We called this the control arm.
Tape 1993 (40) USA Academic Internal medicine
clinic
Range of screening (mammography, Pap
smear, thyroid function, faecal occult blood)
and vaccination reminders
Aggregate of all reminders used in our
analysis
Tierney 1987 (41) USA Academic primary care
general medicine clinic
affiliated to urban hospital
Diagnostic tests – reminding user of the
number and timing of previous requests for
the same test
Only analysed those who visited
Tierney 2003 (42) USA Academic primary care
group practice
Cardiac care suggestions The pharmacist intervention was not
included as we did not consider it to be
delivered at the point of care
Tierney 2005 (43) USA Inner city academic General
Medicine clinic
Prescribing suggestions related to care of
patients with asthma or COPD
As above for Tierney 2003
van Wijk 2008
(44)
Netherlands Dutch general practice Screening and prescribing reminders Data for screening and for treatment
extracted and added to RevMan
separately
White 1984 (45) USA Inpatients in a teaching
hospital
Reminders concerning risk of digoxin
toxicity
We chose the ‘alert day’ as the reminder
opportunity denominator
Table 4.6: Outline of the 41 studies included in the systematic review.
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4.10 A narrative synthesis
Before attempting to synthesise the quantitative data provided by these studies I will
discuss some of the qualitative aspects. These provide at least as much support for this
review and for the thesis.
4.10.1 Methodological quality
A small number of studies were excluded because the data on denominator values was
unavailable both in the trial report and from the investigators. The studies excluded on
this basis tended to be older ones, several dating from before the 1990s. This partly
reflected difficulties in tracking down original datasets, and in one case the principal
investigator was deceased. However, it may also reflect an increased awareness in more
recent times of the necessity to facilitate future meta-analysis. Meta-analysis was
established during the mid to late 1980s (47), and requires sample size data (and not
just proportions) to weight the contribution of a trial to the overall result.
A further quality issue that influenced the final selection was the issue of
before/after trial designs. We originally decided to include such trials in order to widen
our sample, but some of these studies were of particularly poor quality, leading to a
reversal of this decision. Some appeared to have been carried out following either the
introduction of a new CDSS tool or a newly established health policy or initiative. The
study would then compare what was happening since a given point in time with what
had happened (in retrospect) prior to that time point. It is particularly in the setting of
shifting health policy that a controlled study with parallel, contemporaneous trial arms
is required to separate the effect attributable to the intervention from other factors.
Very few of our included studies were supported by published trial protocols
that described the trial design and defined its outcomes. They varied considerably in the
attempts made by investigators to quality assure the data collection processes and
remove potential sources of bias. However, we decided that peer-reviewed publication
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was the minimum acceptable quality standard and this approach removed any of our
own biases or preferences from the selection process.
4.10.2 International issues
In addition to the need to clarify denominator values with trial investigators, I needed to
contact several researchers (all from the United States) simply as a result of my initial
lack of familiarity with North American processes of care. Study reports sometimes
make assumptions about the readers’ understanding of the prevailing health care
context, and clarification was required on several occasions. UK National Health
Service consultations (and their associated software environments), particularly in
primary care, are different in certain important respects to the US system in otherwise
similar contexts. These differences might determine whether or not a reminder
intervention was delivered ‘at the point of care’ as we interpreted the term. This issue
reinforced my later need to describe the e-Nudge intervention in sufficient detail for an
international readership.
4.10.3 Overall results
The majority of the studies produced positive results, although this was by no means
universal. In several cases the trial reported results of borderline statistical significance
(eg Judge 2006), or of non-significant results (e.g. Burack 1998, Eccles 2002, Hicks
2007, Matheny 2008, Tierney 2003 and Tierney 2005). The trials varied very
significantly both in the particular aspect of care under study, and in their scale, some
involving relatively few patients within one general practice (e.g. Dexter 1998) and
others trialling interventions applied to large populations randomised automatically
(e.g. Tamblyn 2003), in ways similar to the e-Nudge trial described later in this thesis.
The impression gained from examining these reports supported the conclusions
of the existing reviews already described: that the impact of reminder interventions on
clinical behaviour was generally positive, but unpredictable, inconsistent, and probably
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context dependent. However, specific aspects of the context predicting success were
difficult to identify. Financial issues were rarely discussed as contextual factors, other
than the health economic implications (for instance laboratory costs) of test ordering
behaviour. The specific issue of ‘payment by results’ to practitioners and the effect of
this factor in determining responsiveness to reminder interventions is almost absent
from the literature that I examined. However, conversations with North American
colleagues made me aware that such factors are important in the US, even if not quite
so directly as under the UK’s Quality and Outcomes Framework. Their lack of
coverage does not necessarily mean that they are unimportant. This reinforced the need
to discuss such factors openly in the e-Nudge report that resulted from my own
reminder intervention trial described later.
4.11 RevMan analysis
Data extraction using the paper forms was followed by entry into RevMan (Version
5.2). All but one paper used binary outcomes and I set RevMan to analyse odds ratios
using the Mantel-Haenszel (MH) method with 95% confidence intervals. The MH
method is the default option in RevMan. Inverse variance is an alternative that was
introduced in the most recent fifth version, and the difference between the two methods
is very slight (46). This difference affects the way that each study is weighted by the
software. Inverse variance gives a weight to each study that is proportional to the
inverse of the variance of the treatment effect of that study (so that larger studies with
lower variance are given proportionally more weight). The MH method uses a slightly
more complicated algorithm for defining weights described in Friedman, Furberg and
DeMets (48). I checked the odds ratios derived in our review using the inverse variance
method and none of them were significantly different.
An early issue arising from this analysis was that of heterogeneity. I questioned
whether or not the individual studies were sufficiently comparable to enable a meta-
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analysis that might add to the qualitative analysis discussed above. If not, could I
identify one or more subgroups that might permit such a synthesis?
4.11.1 Heterogeneity
The Cochrane Handbook (46) identifies three major sources of heterogeneity affecting
studies subjected to meta-analysis. The first is clinical diversity, resulting from
variation in the participants, interventions, or outcomes studied. The second is
methodological diversity, which reflects variation in trial design (even if all are
randomised controlled trials), or factors affecting the risk of bias. The third is statistical
heterogeneity, which refers to differences in measured intervention effects. Statistical
heterogeneity is assumed to be the result of clinical and/or methodological diversity,
and is suggested by forest plots displaying varying effect sizes whose confidence
intervals overlap poorly. Such a finding precludes a meaningful meta-analysis.
4.11.2 Random effects or a fixed effect?
I considered whether the effect that we were investigating was itself a distributed
quantity, or whether the observed variation in its effect between studies was purely due
to measurement error, from whatever source. Each individual study represents an
independent measurement of the reminder effect on clinician behaviour. Are the studies
separately sampling an effect of unvarying magnitude (like independent measurements
of the height of Big Ben), or are they measuring a distributed variable (such as the
average height of all the buildings of central London)? We discussed whether to use a
fixed effect or random effects model for our analysis, which is the implication of this
distinction. We believed that it was meaningful to assume a broadly common effect
influencing clinicians in all of the different trial conditions, but we did not assume that
this effect would be the same in all contexts. We concluded that the effect was likely to
vary naturally in different settings and follow a distribution rather than produce the
same effect in all study scenarios. Variation in the measured effect would not be due
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solely to clinical or methodological diversity. It would in fact be a natural property of
the influence of reminder interventions, and a random effects model would therefore be
appropriate.
4.11.3 Subgroups of identified papers
The forest plots (Figures 4.1-4.4) demonstrate a degree of statistical heterogeneity in
our sample of studies, with quite wide variation in effect size and confidence interval.
This was confirmed through the overall Tau2 value of 0.20 for all binary process
outcome studies. This index is appropriate for measuring the heterogeneity of studies
under a random effects assumption.
I attempted to identify useful subgroups of study that shared common features.
The primary aim of this exercise was to identify categories of intervention that were
more likely to be associated with positive outcomes or larger effect sizes, but I was also
interested in reducing heterogeneity. No two studies examined exactly the same
process, although some were very similar, and there were examples where two different
areas of care using essentially the same software had been trialled and reported
separately.
Subgroups among the papers included those based on statistical form of the
outcome measure (e.g. binary, continuous), whether designed to influence process
outcomes or clinical outcomes, and the area of care under study. Finally, a distinction
could be made based upon the unit of analysis, and this struck me as the most important
means of identifying subgroups (or perhaps just one subgroup) for which meta-analysis
might be particularly meaningful. I identified the studies that used the ‘reminder
opportunity’ as the denominator, i.e. studies that reported the proportion of
opportunities for a clinician to respond to a reminder that resulted in the target
behaviour. By identifying the subgroup of studies sharing this unit of analysis, I was
hoping to measure the efficacy of reminder interventions to influence the immediate
behaviour of clinicians (i.e. within the point of care encounter). The other unit of
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analysis, based on population proportion outcomes, would be comparable with the
more pragmatic studies of effectiveness designed to demonstrate the ultimate benefit of
such interventions at the population level. These studies did not measure how many
times (if any) the clinicians had received a reminder. A patient might have visited the
practice many times during the study (to trigger a reminder each time), or not at all.
4.11.3.1 Binary outcomes versus continuous outcomes
Binary outcomes related either to compliance with reminder suggestions, i.e.
appropriate clinician response to the reminder, or achievement of target outcome as a
result of clinician response to the reminder (such as screening test undertaken or
recommended drug prescribed). However, only one study reported a continuous
outcome: length of hospital stay (37). This was therefore not a useful distinction.
4.11.3.2 Process outcomes versus clinical outcomes
This distinction was important, but in fact all of the included papers involved process
outcomes, with the exception of Kucher 2005, which measured rates of venous
thrombo-embolism (20), and Hicks 2007 (15), which measured the achievement of
blood pressure control. This highlighted the paucity of evidence based on clinical rather
than process outcomes. As discussed in Chapter 1, Montgomery and Fahey (49) and Tu
and Davis (50), had reached a similar conclusion. Another difficulty was that Hicks
2007 measures the effects of reminders on the successful achievement of blood
pressure control, whilst Kucher 2005 measures rates of venous thrombo-embolism. In
the first case, an odds ratio greater than 1 favours the intervention, whilst in the latter
the odds ratio was less than 1, reflecting successful reduction of thrombosis risk.
4.11.3.3 Area of care
The following areas of care served as useful categories, although there was significant
overlap with some reminders covering more than one area:
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 Vaccination
 Screening
 Prescribing
 Monitoring or diagnostic tests
 Condition specific reminders (i.e. multiple reminder systems related to a single
diagnosis such as asthma or diabetes, and perhaps including prescribing and lifestyle
issue reminders)
 Other or multiple reminders (several papers described software interventions
reminding clinicians about numerous unrelated actions).
4.11.3.4 Unit of analysis
Different definitions used for the denominator populations in the trial outcomes
provided a particularly important barrier to data synthesis. I was interested primarily in
the behavioural response of clinicians to a reminder message, and the most useful
examples were those in which the unit of analysis was the reminder message
opportunity itself. For instance, if patients were randomised into two arms (intervention
and control), one arm receiving messages and the other not, then the most useful
studies (in terms of quantitative synthesis) might be those that were able to give the
number of opportunities to influence the clinician as the denominator (i.e. the number
of actual occasions that a reminder was triggered) and the proportion of these occasions
that produced the target response. However, others reported outcomes in terms of the
proportion of patients in the two arms having received a screening test, vaccination,
prescription, etc at the end of the study period, without being able to provide
information on the actual number of ‘point of care’ opportunities involved. In other
words, the outcomes were based on population level data rather than those relating to
individual consultations and their outcomes. During the study, a number of
opportunities might have arisen for a clinician-patient encounter to be influenced by a
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reminder in a consultation. If the number of such actual encounters were reported, this
might provide the denominator most likely to produce comparable estimates of effect
between studies, as the methodological diversity might be reduced significantly in this
subgroup.
Study or Subgroup
Hicks 2007
Kucher 2005
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.14; Chi² = 8.78, df = 1 (P = 0.003); I² = 89%
Test for overall effect: Z = 0.95 (P = 0.34)
Events
449
61
510
Total
859
1255
2114
Events
611
103
714
Total
1168
1251
2419
Weight
53.1%
46.9%
100.0%
M-H, Random, 95% CI
1.00 [0.84, 1.19]
0.57 [0.41, 0.79]
0.77 [0.44, 1.33]
Intervention Control Odds Ratio Odds Ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours experimental Favours control
Figure 4.1: Forest plot of the two studies reporting a clinical outcome. In the case of
Hicks 2007, the numerator has been adjusted to produce the same direction of effect as
for Kucher 2005.
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Study or Subgroup
1.1.1 Vaccination reminders
Chambers 1991
Rosser 1992
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.87; Chi² = 26.86, df = 1 (P < 0.00001); I² = 96%
Test for overall effect: Z = 2.30 (P = 0.02)
1.1.2 Screening
Burack 1996
Burack 1998
Kenealy 2005
McDowell 1989a
McDowell 1989b
van Wijk 2008 (Screening)
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.43; Chi² = 171.04, df = 5 (P < 0.00001); I² = 97%
Test for overall effect: Z = 2.20 (P = 0.03)
1.1.3 Prescribing reminders
Filippi 2003
Judge 2006
Kralj 2003
Krall 2004
Murray 2004
Overhage 1997
Rossi 1997
Rothschild 2007
Tamblyn 2003 (Discon)
Tamblyn 2003 (Pres)
Tamblyn 2008
van Wijk 2008 (Treatment)
White 1984
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.22; Chi² = 555.00, df = 12 (P < 0.00001); I² = 98%
Test for overall effect: Z = 3.73 (P = 0.0002)
1.1.4 Monitoring or diagnostic test reminders
Bates 1999
Litzelman 1993
Lo 2009
Matheny 2008
McDonald 1976
Tierney 1987
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.09; Chi² = 93.82, df = 5 (P < 0.00001); I² = 95%
Test for overall effect: Z = 3.69 (P = 0.0002)
1.1.5 Other or multiple reminders
Dexter (1) 1998
Dexter (2) 1998
Dexter (3) 1998
Dexter 2001
Frank 2004
McDonald 1980
Overhage 1996
Rosser 1991
Safran 1995
Tape 1993
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.31; Chi² = 482.23, df = 9 (P < 0.00001); I² = 98%
Test for overall effect: Z = 4.21 (P < 0.0001)
1.1.6 Condition specific but multiple reminders
McCowan 2001
Sequist 2005
Tierney 2003
Tierney 2005
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.03; Chi² = 7.84, df = 3 (P = 0.05); I² = 62%
Test for overall effect: Z = 2.05 (P = 0.04)
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.20; Chi² = 1501.00, df = 40 (P < 0.00001); I² = 97%
Test for overall effect: Z = 8.09 (P < 0.00001)
Events
137
300
437
426
278
313
173
41
701
1932
3012
606
177
315
74
2763
39
546
1002
16491
680
801
175
26681
320
1300
689
654
175
2315
5453
26
33
67
1347
3749
973
538
473
294
593
8093
111
621
152
161
1045
43641
Total
271
1313
1584
812
960
983
911
255
1079
5000
8030
1982
732
580
255
5967
346
1350
14043
17246
1069
1218
260
53078
437
2827
1685
1421
500
4149
11019
325
236
279
3539
63665
2533
2341
1471
432
3536
78357
330
3129
648
498
4605
153643
Events
65
39
104
366
270
240
130
35
225
1266
2242
513
213
128
64
1191
1
503
1045
16521
300
275
136
23132
245
980
771
606
54
2039
4695
4
4
4
452
3248
229
554
182
166
451
5294
34
546
130
135
845
35336
Total
218
1236
1454
815
964
1550
951
255
882
5417
7313
1861
1438
496
245
5437
373
1546
15586
17430
416
766
246
53153
502
2580
1988
1372
470
3999
10911
92
92
92
3592
72672
1158
2308
1403
360
3227
84996
147
3619
589
416
4771
160702
Weight
2.3%
2.4%
4.8%
2.6%
2.6%
2.7%
2.6%
2.1%
2.6%
15.3%
2.8%
2.7%
2.6%
2.6%
2.3%
2.8%
0.5%
2.7%
2.7%
2.7%
2.6%
2.7%
2.4%
31.9%
2.5%
2.7%
2.7%
2.7%
2.4%
2.7%
15.9%
1.1%
1.1%
1.2%
2.7%
2.8%
2.7%
2.7%
2.7%
2.5%
2.7%
22.2%
2.2%
2.7%
2.5%
2.5%
10.0%
100.0%
M-H, Random, 95% CI
2.41 [1.65, 3.50]
9.09 [6.44, 12.82]
4.69 [1.25, 17.53]
1.35 [1.11, 1.65]
1.05 [0.86, 1.28]
2.55 [2.10, 3.09]
1.48 [1.15, 1.90]
1.20 [0.74, 1.96]
5.42 [4.45, 6.59]
1.82 [1.07, 3.11]
1.36 [1.27, 1.45]
1.16 [1.01, 1.33]
1.83 [1.47, 2.29]
3.42 [2.64, 4.43]
1.16 [0.78, 1.71]
3.07 [2.83, 3.34]
47.26 [6.46, 345.95]
1.41 [1.21, 1.64]
1.07 [0.98, 1.17]
1.20 [1.09, 1.33]
0.68 [0.53, 0.87]
3.43 [2.84, 4.14]
1.67 [1.16, 2.39]
1.67 [1.27, 2.18]
2.87 [2.18, 3.78]
1.39 [1.25, 1.55]
1.09 [0.96, 1.25]
1.08 [0.93, 1.25]
4.15 [2.96, 5.82]
1.21 [1.11, 1.32]
1.62 [1.25, 2.09]
1.91 [0.65, 5.63]
3.58 [1.23, 10.40]
6.95 [2.46, 19.65]
4.27 [3.79, 4.81]
1.34 [1.27, 1.40]
2.53 [2.14, 2.99]
0.94 [0.82, 1.08]
3.18 [2.63, 3.85]
2.49 [1.86, 3.33]
1.24 [1.09, 1.42]
2.24 [1.54, 3.26]
1.68 [1.08, 2.63]
1.39 [1.23, 1.58]
1.08 [0.83, 1.41]
0.99 [0.75, 1.31]
1.24 [1.01, 1.52]
1.83 [1.58, 2.12]
Intervention Control Odds Ratio Odds Ratio
M-H, Random, 95% CI
0.05 0.2 1 5 20
Favours control Favours experimental
Figure 4.2: Forest plot of all studies reporting process outcomes, including either
population or reminder opportunity denominator, grouped by area of care.
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Study or Subgroup
Bates 1999
Chambers 1991
Dexter (1) 1998
Dexter (2) 1998
Dexter (3) 1998
Dexter 2001
Frank 2004
Judge 2006
Lo 2009
Matheny 2008
McDonald 1976
McDonald 1980
Overhage 1996
Overhage 1997
Rosser 1991
Tape 1993
Tierney 2003
Tierney 2005
White 1984
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.27; Chi² = 864.64, df = 18 (P < 0.00001); I² = 98%
Test for overall effect: Z = 5.07 (P < 0.00001)
Events
320
137
26
33
67
1347
3749
606
689
654
175
973
538
2763
473
593
152
161
175
13631
Total
437
271
325
236
279
3539
63665
1982
1685
1421
500
2533
2341
5967
1471
3536
648
498
260
91594
Events
245
65
4
4
4
452
3248
513
771
606
54
229
554
1191
182
451
130
135
136
8974
Total
502
218
92
92
92
3592
72672
1861
1988
1372
470
1158
2308
5437
1403
3227
589
416
246
97735
Weight
5.6%
5.3%
2.8%
2.8%
2.9%
5.9%
6.0%
5.9%
5.9%
5.9%
5.4%
5.8%
5.9%
5.9%
5.8%
5.9%
5.6%
5.6%
5.3%
100.0%
M-H, Random, 95% CI
2.87 [2.18, 3.78]
2.41 [1.65, 3.50]
1.91 [0.65, 5.63]
3.58 [1.23, 10.40]
6.95 [2.46, 19.65]
4.27 [3.79, 4.81]
1.34 [1.27, 1.40]
1.16 [1.01, 1.33]
1.09 [0.96, 1.25]
1.08 [0.93, 1.25]
4.15 [2.96, 5.82]
2.53 [2.14, 2.99]
0.94 [0.82, 1.08]
3.07 [2.83, 3.34]
3.18 [2.63, 3.85]
1.24 [1.09, 1.42]
1.08 [0.83, 1.41]
0.99 [0.75, 1.31]
1.67 [1.16, 2.39]
1.90 [1.48, 2.43]
Intervention Control Odds Ratio Odds Ratio
M-H, Random, 95% CI
0.05 0.2 1 5 20
Favours control Favours intervention
Figure 4.3: Forest plot of all studies using the reminder opportunity as the unit of
analysis.
Study or Subgroup
Burack 1996
Burack 1998
Filippi 2003
Kenealy 2005
Kralj 2003
Krall 2004
Litzelman 1993
McCowan 2001
McDowell 1989a
McDowell 1989b
Murray 2004
Rosser 1992
Rossi 1997
Rothschild 2007
Safran 1995
Sequist 2005
Tamblyn 2003 (Discon)
Tamblyn 2003 (Pres)
Tamblyn 2008
Tierney 1987
van Wijk 2008 (Screening)
van Wijk 2008 (Treatment)
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.17; Chi² = 595.35, df = 21 (P < 0.00001); I² = 96%
Test for overall effect: Z = 6.24 (P < 0.00001)
Events
426
278
3012
313
177
315
1300
111
173
41
74
300
39
546
294
621
1002
16491
680
2315
701
801
30010
Total
812
960
8030
983
732
580
2827
330
911
255
255
1313
346
1350
432
3129
14043
17246
1069
4149
1079
1218
62049
Events
366
270
2242
240
213
128
980
34
130
35
64
39
1
503
166
546
1045
16521
300
2039
225
275
26362
Total
815
964
7313
1550
1438
496
2580
147
951
255
245
1236
373
1546
360
3619
15586
17430
416
3999
882
766
62967
Weight
4.9%
4.9%
5.1%
4.9%
4.8%
4.7%
5.1%
3.9%
4.7%
3.8%
4.1%
4.3%
0.7%
5.0%
4.6%
5.0%
5.1%
5.1%
4.7%
5.1%
4.9%
4.9%
100.0%
M-H, Random, 95% CI
1.35 [1.11, 1.65]
1.05 [0.86, 1.28]
1.36 [1.27, 1.45]
2.55 [2.10, 3.09]
1.83 [1.47, 2.29]
3.42 [2.64, 4.43]
1.39 [1.25, 1.55]
1.68 [1.08, 2.63]
1.48 [1.15, 1.90]
1.20 [0.74, 1.96]
1.16 [0.78, 1.71]
9.09 [6.44, 12.82]
47.26 [6.46, 345.95]
1.41 [1.21, 1.64]
2.49 [1.86, 3.33]
1.39 [1.23, 1.58]
1.07 [0.98, 1.17]
1.20 [1.09, 1.33]
0.68 [0.53, 0.87]
1.21 [1.11, 1.32]
5.42 [4.45, 6.59]
3.43 [2.84, 4.14]
1.78 [1.49, 2.14]
Intervention Control Odds Ratio Odds Ratio
M-H, Random, 95% CI
0.05 0.2 1 5 20
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Figure 4.4: Forest plot of all studies using a population level denominator as the
outcome.
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This distinction was more difficult to make than expected. A number of studies
reported ‘Intention To Treat’ outcomes in which the denominator included identifiable
patients potentially eligible to trigger a reminder but who did not actually present to the
practice to be exposed to the intervention. In other cases, only the patients actually
presenting were analysed. Where both were available, we used the intention to treat
data. However for some studies, presentation at the practice was an inclusion criterion
for enrolment in the study as well as eligibility for a reminder message (e.g. Van Wijk
2008).
A further issue concerns the weighting of studies in which multiple reminders
were used as part of a decision support system, and the numbers eligible for each
reminder were reported at the start and the end of the trial. Through aggregation of the
data provided (to derive an overall figure for the effect of the reminder system) there
was a risk of double or multiple counting, as individual patients may justify more than
one reminder. A related issue is whether a screen reminder listing more than one
different care suggestion is delivering more than one reminder. If a practice identified
100 patients requiring influenza vaccination and 50 requiring pneumococcal
vaccination, there might be 40 people requiring both. These 40 people would receive a
reminder (about both issues at the same time) if they presented to the practice, but our
extracted denominator would be 150, as the articles do not generally report the overlap
between groups eligible for separate reminders. We applied the same policy
consistently in the analysis, regarding each ‘sub-reminder’ as an intervention in itself.
If a clinician responded to the combined reminder by arranging influenza but not
pneumococcal vaccination, this would only ‘count’ as a response to one of two
reminders.
4.11.4 Results of the process outcome studies
As discussed above, the majority of studies investigated the effects of reminders on
processes of care. These were analysed separately in RevMan from the two clinical
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outcome studies and the results are given in Figures 4.3 and 4.4, and Table 4.7. For the
combination of all binary outcome process of care studies an overall Odds Ratio of 1.83
[95% CI 1.58, 2.12] was derived, indicating a significant but modest benefit of the
intervention. One study (Shea 1995) reported a continuous outcome (length of hospital
stay), and a non-significant change.
4.11.5 Clinical outcome studies
Two studies reporting clinical rather than process of care outcomes (Kucher 2005 and
Hicks 2007) are considered separately. In the case of Kucher 2005, a positive effect on
the rates of venous thromboembolism was detected through point of care reminders
related to thrombosis risk in hospital inpatients. An odds ratio of 0.57 [95% CI 0.41,
0.79] for risk of clinically significant thrombosis, was derived.
I adjusted the numerator of the Hicks 2007 study as it would otherwise have
suggested an effect in the opposite direction to Kucher 2005. I calculated the odds of
not having blood pressure controlled (the adverse outcome that the intervention tries to
prevent) rather than the odds of the blood pressure being controlled (as is reported in
the paper). This makes the analysis comparable with the Kucher study, in which the
odds of a thrombo-embolic event are similarly reduced (not increased) by the
intervention. Hicks 2007 dilutes the effect of Kucher 2005 to give an overall non-
significant odds ratio of 0.77 [0.44, 1.33] for the two clinical outcome studies.
4.11.6 Comparability of studies
My attempts to identify a subgroup with a low heterogeneity score were only partially
successful. The areas of care categories that I identified all had high levels of
heterogeneity, with one exception: the Condition specific reminder group. This group
produced a Tau2 score of just 0.03 and a Chi2 test of borderline significance (p=0.05),
in contrast to all the other groups, in which the p value for the Chi2 was <0.00001
(Table 4.7). This p value is the probability that the null hypothesis of no heterogeneity
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is true. Tau2 is the variance of the measured effect of the intervention between the
included studies. Monitoring and diagnostic test reminders also seemed to be less
heterogeneous than others, with a Tau2 of 0.09, but still produced a low p value for the
Chi2 test.
By dividing the studies by unit of analysis I attempted to distinguish between
the efficacy of the reminder intervention at the point of care from its effectiveness in
altering population level outcomes, as discussed earlier. However the Tau2 measures
obtained in these study subgroups were not significantly lower than those of the overall
sample (Table 4.7).
Category Chi2 test for
heterogeneity
(p value)
Tau2 measure
of
heterogeneity
Odds Ratio
[95% CI]
All process of care
studies reporting
binary outcomes
1501.00
df=40
(p<0.00001)
0.20
1.83
[1.58, 2.12]
Vaccination reminders
26.86
df=1
(p<0.00001)
0.87
4.69
[1.25, 17.53]
Screening reminders
171.04
df=5
(p<0.00001)
0.43
1.82
[1.07, 3.11]
Prescribing reminders
555.00
df=12
(p<0.00001)
0.22
1.67
[1.27, 2.18]
Monitoring or diagnostic
test reminders
93.82
df=5
(p<0.00001)
0.09
1.62
[1.25, 2.09]
Other or multiple
reminders
482.23
df=9
(p<0.00001)
0.31
2.24
[1.54, 3.26]
Condition specific
reminders
7.84
df=3
(p=0.05)
0.03
1.24
[1.01, 1.52]
Unit of analysis = the
reminder opportunity
864.64
df=18
(p<0.00001)
0.27
1.90
[1.48, 2.43]
Unit of analysis =
population denominator
595.35
df=21
(p<0.00001)
0.17
1.78
[1.49, 2.14]
Both clinical outcome
studies
8.78
df=1
(p=0.003)
0.14
0.77
[0.44, 1.33]
Use of primary care data for identifying individuals at risk of cardiovascular disease
111
Table 4.7: Heterogeneity values and odds ratios for all the binary outcome studies and
for various subgroups of process outcome. The clinical outcome studies aim to
demonstrate a reduction in events with an odds ratio less than unity.
4.11.7 Sensitivity analysis: exclusion of a study involving rare events
Individual studies may produce very high odds ratio values simply because there are
either no events, or very few events in the control arm. Rossi 1997 was such a study,
with only one event recorded in the control arm, producing an outlying odds ratio of
47.26. A zero value for the numerator in the control arm would produce an effectively
infinite odds ratio. In such cases, RevMan automatically inserts a value of 0.5 to the
empty cell.
Such results are not particularly helpful in a quantitative analysis, but the use of
reminders in settings where there is essentially no activity in the control situation is not
unimportant. The high odds ratio value of Rossi 1997 does not contribute much to the
overall result, as the weight of this study is low (0.5%). The value of the overall odds
ratio was only slightly reduced (OR 1.81, CI 1.56 – 2.09) when it was excluded from
the analysis.
4.11.8 Other studies included in the review but not in the RevMan analysis
Eccles 2002 was a study of a system of reminders to support the care of patients with
asthma and angina. It reported many different outcome measures, and gave individual
odds ratios for all of them, but no single measure was identified as primary. I contacted
the lead author Martin Eccles for advice on the handling of this paper, which had been
included in the Shojania 2009 review. He advised me that a technique had been
developed by the Cochrane EPOC group for synthesising such results to derive a
median effect size estimate for all the measures within the study. As the Shojania
review used a different measure of effect size (based on percentage improvement in
process adherence or clinical endpoint rather than an odds ratio) we decided not to
include this study in our RevMan analysis. It was nevertheless accounted for in the
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narrative synthesis as an example of a high quality, condition specific study reporting
non-significant outcomes.
4.12 Influence of excluded papers
A number of papers were identified that were not ultimately included in this review but
that nevertheless influenced this thesis. Some of these were cited in the e-Nudge trial
protocol as they influenced the design of the e-Nudge intervention and are mentioned in
Section 1.5 of Chapter 1, and in Section 9.6 of Chapter 9.
In a 1992 paper, Clement McDonald (51) described a follow up investigation of
the participants of a previous reminder intervention trial of 1984 (52). The original trial
had measured the effect of reminders on multiple outcomes including vaccination rates.
It was only excluded from our review because denominator data were not reported and
attempts to obtain them from the lead author were unsuccessful. In the second study,
the individuals originally allocated to receive vaccination reminders, and the controls,
were followed up to determine morbidity outcomes (chest xrays, blood gas analysis,
and hospitalisations). All three outcomes were lower in the patients originally allocated
to the intervention arm of the 1984 study. Whilst this second study was not eligible for
our review, the result suggests a significant potential impact of electronic reminders on
clinical outcomes.
4.13 Conclusions
Computer generated, patient specific reminders available at the point of care are
generally beneficial, although the effect on clinician behaviour is not strong. For
studies reporting process of care outcomes, we derived an overall odds ratio of 1.83
[95% CI 1.58 - 2.12]. This is comparable with the results of other, similar reviews
discussed in Chapter 1. Clinical outcomes have been used much less often than process
outcomes as the primary measure. However, the effect of reminders is inconsistent and
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may depend on the organisational context. Trials reported in the published literature are
heterogeneous in their designs, as well as in their operational environments, making
evidence synthesis problematic. As the perceived importance of a reminder by the
target clinician may determine its impact, and priorities differ among clinician groups,
the effectiveness of a new intervention cannot easily be predicted. This perhaps
accounts for the repeated trialling of apparently similar interventions throughout the
last three decades.
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Chapter 5: The e-Nudge trial: preparatory pilot
work
________________________________________________________________
5.1 Introduction
The e-Nudge trial resulted from the opportunities arising from my move to Warwick in
2004 and my new role as deputy director of Warwick West Midlands Primary Care
Research (later Warwick-Coventry Primary Care Research). But the concept of
applying a CVD risk algorithm to general practice data had already been developed in
my previous post and in fact piloted as early as 1997. This chapter will describe how
the background work prior to the trial facilitated its design and implementation.
5.2 Identifying potentially at risk groups
General practice computers have, as described in Chapter 1 provided from the early
1990s a rich source of cardiovascular risk factor data, potentially providing new means
of addressing cardiovascular risk (1). But such resources contain information that is
different from that collected in more formal research settings (2), and inevitably
include missing data points that need to be accounted for to maximise the accuracy of
risk estimates and the usefulness of the data source. Through this research I was able to
measure the proportion of the general practice population whose basic risk profiles
were complete and this will be described in the results chapter. However I also found
that such patients are out-numbered several fold by those requiring further information
to estimate risk, raising practical issues.
One option to overcome the problem of missing information is to insert specific
‘assumed’ values, typically involving a single estimate for each factor applied to all
those in whom these data points are missing. This approach may fail to recognise that
those with missing data are not necessarily representative of the general population
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from which the assumed values are derived, but is a pragmatic means of utilising the
data that are present, and has become commonplace in the development of risk
algorithms as described in Chapter 2. A group characterised by a certain (perhaps
unknown) threshold of sensitivity and specificity for case recognition is then identified,
depending on the set of chosen values for the missing risk factors. In the e-Nudge trial,
these values were based on the median values from the Health Survey for England
2003 (described in the next chapter). This approach does not recognise adequately the
range of potential values for these missing data and the impact this range might have on
case finding. It also misses an opportunity to allow assumed values to be influenced by
the other (known) risk factor values. Known correlations between risk factors represent
a potentially useful means of optimising the estimation of ‘assumed’ values, and could
be based on the relevant background population. This possibility was suggested in my
original publication in this area (3), and has also been used by Marshall (4-6).
Another approach is to recognise the limitations of the data source and to target
subgroups of the population not for treatment on the basis of assumed values, but for
clarification of risk through the systematic gathering of complete risk profiles. This was
the original basis for the advice given in the National Service Framework for Coronary
Heart Disease (2000) (7), which recommended that patients on the general practice
diabetes and hypertension registers should be targeted first for risk assessment (i.e.
before the rest of the practice population). This was advised irrespective of the existing
risk factor data held on individual patients (other than their diagnoses of diabetes or
hypertension), except that older patients would clearly be more likely to produce a
greater yield of high risk cases than younger patients within these groups.
More recently, the same concept has become the basis for the 2008 NICE
guidelines on Lipid modification CG67 (8), which recommends the targeting of groups
for cardiovascular risk reduction using primary care data. These two guidelines
(separated by eight years) both advocate that groups potentially at risk (on the basis of
existing, routinely collected data that are likely to be incomplete in most cases) should
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be identified initially, and then invited for more accurate clarification of risk through
completion of a more personalised risk profile, including data that may not be
electronically recorded, such as ethnicity, family history, obesity, and social
deprivation. This issue became important to an ongoing debate over the relative merits
of the QRISK algorithm and the longer established Framingham algorithm as applied to
UK primary care data. General practice data have improved significantly in quality and
completeness since a decade ago, but are still considered inadequate as a basis for a
definitive recommendation over the need for lipid lowering therapy in the case of an
individual whose CVD risk had been identified purely on the basis of routinely
collected primary care data.
I had explored this area in an early practice based project carried out at in Danby,
North Yorkshire in 1997 that was subsequently published in a book chapter (9). This
project was carried out before I registered for the PhD (and is therefore given in the
Appendix as it is separate from the thesis material) but provides useful background. It
used the Sheffield tables (10) to construct a series of searches in EMIS LV defined by
the tables’ individual ‘cells.’ These tables were at the time the most readily available
means of identifying potentially ‘at risk’ groups requiring cholesterol measurement,
and were (like most other commonly used approaches of that time) based on
Framingham study data. The first published application of a risk algorithm applied
specifically to UK general practice data (11) involved the Sheffield tables. The focus of
the Sheffield table authors was on the targeting of individuals for cholesterol
measurement, rather than on the identification of established cardiovascular risk. In
other words, it aimed to identify groups requiring further assessment of risk, rather than
those whose risk was already demonstrated by the data.
The approach used in this survey was an extremely pragmatic one: rather than
attempting to complete the cardiovascular risk profiles of the entire population,
individuals were only identified if they had a reasonable chance (based on existing,
usually incomplete data) of producing a high CVD risk estimate. This approach would
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support the current recommendation that primary care should host the identification of
candidates for risk estimation. An alternative approach in which all potential candidates
for risk reduction (e.g. the entire 40-74 year age group) were invited for formal risk
assessment irrespective of their (already established) risk factors would not need the
support of primary care data and could be undertaken in alternative (e.g. non-NHS)
settings.
But the conclusion of this pilot work was that despite incomplete data, groups
may be recognised on the basis of just a few risk factors that are likely to have a much
higher yield of cases of raised CVD risk than would be possible using approaches
independent of primary care data.
An equally important suggestion was that targeting might involve a two stage
process: an initial stage identifying a potentially at-risk group and the second stage
more accurately quantifying individualised risk by incorporating information that was
only partially represented by electronic data. This thesis attempts to inform both stages
of this process, and to comment on the adequacy of routinely collected primary care
data to support them.
5.3 The Newchurch experience
After moving to the University of Warwick to commence the PhD I began discussions
with the private software company Newchurch (now Tribal Newchurch). This is an
independent company managing NHS data that provided an integrated system of data
capture and storage for 26 South Warwickshire practices following a ‘Demonstrator’
project completed n 2003 (12). All Read coded data were extracted every 24 hours and
made available to selected NHS professionals in the locality. These included Accident
and Emergency departmental staff, who were able to access data on limited past
medical history, medication, allergies and electrocardiographic records to assist with
the immediate care of patients presenting in the department. When I began in my
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current post in South Warwickshire in 2004 as an academic interested in NHS data
integration (and as a GP working in a practice connected with the Newchurch database)
I was interested to know more about this development. In addition to the experience of
local stakeholders involved in the establishment of this system (who had undergone an
extensive process of negotiation with public and professional bodies over data control
and Caldicott issues) I was also interested in the future potential of the system to
provide the functionality I envisaged for the support of systematic cardiovascular risk
reduction in primary care. Five meetings took place between 18.4.05 and 27.1.06 at
their Teddington, London headquarters, where this database was hosted.
The first meeting with the company’s Junaid Khan involved an exploration of
the possibilities offered by the Newchurch database, and its potential to support the e-
Nudge trial. Further meetings involved an in-depth study of the data extracted from my
own practice (Castle Medical Centre, Kenilworth) by Newchurch that, along with all
the other practices, were updated every 24 hours. Permission was gained to proceed
with this from my partners and practice managers. The most interesting and relevant
work involved the construction of the Framingham equation as a search algorithm by
Newchurch’s Muhmud Ahmad, with whom I spent several hours at each meeting
examining remotely my own practice’s data via the NHS Net. This work preceded the
subsequent publication (using a similar technique) by Marshall (5), and the more recent
QRISK studies that used the same approach on a much larger scale (13, 14). It
represented a significant advance on the previous Sheffield audit carried out in Danby
in 1997. Instead of identifying groups justifying cholesterol measurement, it identified
groups whose existing data were sufficiently complete to suggest raised cardiovascular
risk. More importantly for my purposes at the time, it enabled me to experiment with
alternative values of the missing variables, to measure the impact that a range of
assumptions would have on the numbers identified. Some of the results of this work are
given in Tables 5.1 and 5.2 and the Box).
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Applied 14
Deceased 1250
Permanent 10709
Temporary residents 18
Transferred out 15715
Undefined 1702
Effective active practice population: 12,425 (Applied+Permanent+Undefined)
Table 5.1: Castle Medical Centre list size on 10.1.06
Search
number
Assumed
systolic
BP if
absent or
out of
date
Assumed
total serum
cholesterol
if absent or
out of date
Assumed
serum
HDL
cholesterol
if absent or
out of date
Assumed
smoking
status if
absent
Assumed
diabetes
status if no
recent
blood
glucose
Number
identified
1
143
(male) or
142
(female)
5.8 (male)
or 6.25
(female)
1.2 (male)
or 1.5
(female)
Non-
smoker Positive 2578
2
143
(male) or
142
(female)
5.8 (male)
or 6.25
(female)
1.2 (male)
or 1.5
(female)
Non-
smoker Negative 1554
3
143
(male) or
142
(female)
5.8 (male)
or 6.25
(female)
1.2 (male)
or 1.5
(female)
Smoker Positive 2878
4
143
(male) or
142
(female)
5.8 (male)
or 6.25
(female)
1.2 (male)
or 1.5
(female)
Smoker Negative 2085
Table 5.2: Experimenting with my own Kenilworth practice’s (anonymysed) data
remotely from Newchurch’s Teddington data warehouse on 10.1.06. The aim was to
tune the assumed values to produce a manageable population size likely to benefit from
further data collection. The assumed values later used in the e-Nudge software were
based on the more recent Health Survey for England 2003 (15).
However, the derivation of these results brought up immediate problems with data
quality that took some time to investigate and proved impossible to overcome within
the Newchurch system. My ability to follow up individual examples of patients with
irregularities (identified at Newchurch through their EMIS computer number) back at
the practice in Kenilworth facilitated this process. For instance, patients were identified
with no apparent record of cardiovascular disease but who appeared in the searches as
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if such a record were present. A practice based audit trail was necessary to explain this
anomaly. Such patients had been diagnosed (perhaps provisionally) with some form of
CVD whilst our clinical software system was EMIS GV, the system used until 2002.
During that year the practice changed from EMIS GV to EMIS PCS, and the electronic
records were transferred to the new system through a data migration process. During
this process any previous codes that were considered irrelevant (such as unconfirmed
CVD) were lost from the clinical notes but were still detectable in the Newchurch
searches. This finding could be assumed to apply to all of the practices connected to
Newchurch, and clearly threatened the ability of this system to support the trial,
particularly as such examples were not uncommon.
A further, equally important problem that became evident was that Newchurch
practices were not generally using their system to any extent in everyday practice, with
a few exceptions. Each connected practice (including my own) had a Newchurch server
installed that could be accessed from consulting room computers, and a wide range of
information was available including practice based demographic and morbidity
patterns. However, the usage of this resource appeared to be low. This was evident not
only through visiting and contacting Newchurch practices, but also through actually
asking Newchurch to provide data on system usage through ‘logging in’ reports. As
discussed in the paper I co-authored with Ian Allwood (12), it emerged that the main
role for Newchurch in the area was to provide access to patients’ records by out of
hours providers including the Warwick Hospital Accident and Emergency Department.
This was an important and valuable resource, but unless the search results on
cardiovascular risk patterns could be fed back to clinicians during routine primary care,
the e-Nudge trial could not be supported. This experience provided an important lesson
that had been relevant to the literature review of this thesis, over the availability of
‘feedback’ information within the consultation environment, without which electronic
reminder interventions are less likely to influence the behaviour of health professionals.
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5.4 Original links with Egton Medical Information Systems
(EMIS)
Before moving to the University of Warwick I had established connections with Egton
Medical Information Systems (EMIS) partly through the geographical proximity of my
former practice with the nearby Egton practice where the company was established, but
also more specifically because of opportunities I used to share ideas with the company
over the use of general practice data to target patients for cardiovascular prevention.
After I moved to Warwick, EMIS were willing to support the research that resulted in
the e-Nudge trial and, when it became apparent that Newchurch could not provide a
sufficient platform, EMIS’s Medical Director David Stables agreed to provide the
necessary technology and expertise.
Collaborative work with EMIS began during late 2005, and the e-Nudge
algorithm was programmed early in the following year. The Framingham equation
coefficients from Anderson et al 1991 (16) were programmed in SQL to run on their
LV system and adapted to receive primary care data as inputs to the algorithm. The
SQL program is given in the Appendix.
5.5 Developing links with local health care organisations
Preparing for the trial also brought me closer to South Warwickshire Primary Care
Trust, their Head of Information Technology David Harry who was Newchurch’s main
contact, their information technology lead and Stratford GP Dr Ian Allwood, and their
director of Public Health Dr Stephen Munday. All three had been actively involved
with the Newchurch ‘Demonstrator’ project that had established this local resource. In
addition, I began working closely with their front line IT technicians Paul Elwell and
Olly Scholefield, who were actively involved in administering IT solutions and
conducting audit work throughout the practices of South Warwickshire. At a PCT
meeting with Olly Scholefield in 2005 I was introduced to Juelene White, Service
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Improvement Manager for the South Warwickshire (and subsequently Warwickshire)
PCT who recruited me to join the Trust’s Coronary Heart Disease National Service
Framework Local Implementation Group, and later their Long Term Conditions Group.
This helped me ensure that my research remained aligned with the priorities of service
based as well as academic primary care. Through my University role I also sat on the
Research Strategy Board of South Warwickshire PCT (Research Management and
Governance), its Research Steering Group, and (following the merger of local PCTs
and the creation of the National Institute for Health Research’s Primary Care Research
Network), the PCRN (Central England)’s Executive Board.
5.6 Funding for the trial
The e-Nudge project was funded by a PhD studentship from Warwick Medical School
which in 2005 benefitted from money distributed by the Department of Health to the
newer UK medical schools. A grant of £104,304 was obtained to study the use of
primary care data to support cardiovascular risk estimation. Whilst the application
process was peer reviewed this was carried out on an internal or local basis, and the
trial did not therefore qualify for later inclusion in the UKCRN portfolio. Such
inclusion might have benefitted the trial in its later stages (through access to service
support payments) but did not hold it back in any other way, as the recruitment of trial
practices and the instalment of the e-Nudge algorithm did not require such support.
5.7 Ethical and R&D approval
Ethics approval for the e-Nudge trial was gained from Warwickshire Local Research
Ethics Committee in August 2005. By this time I had successfully engaged Newchurch
and EMIS but it was still not clear which of the two would actually provide the
platform for the trial. One ethical issue that required consideration was the ability of
Newchurch to process the data using the Framingham algorithm to identify at risk
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patients (a process that would have to take place in Teddington), and to then transmit
results back to the practices, without breach of confidentiality. Permission was gained
for this on the basis that Newchurch were contracted by the NHS, bound by its
Caldicott regulations, and connected to practices via the NHSNet, but in the end only
EMIS were able to provide a platform for the searches that identified individuals
without any information leaving the practice, a more satisfactory arrangement. The
results of these searches could in principle be accessed remotely by EMIS (which
facilitated numerous de-bugging and trouble-shooting exercises following e-Nudge
installation) but the searches actually took place in the practices following the
installation of the software to each participating practice’s main server.
NHS Research and Development (R&D) permission was gained initially from
South Warwickshire Primary Care Trust (PCT). This PCT was the Research,
Management and Governance PCT for the West Midlands South Consortium of PCTs,
which at the time included Coventry, Rugby, and North Warwickshire PCTs. After
EMIS took over from Newchurch as the platform provider for the trial, the number of
practices able to take part increased dramatically.
5.8 ISRCTN Registration
I registered the trial with ISRCTN on 15 March 2006 This registration facilitated the
publication of the trial protocol in April 2006 (17).
5.9 Peer review
Feedback on the design of the trial was obtained from:
 Peer review of the successful PhD Studentship obtained from Warwick Medical
School in 2005. Initial feedback questioned whether the project was feasible within
budget but was otherwise very positive and the PhD was funded.
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 Professor Sallie Lamb and Dr Simon Gates of the Warwick Clinical Trials Unit.
Their written feedback guided the subsequent implementation of the trial.
 Dr Sandra Eldridge of Queen Mary University of London, who advised on
statistical issues arising from an earlier draft of the trial protocol.
 The School of Health and Related Research (ScHARR) in Sheffield. I was invited
to give a seminar on 6/3/06 at ScHARR in which I discussed the design of the trial and
the potential for primary care data to provide the basis for more complex, adaptive
algorithms for recognising cardiovascular risk through data mining techniques. Useful
feedback was obtained over the implementation of the trial even though it was too late
at this stage to influence its design.
 A visit funded by Warwick Medical School to Montreal and New Brunswick in
October 2006, through which I presented the design of the trial to colleagues at McGill
University and to the University of Moncton, where my colleague Sylvie Robichaud-
Ekstrand is now based. Sylvie had previously worked at McGill with Robyn Tamblyn,
who hosted the McGill meeting, and whose work on the ‘Medical Office of the
Twenty-first Century (MOXXI)’ was to feature in the subsequent literature review.
 The Randomised Controlled Trials course, Oxford University, April 2006. Whilst
it was by this time too late to change the trial protocol, valuable lessons were learnt
particularly relating to the issue of Intention To Treat that were later to become
important in the analysis of the results.
5.10 Summary
The preparatory work described above was important for formulating the ideas and
hypotheses to support the design of a randomised controlled trial of a (fairly) complex
intervention. A particularly significant ‘thread’ emerged through this process: the
distinction between identifying potentially at risk individuals and the clarification of
risk status through more formal assessment. This distinction originated through the
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Sheffield project work (prior to commencing the PhD), was developed during the PhD
through collaborations with Newchurch, and later became the basis for the e-Nudge
software programmed by EMIS as a ‘case finding’ tool rather than a definitive risk
calculator. The design of e-Nudge, specifically for the purposes of a randomised
controlled trial in primary care is discussed in the next chapter.
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Chapter 6: Detailed methods for the e-Nudge trial
____________________________________________________________________
6.1 Introduction
The aim of this research was to investigate the use of primary care data to support
targeted cardiovascular risk reduction. The more specific objective of the e-Nudge trial
was to test the effect of electronic reminders designed for the same purpose in the
routine general practice environment. Some of the methodological details discussed
here are adapted from the e-Nudge study protocol published in the journal Trials (1),
and others from the final trial report (2). The first of these publications (describing the
design and methods) was aligned where possible with the revised CONSORT statement
of 2001 (3). The final report was also guided by a more recent extension of the
statement specifically for pragmatic trials published in November 2008 (4).
6.2 Outline of the e-Nudge trial design
6.2.1 Hypotheses
I hypothesised that an automated system of electronic reminders drawing on routinely
collected primary care data would improve the visibility of the population at risk of
cardiovascular disease (CVD), the adequacy of cardiovascular risk factor data, and
ultimately cardiovascular event rates.
6.2.2 Setting
The trial was set in the routine environment of primary care in the United Kingdom
(UK).
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6.2.3 Participants
The over 50 year old population registered with 19 general practices in the West
Midlands of the UK.
6.2.4 Intervention
The ‘e-Nudge’ software tool was designed to extract data from practice systems and
generate regularly updated lists of patients in six groups. These were based on
estimated risk of cardiovascular disease, adequacy of data to support risk estimation,
the need for clarification of diabetes status, and persistently raised blood pressure in
patients over 75 years. Intervention patients currently identified in any of the lists
received a screen reminder whenever their electronic record was accessed. Practice
teams could examine the lists of identified patients if they wished and were reminded
about them every eight weeks by an email sent to a nominated team member.
Responses to the notification mechanisms (lists and screen reminders) were entirely
optional.
6.2.5 Control condition
The control arm would receive usual care without the assistance of e-Nudge software,
but practitioners would employ their usual means of assessing cardiovascular risk,
including the use of currently available software tools. The use of such tools in UK
practice during the trial was not very commonplace. All practitioners involved in the
trial were in receipt of the British National Formulary (updated every six months),
which contains risk charts recommended by the Joint British Societies for calculating
cardiovascular risk.
6.2.6 Outcomes
1. Annual rate of cardiovascular events in the over 50 year population.
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2. Proportion of the trial population identified in each of the e-Nudge Groups at the end
of the study. The mean of the proportions in the final three eight-weekly data captures
would be used to define this outcome.
6.2.7 Duration of the study
Twenty-four months.
6.2.8 Analysis
By intention to treat, using Poisson inference techniques for cardiovascular event rates
(primary outcome), and Chi-squared tests for Group differences (secondary outcomes).
6.2.9 Quality assurance
A sub-study of the trial population was used to confirm the validity of the primary
outcome search techniques.
6.3 The e-Nudge algorithm
The e-Nudge algorithm was only part of the e-Nudge intervention. A flow diagram
defining the e-Nudge Groups 1-6 is given in Figure 1. The code sets were wherever
possible the same as for the quality and outcomes framework (QOF). The inputs were
based on the most recent values of the risk variables (or in the case of systolic blood
pressure, an average of up to three recent values). I chose this option over alternatives
(e.g. pre-treatment levels, where available, or highest ever level) for two main reasons.
First of all, there was an increasing move to base risk estimates on current data rather
than ‘pre-treatment’ data, recognising that for many patients it will not be clear enough
which category an electronically retrieved measurement fits. In principle it is possible
for a general practice computer to identify the date of onset of anti-hypertensive or lipid
lowering drug therapy within that practice, but the patient might have already been
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taking such therapy when registering with the practice. In other cases, the pre-treatment
levels may pre-date the establishment of electronic records, making retrieval of the
original levels impossible. This is an example of compromise (as both JBS2 and the
later NICE CG67 stated a preference for pre-treatment values if available) due to the
limitations of the source data. Its main implication was that a patient currently on
treatment for either blood pressure or cholesterol might have their true risk under-
estimated by e-Nudge. For this reason, I was careful to emphasise to e-Nudge users that
the software was a case-finding tool, not a definitive risk scoring algorithm. Estimated
risk should be confirmed by practitioners if they considered it necessary. This might
also include the use of other factors not included in Framingham but recommended in
JBS2 for correcting the estimate. These factors include male Asian ethnicity, family
history of CHD, impaired glucose regulation, hypertriglyceridaemia, low physical
activity, and impaired renal function. The e-Nudge would be unlikely to actually over-
estimate risk, as most corrective factors inflate rather than reduce the initial estimate,
and this was one of its strengths. A patient identified as at high risk would be unlikely
to have a risk estimate less than 20% following the inclusion of corrective factors, and
the use of most recent blood pressure and cholesterol data made this even less likely if
these values were taken on treatment.
The second reason for using most recent levels as a basis for risk estimation
was related to the trial design itself. The impact of the e-Nudge reminders on the Group
proportions would be evident through the trial by determining the change in estimated
risk based on these most recently recorded data. Action taken on the basis of a reminder
(e.g. measurement of blood pressure in a patient requiring this to complete the risk
profile, or correction of raised blood pressure by drug therapy) would only be evident if
the most recent measurements were used.
A related issue is the existence of patients with diagnoses that have later
resolved. The only disease diagnoses relevant to e-Nudge were those of ischaemic heart
disease, cerebrovascular disease, and diabetes. In the first two cases, a patient is always
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considered to be eligible for indefinite follow up if the diagnosis is confirmed and will
remain on the register. This also applies to most cases of diabetes, but there are
occasions when diabetes may arise temporarily (e.g. during high dose corticosteroid
use) and later be considered to have resolved. The QOF recognises a code for ‘Diabetes
resolved’ and this is included in the definition of QOF Diabetes disease registers. The e-
Nudge was therefore able to incorporate this as well as it drew on QOF registers for this
and the vascular diagnoses.
6.3.1 Framingham algorithm
The Framingham CVD algorithm as defined by Anderson et al (5) was used to identify
patients for Groups 2 and 3 (later termed B and A). It has the following structure:
 μ = Σ βixi
 σ = exp(θ0+θ1μ) 
u = (ln(t)-μ)/σ 
p = 1 - exp(-exp(u))
where
βi = the coefficient for each risk variable xi
xi = the value of the corresponding risk variable
θ 0 and θ 1 = constants
e = the base of the natural logarithm
t = timescale for the risk estimate (10 years for this trial)
p = the probability of a cardiovascular event within this
timescale
The values of the constants (θ 0 and θ 1) and coefficients (βi) for this equation are given
in the SQL program in the Appendix. These coefficients are for the CVD algorithm
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(not CHD, Acute MI, CHD death, stroke, or CVD death functions, which have different
coefficient values). The risk threshold used to identify patients in this study is >20% in
10 years, which was the threshold recommended by the BHS Guidelines (6) and the
JBS2 report (7).
6.3.2 Groups identified by e-Nudge
Six groups 1-6 (later just four, relabelled A-D) were identified automatically using
patient data and were updated every 24 hours to take account of new information. The
search protocol is described in Figures 6.1-6.3. The original six groups can be
summarised as:
Group 1: Patients over 50 years with existing cardiovascular disease or diabetes, whose
blood pressure or cholesterol level is outside the Quality and Outcomes Framework
(QOF) target range at the last estimation, or no “in date” level is recorded.
Group 2: Patients who are not known to have cardiovascular disease or diabetes, are
under 75yrs old, and whose risk profile is incomplete – more information is required to
perform a risk estimate - but whose cardiovascular risk would be greater than 20% if
the “assumed” values of the missing factors were used (see below for definitions).
Group 3: Patients who are not known to have cardiovascular disease or diabetes, are
under 75yrs old, and whose most recent Framingham variable values indicate that their
risk level is raised.
Group 4: Patients who are not known to have cardiovascular disease or diabetes, are
greater than 75yrs old and who have persistently elevated blood pressure based on the
three most recent consecutive readings.
Group 5: Patients with possible undiagnosed diabetes, on the basis of at least one
previous high blood glucose record (see below for more detailed definition).
Group 6: Patients with CVD but not diabetes, who have not had a blood glucose
measurement in the past three years.
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6.3.3 Definitions
"In date" means:
 A blood pressure reading within the last fifteen months for patients who have
CHD/stroke/TIA or diabetes, otherwise three years.
 A blood glucose level within the last three years (for those without diabetes).
 A cholesterol level in the last fifteen months for CHD, Stroke/TIA or Diabetes
patients, and three years for non-CHD/Stroke/TIA, non-Diabetes patients (applies to
possible Group 2 patients).
"Framingham variable” means:
 Age
 Sex
 Smoking status (considered positive if record of smoking tobacco at last use of this
Read code group, however long ago). A previously recorded smoker who has stopped
will be considered a non-smoker only if 1 year has elapsed since quitting. A smoker is
anyone who has smoked tobacco regularly in the past 1 year.
 Systolic blood pressure – average of last three "in date" values if available. If there
are fewer measurements available, then the average of these is taken.
 Total serum cholesterol at most recent measurement, if "in date"
 Serum HDL cholesterol – as for total cholesterol
 Left Ventricular Hypertrophy status – assume negative unless there is any positive
electronic record of LVH.
 Diabetes status, according to whether or not the patient is on the Diabetes register.
However, if a primary prevention patient less than 75 yrs does not have a diagnosis of
diabetes, but there is no blood glucose level "in date" (i.e. in the past three years), then
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the risk algorithm will base the risk calculation on an assumption of positive diabetes
status, and if the risk level is then high, the practice will be notified with this
assumption stated, as a Group 2 message. If a patient (this time including those above
75 yrs) is not on the Diabetes register but there is a record of a blood glucose level >
11.1 mmol/L, then the practices will be notified for clarification, regardless of the
patient's CHD/Stroke status or calculated risk level, as a Group 5 patient. The matter
can be clarified by the practice teams if they wish, by organising a fasting blood
glucose (FBG) or oral glucose tolerance test (OGTT). A FBG ≤6.9 mmol/L or OGTT 
code following (at a later date to) the high random blood glucose level would mean that
the patient is no longer in Group 5 (but may re-enter it if further raised blood glucose
levels occur). The FBG or OGTT must be clearly recorded electronically by the
practices using appropriate codes (to distinguish fasting values from random blood
glucose values), or the patient will continue to be flagged up in subsequent searches. If,
despite a normal FBG result or OGTT, a further raised random value subsequently
occurs (≥ 11.1 mmol/L) then once again the e-Nudge will question whether or not the 
patient has diabetes by including them in Group 5, until a further FBG ≤ 6.9 or OGTT 
code is recorded, or the patient is diagnosed and added to the Diabetes register.
"Assumed values" for the missing variables means:
For systolic blood pressure: Male 135 mmHg, Female 132 mmHg
For total serum cholesterol: Male 5.7 mmol/L, Female 6.2 mmol/L
For HDL cholesterol: Male 1.4 mmol/L, Female 1.7 mmol/L
For diabetes status: positive.
For smoking status: non-smoker.
The blood pressure and cholesterol thresholds are the approximate median or mean
values in the 50–74 year age group taken from the Health Survey for England 2003 (8).
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Total population over 50 yrs
On CHD, Stroke or Diabetes registers?
Yes No
If most recent systolic BP > 150 mmHg
(>145 if patient has diabetes) Less than 75 years old?
or
most recent diastolic BP > 90 mmHg No
(>85 mmHg if patient has diabetes)
or
most recent cholesterol > 5.0 mmol/L Yes Are all of the
or last three BPs
BP or cholesterol value not recorded in >160 (systolic)
the past fifteen months or >100(diastolic)
(where available)
GROUP 1 Does the record
contain “in date”
information on all the
“Framingham variables”? No
Yes
No Yes GROUP 4
Inserting “assumed” values Estimated 10 yr CVD risk >20%
for the missing variables, based on most recent values?
would the 10 year CVD risk be >20%?
Yes No Yes No
GROUP 2 GROUP 3
Figure 6.1: Identification of Groups 1-4.
Total population over 50 yrs
On Diabetes register?
No
Is there a random blood
glucose value > 11.1mmol/L?,
without a subsequent FBG < 6.9
or ‘Normal OGTT’ code
Yes
Yes
No
GROUP 5
Figure 6.2: Identification of Group 5.
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Total population over 50 yrs
On CHD or Stroke/TIA register?
No Yes
Is there a blood glucose measurement
in the record in the past 3 years?
Yes No
GROUP 6
Figure 6.3: Identification of Group 6
The combination of groups 5 and 6 are those with ‘undefined diabetes status.’
6.3.4 Changes to Group labels
Groups 1 and 5 were later withdrawn for reasons discussed in Chapter 8, and the Group
labels in the final report were altered as follows:
Group 2 became Group B
Group 3 became Group A
Group 4 became Group D
Group 6 became Group C
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These changes were made also to emphasise the main focus of the trial, that was related
to the primary prevention population at identifiable risk of CVD (Group 3/A).
6.4 The “e-Nudge” Intervention
6.4.1 Screen reminders and lists
Following the installation of the e-Nudge software to each practice’s database, searches
occurred every 24 hours, and an automated system of reminders was created. Practice
teams had the following notifications for intervention patients identified in the
searches.
 An eight-weekly email was sent by me (based at the University of Warwick) to a
nominated member of the practice reminding them of the availability of the e-
Nudge lists stored in their system and accessible for the intervention patients.
 Reminder messages were displayed automatically on the computer screen each
time an identified patient’s electronic notes were opened. Messages take two
alternative forms in EMIS LV (for all types of reminder, not just e-Nudge): those
appearing in the bottom right hand corner of the screen, and those appearing
centrally. For practices using the corner message format, the message remains
visible for the entire consultation unless the practitioner actively minimises it. This
requires a mouse click on the screen message balloon. For those using the central
screen format, a single ‘Return’ key stroke (or a mouse click on the message
balloon) removes the message permanently from the screen for the rest of the
consultation (although if a practitioner wished to be reminded of its message s/he
could press keys Ctrl+F5 and it would appear again).
The messages contained the following wording:
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Group 1 reminder: The same as the existing QOF wording, as such patients represent
an ‘out of QOF target’ group for risk factor control.
Group 2 reminder (later Group B):
This patient may be at high cardiovascular risk, but values for the following risk
variables are either missing or out of date:
Missing variables: (Only lists those that are missing)
No recent systolic blood pressure value
No smoking status recorded
No recent total cholesterol value
No recent HDL value
Diabetes status needs clarifying
Note: Diabetes status is considered a missing variable if there is no blood
glucose value recorded in the past three years, AND diabetes would put the
patient in the high-risk category if positive)
Group 3 reminder (later Group A):
This patient’s estimated cardiovascular risk may be elevated, based on the most
recent risk variable values.
Assumptions (For this group all are listed)
Average of recent systolic blood pressures:
Smoking status:
Most recent total cholesterol value:
Most recent HDL value:
Group 4 reminder (later Group D):
This patient’s blood pressure is persistently elevated based on three consecutive
values.
Group 5 reminder:
This patient may have undiagnosed diabetes based on a previous raised blood
glucose level >11.1 mmol/L.
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Group 6 reminder (later Group C):
This CHD/Stroke patient (states which) has no recorded blood glucose measurement
in the past three years.
6.4.2 Amendments made to the wording of the e-Nudge alert messages
Fairly early feedback from practices indicated that the screen messages needed
shortening. This was particularly a problem for practices using the ‘corner alert’ format
appearing at the bottom right hand side of the screen, as opposed to those using the
centrally placed message format. This issue is discussed in Chapter 8. The messages
were reduced in length (but to contain the same information) with agreement of
Warwickshire Local Research Ethics committee, approximately nine months into the
trial. The new wording was as follows:
New Group 2 message:
Possible CVD risk. Information needed:
Missing variables:
Blood pressure
Smoking status
Total cholesterol
HDL cholesterol
Glucose
New Group 3 message:
CVD risk may be elevated, based on:
Assumptions
Average of recent systolic blood pressures:
Smoking status:
Most recent total cholesterol:
Most recent HDL:
New Group 4 message:
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Persistently raised blood pressure
New Group 6 message:
CVD but no glucose recorded in past three years
6.5 Outcome measures
The primary outcome measure was the incidence of cardiovascular events per over-50
year population (overall number of events/patient years) during the two years of the
study. Cardiovascular events are defined in the Box. The secondary outcomes were the
difference in proportion of the over-50 year population in each of the Groups between
the two arms at the end of the study. This would be measured as the mean of the last
three eight-weekly data captures. I also measured the change in proportion from
baseline.
Box: Definition of a cardiovascular event
A new diagnosis of ischaemic heart disease
A new diagnosis of cerebrovascular disease
A myocardial infarction (patient may already be known to have ischaemic heart
disease)
A transient ischaemic attack (TIA) (patient may already have cerebrovascular
disease)
A stroke (patient may already have cerebrovascular disease e.g. past stroke or TIA)
Sudden death from cardiovascular disease
An entry of ‘Angina’ in someone who is already known to have IHD was not a new
event unless it were associated with acute admission for a coronary artery procedure
e.g. angioplasty. However it was a new event in someone who did not already have
diagnosed IHD. An elective coronary artery procedure was not counted as a
cardiovascular event.
6.6 Sample size calculation
6.6.1 Outline estimate of sample required
The incidence of cardiovascular events was the primary outcome used for the power
calculation. Assuming a cardiovascular event rate of 1260 events per 100,000 person-
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years (all ages) in the control arm (9, 10) and 10% lower event rate in the intervention
arm (rate ratio of intervention to control of 0.9) I estimated that a total sample of about
70,000 patients followed up for 2 years would give 80% power at 5% significance
(two-tailed), allowing for 15% withdrawal (11). This calculation was based on all age
event rate as I was unable to find an event rate specifically for the over 50s. The
intervention was applied to the over 50 year population and I measured the outcome in
this age group only. I assumed that the cardiovascular event rate followed a Poisson
distribution, in keeping with other studies of vascular outcomes such as OXVASC (10).
6.6.2 Individual or cluster randomisation?
I considered the option of cluster randomisation, which had been raised by two local
reviewers of the e-Nudge protocol and also during the seminar that I gave at ScHARR,
discussed in Chapter 5. This approach removes any risk of contamination of the
intervention into the control arm and is generally preferable for trials of complex
interventions, but usually requires a significantly (and often prohibitively) larger
sample size. I estimated the necessary inflation of the sample (the ‘design effect’) due
to clustering (12).
The design effect is related to the cluster size and the intra-class correlation
coefficient (ICC). The ICC can be estimated using the formula:
ICC = variance between clusters/(variance between + variance within clusters)
If clustering effects are marked (giving a high ICC) then observations within
the cluster have a tendency to be similar, and a higher proportion of the variability is
between clusters. More clusters are then required to provide the same power. If the ICC
is low then the design effect is reduced. In the extreme case the ICC would be zero,
indicating that observations of the intervention effect on all individuals in the study are
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independent measures of the effect and unrelated to the cluster to which the individual
belongs.
The formula for the inflation in sample size to account for clustering is:
N+ = N(1+(m-1)ICC)
Where: N+ = sample size following inflation
N = initial sample size
m = cluster size
ICC = Intra-class correlation coefficient
When designing the trial I did not have a reliable estimate of the ICC related
specifically to this area of care. However it was clear that m would inevitably be large.
The mean number of patient records to be randomised per practice was estimated using
Primary Care Trust data to be 2355 based on the mean over 50 year population in all
practices in South Warwickshire during 2005. Even if I interpreted ‘m’ to be the
number of patients identified in the groups by the e-Nudge rather than the whole over-
50 year population, and if by excluding the large Group 2 whose size was defined
arbitrarily, I was still left with m=111 as a minimum. In fact these assumptions were
not strictly valid (as the primary outcome denominator was the over-50 year
population, not the population identified in the e-Nudge groups), but in an early
discussion document I derived the necessary sample sizes based on this value for m and
a range of ICC values taken from the published literature. I also sought informal advice
on this from Sandra Eldridge of Queen Mary’s University of London, who has special
expertise on cluster-randomisation. She suggested that a value of around 0.03 might be
appropriate for a trial of this type. Table 6.1 gives the values obtained.
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ICC Source Design effect Necessary sample
size
Zero (disregards
clustering)
1 70,000
0.0036 Kerry and Bland
(12, 13)
1.4 98,000
0.03 Advice from
Sandra Eldridge
4.3 301,000
0.045 Kinmonth et al
(14)
5.95 416,500
0.0644 Fahey and Peters
(for UK) 15)
8.1 567,000
0.199 Cosby et al (for
mean systolic blood
pressure) (16)
21.9 1,533,000
Table 6.1: A range of possible values for the intra-class correlation co-efficient and
their implications for the e-Nudge sample required based on m=111.
This very conservative approach (i.e. using the above assumption for the value of m)
demonstrated that only if the ICC were extremely small would cluster-randomisation
be an option given the practice capacity available. I considered whether there might be
some way of estimating the ICC using locally available data. I approached Greg Wells,
Consultant in Public Health at South Warwickshire Primary Care Trust for data on the
recording of vascular diagnoses across practices in the region. He provided prevalence
estimates of coronary heart disease and stroke/TIA at the practice level as well as the
indirectly standardised prevalence ratios (Figure 6.4). Whilst these data were different
from the outcomes of a trial, they were a potentially useful indicator of the extent to
which practice specific processes might influence the recording of cardiovascular
events, my primary outcome measure.
The indirectly standardised prevalence ratio (ISPR) is the ratio of
observed/expected prevalence of the condition. Expected prevalence is based on
PRIMIS data (17) and is adjusted for practice demographics. If all practices were
recording the expected number of cases electronically then the crude prevalence would
vary by practice but the ISPRs would all be about 100 if variation in practice
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demography had been sufficiently accounted for in determining expected prevalence.
Whilst this is an imprecise process, practices varied in their ISPRs from 60.5 to 124 for
CHD (a 2.1 fold difference) and from 17 to 179 for Stroke/TIA (a 10.5 fold difference,
although one of these practices was quite an extreme outlier).
I concluded from this that despite recent improvements in the recording of
these conditions described in Chapter 2, the observed variation was likely to be at least
partly a reflection of practice-level processes, and not just the risk of the condition
itself, particularly for stroke/TIA. Important factors might include the tendency of the
practice team to investigate possible vascular symptoms, the handling of hospital
discharge reports, the process through which neurovascular or chest pain clinic referral
outcomes were recorded, and the threshold for attributing symptoms to vascular events
within the practice team. Whilst there is variation in the practices of all clinicians
across UK primary care, these tendencies might be influenced by team communication
and shared learning at the practice level.
An individual patient’s risk of being on a vascular disease register was
probably determined therefore not only by the actual presence of the condition but also
by the practice that he or she happened to be registered with. This provided indirect
evidence that clustering of recorded vascular data would be significant. It was probably
unrealistic to assume a low ICC for e-Nudge study outcomes, and the option of
individual randomisation was taken.
Use of primary care data for identifying individuals at risk of cardiovascular disease
151
South Warwickshire PCT practice registers: coronary heart disease crude
prevalence and indirectly standardised prevalence ratios
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Figure 6.4: Crude prevalence (columns) and indirectly standardised prevalence ratios
(joined points) for Coronary Heart Disease and Stroke/TIA among the 36 practices of
South Warwickshire in March 2005. The practice numbers are unrelated to those used
for e-Nudge trial practices elsewhere in this thesis.
6.7 Recruitment
Practices using the EMIS LV clinical system were identified from Primary Care Trust
sources of South Warwickshire, Coventry, Rugby and North Warwickshire. This was
required to install the e-Nudge software, but no other eligibility criteria were applied.
EMIS supply clinical and administrative software to nearly 60% of UK practices, and
80% of their systems use the LV version. The majority of EMIS LV practices in
South Warwickshire PCT practice registers: stroke-TIA crude
prevalence and indirectly standardised prevalence ratios
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Coventry and Warwickshire (41 out of 71 available practices) were invited to take part
and all that were willing were accepted into the trial. An invitation letter was sent to the
senior partner (unless another GP was more clearly the lead on cardiovascular disease,
or research). I telephoned practice managers initially to prime them that an invitation
was about to be sent, and to confirm that the practice was still running EMIS LV.
Positive responses were followed up through meetings with practice managers and in
most cases presentations to general practitioners.
6.8 Randomisation and allocation concealment
As discussed above, randomisation was at the level of the individual patient record.
The e-Nudge software automatically randomised registered patients within each
practice to intervention and control arms depending on whether the last digit of the ten
digit National Health Service (NHS) number was odd or even. This number is a unique
identifier allocated to all individuals registered with the NHS and is generated using an
algorithm which takes no account of age, socioeconomic group, or any other factor
relevant to cardiovascular risk. The 10th digit is calculated according to the Modulus 11
algorithm (18) and serves as a ‘check digit’ to confirm the number’s validity.
New patients registering with a practice during the study were randomised as
soon as the NHS number was available in the record. Throughout the trial users of the
e-Nudge were kept unaware of the odd/even rule, but if an alert appeared on opening a
record it would be evident that the patient was in the intervention arm. It was made
clear to users at the outset that patients who did not trigger alerts were not necessarily
at low cardiovascular risk, as they might simply be in the control arm.
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6.9 Extracting and cleansing of outcome data
6.9.1 Primary outcome
Data on the primary outcome (CVD event rates) were collected after the first year of
the trial (for the purposes of data monitoring) and at the end of the trial. This involved
searches carried out on each practice database either by the Research Nurse Rachel
Potter (for the first year) or by myself (for the second year). The standard operating
procedure used for this collection process is given in the Appendix. It was designed to
be as straightforward as possible so that the process used for each year was the same.
For each identified patient experiencing a CVD event during the year, the entire 12
month period was examined to count exactly how many events had occurred. In the
trial protocol, we had specified that this process would only be necessary for those who
had apparently experienced more than one event during the study. But in practice this
task was greater than expected. First of all, it proved impossible to build searches using
EMIS LV that would identify only those with more than one event. Secondly, the
problem of duplicate entries for the same event was clearly commonplace. Thirdly, the
recording of an event that had in fact occurred outside the trial period was sufficiently
common that a check on all recorded events was necessary.
6.9.2 Secondary outcomes
Data on the secondary outcomes (Group proportions) were generated automatically by
the e-Nudge software. Every eight weeks the e-Nudge recorded the numbers of patients
in each group (for both trial arms) and stored these data away as Text files in the
‘shared’ folder of the practice main server. It also recorded the number registered in the
over 50 year practice population as the denominator at that particular time point. As
specified in the protocol, the average of the final three 8-weekly data collections at the
end of the 24 month trial period was used as the outcome group proportion.
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6.9.3 Quality assurance
Recording of cardiovascular outcomes is prone to several sources of error recognised in
the trial protocol (1). Not all cardiovascular events result in a new coded entry into a
primary care record, and sometimes a single event is recorded more than once using
different codes or entry dates. When a patient dies the need to record the final event
electronically is no longer a priority for clinical care, although it is usual practice to do
so. For these reasons every electronic record identified in the primary outcome searches
was examined. I also carried out a small sub-study in four practices to check whether
any sudden cardiovascular deaths had been missed. For this sub-study, extra code
groups were included in the searches to increase the retrieval of cases: ‘Death
administration,’ ‘On examination – Dead,’ and all of their lower level codes. The
results are given in the next chapter.
6.9.4 Changes to the trial protocol
In the original protocol, patients with existing CVD or diabetes whose blood pressure
or serum cholesterol were out of the QOF target were to be identified as Group 1.
However, screen alert messages were introduced to all EMIS systems to support the
QOF just before the start of the trial. This group was therefore withdrawn from the
trial.
The e-Nudge was initially designed also to identify individuals with possible
undiagnosed diabetes based on previous raised blood glucose measurements. A number
of such individuals were identified at baseline following installation of the e-Nudge
software and during the preparatory work. This led to a nationwide QRESEARCH
survey to demonstrate that such patients are identifiable across the UK (19), and the
result was the introduction of a new software module to all EMIS systems nationally to
support early diabetes detection, including of course both control and intervention
patients in the e-Nudge practices (20). This group was therefore withdrawn from the e-
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Nudge within the first six months of the trial. The QRESEARCH survey is described in
more detail in Chapter 8.
During practice visits I discussed practical issues surrounding the usability of
the software which were noted and acted on. After approximately nine months the
wording of the screen messages was shortened in response to practice feedback as
discussed above.
6.9.5 Statistical analysis and intention to treat
Analysis was carried out using STATA 10 and SAS software. For the cardiovascular
event rates the rate ratio (intervention/control) was derived with a two-tailed 95%
confidence interval. We used standard likelihood inference techniques for Poisson
counts (21). The group proportions were compared using Chi2 tests to derive two-tailed
P-values. We analysed data from all patients whether or not their computer record had
been accessed by primary care staff during the trial (i.e. whether or not they had
actually been exposed to the intervention).
One practice withdrew from the study after less than six months, but consented
to its data being included in the analysis. However the automatically captured group
data were no longer available from this practice after the software was switched off, so
only the cardiovascular event rate data were used as part of the final analysis. In
another practice, a failure of data capture occurred at baseline and the earliest data
available at this site were extracted after the intervention had been in place for 25 days.
6.10 Summary
The design of the e-Nudge trial was tailored to the pragmatics of routine primary care.
In particular, the screen reminders took the same format as the QOF alerts, but perhaps
most significantly, they drew on the most recent risk factor data available in the record
to identify potentially at risk individuals. This approach supported contemporary (and
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more recent) guidelines towards case finding for CVD risk in a situation where pre-
treatment values (of serum cholesterol and blood pressure) are often unavailable,
whether or not they are considered preferable to current values as a means of defining
this risk.
Two of the original six e-Nudge groups were withdrawn from the intervention
for practical reasons. The first of these withdrawals resulted from the arrival of
identical alerts into routine care as part of the QOF during 2005/06. The second
involved the identification of patients with possible undiagnosed diabetes, and led on to
a separate project resulting in new reminders established nationally as part of routine
care for all EMIS users.
The next chapter will detail the results of the trial recruitment, the baseline data
extraction, the quality assurance sub-study, and the effect of the intervention on
primary and secondary outcomes.
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Chapter 7: Results of the e-Nudge trial
7.1 Introduction
The general hypothesis tested through the e-Nudge trial was that an automated system
of electronic reminders operating in the environment of routine primary care could
usefully support CVD prevention in UK general practice. A number of more specific
hypotheses defined the trial outcomes. These included not only clinical events but also
process measures relevant to the estimation and control of cardiovascular risk. Some of
the following text is adapted from the e-Nudge trial final report accepted by the British
Journal of General Practice.
7.2 Practice recruitment and study population
7.2.1 Approaching practices
Each practice was offered a visit and presentation to the general practitioners to explain
the trial and gain their written consent. Fourteen practices accepted this invitation, four
were recruited through a less formal meeting with the key GP partner, and one accepted
without the need for a visit (other than to meet the practice manager, which happened
in all cases). The 19 practices had a combined list size (all ages) of approximately 121
000, of which 38 147 were in the over 50 year age group at baseline. The practices
were based in diverse settings including rural, suburban and inner city environments.
The practice list sizes varied from fewer than 2000 to greater than 14,000 patients, and
from single handed practitioners to large group practices with more than six partners. I
estimated 77 208 person years of follow up over two years (38 382 for intervention
participants and 38 826 for control participants). Recruitment began in May 2006 and
was completed in September 2006. The first practices started using the e-Nudge on 6th
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June. A total of four waves of installation occurred during the summer of 2006 each
involving four or five practices.
7.2.2 Revision of the sample size calculation
The original sample size calculation used an expected CVD event rate based on ‘whole
population’ level incidence data (from the British Heart Foundation (1) and the
OXVASC study (2)). With statistical advice, I initially estimated that 70,000 of all ages
were required, and this is the figure published in the trial protocol (3). This figure
appeared to be comfortably reached by the 121,000 patients registered with the 19
practices. After the trial began however, new statistical advice suggested that the
70,000 figure was in fact that required for the over-50 year population alone. This left
me in a dilemma as the study appeared to be under-powered for the primary outcome.
However, I assumed that a significantly higher event rate in this older age group might
well offset this reduction in power, and I decided to continue. It would have been very
difficult to have recruited sufficient numbers for this re-estimated sample with existing
resources, and the (perhaps equally important) secondary outcomes were likely to be
very adequately powered.
7.2.3 Age distribution
The age structure of the over 50 year population in each practice is given in Table 7.1
and Figure 7.1. This demonstrates the range of practice list sizes, but practices also
varied considerably in the proportion of the over 50 year population that were over 75
years with range 0.09 to 0.51.
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Practice
No
Number of
patients 50-74
years
Number of
patients over 75
years
Proportion over 50
years also over 75
years
1 958 231 0.19
2 247 137 0.36
3 1902 837 0.31
4 837 195 0.19
5 1629 596 0.27
6 629 144 0.19
7 2807 900 0.24
8 2454 941 0.28
9 2146 785 0.27
10 2614 796 0.23
11 1586 428 0.21
12 2161 789 0.27
13 2128 636 0.23
14 846 321 0.28
15 1301 330 0.20
16 826 266 0.24
17 673 700 0.51
18 1257 125 0.09
19 471 123 0.21
Table 7.1: Numbers of patients in age groups 50-75 years and over 75 in each practice
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Figure 7.1: Numbers of registered patients identified 50-74 years and over 75 years in
each practice.
The e-Nudge population was very similar to the overall UK population taken from the
Office of National Statistics (Figure 7.2), but with a slightly smaller 50-74 year
population. The estimates for the e-Nudge 0-49 year age groups were not known quite
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as accurately as those of the over 50 years group, whose value at baseline was known
exactly through automated data capture.
Age structure of study population
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Figure 7.2: Age structure of the study population and background UK population.
7.2.4 Deprivation and coronary heart disease standardised mortality ratios
Demographic variables were obtained from Primary Care Trust sources for the study
population. These demonstrated a range of coronary heart disease indirectly
standardised mortality ratios (SMR) ranging from 74 in Stratford to 110 in North
Warwickshire. The Index of Multiple Deprivation scores for the Super Output Areas of
the practices ranged from 8.35 in Stratford to 67.03 in Coventry, whilst the Health
Deprivation and Disability Score ranged from -0.79 to 1.86. All four quartiles of the
deprivation scores for England were sampled during the recruitment of practices (Table
7.2).
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Practice
Number
Index of
Multiple
Deprivation
Health related
Deprivation
CHD
SMR
Stratford
area
Practice
score
Quartile Practice
score
Quartile
74
1 8.35 4 -0.68 4
6 10.27 3 -0.78 4
15 9.83 3 -0.61 3
19 8.95 4 -0.92 4
2 9.95 3 -0.79 4
Warwick
area 75
8 21.14 2 0.12 2
7 14.65 3 -0.26 4
Coventry 89
10 11.63 3 -2.8 4
18 51.26 1 1.29 1
3 23 2 0.46 2
11 43.69 1 0.92 1
16 67.03 1 1.86 1
9 23.94 2 0.28 2
17 55.52 1 1.75 1
Rugby 94
4 13.64 3 -0.44 3
12 18.69 2 -0.1 3
North
Warwick
shire 110
14 27.32 2 0.57 2
5 31.44 1 0.8 1
13 28.99 2 0.66 2
Table 7.2: Deprivation indices for the super output areas of the trial practices and
Coronary Heart Disease indirectly standardised mortality ratios (based on ICD-10
I20-I25). The deprivation quartile 1 is the most deprived, and 4 is the least deprived.
7.3 Baseline characteristics of control and intervention arms
The numbers identified at baseline in e-Nudge Groups A-D are given in Table 7.3.
There were no significant differences between the trial arms, except for Group B
(originally Group 2), where more were identified in the intervention arm, although this
was of borderline significance. This was the group that identified individuals with
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missing data but potentially at risk of CVD. I discussed this with our statistician Dr
Tim Friede. He advised that as the group was only one of numerous groups, this
finding did not necessarily question the validity of a randomisation technique that was
very unlikely a priori to be biased. Group 2/B was defined in terms that were
essentially arbitrary (e.g. the cut off values for risk factor thresholds). Alternative
choices for these parameters would have identified overlapping but non-identical
groups, and each would have a slightly different control/intervention ratio. It happened
that the group definition that I chose displayed a small but significant (at the 5% level)
excess of intervention patients. All the other groups, as well as the original Groups 1
and 5 that were later excluded from the trial (see Chapter 8) had baseline ratios that
were not significantly different from unity.
I was unable to measure any other characteristics of the groups identified (such
as age, sex, or other risk factor distributions), as the e-Nudge was designed only to
record the actual numbers. Nevertheless these figures provided an estimate of the
relative proportions with adequate data for a risk estimate (5.93%) compared with those
who would require further data collection to support an estimate but might be at high
risk (26.40%). In a brief report to the British Journal of General Practice (4) we
presented these data as a cross-sectional survey and discussed the possible implications
for NHS priorities and resources. I was also able to measure the proportion of the over
50 year population in the original Group 1, those with existing cardiovascular disease
or diabetes whose blood pressure or cholesterol levels were out of target for the QOF
(9.10%). This demonstrated that the population at immediately identifiable risk (based
on CVD risk factors that are only partially modifiable) is significantly smaller than the
population with clearly modifiable risk factors. This might be relevant to the issue
discussed in Chapter 3 over the appropriate allocation of resources. The data presented
in Table 7.3 followed a minor correction to those published in BJGP (required due to a
data capture problem at baseline in one practice) but this did not significantly affect the
proportions identified.
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The finding that most patients in the study population require further data
collection is unsurprising and concurs with the findings of Marshall et al in the
Sandwell project (5, 6). The proportion identified in Group A (those with identifiably
high risk) might be compared with the number expected to be at high risk in the
population (if all patients were invited for completion of data and then risk assessed).
This figure is given as 22.8% for men and 7.9% for women in the JBS2 for the 40-75
year age group at the >20% over 10 year level. Increasing the visibility of this group to
practice teams was the function of the e-Nudge intervention, by targeting those most
likely to produce a raised risk level if their risk profiles were completed (Group B) to
raise the prevalence of identifiably raised risk (Group A).
Numbers
identified
at baseline
Proportion of
over-50 year
population
(%)
Intervention Control
P value
(H0 = no
difference
between
arms)
Total Popn 38147 100 18 912 19 235 0.099
Group A 2 261 5.93 1 124 1 137 0.894
Group B 10 069 26.40 5 079 4 990 0.043
Group C 1044 2.74 525 519 0.641
Group D 170 0.45 81 89 0.614
Table 7.3: Numbers identified and proportions of the over-50 year population in each
Group at baseline.
7.4 Trial denominator populations
Following installation of the e-Nudge software, the over 50 year denominator
population was measured as discussed above. This denominator changed during the
trial due to natural migration effects (new people registering with practices and those
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moving away from the area). In addition, one practice withdrew from the trial after less
than 6 months. For the purposes of measuring the primary outcome (CVD event rates),
for which I was able to include this practice (for the purpose of intention to treat), I
calculated the mid-trial denominator population on the basis of all 19 practices. For the
secondary outcomes (Group proportions) I was unable to include the practice that
withdrew as the e-Nudge was switched off and therefore no longer able to generate the
eight weekly reports. The result was that three denominator populations were used: the
baseline denominator, the mid-trial denominator, and the final denominator at the end
of the trial. Table 7.4 provides these denominator data.
Baseline population
(19 practices)
Estimated mid-trial
population for primary
outcome
(19 practices)
Outcome population for
secondary outcomes
(18 practices)
Int Contol Overall Int Contol Overall Int Contol Overall
18912 19235 38147 19191 19413 38604 18021 18071 36092
Table 7.4: Denominator population values during the e-Nudge trial. For the purposes
of Intention to Treat the data from all 19 practices were used for the primary outcome
measure (cardiovascular event rates), and to estimate the mid-trial population even
though by this time one practice had withdrawn.
7.5 Primary outcome: cardiovascular event rates
A total of 2121 individual records were examined in the search for new events during
the two years of the trial. This process detected 930 events occurring in the trial
population. In year one 492 events occurred in 454 individuals (21 experienced two
events, 7 experienced three, one experienced four). In year two 438 events occurred in
412 individuals (19 experienced two, 2 experienced three, and one experienced four).
Because the annual searches were run separately it is not known how many individuals
affected in year 1 were also affected in year 2.
The cardiovascular event rates in the intervention and control arms are given in
Table 7.5. The rate ratio was 0.96 [95% confidence interval 0.85 - 1.10], two tailed
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P=0.59 indicating a non-significant difference. These confidence intervals were
estimated using an inference technique for Poisson counts described by Ng and Tang
(7).
Cardiovascular
EventsArm
Year 1 Year 2 Total
Patient years
of follow up
Rate/100,000
population/year
Intervention 235 219 454 38 382 1183
Control 257 219 476 38 826 1226
Overall 492 438 930 77 208 1205
Table 7.5: Cardiovascular event rates in the two arms of the trial
7.6 Secondary outcome measures: proportions in Groups A, B,
C and D
The overall proportion of the over 50 year trial population identified in each arm at the
end of the trial is given for the four e-Nudge groups (A-D) in Table 7.6. The
differences (intervention-control) in this outcome for each group at the end of the trial
are given in the final row. These were the secondary outcome measures for the trial. I
also measured change from baseline for each group.
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Percentages in groups (number in parentheses)
Group A Group B Group C Group D
Intervention
Baseline
(N=18912)
5.94 (1124) 26.9 (5079) 2.78 (525) 0.43 (81)
Outcome
(N=18021)
8.91 (1606) 19.4 (3502) 0.55 (99) 0.33 (59)
Absolute
change (%)
2.97 -7.48 -2.23 -0.10
Control
Baseline
(N=19235)
5.91 (1137) 25.9 (4990) 2.70 (519) 0.46 (89)
Outcome
(N=18071)
6.97 (1260) 23.1 (4177) 1.01 (183) 0.31 (56)
Absolute
change (%)
1.06 -2.83 -1.69 -0.15
Intervention-
Control
difference at
outcome [95%
confidence
interval]
1.94
[1.38; 2.50]
P<0.0001
-3.68
[-4.53; -2.84]
P<0.0001
-0.46
[-0.64; -0.28]
P<0.0001
0.02
[-0.10; 0.13]
P=0.7679
Table 7.6: Group proportions in the baseline and outcome populations by trial arm.
(Group A: Patients who are not known to have cardiovascular disease or diabetes, are
under 75 years old, and whose most recent Framingham variable values indicate that
their CVD risk level is raised. Group B: Patients who are not known to have
cardiovascular disease or diabetes, are under 75yrs old, and whose risk profile is
incomplete – more information is required to perform a risk estimate - but whose CVD
risk would be greater than 20% if the “assumed” values of the missing factors were
used. Group C: Patients with CVD but not diabetes, who have not had a blood glucose
measurement in the past three years. Group D: Patients who are not known to have
cardiovascular disease or diabetes, are greater than 75yrs old and who have
persistently elevated blood pressure based on the three most recent consecutive
readings.)
The percentage increases and reductions in this table are absolute rather than relative
changes. A significant increase in the number identified in Group A (those whose
raised risk was identifiable due to adequate risk factor data) occurred with a
corresponding reduction in Group B (those with incomplete profiles but potentially at
risk). A reduction was also seen in Group C (those with CVD but no recent blood
glucose measurement). Whilst there were background improvements in the control
population during the study, the improvements in the intervention arm were
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significantly greater for these three groups. However no significant change was seen in
intervention patients over 75 years with persistently raised blood pressure (Group D).
7.7 Practice level changes in group proportions
Considerable variation was seen between practices in the impact of the e-Nudge on
group proportions. The change in proportion of intervention patients identified in the
four groups in each practice during the trial is an indicator of the degree to which
different practice teams responded to the reminders. For example, the median absolute
increase in the Group A proportion was 3.45% with range -1.3% to 8.2%. The median
absolute reduction in the Group B intervention population was 5.1% with a range 2.5%
to 20.3%. These values are given in Table 7.7 for all the practices. For Group A, 8 out
of 18 practices demonstrated change that was not significant at the practice level.
Changes in Group B proportions were significant in all but three practices. Groups 4/D
and 6/C are not tabulated as the numbers are small and generally non-significant at the
practice level.
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Table 7.7: Intervention patients identified as proportion of the over 50 year population at baseline and after two years in the eighteen practices that
completed the trial for groups A and B. Those marked * are not significant at the 5% level.
Group A Group B
Practice
Baseline
(%)
Outcome
(%)
Change
(%) P value
Baseline
(%)
Outcome
(%)
Change
(%) P value
1 4.2 11.5 7.3 <0.001 42.7 27.3 -15.4 <0.001
2 5.3 6.3 1 0.207* 30.2 27.7 -2.5 0.098*
3 6.8 10.5 3.7 <0.001 24.4 13.3 -11.1 <0.001
4 4 12.2 8.2 <0.001 38.5 18.2 -20.3 <0.001
5 5.8 9.9 4.1 0.072* 21.5 12.2 -9.3 0.004
6 10.9 9.7 -1.2 0.519* 22.4 19.1 -3.3 0.163*
7 8.7 7.4 -1.3 0.194* 26.1 23.4 -2.7 0.094*
8 4.8 7.5 2.7 0.059* 18.3 13.5 -4.8 0.025
9 6.3 12 5.7 <0.001 21.9 16.8 -5.1 0.002
10 7.2 8.8 1.6 0.066* 16.5 13 -3.5 0.009
11 5.6 7.6 2 0.024 21.7 18.3 -3.4 0.023
12 5.3 9.1 3.8 0.001 33.4 20.4 -13 <0.001
13 5.1 8.3 3.2 0.001 27.6 23.8 -3.8 0.017
14 5.1 10 4.9 0.001 28.2 17.6 -10.6 <0.001
15 2.9 7.3 4.4 <0.001 42.1 29.6 -12.5 <0.001
16 8 9.8 1.8 0.511* 18.3 10.4 -7.9 0.038
17 7.3 12 4.7 0.007 24.4 16.4 -8 0.001
18 4.5 5.4 0.9 0.582* 9.8 5.5 -4.3 0.020
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However, some of this change was due to secular (non-study related) effects also
influencing the control population, improving adequacy of CVD risk factor data during
the trial. The Box gives a vignette of how the e-Nudge influenced care in the practice
with the median list size.
Box: Example of how the e-Nudge helped a practice identify patients for CVD risk
reduction
The median list size practice in this study had 1381 registered patients over 50 years at
baseline, of which 681 were in the intervention arm.
After installing the e-Nudge, 35 patients were identifiable at raised cardiovascular risk
based on existing data (Group A) whilst 192 patients were possibly at risk but required
further data for a risk estimation (Group B).
After two years of using the e-Nudge during routine care there were 65 patients
identifiably at risk, whilst the number requiring further data had fallen to 114 patients.
Lists were available of these groups making them easy to target for risk reduction
interventions including lipid lowering therapy, or completion of risk profile data.
Some of these changes would have happened anyway due to background improvements
in data quality. However, the 700 control patients in this practice showed a lower rise in
Group A (from 38 to 50 patients) and a fall in Group B of only 38 (from 211 to 173).
7.8 Quality assurance sub-study
As described in Chapter 6, a small sub-study was undertaken in four practices to assess
the rate of fatal unrecorded events. In addition to the 73 events already confirmed in
these four practices through the standard searches, a further 34 records were then
identified (that included deaths from all causes). When these extra notes were examined,
two definite ‘missed’ cardiovascular deaths were identified. A further two possible
missed events were found, but it was not clear from the information available whether
these satisfied the definition of a cardiovascular event used in this study. Depending on
whether we assume two or four missed events, this suggests that either 2.6% or 5.2% of
events are missed by the standard searches. This error should apply equally to both
arms of the trial. This proportion is similar to the rate of ‘unclassifiable deaths’
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measured at 3% in the OXVASC study (2), which estimated CVD events using a
combination of ‘hot’ and ‘cold’ pursuit methods. The OXVASC investigators used the
term ‘unclassified’ to mean that the CVD event could not easily be attributed to a
particular cardiovascular territory (coronary, cerebral, or peripheral), rather than
questioning whether or not it was vascular in nature. In our study, the undetermined
events were not necessarily vascular, but no other cause was evident on thorough
perusal of the medical records (including hospital letters in the primary care notes), and
no evidence for a final illness was found, so that the event was certainly acute, if not
definitely vascular.
7.9 Intention to treat
I applied the intention to treat principle (ITT) in two ways through this study. First of
all, the e-Nudge was in principle applied to the whole over 50 year population, but only
those presenting to the practices were likely to be exposed to the intervention, as the
screen reminder messages required that notes were accessed by practice staff. This was
likely to happen only if the patient interacted with the practice in some way. There was
little evidence through my field notes and discussions with practices that the lists of
intervention patients had actually been used systematically. However, the denominator
for the primary and secondary outcomes was the entire over-50 year population, not
simply the subgroup that had been exposed.
Secondly, I applied ITT in measuring the primary outcome, by including the
cardiovascular event rate data from the practice that had withdrawn after less than 6
months. This practice population had spent most of the two year study period with the
e-Nudge switched off, but its data were included in the primary outcome analysis. It
was impossible for technical reasons to include them in the secondary outcomes, as the
group proportion data required the e-Nudge to store the information automatically in
the practice’s main server.
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7.10 Conclusions of the e-Nudge trial
The e-Nudge trial demonstrated a significant effect of automated electronic reminders
on processes of care related to CVD risk reduction. These processes involved
specifically the adequacy of data relevant to cardiovascular risk in general practice.
Interpretation of electronic data is only one element of the clinical assessment of CVD
risk, but it is an important one in current practice. Assessing risk of CVD is only
possible through the algorithmic processing of information, which is very amenable to
software support for the clinician. Processing of routinely collected data not only
facilitates targeted CVD risk reduction interventions, but also the completion of risk
factor profiles in those most likely to benefit from this exercise. It might be hoped that
given a longer timescale the benefits on processes of care would result in improvements
in hard clinical outcomes, but it was not possible to demonstrate such an effect within
the two year duration of the trial. Variation in response to the reminders between
practices was quite noticeable. This finding is in keeping with the results of the
systematic review described in Chapter 4. Further work is required to clarify the
organisational and contextual factors that determine responsiveness in this particular
clinical area.
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Chapter 8: The research process
8.1 Introduction
The e-Nudge trial tested the effects of applying a cardiovascular risk algorithm to a
practice population and flagging up identified individuals during routine care. In
designing and implementing the trial I was aware that cardiovascular prevention is
delivered at a personal as well as at a practice based level. Individual needs and
priorities are bound to influence this activity. The sociological aspects of CVD risk
reduction became important to the research process and are probably important also for
addressing the CVD prevention problem in general practice, although this topic is too
broad to investigate within this thesis. This chapter discusses insights gained through
the practicalities of conducting the e-Nudge research.
It might be assumed that the identification of raised cardiovascular risk in an
environment where a clinician is immediately available to prescribe treatments known
to reduce this risk would reliably influence professional behaviour, patient choices, and
perhaps ultimately clinical outcomes. The e-Nudge intervention, as discussed in
Chapter 7, had a significant impact on process outcomes but the variation in this effect
between practices was wide. At the outset I postulated that a number of factors might
influence receptiveness to its flagging mechanisms. These included both clinician and
patient factors, as well as factors related to the practice environment and the prevailing
organisational context of primary care under the newly established QOF. I took detailed
field notes throughout the PhD project together with a number of informal surveys in a
test practice. I also carried out a series of in-depth interviews with members of the
public registered with one of the e-Nudge practices. The field notes are the basis for
much of the detail described in this chapter. The interview transcripts were subjected to
a thematic analysis, and these are given in the Appendix.
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8.2 Designing the e-Nudge software
8.2.1 The software platform
EMIS’s Medical Director David Stables chose to programme the e-Nudge using their
LV software platform, a version of the EMIS clinical system that is older than their GV,
PCS, and (most recent) EMIS-Web systems. EMIS-Web is a web-based platform that
can support either LV or PCS, but was not sufficiently developed to be available to us
when the e-Nudge was originally conceived. Few EMIS practices use GV as this was
superseded by PCS but the majority (80%) were still using LV at the time of the trial. I
was familiar with the LV system in my previous North Yorkshire practice. The LV
version of EMIS is supported by an older operating system but retains certain features
(including search functions) that are considered superior to the newer PCS. A Primary
Care Trust source told me that many of the practices in the city of Coventry began using
EMIS LV following a wave of computerisation during the early 1990s, in which this
version was encouraged in that area. Of the options available LV was certainly the
commonest and therefore offered the best recruitment potential.
8.2.2 Choice of CVD risk algorithm
During the e-Nudge trial the QRISK algorithms were published, and an ongoing debate
began over the relative merits of these new, UK population based algorithms compared
with the long established Framingham equation. However the design phase of e-Nudge
preceded these developments and the question at this stage was simply over which
‘version’ of Framingham to use. I was aware that the approach recommended in the
back sheets of the British National Formulary (a widely circulated publication updated
every six months) utilised risk charts that were essentially based on Framingham but
simplified to include age bands rather than individual ages. I found it difficult to find a
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published source for the programming behind these charts, or for other electronic risk
calculators that were available. One of these, designed by Hingorani and Vallance was
published in the British Medical Journal (1) and had been recommended in the NSF for
CHD 2000 (2). I had originally contacted Aroon Hingorani for advice on this in 2003.
He named the Anderson 1991 paper (3) as one of the most relevant descriptions of the
Framingham algorithm. The BNF charts were designed according to the 1st Report of
the Joint British Societies (4) but this did not actually provide equation coefficients.
Whichever risk equation were used, such coefficients would be required to programme
the e-Nudge into the EMIS system. I then contacted Rupert Payne at Edinburgh
University, who programmed the on-line CVD risk assessment algorithm that I myself
use in practice and which includes both the BNF/JBS algorithm and various
Framingham options such as CVD, CHD, and Cerebrovascular disease
(http://cvrisk.mvm.ed.ac.uk/calculator.htm). He explained the broad issues around the
programming of the risk charts and how he had translated the Framingham algorithm
into a usable on line calculator based on these principles, which he agreed were not
clearly evident in the literature.
In December 2005 the JBS2 report was published, a document that might have
impacted on the e-Nudge design as it explained with greater clarity than previous
sources exactly how these risk charts are constructed. The age bands (less than 50, 50-
59, and over 60 years) were based on a calculation that assumed an age of 49, 59, or 69
years respectively. In addition, the Framingham algorithm that was used involves a
summation of the CHD and cerebrovascular disease risk functions, but excluded heart
failure and peripheral vascular disease outcomes in the risk estimate. The full CVD
algorithm includes all of these.
It was not at all clear to me that this approach was appropriate, particularly in a
research context where the age assumption might be difficult to defend. Essentially the
BNF risk charts would give a 42 year old a risk estimate based on an age input of 49
years. In other words, the most accurate risk estimate available to the clinician is not the
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one that is explained to the patient. I was careful not to allow my own personal opinion
to dictate the choice of approach for e-Nudge, but I became aware through discussions
with a number of others that they shared my view. Tom Marshall did not include the
age assumption in his Sandwell project (5), nor in his other project published in the
British Journal of General Practice in 2006 (6). Peter Brindle and Julia Hippisley-Cox
were not using it for the QRISK project (7, 8). However, in the latter example they did
define the Framingham algorithm as the summation of CHD and cerebrovascular
disease risks rather than the full CVD equation, and if I were starting over again I
would also have designed the e-Nudge using only these outcomes. In opting for the
unmodified Framingham CVD algorithm I was also aware that should the e-Nudge
prove in the trial to be an effective intervention, I would need to be able to describe its
structure in detail to academics or clinicians anywhere in the world. These would
include those from countries outside the UK who might not consider the JBS age
adjustments appropriate in their setting.
By the New Year 2006 it was becoming late anyway to make significant
changes, particularly as the Ethics committee had already approved the trial protocol.
At this stage I was hoping to install the e-Nudge into the participating practices within a
few weeks, and this could only follow successful performance testing of the software as
described below. March 31st 2006 would mark the end of the second QOF year, making
it unlikely that the trial practices would in fact be ready to engage until the late spring,
but I wanted to be ready to go ahead in early April. The earliest practices actually
commenced on June 6th 2006.
8.2.3 Programming the e-Nudge software
The e-Nudge software was programmed for EMIS LV during early 2006. This work
had followed my initial meetings with Newchurch during 2004/05 using their South
Warwickshire data warehouse hosted in Teddington, described in Chapter 5. At the time
of the August 2005 Ethics application, I was still expecting Newchurch to provide the
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trial platform, but as discussed in Chapter 5, this proved not to be possible. The final
phase of the e-Nudge design was consolidated at a meeting in EMIS’s Rawdon, Leeds
head quarters on 20.3.06 with David Stables. During this meeting a number of issues
were clarified including the definition (based on electronic data) of a non-smoker, an
issue that I had also discussed with Newchurch.
My tasks following this meeting were to send David Stables the equations and
co-efficients of the Anderson Framingham algorithm, together with some examples for
testing following his programming. We planned to install the e-Nudge into the test
practice (Kenyon Medical Centres, Coventry) on 1st May 2006. Further discussions
were carried out by email and telephone and included EMIS’s Clinical Design Director,
Shaun O’Hanlon. All three of us were trained as general practitioners, increasing our
ability to identify important practical issues related to the process of identifying CVD
risk at the point of care.
The equation co-efficients are given in the Appendix. I invented some case
examples for CVD risk calculations and personally tested them using our Framingham
equation. These were effectively ‘back of an envelope’ calculations and required no
computer software other than a pocket calculator, but each step was recorded in detail
in the field notes. The purpose of this exercise was to check that the algorithm that we
intended to programme into EMIS as the e-Nudge would faithfully reproduce the
estimates available elsewhere. Having calculated the risk level for each case based on
the four component equations of the Framingham algorithm (see Figure 8.1 below), I
then used Rupert Payne’s Edinburgh University risk calculator on the same examples.
μ = Σ βixi
 σ = exp(θ0+θ1μ) 
u = (ln(t)-μ)/σ 
p = 1 - exp(-exp(u))
Figure 8.1: Four components of the Anderson 1991 Framingham algorithm (3)
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Example 1: Male, aged 55 years, no diabetes, non-smoker, total cholesterol 5.2
mmol/L, HDL 1.2 mmol/L, systolic blood pressure 142 mmHg, no left ventricular
hypertrophy (LVH).
e-Nudge calculation (from my field notes):
µ = 18.8144-(7.391)-(6.9540)-(0.7904)
= 3.679
σ = exp(0.6536-0.2402x3.679) 
= exp(-0.23009)
= 0.79446
u = 2.3026-3.679/0.70446
= -1.7325
p = 1-exp(-exp(u))
= 1-exp(-0.1768)
= 1-0.838
= 16.2% (probability of a CVD event over 10 years)
CVD Framingham score (from http://cvrisk.mvm.ed.ac.uk/calculator.htm): 16.2%
Using the same process on other examples (without showing the working from the field
notes):
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Example 2: Male, aged 55 years, no diabetes, smoker, total cholesterol 5.2 mmol/L,
HDL 1.2 mmol/L, systolic blood pressure 142 mmHg, no LVH (i.e. same as Example 1
but a smoker).
e-Nudge calculation: 27.6%
CVD Framingham score: 27.6%
Example 3: Female, aged 51 years, with diabetes, smoker, total cholesterol 6.2
mmol/L, HDL 1.2 mmol/L, systolic blood pressure 138 mmHg, no LVH.
e-Nudge calculation 33.1%
CVD Framingham score: 33.1%
Example 4: Female aged 62 with diabetes, smoker, total cholesterol 5.0 HDL 1.5,
systolic blood pressure 162 mmHg, LVH present.
e-Nudge calculation: 55.7%
CVD Framingham score: 55.8%
(I considered it safe to assume that this discrepancy was due to rounding up errors.)
Example 5: Female, aged 50 years, non-smoker, no diabetes, total cholesterol 6.8
mmol/L, HDL 2.0 mmol/L, systolic blood pressure 140 mmHg, no LVH.
e-Nudge calculation: 6.1%
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CVD Framingham score: 6.1%
To clarify, we were not intending ever to calculate the CVD risk of a person
known to have diabetes, but the diabetes input was required for e-Nudge because for
Group 2/B (those with incomplete data but potentially at high CVD risk) it uses positive
diabetes status as an ‘assumed value’ for anyone with no blood glucose on record for
the past three years (and in whom it therefore might be unsafe to rely on their absence
from the diabetes register). The Edinburgh on-line algorithm now no longer requests
diabetes status as an input, but at the time that these field notes were recorded it
continued to do so, facilitating our ability to test the e-Nudge against what I considered
to be a ‘gold standard’ tool.
These five examples (and a number of others that I tested but did not record in
field notes) made me confident that the algorithm we planned to use for e-Nudge was
effectively reproducing the Edinburgh Framingham CVD risk calculation. We had
tested it in both sexes, with a range of cholesterol and blood pressure values, and in the
presence and absence of both diabetes and of left ventricular hypertrophy. Even though
five is not a large sample, this testing process should have detected any discrepancy, as
errors in co-efficient values or equation structure would almost certainly have been
amplified during what was a fairly complicated, non-linear computation.
8.2.4 Randomisation mechanism
The e-Nudge was programmed to randomise automatically patients on the basis of the
last digit of their ten digit NHS numbers. This number does not change, and is
permanently available in the record as soon as the patient registers with the practice (or
very shortly after). We considered the alternative used in other studies (9) of using the
computer record number as the basis for randomisation. However, in UK practice these
numbers tend to be allocated sequentially (i.e. in numerical order) as patients register.
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This means that two patients registering on the same occasion (such as a married
couple) would have almost inevitably received adjacent numbers. Because adjacent
numbers are always different in their odd/even allocation, married couples would have
tended consistently to be allocated to different treatment arms. Randomisation by NHS
number overcomes this as the last digit is derived using the Modulus 11 algorithm (10)
and there is no such tendency. However, despite the fact that my NHS number approach
was more random than the computer number approach, the trial might still be termed
‘quasi-randomised’ rather than truly randomised, according to the definition used by
Shojania et al (11).
8.3 Troubleshooting the software
8.3.1 Performance testing the software ‘live’ in the test practice
The next stage was for David Stables to programme this algorithm into EMIS LV along
with the other components of the overall e-Nudge algorithm and install it into the test
practice, which he did to schedule, and my first opportunity to investigate its
performance in the test practice was on 5.5.06.
It was by no means obvious that the success of our algorithm demonstrated in
my field note calculations would automatically produce the same results when
programmed in to a practice database. The challenge of achieving this transition is an
important focus of this research, as it depends on the ability of the algorithm to draw on
existing, routinely collected data to support automated risk calculations. Many different
issues are involved in this transition, most importantly the specific choices of risk factor
Read codes used to feed into the algorithm. These were essentially selected by David
Stables and were similar to the codes serving a similar CHD (not CVD) risk assessment
tool already available in EMIS LV. We also discussed the choice of Read codes in some
detail with Shaun O’Hanlon. My main role was to check whether our choices and
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assumptions had succeeded in producing a workable CVD risk algorithm producing
valid risk estimates for everyday UK primary care.
However, the testing stage of the e-Nudge programme explored more than this
issue alone. I was interested not only in confirming that the programme would
accurately identify those with a high Framingham risk score, but also in the likely
impact of the software during routine practice, as this would determine its utility and
acceptability for general practice teams.
During this testing phase (May 2006), I gained permission from the test
practice to look at the lists generated by e-Nudge and the reminder messages that it
triggered. At the time of this process I was working as a part time locum GP in the test
practice. I had Ethics committee approval for the trial and the permission of the
appropriate Caldicott guardians to ensure that the software was ‘fit for purpose’ to
answer the questions addressed by the research. I also had the permission of the practice
to investigate any problems identified.
The initial result of the e-Nudge applied to the test practice database on 5.5.06
is given in Table 8.1. The total practice population at this time (of all ages) was 11,086.
Over-
50 popn
Group
1
Group
2
Group
3
Group
4
Group
5
Group
6
Intn 1737 203 541 131 10 1 69
Control 1685 233 456 123 4 0 67
Table 8.1: Initial Group proportion results at the test practice on 5.5.06.
Group 3 was the main group of interest, as these were the patients with
sufficient risk factor data for a risk estimate and at identifiably raised CVD risk. This
result produced a replication of the work that I had attempted remotely at Newchurch’s
Teddington database, as described in Chapter 5. But it felt much more real, because the
patients involved were identifiable within the practice and, provided they were in the
intervention arm, reminder messages would appear on the screen whenever their notes
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were opened. This provided the potential for feedback that I had sought in designing the
trial.
My next task was to investigate the impact that the identified individuals (and
their screen alerts) might have on everyday practice. To do this, I needed to find out
what proportion of patients seen in clinics on that day (and on subsequent days of
testing) would have generated e-Nudge reminders, and of which type. This would give
an indication over whether the intervention would be sufficiently ‘high profile’ to be
noticed by health professionals in the everyday working environment. It might have
been the case, for instance, that the people identified were all ‘hard to reach’ or
housebound patients who were rarely seen in the practice to have their notes accessed.
If so, the e-Nudge would probably be too inconspicuous to make an impact on practice
activity. At the other extreme, if e-Nudge alerts were likely to be triggered for the
majority of patients seen during an everyday clinic, the practitioners might (at best) tire
of it and become less responsive to the reminders. At worst, they might conclude that
involvement in the e-Nudge trial was too disruptive to everyday workflow and decide to
withdraw. Even during May 2006, with software installation planned in the very near
future, the opportunity remained to tune the e-Nudge parameters if either extreme had
become apparent during this testing phase.
This question, explored through the testing of the software in Kenyon Medical
Centres during May 2006, could not easily have been addressed without this field work.
Even though the Framingham algorithm was well defined, its co-efficients confirmed
and validated, and its structure programmed into the necessary clinical software, it was
impossible to predict how many people would be identified during an average working
day in current UK general practice. A rough estimate of the proportion of patients
identifiable in each group had been gained through the Newchurch work, although the
proportions differed considerably when compared to Table 8.1 above. But the question
that could not be answered prior to the e-Nudge installation was the proportion of those
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identified that would actually present during a routine practice session for a doctor,
nurse, or other primary care professional.
This phase was not a formal research project in itself, although it could
potentially have been developed into an interesting one. It involved just a small number
of sample clinics in one particular practice during a fairly narrow time window.
However, it gave me a rough idea of the likely everyday impact of the e-Nudge on a
practice of this size. This information was extremely useful later during the spring and
summer of 2006, as I recruited practices in four waves to join the e-Nudge trial, and
was able to negotiate on the basis of the testing phase findings.
I examined a general practitioner’s clinic on the first test day of 5.5.06. Twelve
patients were seen during the clinic, of which ten were in the over 50 year range
amenable to the e-Nudge intervention. Of these ten, five were identifiable by e-Nudge
(two in Group 1, three in Group 2). However, only two of these five were intervention
patients. Two reminders would have therefore arisen out of the twelve patients seen.
This result seemed acceptable, but of course represented only one clinic. As I
tested other clinics I became aware that a high proportion of the reminders were from
Group 2 (those potentially at risk but with incomplete data). I decided to look into
Group 2 in more detail by accessing the list of all current Group 2 patients and finding
out what factors were most important in determining their identification in this Group.
Seven cases were selected from the e-Nudge lists, and the following results were found
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Age Sex Missing data Comments
67 M TC, HDL Smoker
68 M HDL, Diabetes status “Stopped smoking” 1.9.2003
62 M SBP, TC, Diabetes status Recent smoker
60 M Diabetes status ?Ex-smoker. Ratio only 2.1
74 M SBP, TC, Diabetes status Smoker, Diabetes status makes
no difference
63 M TC, Diabetes status Smoker
56 F TC, Diabetes status Smoker, Diabetes status makes
all the difference
Table 8.2: Characteristics of a sample of Group 2 individuals identified on 5.5.06
This sample was representative of an overall impression that I was gaining from
testing the software. This was that the Diabetes status assumption in Group 2 was
making a large difference to the size of this Group. It was at least partly involved in the
identification of all but the first of this sample. In only one case would the person still
have been identified had the Diabetes status been clearly negative (through a recent
blood glucose value and absence from the diabetes register). This was a 74 year old
male smoker. In the case of the 56 year old female smoker, this assumption made all the
difference over whether or not she was identified, and the same applied to numerous
other cases that I found.
Table 8.1 above suggested that about 1000 patients out of a total list of 11,000
would be identified within Group 2. All of these 1000 would be over 50 and therefore
above averagely likely to be dealt with during regular care, although it could be argued
that the patients with missing data might be those with less regular contact with the
practice. I therefore expected that between 1/10 and 1/5 of patients presenting to the
practice would be identified in Group 2 on an average day. This sort of figure seemed
roughly supported by the GP clinic samples I had examined. I was interested to know
what impact the removal of this diabetes assumption would have, in order to make a
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final decision over whether or not it should be included. I therefore contacted David
Stables and arranged for the Diabetes status assumption to be removed from e-Nudge
on a trial basis. Following this change, patients would be assumed to not have diabetes
if they were not on the Diabetes register, even if they had no recent blood glucose level
to support this assumption.
In addition to this change, a number of other issues required action, to correct
problems including coding issues that I identified. These were brought to light by the
systematic checking of samples of patients listed in Groups 2, 3 and 4. From my field
notes of 5.5.06, the following corrections were required:
1. A Group 3 patient was discovered whose alert indicated that the total cholesterol
(TC)/HDL cholesterol ratio was 6.60. However, when I checked the record the most
recent TC was 5.7 mmol/L (using Read code 44PJ), and HDL 1.0 mmol/L. A previous
TC value was 6.6 mmol/L (using Read code 44P), and this was apparently the value
that e-Nudge was using. It became clear (after discovering two other examples that I
noted) that the e-Nudge was ignoring total cholesterol values recorded using 44PJ, and
this required action.
2. There were one or two examples of deceased patients inappropriately identified by
e-Nudge.
3. Clarification was required over the recognition of smoking status, brought to light
by two patients identified in Group 2.
I spoke to David Stables from the test practice and he was able to remove the Diabetes
status assumption more or less immediately, on a trial basis. I recorded receipt of a text
message from him later the same day:
“153 intervention 126 control Group 2”
Use of primary care data for identifying individuals at risk of cardiovascular disease
189
He also took action on the other issues identified. I then revisited the practice
on 9.5.06 and found that as a result of these changes, other Group numbers had also
changed (as well as Group 2). This was probably largely in response to the more
effective detection of cholesterol levels through inclusion of Read code 44PJ, which
reduced the numbers identified in Group 1 in particular. These were the patients with
CVD who were out of the QOF targets for cholesterol or blood pressure. This change
had also (predictably) increased the numbers identifiable with complete risk factor
profiles and identifiably at risk (Group 3). Groups 4 and 5, identifiable only through
blood glucose or blood pressure codes, were unchanged.
As expected, Group 2 had diminished significantly through removal of the
Diabetes status assumption (and also to some extent through improved cholesterol value
detection). Table 8.3 gives the new numbers identified in all the Groups, for comparison
with Table 8.2 above.
Over-
50 year
popn
Group
1
Group
2
Group
3
Group
4
Group
5
Group
6
Intn 1737 92 153 166 10 1 55
Control 1685 119 126 149 4 0 50
Table 8.3: Numbers identified in the test practice on 9.5.06. This followed temporary
removal of the Diabetes status assumption for defining Group 2 and correction of a
number of software problems.
The overall numbers identified in Group 2 were clearly lower, but the
difference that this would make to everyday practice needed looking into. I therefore
carried out the same exercise as discussed above, by examining four routine practice
surgeries, three by a GP, and one from a practice nurse.
Clinic 1 (GP)
Twelve patients seen
Just one less than 50 (i.e. out of e-Nudge age range)
One Group 1 reminder
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One Group 2 reminder (Systolic BP and cholesterol data missing)
One Group 3 reminder (71 year old male non-smoker SBP 124 TC/HDL ratio 4.33)
Clinic 2 (GP)
Eighteen patients seen
Six less than 50 (i.e. out of e-Nudge age range)
Two Group 2 reminders only (One had just TC missing, the other both TC and HDL
missing)
Clinic 3 (GP)
Seventeen patients seen
Twelve less than 50 (out of e-Nudge age range)
No e-Nudge reminders at all
Clinic 4 (Practice nurse)
Fourteen patients seen
Five less than 50 years (out of e-Nudge age range)
Three Group 1 reminders
This survey suggested that the profile of the e-Nudge had become significantly
reduced as a result of the changes, most important of which was the removal of the
Diabetes status assumption for Group 2. By the time the e-Nudge trial began (and
during this testing phase), Group 1 had been effectively removed, as screen reminders
to support the QOF had become commonplace and it was therefore no longer possible
to withhold such reminders from control patients (see below). Based on this sample of
four clinics, it appeared that the e-Nudge would only be active in a total of four out of
61 consultations. This seemed too inconspicuous an intervention to be expected to
impact on processes of care. Largely for this reason (but also because I was becoming
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particularly interested in the identification of patient groups most likely to benefit from
testing for diabetes), we decided to reinstate the Diabetes status assumption for Group
2.
8.3.2 Recording of fasting blood glucose results
A further issue became apparent at this stage that I had not recognised before. This was
that for Coventry practices (served by the clinical chemistry laboratory at University
Hospitals Coventry and Warwickshire, UHCW), the vast proportion of blood glucose
measurements were reported using the Read code ‘Serum Glucose level’ (44f), and very
few using the code ‘Plasma fasting glucose’ (44g1). Despite the fact that this practice
commonly requested blood glucose measurements on fasting samples, and using
fluoride samples, the laboratory chose to use this code for reporting. It was this code
that would therefore be placed in the patient’s electronic record. The Warwick Hospital
laboratory serving South Warwickshire practices also used the same policy of avoiding
the Fasting plasma glucose code, but at least used plasma or blood glucose rather than
serum codes in the reports. I carried out a search in the test practice on 9.5.06 for all
patients whose record contained the two codes recorded from 1.1.04 to 1.1.06. The
result is given in Table 8.4 and made me aware of how rarely the Fasting code was
used.
Read code Description Number identified
44g1 Plasma fasting glucose 4
44f Serum Glucose level 1514
Table 8.4: Numbers of patients at the test practice identified with two Read codes
present in their record between 1.1.04 and 1.1.06. The practice lists size was 11,086.
I discovered later through discussions with both the laboratories of UHCW and
of Warwick Hospital that a reason for this was that they do not like to assume that the
blood glucose sample was definitely fasting. It is not uncommon for patients to present
to a phlebotomist for a fasting blood glucose measurement having forgotten the
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instruction to omit breakfast. In such cases, a blood glucose level between 7.0 and
11.0mmol/L might be interpreted incorrectly as indicating diabetes if reported using a
fasting code. If they report it using a random or non-specific code then the clinician can
decide how to interpret it by confirming with the patient whether the sample was truly
fasting or not. This provided an interesting reminder to me that even in the case of
machine operated blood testing and computer generated reporting by laboratories,
followed by automated electronic transmission of results to practice records, valid
concerns and opinions of essentially human origin may influence processes and
outcomes of care. Primary care is a complex environment, but here was an influential
perspective coming from a completely unexpected direction. Whether the potential
barrier to the early detection of diabetes resulting from this stance is justified is unclear,
but is perhaps worth exploring in a future project.
The follow up of borderline blood glucose values became an interest as a result
of the e-Nudge experience and I was later invited by the British Medical Journal to co-
author a ‘Ten minute consultation’ piece on the issues surrounding it. The lack of
clarity over whether a sample was truly fasting or not was mentioned in the published
article (12), as it is an issue of some importance to the creation of high quality diabetes
registers in primary care.
The other issue brought to light by the discovery of relatively few fasting codes
was that the identification of patients in Group 5 would require some work by the
practices. I had already recognised this issue, but had not realised quite how rarely
laboratories actually used the Fasting code. Group 5 identified patients with possible
undiagnosed diabetes based upon:
Random glucose > 11.1mmol/L OR Fasting glucose > 7.0mmol/L anywhere in
the record
AND
No subsequent Fasting glucose level <7.0mmol/L OR ‘Normal OGTT’ code
Use of primary care data for identifying individuals at risk of cardiovascular disease
193
A patient with a raised blood glucose value in the diagnostic range would
therefore continue to trigger a Group 5 alert unless a new value at a later date was
added that gave the fasting level as less than the diagnostic threshold for diabetes.
Given that fasting samples taken to clarify diabetes status in such individuals would
usually be reported by the laboratory using a random or non-specific code, this meant
that to stop the Group 5 alerts from inappropriately appearing, the practice would need
to insert the fasting level, properly coded by manual data entry rather then relying on
electronic laboratory links. This was unfortunate, as it meant that e-Nudge could not be
an entirely automated tool, but in practice the number of Group 5 individuals identified
in each practice was very small. Nevertheless, the action required by practices to
‘manage’ their Group 5 lists and avoid unnecessary reminders was described clearly in
an ‘e-Nudge User’s Guide,’ which I emailed to all practices as well as sending a hard
copy (see Appendix).
In fact, Group 5 was soon withdrawn from the e-Nudge trial. The tool that
replaced it, resulting from the subsequent QRESEARCH project described below, uses
a simpler search protocol. It specifically accounts for this limitation in UK blood
glucose data reporting.
8.3.3 Estimating the task of outcome data retrieval
During the troubleshooting phase I took the opportunity to estimate the work required
to retrieve the primary outcome data, i.e. identifying individuals experiencing CVD
events during the trial, and counting/validating the overall number of events in each of
the trial arms. The trial protocol (which was in fact published in April 2006, before the
software was actually available for testing) stated that most CVD events would be
identified by simple searches on practice registers, but that two groups of patient would
be examined in more detail to confirm the number of truly new events. The first of
these groups was those who had recently registered with the practice (who might have a
Use of primary care data for identifying individuals at risk of cardiovascular disease
194
code for e.g. Myocardial infarction applied at a first consultation, even though the event
had in fact occurred several years before). Such recording may occur whilst the
patient’s notes are awaited from the previous practice and the exact date is not yet
known. The other group were those with a record of more than one event recorded
during the trial. CVD events are quite often recorded more than once. For instance, in
the case of a person experiencing acute myocardial infarction (AMI) as a first
manifestation of ischaemic heart disease (IHD), both a code for AMI and a less specific
IHD code might be applied, when in fact the patient has only had one event.
The first of these groups was quite straight forward, as the date range for
identifying events simply needed adjusting. For the second group however, it became
evident that the EMIS LV search engine would not easily identify people on the basis of
having experienced more than one event. This is because the usual approach to practice
searches is to identify groups of individuals sharing certain characteristics (such as at
least one event), rather than identifying the events themselves. It became evident that in
order to accurately measure the number of events occurring during the trial, every
patient with any number of events would need to be examined and the number
confirmed.
To get an idea of the numbers and the task involved in checking them all, I ran
a search at the test practice on 9.5.06. This identified any individual who had AMI, a
stroke (CVA), or transient ischaemic attack (TIA) over the three years 1.1.03 to 1.1.06.
118 patients were initially identified
Two of these were Temporary residents and so not counted, leaving 116
One had had a record of ‘Vertebrobasilar insufficiency’ which is not considered
a relevant CVD event (see Chapter 2)
This left 115 patients with at least one cardiovascular event out of a background
practice population of 11,086.
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AMIs: 42
Strokes: 40
TIAs: 37
Two patients had had both one AMI and one TIA
Two patients had had one CVA and one TIA
One patient had had two CVAs
One patient had had two TIAs
I therefore recorded 119 events occurring in 115 individuals. 109 had one
event, and six had two events. I found no examples of more than two events in the same
individual in this survey.
The overall estimated event rate for AMI, CVA and TIA, based on these figures
was therefore approximately 358 per 100,000 patient years. This exercise aimed to
estimate the number of AMIs, CVAs and TIAs occurring more than once in the same
individual. It did not include new diagnoses of IHD without AMI (eg onset of angina).
These would have brought the estimated event rate closer to the predicted value of 1206
per 100,000 patient years used in the power calculation and based on published
estimates. However it confirmed that despite our original hopes that the primary
outcome measure could be extracted largely through electronic searches, an
examination of every event recorded during the study would be required to derive an
accurate figure.
8.4 Issues affecting recruitment
I aimed to recruit up to twenty-six general practices in Coventry and Warwickshire to
participate in the trial. This figure was based on the total number of practices connected
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with the Newchurch database. At the initial stage (including the time when Ethical
approval was gained in August 2005) I expected that Newchurch would be instrumental
in the e-Nudge project and this was the maximum number available, all of them within
South Warwickshire, even if we included all software providers.
After EMIS took over as the platform provider for the trial software, this
approved number remained my target, but I was then able to recruit over a much wider
area, including Coventry, Rugby and North Warwickshire. The availability of EMIS
practices (of which 80% ran the LV version for which the e-Nudge was programmed)
meant that practice numbers were not a problem. NHS Research and Development
approval was however, delayed particularly for North Warwickshire Primary Care Trust
(PCT), almost to the point of excluding this PCT due to the time pressure to commence
the trial. However we recognised the importance of including an above averagely
deprived area in which coronary heart disease standardised mortality ratios were known
to be particularly high.
By the time we were ready to test the e-Nudge software in the test practice
(Kenyon Medical Centres) my attempts to recruit practices were well underway. In
retrospect, I look back with some anxiety at my confidence in moving this recruitment
process forward before the e-Nudge software had been finalised and tested. However,
from the start of recruitment I knew that EMIS would support the trial, and this made a
huge difference to practice receptiveness.
An interesting field note that I made on the 14.4.06:
Invitation letters sent out to further practices working through the list on the
Excel sheet ‘EMIS LV practices in Coventry’. Stopped at No. 30 as we may have
enough Coventry practices, and to make room for IPCRESS.
IPCRESS is an ongoing multi-centre study of an on-line cognitive behavioural
therapy intervention for depression, for which the University of Warwick was actively
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recruiting around that time. As Research Practice Lead for Warwick-Coventry Primary
Care Research (WC-PCR) I was involved in this recruitment drive. This field note
reminds me of the competing priorities that my own research was exposed to and my
responsibility in the Medical School to assist with recruitment for primary care studies
in general.
The total number of patients required for the primary outcome was 70,000.
Unfortunately, as discussed in the previous chapter this was initially believed to be the
total population sample figure but after a revision to the calculation I required he same
number over 50 years. Resources were limited and I stopped at 19 practices, providing
approximately 38,000 over 50 years. Limiting factors included my own time, and that
of the Research Nurse Rachel Potter, who became involved with a number of other
projects during this time. Increasing the number of practices by a factor of nearly two
would have substantially changed the scale of the endeavour and would have required
both Ethics Committee and R&D re-approvals, as I only had permission to recruit a
maximum of 26 practices.
However, I was confident that whist we might be under-powered to
demonstrate a reduction in the primary outcome (cardiovascular events), we had a very
ample number through which to demonstrate changes to processes of care which, as
was becoming evident in the literature review, would probably be more likely to be
influenced by a reminder intervention.
8.5 Problems occurring during the trial
The first problem occurring during the trial was the result of an initial data capture
problem at baseline. The outcomes of the trial were the annual CVD event rate over two
years and the proportions identified in each of the Groups at the end of the trial. They
did not therefore depend upon the baseline data. However, I was keen to record these
data for two reasons. Firstly, to demonstrate the success of randomisation and secondly,
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to publish the baseline proportions as a reflection of the adequacy of UK primary care
data to support CVD risk assessment. This publication (13) was delayed significantly as
all of the searches needed to be re-run by EMIS back dated to the start date in each
practice.
During this process, a more specific data capture problem occurred in one of
the 19 practices, for no reason that came to light. This was not actually evident until
much later, when the original figures for the background denominator population (i.e.
those over 50 years) from this practice were seen to be low compared to subsequent
figures. The difference was too large to be attributable to new practice registrations. It
was possible to retrieve accurate figures from 25 days after the installation of the e-
Nudge at this site, but not before this. This did not (as discussed above) affect the trial
outcomes but it was mentioned in the final published trial report (14).
Meanwhile, the e-Nudge continued to operate successfully, in every respect
other than the identification of Group 5, those with possible undiagnosed diabetes. The
algorithm for identifying this group was clearly malfunctioning (based on examples
arising in the trial practices). Through discussions with a GP who spotted the problem
and EMIS, we were able to correct this problem quickly, but soon after this the Group 5
was withdrawn from the trial for reasons discussed in the following section.
8.6 Changes to the protocol after commencing the trial
8.6.1 Shortening of the e-Nudge reminder messages
After nine months I arranged for a shortening of the e-Nudge reminder messages.
Originally these were designed to provide a clear justification for the identification of
an individual in whichever Group was involved. However, it became apparent that (as
discussed in Chapter 6) the messages were unnecessarily wordy and, particularly in the
cases of practices using the reminder format that appears at the bottom right corner of
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the screen, they were potentially obstructing other information during the consultation.
This format appears spontaneously and remains visible during the consultation unless
actively removed by a mouse click, whilst the centrally appearing format requires an
obligatory keystroke to remove it, after which it is no longer visible unless actively
called up again. Practitioners using the first type were not used to having to clear
reminders from the screen at all, as they were generally small enough to allow visibility
of the other screen information, and their persistence during the consultation may be a
positive feature. The original e-Nudge messages however were relatively obstructive
and would make removal by key-stroke essential. This created problems for the one
practice that withdrew after less than 6 months, and another practice discussed
withdrawing with me for the same reason. In fact, this latter practice (and another) also
mentioned the effect of the lengthy messages on reception staff, which made me aware
that the e-Nudge was affecting workflow generally in the practices and not just the
clinicians. However this practice agreed to remain in the trial once the messages had
been shortened.
8.6.2 Withdrawal of Group 1
Group 1 represented those with established cardiovascular disease or diabetes who were
out of the QOF target for blood pressure or cholesterol levels. During 2004 (the first
QOF year) and into 2005, screen reminders were not routinely used by all practices to
support QOF targets. Including this group in e-Nudge was expected to make
involvement in the trial more attractive to practices, as the software would help them
identify patients who required action and might therefore improve their payments.
However, by the end of 2005 (and after the Ethics committee application) it became
evident that QOF reminders had become ‘usual practice’. It was still an option to switch
them off, but few practices were likely to take this option, as their QOF performance
might suffer. By the time EMIS were making the final adjustments to e-Nudge in May
2006, it was clear that to withhold QOF reminders from control patients would mean
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depriving them of an important part of ‘usual care.’ The decision was therefore taken to
remove the e-Nudge Group 1 screen reminders. In principle the list of identified
patients was still available (for intervention patients), but the flagging mechanism had
been removed.
8.6.3 Withdrawal of Group 5
Group 5 identified individuals with possible undiagnosed diabetes, based on past blood
glucose values in the record. In the baseline data (following the re-run as described
above) there were 33 such individuals identified in both arms of all the trial practices
combined. The original idea of including this group was essentially to support the
quality of the practice diabetes registers, to ensure that the e-Nudge did not conduct a
CVD risk estimate on someone known to have diabetes. Such an individual might be
under treatment for diabetes but for some reason not be on the diabetes register, in
which case it might assist practices to have this pointed out. This number was not great,
but it was sufficient to make us question the ethics of not acting upon those in the
control arm, as they would not be flagged up to the practice teams. Their names would
be listed in the practice servers but inaccessible to practice team members for control
patients.
The e-Nudge software could identify these individuals, but it could not tell us
how many of them had truly been ‘missed’ from those whose raised blood glucose
value was in fact measured the week before and who were planning to be reviewed in
the near future to discuss the results. In such cases their identification would create no
ethical issue and no intervention into the usual process of care would be required.
The existence of such identified patients was discussed in my meeting with
David Stables on 20.3.06. At that stage it was unclear how many were likely to be
identified in e-Nudge, and whether this might present an ethical issue. One of the
unknowns was over whether individuals identified in Group 5 had actually had their
raised blood glucose measurement ‘missed’ or whether in fact it was already in the
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process of follow up. To clarify the situation, David Stables and I approached Julia
Hippisley-Cox at the QRESEARCH database in the University of Nottingham.
8.7 The QRESEARCH survey
The QRESEARCH database contains anonymised data from over 500 EMIS practices
all over the UK. We designed a new project to estimate the number of people registered
with general practice with biochemical evidence of undiagnosed diabetes, using a
similar (but modified) approach to e-Nudge. The research question was developed into
a cross-sectional survey protocol. This was approved by the QRESEARCH Scientific
Advisory Committee and was covered (as are all QRESEARCH projects) by Trent
Multiple Research Ethics Committee. This survey was undertaken in June 2006, and
involved the application of a modified version of the e-Nudge Group 5 search on the
QRESEARCH database. David Stables, Julia Hippisley-Cox and I were joined on this
project by Shaun O’Hanlon (EMIS Clinical Design Director) and Azeem Majeed
(Professor of Primary Care at Imperial College, London). This was a collaborative
project and I present an outline of the survey here as a secondary output of the research
and not primary data for this thesis. A more detailed description is given in the final
published report included in the Appendix (15).
8.7.1 Survey sample
A total of 480 practices over the UK met the eligibility criteria for inclusion in the
survey, (complete data transmission to QRESEARCH to 1st June 2006). This provided
3,630,296 records of patients registered on that date. QRESEARCH has been validated
against other sources to be representative of the UK population registered with general
practice (16).
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8.7.2 Search strategies
We decided to simplify the search protocol used in e-Nudge as we recognised that it
was unnecessarily complicated and, as discussed above, it relied on uncertain
fasting/random blood glucose coding that was potentially resolvable at the practice
level but not through QRESEARCH. We chose the following search criteria on patients
of all ages with no diagnosis of diabetes and no history of impaired glucose tolerance:
Strategy A: Patient identified if the most recent blood glucose measurement is
either a fasting level of 7.0 mmol/L or higher, or a random level of 11.1
mmol/L or higher. If the code is non-specific then a random level is assumed.
Strategy B: Patient identified if the most recent measurement is 7.0 mmol/L or
higher, regardless over whether the code was fasting, random, or non-specific.
8.7.3 Rationale for the search strategies
In designing these strategies, we had in mind a new software module for use in clinical
practice, that could run the same searches on a nightly basis, as for e-Nudge and for the
QOF. EMIS had committed to develop and install such a module if significant numbers
of patients were identified in the survey. We wished first of all to identify patients with
definite biochemical evidence of undiagnosed diabetes (by using the diagnostic
thresholds, Strategy A). Secondly, we wished to identify patients who justified follow
up testing for a borderline or raised blood glucose. Strategy B in fact includes Strategy
A, but also includes those with more modestly raised random readings. The recently
published JBS2 guideline of December 2005 (17) recommended that during the process
of cardiovascular risk estimation, random blood glucose values of 6.0 or higher should
be followed with a fasting sample. If in such a case the fasting value were returned as
less than 7.0mmol/L then diabetes was not evident (although the patient might have
impaired glucose regulation), and such a patient would then no longer appear on the
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Strategy B list if this were updated regularly through a software module. If the follow-
up fasting level were greater than or equal to 7.0 mmol/L then the patient should be on
the diabetes register, provided the diagnosis was considered sound on clinical grounds.
Either way, they would be removed from the Strategy B group. This was the reason for
selecting 7.0 rather than 6.0mmol/L as the threshold for this group. It produced an
identifiable population with a clear, unmet health need.
The assumption concerning non-specific codes for Strategy A was a
conservative one. Individuals with diabetes might be missed if a fasting measurement
between 7.0 and 11.0mmol/L were reported by the laboratory using a random or non-
specific code. This appeared to be happening in the local laboratories serving the e-
Nudge practices (see Table 8.4 above).
The results of the QRESEARCH survey were published in the British Journal
of General Practice in March 2008 (15). We found that out of the denominator
population of 3,630,296, Strategy A identified 3758 patients (0.1%), whilst strategy B
identified 32,785 (0.9%). We found that a third of the population over 40 years have a
blood glucose measurement electronically recorded in the record, suggesting that this
information is recorded commonly enough to be useful for such targeting. The survey
also indicated that 15.9% of results nationally were reported using a definitely fasting
code, 22% definitely random, but in 62% a non-specific code was used. A number of
the non-specific codes may have been reported on samples that were actually fasting.
This project was able to answer a question that the e-Nudge data could not.
How long ago was the blood glucose measurement leading to a patient’s identification
in a search made, and how was this distributed over the identified population? Were the
people requiring follow-up of borderline or raised levels in fact those whose test had
been carried out very recently and for whom no additional action was required? This
outcome was included in the published paper, and suggested that over a third of strategy
A patients and over half of the Strategy B patients the blood glucose measurement that
required follow up was taken over a year ago. In addition, we found that 440 out of the
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480 practices surveyed had at least one Strategy A patient, and all but one had at least
one Strategy B patient.
Projecting the figures to the UK population, around 60,000 patients might be
identified through Strategy A, and 528,000 through Strategy B (18). This might
therefore make a substantial impact on the problem of undiagnosed or late-diagnosed
diabetes, provided that the identification of such individuals could be linked to practice
based processes of care, both opportunistically (at the point of care) and systematically
(through the availability of lists in practice systems).
The result of this project was that a new software module was designed and
installed into all EMIS practices throughout the UK to run the Strategy A and B
searches every 24 hours. This was a major output of this research and is discussed in
Chapter 10. The module was initially installed by an EMIS patch transfer around
October 2006 as an optional facility to assist practices in identifying such patients. At
this point we decided that it was no longer appropriate to keep Group 5 in the e-Nudge
trial and I wrote to all practices to inform them of this change and to draw their
attention to the existence of the new EMIS module which they could access if they
wished. I also applied to the Ethics committee for a substantial amendment to the
protocol, which was approved. However, given the scale of the problem EMIS
considered this to be a safety issue and around April 2007 the lists of identified
individuals became linked non-optionally to screen alert messages to highlight the
previously raised blood glucose value. The reminder message is in the same format as
QOF alerts and states: “RULE OUT DIABETES, LATEST GLUCOSE HIGH.”
8.8 Collecting the trial results
The collection of CVD event data was conducted at the end of the trial (and after the
first year for the purposes of data monitoring). The Standard Operating Procedure for
collecting the primary outcome is given in the Appendix. One of the advantages of the
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e-Nudge software design was its ability to automatically store the Group data every
eight weeks in the practices’ servers (for the secondary outcomes). However, a number
of problems arose during the final collation process. These were instructive, not only
for this project, but perhaps in a more general way given the increasing tendency for
primary care research to depend on electronically coded outcome data.
8.8.1 Access to the Bureau system server
Three of the e-Nudge practices were linked to a ‘Bureau’ system hosted by Coventry
Primary Care Trust (PCT) that included a total of ten EMIS LV sites. For these
practices, a shared server supported administrative data and, importantly for the trial,
this server was the destination for the 8-weekly e-Nudge outcome data retrievals.
During the summer of 2008, around the time when the outcome data were ready to be
collected, a disruption occurred, limiting access to this server for these practices for
several weeks. This did not affect the use of the practices’ clinical software, and the e-
Nudge alert messages still operated, but it did mean that documents stored in the
Bureau system were temporarily unavailable. This included the automatically stored
figures for the numbers of people identified in each e-Nudge Group. I initially contacted
Coventry PCT to overcome this problem, and visited their technicians to attempt to
resolve it within the Bureau system at the PCT offices. However, it was only by
contacting EMIS technicians based in Leeds that the documents were recovered. This
problem did not affect the trial and no information was ultimately lost, but for a time I
wondered whether important outcome data might be irretrievable. This highlighted the
risk involved in embedding a research study within the NHS to the extent that essential
outcome data were dependent upon routine care processes.
8.8.2 Distinguishing new cardiovascular events from follow up entries
A problem evident early on in the first round of data collection (conducted by Research
Nurse Rachel Potter for data monitoring after the first year) was the sheer scale of the
Use of primary care data for identifying individuals at risk of cardiovascular disease
206
task, due it emerged to the inappropriate identification of codes for ‘Review’ of a
vascular diagnosis, where a new event had not in fact been experienced. This problem
was fortunately resolved by revising the search protocol slightly (through EMIS LV’s
Advanced Code Options) to only include ‘First’ or ‘New’ instances of the G3 or G6
code groups. G3… and G6… are the ‘parents’ of all lower level coronary artery and
cerebrovascular disease codes respectively.
8.8.3 Home grown codes and unwanted G6 codes
The problem of ‘home grown’ codes was discussed in Chapter 1. Clinical software
systems allow practices to create their own codes to manage (usually administrative)
issues within the practice. These codes may be very useful but their use is now
generally discouraged as it is seen as an obstacle to data integration and interoperability
above the practice level. In one South Warwickshire practice, a code named ‘Cardiac
diabetic’ had been created and whilst this was not a ‘child’ of G3 or G6, it had been
linked to the G3 group, and so was identified inappropriately in my search for
cardiovascular outcomes. The linkage may have been through an unidentified template
stored in the system but this was never discovered despite attempts by the practice
manager.
The possibility of capturing patients inappropriately though codes that were
linked to (rather than actually children of) the G3 and G6 codes had not occurred to me,
so this was useful. It reinforced the need to check every single patient identified to
confirm the number of truly new G3 or G6 coded events during the study. However,
this did not solve the practical problem of completing data collection in practices where
large numbers of patients were being identified inappropriately. Another such practice
was based in Coventry, and in this case ten codes linked to G3 (including Cardiologist
seen, Beta-blocker contra-indicated), and seven identified under G6 (including Basilar
artery syndrome, Subclavian steal syndrome) were detected. This latter group included
‘Vertebrobasilar insufficiency’ which has the code G65-1, a child of G65 (Transient
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cerebral ischaemia). I was aware (as discussed in Chapter 2) that this commonly used
code would lead to the identification of patients who had not in fact had a true
cardiovascular event in the commonly used sense of the term. Through liaison with the
lead general practitioner for IT issues in this practice, we arranged for a slightly more
detailed repeat search that excluded unwanted codes whilst retaining the identification
of patients with appropriate codes. This reduced the number identified in this practice
from over 600 to 58. A much smaller practice that was less computerised had just 16
patients identified, and I needed to examine the paper records of three of them. Three
out of the sixteen had been coded with vertebrobasilar insufficiency (G65-3) and one
with ‘Drop attack’ (G65-1), another example of a G6 code that does not usually signify
a true cardiovascular event.
Despite the efforts made to exclude inappropriately identified individuals from
the searches, I was careful not to miss any cardiovascular events, and the result was that
2121 electronic records were checked in the 19 practices to identify the 930 events.
8.9 Interviews with members of the public
As part of a process evaluation (for which Ethics committee approval was gained), eight
members of the public registered with an e-Nudge practice agreed to take part in 60
minute in-depth interviews concerning their beliefs and attitudes towards cardiovascular
risk and prevention. The aim of this was to explore some of the human obstacles and
enablers to CVD risk reduction that might impact on the e-Nudge trial. In the process I
also gained an awareness of the importance of including a qualitative element to a
clinical trial through involving appropriately trained colleagues, in the same way that I
would involve statistical expertise as part of a complete research team. As this study
was limited in scope it is included only in an appendix to the main thesis. It
nevertheless gave me some insights into patient perspectives regarding cardiovascular
risk reduction.
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8.10 Clinician interviews
Semi-structured interviews were conducted with a number of practice based staff (two
general practitioners, two practice nurses and a practice manager), but these proved not
to be useful. This was perhaps because I was the researcher leading the e-Nudge trial in
which they were engaged, and opinions appeared to be biased in favour of the software
and the e-Nudge approach in general. We had initially intended to conduct a total of 24
such interviews, but decided not to continue as the data were not sufficiently useful.
Recruitment of a research fellow to continue the interviews on my behalf might have
overcome this problem, but could not be resourced within the PhD budget.
The exception to this was an interview that I conducted with a GP who was
particularly interested in CVD risk reduction. In contrast to the statements of health
professionals in other practices who regarded the e-Nudge approach to be very
proactive compared to what they were offering, he seemed to suggest that such action
was a minimum standard and a basic responsibility of general practice teams.
8.11 Summary
This thesis has relied very much on qualitative information as well as on the
quantitative data generated in the e-Nudge trial. The field notes that I made prior to,
during and after the trial have enabled me to place the findings in context and also to
answer questions that the trial alone could not. Relevant issues included bureaucratic
obstacles, resource limitations, unforeseeable developments causing slippage,
dependency upon goodwill, acceptability of an intervention to clinicians and other staff,
and the importance of patient perspectives. Some of these issues were lessons learnt the
hard way through the process of my training and would be less likely to occur in future.
But most are an inevitable consequence of conducting research in a setting of
competing priorities and this perhaps applies to the majority of primary care research.
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Chapter 9: Reflections on the completed research
9.1 Introduction
This chapter provides some reflections on the practicalities of conducting primary care
research at the end of this PhD project, on how I might have chosen to act differently if
starting again, and on general lessons learnt at the completion of this thesis. The two
main areas of research were the systematic review and the e-Nudge trial itself.
9.2 The systematic review
The systematic literature review was described in Chapter 4. This taught me a lot about
evidence synthesis, the dangers of poor trial design, the value of a pre-published trial
protocol, and the difficulties created for future researchers if interventions are not
described in detail and results not reported clearly. A number of specific lessons would
help me proceed differently in future. Difficulties with bibliographical software were
resolved within the timescale of this project that initially were a significant barrier to
progress but would not be a problem again. Whilst I chose a fairly comprehensive range
of databases to include, if I were starting afresh I would apply a wider range of terms in
the initial search. The requirement that our papers all included ‘Reminder systems’ as a
term was one of the reasons for the lack of overlap with the Shojania 2009 and
Kawamoto 2005 reviews as discussed in Chapter 4.
I learned a more general lesson about evidence synthesis through this work.
This involved the use of binary outcome measures in the trialling of interventions.
Binary outcomes are required to derive odds ratios or risk ratios. This is the basis for
logistic regression and other models used to determine the relative influence of
predictor variables as discussed in Chapter 2. In the systematic review, a distinction was
made between studies using binary outcomes (subdivided into process outcomes and
Use of primary care data for identifying individuals at risk of cardiovascular disease
212
clinical outcomes) and continuous outcomes such as length of hospital stay. Whilst
RevMan software is designed to incorporate either binary or continuous outcomes, it is
difficult to synthesise both at the same time, and binary outcomes seemed to be much
easier to handle. Binary outcomes are the basis for measurements of absolute risk
reduction, from which the number needed to treat is derived for the intervention.
In studies of cardiovascular disease, dichotomous outcomes seem particularly
apt, because generally speaking important CVD events (e.g. myocardial infarction,
stroke) have either ‘happened’ to an individual by a certain time point, or they have not.
They are discrete events. The development of disease registers in primary care has
emphasised (and perhaps amplified) this dichotomy: the recommended management of
a patient for control of vascular risk depends very significantly on whether s/he is or is
not on a vascular disease register. But in clinical practice we need to advise patients
about all potential benefits and risks, and not all of these are as easily conceptualised in
binary terms. Benefits of lipid lowering or blood pressure reduction might in theory, for
instance, have a long term effect on cerebrovascular perfusion that is more
appropriately measured using continuous measures of cognitive function. Similarly,
adverse effects of such medication might include non-discrete outcomes such as
reduction in quality of life that are less likely to be the primary outcome measure of
randomised controlled trials. These are more likely to focus on the binary outcomes that
may make different trials (often already heterogeneous in their specific interventions
and settings) potentially comparable. So whilst I found binary outcomes much easier to
handle than continuous outcomes in conducting the systematic review, their potential to
over-simplify quite complex clinical phenomena concerned me a little as a clinician.
Even if we define CVD ‘events’ (such as myocardial infarction or stroke) as
binary phenomena, risk of a CVD event is a continuously distributed variable. However
there is a tendency to dichotomise this concept as well, in the quest for the ‘high risk’
population defined by an essentially arbitrary threshold of risk. Marteau and Kinmonth
Use of primary care data for identifying individuals at risk of cardiovascular disease
213
discuss the implications of this tendency for the communication of risk to individuals
considering CVD risk assessment as a screening procedure (1).
A further example where priorities may potentially conflict is in the use of
composite endpoints, which increase the power of a study by providing more events
than would occur for a single endpoint. The impact of the intervention may then be
more visible and the result more likely to be significant. However, the individual
outcomes within the composite endpoint may have quite separate importance and
relevance to the patient (2), who ultimately needs to decide whether or not potential
benefits of the intervention concerned are outweighed by potential adverse effects.
9.3 Realities of conducting primary care research
The literature review was completed relatively late and I would have benefitted by
conducting it earlier on during the preparatory phase of the e-Nudge trial. However
there were good reasons for the delay.
Firstly, there was significant time pressure to develop the trial protocol, design
the actual software (programmed by EMIS), and recruit the participating practices in
order to generate the outcome data within the necessary timescale. Part of this pressure
was the result of the PhD submission deadline, but part of it was due to developments in
primary care that might make the trial impossible. The original e-Nudge ‘Group 1’ was
withdrawn simply because screen reminder interventions became routine practice
during 2005/6, making their absence from the trial’s control arm impossible (and
perhaps unethical). I was aware that other developments might include the targeting of
the population that I defined as e-Nudge Group 3 (Group A in the final report), the main
group of interest. Had similar reminder interventions become routine then this would
have jeopardised the entire trial. Whilst the targeting of primary prevention candidates
has indeed become recommended through the UK vascular screening programme, the
requirement to provide screen reminder interventions that would be expected by
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practices if linked to remunerative payments (David Stables, personal communication),
has not yet occurred. An important lesson from this related to the risk to research posed
by an evolving clinical or organisational environment that may quickly make research
questions either out of date or unanswerable. This particularly applies to research into
areas of care that are topical, in which policy may alter rapidly.
Secondly, the focus of the research changed during the five year time course. It
originated from my interest in pattern recognition in primary care data (an activity,
however complex, that requires a unidirectional flow of information from database to
investigator), but also included a broader interest in feedback (i.e. bidirectional flow)
particularly within the consultation environment, with its potential for more
unpredictable outcomes. This unpredictability includes the sometimes irrational (from a
traditional biomedical perspective) decisions made by individuals who may have
different priorities to the designers of clinical decision support systems. The
sociological aspects of influencing practitioner and patient behaviour at the point of
care became at least equally interesting as the pattern recognition aspects. This then
refocused the research around consultation based reminder interventions. Any shift in
the emphasis of a developing research programme makes the achievement of deadlines
more difficult, even if projects within it are tightly time-managed.
9.4 Design issues of the e-Nudge trial
A number of issues and problems arose during the design of the e-Nudge trial. Some of
these occurred during the preparatory phase and have been discussed earlier. Others
arose after the trial was underway and led me to reflect on how I might have done
things differently had I had the chance to start afresh.
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9.4.1 Clustering and contamination
The first issue concerns the decision to randomise individually rather than by practice.
This question was raised by two colleagues at the Warwick Medical School Clinical
Trials Unit who commented on a draft trial protocol and pointed out the potential
benefits of cluster randomisation. However they also recognised the finite recruitment
capacity of local practices and the benefits of individual randomisation.
Individual randomisation within the practice runs the risk of contamination,
through which the beneficial effects of the intervention may spill over into the control
population. In the e-Nudge trial, a control patient might be more likely to have his or
her cardiovascular risk factors recorded, controlled, or in other ways addressed if the
clinician has recently been triggered to action by a reminder related to a similar
intervention patient. The effects of the intervention may then be less evident because
the difference between the care provided in each arm is reduced. An effective
intervention might then produce a non-significant result. Whether contamination would
be likely to occur for the e-Nudge intervention was discussed during the planning
phase. For some parts of the e-Nudge, e.g. the group that identified individuals with
CVD requiring a blood glucose measurement, there was significant risk of
contamination, as the practitioners’ awareness of the need to complete such data might
be raised in a general way during the trial due to intervention alerts. However, for the
more important Groups 3/A and 2/B, a risk estimate was required to identify the patient
as justifying action, requiring a computation much less likely to occur in the mind of a
clinician without the help of software or other such tool. McManus et al have
demonstrated the limited ability of health care professionals to make such estimates
without the help of risk calculation tools (3). The alerts resulting from this automated
computation would not occur for control patients, and so contamination was less likely
for these e-Nudge Groups. A further factor that led me to assume that contamination
would not be a major problem was that (as mentioned in Chapter 4), the effects of
reminder interventions on practitioner behaviour may decay quite rapidly when the
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intervention is withdrawn (4). There is evidence that reminders that require an active
initiative on the part of clinicians are more likely to influence practice than those
appearing spontaneously (5). These effects might also reduce the chances that any
impact of the e-Nudge would persist in future consultations with control patients.
Finally, a study by Chambers et al (6) deliberately tested the effect of potential
contamination. Physicians caring for patients requiring influenza vaccination were
randomised into a group always reminded of this requirement at the point of care, those
never reminded, and an intermediate group reminded only 50% of the time. The rate of
vaccination in the intermediate group, on occasions when the reminder was absent, was
lower than the rate in the group never reminded. This suggests that physicians who are
sometimes reminded become dependent on the reminders, and that the effects of
reminders do not persist in future consultations in which they are withheld.
Cluster randomisation at the practice level protects against contamination, but
needs to be balanced against other issues. One of these is the inflation of sample size
resulting from the ‘design effect’ due to clustering (7). This may make the necessary
sample size prohibitive, depending on the intra-class correlation coefficient (8), which
is often poorly quantified for the current study population and needs to be estimated
from published values measured in comparable researched populations. Another
negative aspect is the need to identify the important criteria for stratification in the
randomisation of clusters. If these are not identified adequately, important differences
may become evident between the trial arms that undermine the trial’s internal validity.
An example of this is the study by Mitchell et al (9), in which a failure to recognise
training practice status as a basis for stratified randomisation was recognised by the
authors as a possible weakness of the trial.
I concluded that individual randomisation was the most appropriate approach for
the e-Nudge trial given the resources available, but a similar trial carried out on a much
larger scale involving many more practices would lend itself better to a cluster
randomised design.
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9.4.2 Choice of primary and secondary outcomes
Whilst we named the CVD event rate as the primary outcome, the chances of actually
influencing it over a two year timescale seemed very low given the high number needed
to treat for CVD risk reduction interventions such as lipid lowering therapy in primary
prevention settings, and I was more interested in the changes in group proportions, for
which the trial was more than adequately powered. But as the CVD event rate seemed
likely to be the most difficult outcome to change, and given (based on the existing
literature, as discussed in Chapter 4) that hard clinical outcomes are generally more
valued than changes in process measures, we considered that this was the most
appropriate primary outcome. If we had called this a secondary outcome instead the
trial would not appear to have been underpowered and non-significant in its primary
result. If I were to repeat the e-Nudge trial with similar resources available I would
consider either reversing the choice of primary and secondary outcomes, or stretching
the trial resources to include more practices. An even better option would be to obtain
sufficient funding for a larger trial more adequately powered to detect a reduction in
CVD events.
9.4.3 All events versus first events
The chances of demonstrating an effect of an intervention under trial is improved if the
‘signal/noise’ ratio is maximised. This issue was emphasised at the Randomised
Controlled Trials course that I attended at Oxford University in April 2006, after the e-
Nudge trial design had been finalised. A missed opportunity to improve this ratio was to
consider only first cardiovascular events in the primary outcome measure. The reason
why I initially deemed this inappropriate was that as the trial went through the Ethics
committee I was still including secondary prevention patients (those with existing CVD
or diabetes with uncontrolled blood pressure or cholesterol) as the separate Group 1. As
long as this group were included, it made sense to include all CVD events in the over
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50 year age group occurring during the trial as the outcome. There were also secondary
prevention patients identified in Group 4/D (patients over 75 with persistently raised
blood pressure), in the original Group 5 (those with possible undiagnosed diabetes), and
in Group 6/C (those with CVD but no recent blood glucose on record). When Groups 1
and 5 were withdrawn (for reasons discussed in Chapter 8) it was too late to revise the
outcome measures as the trial had started. But the study had become a trial almost
exclusively on the primary prevention population. Groups A and B (which were always
the groups of greatest interest simply because they were the only ones requiring the
Framingham computation) by definition did not include secondary prevention patients.
Whilst the patients included in these groups changed during the study (and they
therefore could not easily have been used as a denominator population for the trial
outcome), I could have confined the CVD event outcome exclusively to the primary
prevention population. This would have been easy to do using EMIS LV (the software
platform used for he trial), as the outcome searches defined in the data collection SOP
(see Appendix) could simply have identified ‘First’ events rather than ‘First or New’.
This change would have reduced the number of CVD events analysed (reducing the
power) but confined them to a smaller, more relevant denominator population,
improving the signal/noise ratio in the outcome analysis. As it stood, the e-Nudge trial
outcomes still included events occurring in patients with established CVD at the start of
the trial, who by definition could not have been exposed to the Group A or Group B
reminders. These patients were experiencing CVD events for at least the second time,
which had implications for the statistical analysis, which was based on the Poisson
assumption that events were occurring randomly in the population. A much ‘cleaner’
outcome would have been the incidence of first events in those with no history of past
events. This would actually have been easy to detect using the EMIS LV software, but
the sample size would have needed to be significantly higher as it would have only
involved the primary prevention population.
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9.4.4 Imputation of missing risk factor values
The final stages of the e-Nudge software design took place with considerable time
pressure. One area that could have been improved was the issue of ‘missing data,’ i.e.
the assumptions made for Group B patients whose risk profiles were incomplete and for
whom ‘assumed values’ were inserted where a risk factor datum was either missing or
out of date. During this time I was influenced by existing CVD risk assessment
software designed for use on individuals rather than for populations like e-Nudge.
These tended to input one single value for a missing datum, e.g. 1.0 for HDL
cholesterol. Slightly more elaborate options would define different values for different
genders, but these were still fairly limited. This area interested me for two reasons.
Firstly, I was aware from personal communication that Tom Marshall at the University
of Birmingham was developing means of basing such assumptions on other existing
information in the record. The Sandwell project that he led used this approach and was
later published in BMC Public Health (10). He would, for instance make an assumption
for missing diabetes or smoking status data based on age, sex and other variables that
were recorded. Secondly, it was an area that I had discussed with Lucila Ohno-
Machado prior to the publication of our own paper (11), which proposed more complex
algorithms to account for incomplete primary care data. However, in finalising the e-
Nudge software, time was too limited to develop such approaches beyond the
imputation of gender-specific assumed values for total cholesterol, HDL cholesterol,
and/or systolic blood pressure based on their median levels from the entire 50-75 year
age range in the Health Survey for England 2003. This might have been refined to
identify such assumed values based on 5-yearly age bands, or on other risk factor
values. Smoking status was simply assumed to be ‘Non-smoker’ if absent, and this
again might have been improved.
More recently, a key paper has been published by Sterne et al (12) specifically
addressing this problem of missing data in the context of cardiovascular disease risk. It
followed the first QRISK article (13), whose risk estimates were carried out with only
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50% of HDL cholesterol values available (see also Sterne et al: Multiple imputation
needs to be used with care and reported in detail, BMJ Rapid responses, posted
21.8.07). This is a clearly non-trivial issue. More importantly, the problem of imputed
data values was later found to be the source of the implausibly low CVD hazard ratios
for total cholesterol/HDL in QRISK, an outcome that immediately questioned the
validity of the algorithm (Richard Peto, Doubts about QRISK score: total / HDL
cholesterol should be important, BMJ Rapid responses, posted 13.7.07). This required a
repeat analysis as QRISK2 (14). The Sterne et al paper identified the important issue
that participants with missing data do not necessarily represent the same population (in
terms of their risk factor distribution and average risk) as those with complete data.
One further point relevant to the ‘missing data’ issue is the problem of estimating
risk based on single values of risk factor variables such as serum cholesterol. Reynolds
and colleagues (15) highlight the wide confidence interval for a risk estimate, so that an
estimated risk value of 20% may have a 95% CI of 14%-26%. Basing risk on the
average of multiple measurements reduces this confidence interval, but individuals may
have only a single cholesterol value available in the record to support the estimate. Such
values may be used as a basis for advice on treatment without the clinician necessarily
being aware of this variation.
9.5 Feedback from students
Since commencing the e-Nudge trial I have discussed its design and implementation on
a number of occasions in formal presentation settings. On four of these, all involving
Masters teaching programmes at the University of Warwick, I have set the students an
exercise. Having described in some detail the design of the trial, I have given them the
opportunity in break out groups to discuss the question: Why might the e-Nudge
intervention fail to influence cardiovascular event rates over the timescale of the trial?
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The aggregated responses to this question have been useful in informing my own
thinking about how such a trial design might be improved. The responses are varied in
their details but can be distilled under the following eight headings:
1. The clinicians don’t respond to the alert messages or the lists, i.e. neither of
these change clinical practice. This might occur due to lack of interest in, or perceived
importance of the messages, particularly in the everyday environment of primary care,
or to competition between these and other reminders for the clinician’s attention. It
might also result from skepticism over whether the Framingham algorithm is useful in
today’s clinical environment, where issues that it does not account for (such as body
mass index or waist circumference) arguably receive at least as much discussion.
2. The reminders might change clinical practice, but not patient behaviour.
Even if an e-Nudge alert triggered a clinician to instigate a risk lowering intervention,
lack of responsiveness to the issue by a person who had visited the practice to discuss
an unconnected problem (and who might actually have no interest in CVD prevention)
would offset any e-Nudge effect.
3. Software problems (e.g. platform instability) might prevent the effective
delivery of the intervention. The currently available clinical software platform might
fail for purely technical reasons. The troubleshooting discussed in Chapter 8 covers this
issue although the majority of problems were due to e-Nudge software rather than
background platform problems, which was what these students had in mind. The
problem discussed in Chapter 8 concerning the Coventry ‘Bureau’ system and its
inaccessibility during the trial’s outcome data capture was a platform issue but affected
the trial data collection, not the effectiveness of the intervention. This was nevertheless
an important and useful issue to raise.
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4. The e-Nudge trial won’t continue for long enough for its effect to have a
measurable impact on cardiovascular event rates. This aspect is related to several
different timescales:
 The time between receiving a reminder message and the delivery of an
effective intervention, which might not occur during the same consultation, e.g.
prescription of a lipid lowering agent, delivery of a smoking cessation intervention, or
effective reduction of blood pressure.
 The time between the delivery of such an intervention and the benefits this may
have on CVD risk. The shortest recorded timescale for a significant impact through
lipid lowering is the recently reported JUPITER trial (16) that was halted after a median
follow up of 1.9 years. The effectiveness of blood pressure reduction on stroke rates
was evident soon after successful reduction in diastolic pressure in the early trials of
antihypertensive drugs summarized by Collins et al (17).
 The turnover of registered patients in the practice. If a high proportion of
patients were to move from the practice each year to be replaced by newly registered
patients then the effectiveness of the e-Nudge on CVD risk would be reduced at the
practice population level even though individuals later emigrating from the trial area
might still benefit in an undetectable way.
5. The variables used to determine risk are not the best selection from those
available. It could be the case that in 21st century UK practice the Framingham risk
factors used in e-Nudge are not an effective means of identifying the highest risk
population. Given the efforts recently made to improve this algorithm (described
earlier) this is not an unreasonable suggestion. A related issue involves the very concept
of targeted risk reduction. The case has been made that as most events actually occur in
low or intermediate risk groups (because of their greater numbers), CVD prevention
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initiatives based on targeting higher risk groups will be less effective than a non-
targeted population approach. Marshall and Rouse (18) modeled six different strategies
to address the problem of CVD risk reduction in primary care. They concluded that the
use of existing data (with assumptions for missing data points) to prioritise individuals
for risk assessment could improve efficiency above screening the entire unselected
population, particularly in terms of staff time. However, an approach based on intensive
treatment of higher risk individuals would be less efficient than one that offered low
cost drugs to many people.
6. The variables used are the most appropriate ones, but are not sufficiently
modifiable. It is possible that a risk algorithm such as e-Nudge could identify the
highest risk individuals, but that their risk depends largely on factors that are non-
modifiable, such as age and sex. This is indeed a common criticism of the Framingham
algorithm used in e-Nudge, although risk can be modified by lipid lowering or anti-
hypertensive medication even though this may have little calculable effect on the post-
treatment risk score. Indeed, according to some current opinions we should use raised
CVD risk as the only basis for the decision to use lipid lowering or anti-hypertensive
drugs rather than a person’s pre-treatment levels of cholesterol and blood pressure (19,
20).
7. The risk factor measurements taken and recorded in general practice are
not a good reflection of the actual variable values. Risk factor values are recorded
(and used as a basis for risk estimation) that are only an approximate (and perhaps less
than adequate) measure of the true values. The issue of variability within individuals in
serum cholesterol levels over time and its impact on estimated CVD risk has already
been discussed above. This variation adds to the effect of laboratory measurement error
on a single sample. Both of these effects introduce a random element, reducing the
accuracy of risk estimates without necessarily introducing systematic bias. But the
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validity of blood pressure measurements has been discussed ever since the MRC trial of
mild hypertension reported in 1985 (21), which highlighted the potential for subjective
interpretation. The Hawksley random zero sphygmomanometer was used to remove
such bias from the measurement of blood pressure in the trial. Following the advent of
target based payments for control of risk factors through the Quality and Outcomes
Framework, the question of ‘game-playing’ over the recording of blood pressure
measurements has been raised (22). In 2009 a UK general practitioner was removed
from the medical register for fraudulently inventing data to improve QOF performance
(23). To clarify this issue, the blood pressure measurements stored in primary care
research databases might be subjected to the same techniques (described in Chapter 2)
used by the MONICA investigators to quality check blood pressure data. These
included the last digit preference and the proportion of identical duplicate
measurements, both readily accessible electronically recorded data.
8. The statistical model used to identify high risk individuals is not adequate.
It is possible that even where the strongest independent risk factors are known and used,
and other less independent but still relevant factors are included, the risk algorithm fails
to identify the highest risk individuals because the statistical model does not combine
them in the most effective way to optimise risk estimation. This issue applied to CVD
risk is still a theoretical one, important to identify and discussed in Chapter 2, but
generally beyond the overall scope of this thesis.
The students own initial suggestions fell into the first four of these categories, and
the final four only came out through further discussion. In the case of the third heading
(related to platform instability), I had not personally identified this as a potential barrier
prior to these exercises. Whilst aware of potential (and actual) software problems that
required correction in the preparatory phase of the trial, I had not actually doubted the
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stability of the clinical software system on which the e-Nudge itself ran. But this issue
is an important one and platform stability is often taken for granted in primary care.
9.6 What would a revised e-Nudge trial design look like?
The practical issues discussed above made me reflect on how the trial design might
have been improved. The systematic review was also important in identifying features
of such reminder interventions that may predict successful outcomes. A fresh attempt to
test the effect of the same type of intervention whilst addressing these issues would
involve the following refinements:
 The sample size would be large enough to make cluster randomisation (with its
‘design effect’ on the sample size) possible, removing any risk of contamination. A
much higher number of practices would offset the risk of inadequate risk stratification
mentioned earlier. Recruitment over a wider area of the UK would also address any
uncertainty over the generalisability of the results to the UK population although the e-
Nudge trial population represented a broad demographic mix and its external validity
has not been questioned.
 The intervention would be applied exclusively to the primary prevention
population, i.e. those with no past history of a CVD event. It would be confined simply
to the e-Nudge Groups 3/A and 2/B, i.e. those either with complete data and a raised
estimated risk, or those with incomplete data but potentially at high risk based on
imputed values for the missing data. This primary prevention focus might help engage
the attention of practitioners in a way that a multifaceted intervention might not.
 The CVD risk algorithm would include only CHD and cerebrovascular outcomes
as these would correspond exactly with the study outcome measures.
 The imputation algorithm for assumed values of missing data would be refined
to maximise the influence (where justifiable) of known correlations between risk factors
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in the profile. This could be done in a more detailed way than the e-Nudge algorithm, in
the way suggested by Tom Marshall (24) (and personal communication), by imputing
values for missing data based upon the patients other, known factors. If possible, it
might go beyond this to utilise a more complex algorithmic process to derive such
estimates by drawing on known correlations between risk factors that may be
inconsistently recorded. But for the purposes of an intervention trial such complex
approaches might be unnecessary. The assumption of missing values based on a ‘best
guess’ available through simple approaches might be perfectly adequate.
In addition to these adjustments, a new trial might more adequately assess the
behavioural influences relevant to the use of screen reminders. Existing literature might
inform this approach. Menke at al suggest that from the user perspective screen
reminders are ‘carrots, sticks, or flies’ (25). They may encourage a response by offering
help, force a response, or be simply ‘swatted away’ with a mouse click. These authors
emphasise that successful design of screen alerts requires an understanding of the way
that such reminders are likely to affect the user.
A further challenge is the integration of automated reminders into clinical
workflow. Kawamoto et al, as mentioned earlier in Chapter 1, identified this factor as
among the most important determinants of the success of computerised decision
support systems (26), whilst Maviglia et al regard it as the most difficult of all the
numerous obstacles to the success of such systems in chronic disease management (27).
Dexheimer and colleagues used a 46 item questionnaire to investigate
emergency department clinicians’ attitudes towards screen reminders prior to the
implementation of an intervention to promote pneumococcal vaccination (28). This
study again highlights the relevance of the health care setting as well as the clinicians’
attitudes as determinants of likely responsiveness. Whilst the emergency department
was seen to be an appropriate setting for vaccination, and vaccination was believed to
be cost-effective, time constraints and the availability of relevant information
determining eligibility were found to be important obstacles.
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Mayo-Smith and Agrawal reviewed the literature concerning the factors likely
to promote responsiveness to reminders and identified a number of potential
characteristics of the reminders, practices, and users (Table 9.1). They then undertook a
large study of clinicians exposed to a newly introduced system of reminders in the New
England VA Healthcare system (29). They were able to correlate the provider and
practice characteristics with the likelihood of completing the suggestions displayed by
the computerised reminders. By undertaking a postal survey, they were also able to
incorporate provider attitudes into this analysis. Interestingly, no single attitudinal
characteristic was found to be important in this study. However, feedback to providers,
and the incorporation of support staff into clinic processes were associated with very
significantly improved reminder completion rates.
Reminder characteristics
Possible facilitating factors
Minimization of keystrokes, mouse clicks, scrolling, window changes and
complexity
Facilitation of alert completion with pre-populated alternatives
Minimization of time required to document why reminder did not apply
(“exceptions entry”)
Correct assignment of patient eligibility with updating easy and rapid
Utilization of stored patient data to more precisely target patients
Selective targeting of users based on department, degree and other user
characteristics
Provision of enough information to allow a triage decision at a glance
Presence of links to other information resources
Provision for users to have some control of reminders so that they can avoid
unnecessary ones
Presentation of CR in use of electronic medical record at the point of decision
and action
Including all clinically appropriate options for action, including patient refusal
Ensuring CRs easy to locate in EMR
Practice characteristics
Possible facilitating factors
Easy accessibility to computers
Presentation of CRs at the appropriate time within the clinic workflow to the
appropriate staff
Coordination between nurses and providers
Limitation of number of reminders to minimize “reminder fatigue”
Ability for providers to document problems with CRs and receive prompt
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feedback
Possible inhibiting factors
Provider workload and inadequate time during visit
Interference with provider-patient interaction
Use of paper records or forms in completion process
Using reminder while not with patient
Slow computer processing time
CRs that benefit administration more than providers
Lack of reimbursement for reminder completion
User characteristics
Possible facilitating factors
Adequate training on reminder use
Staff provider vs. resident physicians
Table 9.1 List of factors identified by Mayo-Smith and Agrawal (29) in the published
literature potentially determining effectiveness of computerised reminders (CRs).
Taking these issues into account, pilot work that assessed clinician
responsiveness and the successful integration of the proposed intervention into the
workflow might usefully inform the design of the final product if a future trial of
reminders supporting CVD risk reduction were to be planned on a larger scale in the
UK.
Health economic implications are also important, and were not assessed in the
e-Nudge trial given the time constraints. Differences in prescribing and referral patterns
between the trial arms might have detected influences of the intervention on clinical
behaviour in ways that were not visible in the trial.
The issue of potential harm was also not assessed, other than through the field
notes recorded during discussions with practice teams, including the one practice that
withdrew. As well as interference with the visibility of other information on the screen
discussed in Chapter 8, the potential for screen reminders to lengthen consultations is a
quantitative outcome that could be measured fairly easily in this type of trial.
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Qualitative methods would be required to determine whether such added consultation
time was, or was not welcomed by clinicians and patients. In particular, the question
over whether the latter group considered this a threat to personal autonomy, as
suggested by Getz (30) and discussed in Chapter 3, would be an interesting and
important matter to investigate.
9.7 Summary
The e-Nudge trial and associated research identified a number of issues determining the
ability of a software intervention installed in general practice systems to facilitate CVD
risk reduction during routine primary care. The trial demonstrated a significant effect in
improving data adequacy through influencing practice team behaviour, but did not
demonstrate within two years an effect on CVD event rates. To do so would probably
require a larger sample size, a longer timescale, and a more focussed intervention
confined to the primary prevention population. Through the conduct of this research
various other issues came to light. These concerned the importance of the data source,
the processes of care on which a pragmatic trial of this type depends, their vulnerability
to health policy changes during a trial, and the relevance of perspectives originating
from unexpected sources.
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Chapter 10: Outputs of the research
10.1 EMIS software for recognising undiagnosed diabetes
A major output of this research was the design of a software module to assist in the
early detection of diabetes using electronic data in primary care. This module resulted
from the QRESEARCH project described in Chapter 8, triggered by the e-Nudge trial’s
preparatory phase, and was subsequently installed in all 5000+ EMIS practices across
the UK (1). In a subsequent paper in the British Journal of Diabetes and Vascular
Disease I described how these two projects had led to this outcome, and provided the
projected numbers of people in the overall UK population at risk of undiagnosed
diabetes identifiable through this approach (2). This number (528,000) is comparable
with the estimated figure for the undiagnosed diabetes population (up to 1% of the total
UK population based on one source (3)). The installation of this module in practices as
a standard component of EMIS clinical software allows such individuals to be
recognised during routine care, either opportunistically through screen messages or
more systematically using regularly updated lists, very much in keeping with the e-
Nudge approach. The QRESEARCH searches required for this project were carried out
during June 2006. Whilst it would take until March 2008 to publish the paper, the
EMIS software was installed in all of their sites and linked to screen alerts by April
2007. This development was the first example of a new algorithm based on nationwide
primary care data resulting in a system of screen reminders to assist in identifying risk
of disease.
Whilst another software provider (Vision) has independently developed a
similar module to support case finding for diabetes under the QOF, only EMIS have
nationwide data (due to these projects) on the numbers of people identified and
(perhaps more interestingly) the time interval since the measurement of the abnormal
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blood glucose level in affected individuals. The Vision software needs to be actively
configured to provide screen alerts, whilst the EMIS reminders are a non-optional
feature of their software considered essential for clinical safety (David Stables and
Shaun O’Hanlon, personal communications).
In 2008 I applied to Diabetes UK for a project grant to test the effectiveness
of the EMIS software at detecting confirmable cases of undiagnosed diabetes. This
project was designed to identify a sample of patients in a demographically diverse
selection of EMIS practices and test them for diabetes using fasting glucose
measurements or oral glucose tolerance tests where appropriate. The objectives were to
measure and report the ‘number needed to screen’ to detect one new case of
undiagnosed diabetes in this subgroup of the practice population – those not on the
diabetes register but whose most recent blood glucose level was either frankly raised (in
the diagnostic range for diabetes) or borderline and justifying follow up testing. Such
patients are now readily identifiable in the computer system of any EMIS practice,
through the lists created and maintained by the new software. My aim was to replicate
the approach of the New Zealand study investigators (4) who had randomly targeted
householders in an ethnically diverse region of South Auckland and tested them for
diabetes after initially measuring random blood glucose levels. These researchers had
demonstrated that random blood glucose measurements were superior to traditional risk
factor profiles as a means of identifying those most likely to benefit from screening for
diabetes (e.g. by oral glucose tolerance test), particularly in the European population.
However, the Diabetes UK application was unsuccessful. One problem in the
design was the issue over whether a research funder should be responsible for paying
for the necessary blood tests when their clinical justification was clearly evident and
expected under current guidelines. Another problem was over whether a general
practitioner inviting a patient to take part in the project (through having his/her diabetes
status clarified) should potentially confuse the clinical need for this clarification with
the usual patient’s right to consent (or decline) to take part in a research study. Testing
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patients identified by the software for diabetes was clearly justified on clinical grounds
and not required merely to answer a research question. The Warwickshire Research
Ethics Committee approved the application but deliberated over whether the project
was in fact audit or research, as it was designed to collate information (blood glucose
results) from multiple practices that involved data collected (albeit systematically and
prospectively) in a clinical rather than a research setting.
A potentially important research question therefore remains unanswered. I
suspect that the ‘A’ and ‘B’ lists in the EMIS software are likely to provide the highest
yield of undiagnosed diabetes cases of all the electronically identifiable subgroups of a
practice population in UK primary care. However, this impression is unproven and
needs to be reworked into a new research proposal. Since 2008 when the original
application was declined, a new algorithm (the QDScore) for identifying patients at risk
of future diabetes has been published (5). This is similar in its risk factor profile to a
previously published algorithm designed for targeted case finding (6). Whilst there is an
important distinction to be drawn between prevalent undiagnosed diabetes and future
incident diabetes, it would be interesting to compare these algorithms with the EMIS
‘A’ and ‘B’ lists in their ability to identify undiagnosed cases.
10.2 Advice to the National Institute for Health and Clinical
Excellence on CVD risk estimation in primary care
In 2006 I was approached formally by the Guidelines Development Group for the
National Institute for Health and Clinical Excellence (NICE), who were considering
evidence provided by an academic advisor on CVD estimation using primary care data
and required peer review. This invitation gave me the opportunity to allow my
experience of e-Nudge to influence what became an important policy document, the
2008 Clinical Guideline 67: Lipid Modification (7).
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10.3 e-Nudge as a software option in UK general practice
On a less formal basis, I was able to feed into UK policy on the emerging vascular
screening programme through contacts with the authors of The Handbook for Vascular
Risk Assessment (8). This manual described a small number of software options
available in the UK for identifying individuals at raised cardiovascular risk, and
includes a description of the e-Nudge. Of all these options, e-Nudge is the only one that
has been subjected to a randomised controlled trial.
10.4 The EMIS Primary CVD Prevention toolkit
Following the e-Nudge trial, I prepared and submitted to EMIS a brief advisory
document describing means of meeting the needs of the National Vascular Screening
Programme and more specifically NICE CG67 (Lipid Modification) within primary
care, based on the e-Nudge experience. This experience has fed into the development of
a new EMIS module, the Primary CVD Prevention Toolkit, which builds lists of
patients at risk based on existing data, and also those in need of further data collection,
very much in the style of e-Nudge. The risk algorithm used is QRISK2 rather than
Framingham. My advice had been that both QRISK2 and Framingham might be
optionally available to practices, as the current guideline (NICE CG67) still
recommends Framingham as the tool to support case finding under the vascular
screening programme.
10.5 GE Healthcare searches
As a result of the international publicity surrounding the QRESEARCH project
published in 2008, I was approached by GE Healthcare (a subsidiary of General
Electric) to explore the use of the same approach in their US ‘Centricity’ database. This
database hosts just over 11 million electronic medical records from a variety of source
health care organisations (including over 9,000 ambulatory practices) across the US.
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The Medical Quality Improvement Consortium (MQIC) has access to run queries on
the Centricity system for research as well as clinical purposes.
Initial searches (using the same ‘A’ and ‘B’ protocols as the QRESEARCH
project) were carried out by GE Healthcare. These suggested that large numbers of
individuals with possible undiagnosed type 2 diabetes are also identifiable in the US.
The GE team presented these findings (in a direct comparison with our QRESEARCH
project) at the Conference of the International Society of Pharmaco-economics and
Outcomes Research, Paris, in September 2009.
This US based result suggests that individuals with biochemical evidence of
undiagnosed diabetes may be identifiable in other health settings outside the UK. This
is not simply a result of the failure of health care providers. It may be due to the fact
that borderline blood glucose levels, whilst a serious health concern, are commonplace,
generally asymptomatic (or producing very low grade symptoms), and may be missed
in people who are either ‘hard to reach’ or are, as well as their health care providers,
focussed on more obvious immediate demands.
.
10.6 Publications and dissemination
Seven peer-reviewed publications resulted from this PhD research (1, 2, 11-15),
including the final report that was in press when the thesis was submitted. I also plan to
publish the systematic literature review described in Chapter 4. As well as publishing in
journals, I have disseminated this research through the following channels:
1. Formal academic presentations. These included regional events including the
South West SAPC conference (18.6.09), in which I presented the results of the e-Nudge
trial. On earlier occasions the design of the trial was presented at ScHARR, University
of Sheffield (3.6.06); McGill University, Montreal (6.11.06); Moncton University, New
Brunswick (10.11.06); and the Coventry and Warwickshire Cardiac Network ‘Good
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Practice Day’ at the Ricoh Arena (16.5.08). The Canadian visit was funded by the
University of Warwick’s North American Collaboration scheme.
2. Feedback to the Primary Care Trusts. Formal feedback to PCT Executives over
updates on the e-Nudge trial was presented at three meetings designed to strengthen
collaborative links between the University of Warwick and the local NHS.
3. Feedback to practices. At each stage the participating practices have been kept
aware of the outcomes and impacts of the trial. PDFs of published articles have been
forwarded to them on each occasion.
4. Feedback to policy makers. As discussed above, I was invited to contribute towards
the development of the NICE CG67 Guideline and with the group that produced the
Handbook for Vascular Risk Assessment.
5. Media publicity. The recognition of undiagnosed diabetes in the QRESEARCH
study was disseminated in the lay press throughout the UK as well as internationally
(e.g. news websites in Germany, Australia, Sri Lanka).
6. University of Warwick i-Cast. The University arranged for an i-Cast to be filmed to
illustrate the story of how the initial e-Nudge work resulted in a nationally distributed
software module. This featured a patient of mine who was identified by some
preliminary searches in my own practice as having undiagnosed diabetes. He went on to
lose several stones in weight, effectively reversing his hyperglycaemia. The i-Cast is
available at:
http://www2.warwick.ac.uk/newsandevents/pressreleases/gp146s_databases_could
10.7 Summary
This chapter has described some outputs of the e-Nudge research including national
impacts. The final chapter will summarise the main conclusions of this research and
outline potential future directions.
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Chapter 11: Thesis summary and future research
directions
11.1 Overall conclusions of the research
The original aim of this research was to investigate the potential of routinely collected
general practice data to support a programme of cardiovascular risk reduction in the
UK. Major questions concerned not only the completeness of existing data
(completeness in the sense of fulfilling the minimum requirements of a basic
Framingham calculation) but also its quality, its accessibility to primary health care
professionals, and its utility as an input to software programs designed to compute risk.
Other issues included ethical aspects related to the process of risk assessment and its
potentially negative consequences. Finally, I questioned whether electronic reminders
and flagging mechanisms in the primary care environment could influence clinical care
in a way likely to reduce future cardiovascular events. This question was developed into
a randomised controlled trial that became the main focus of the research, together with
a systematic review of similar interventions applied to health care contexts.
11.1.1 Two stage process of risk estimation
Preparatory work discussed in Chapter 5 was extremely useful in guiding the design of
the e-Nudge trial as it helped to identify problematic areas such as the definition of an
ex-smoker. It was through this pilot work that I became aware of the distinction
between the process of prioritising candidates for risk assessment and the process of
clarifying and confirming their risk level through more detailed assessment. This PhD
project has confirmed that routinely collected data are extremely useful for the first
stage but less than adequate for the second. In a rapid response to the initial QRISK
paper, McManus and Mant drew a similar distinction, and suggested that different
algorithms may be appropriate in different settings, QRISK for identifying high risk
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groups at the population level, and Framingham for estimating the risk of an individual
patient [McManus R and Mant J, Setting for risk calculation will affect performance of
QRISK. BMJ Rapid Responses, posted 21.8.07].
11.1.2 Adequacy of data
The e-Nudge trial itself informed two issues that were important for current practice.
The first of these concerned the baseline data following software installation, which
provided a comparison between the proportion of the over 50 year old population
having ‘complete’ profiles (as defined above) with those whose profiles would require
more data for a basic risk estimate. These results suggested that whilst a readily
identifiable population exists whose raised risk is already evident through existing data,
the group is outnumbered perhaps 4 or 5 times by those possibly at raised risk but
requiring further data to estimate risk. It also suggested that the group whose raised risk
is already evident (a group that includes those whose major risk factors are their age
and sex) is significantly smaller than those with existing cardiovascular disease and
modifiable risk factors that are out of target (1).
11.1.3 Impact of electronic reminders
A systematic review of literature on controlled trials of reminder interventions aiming
to influence the behaviour of clinicians in the consultation environment found their
impact to be generally positive. The effect was variable, usually modest and appeared to
be dependent on the health care context. Specific factors consistently predicting the
effect size were difficult to identify.
Electronic reminders incorporating a cardiovascular risk algorithm and drawing
on routinely collected UK primary care data were tested through the e-Nudge trial. This
demonstrated that such reminders can improve the adequacy of risk factor information
during everyday care to improve the visibility of the at risk population for risk
reduction. At the same time, the group requiring further data to calculate risk was
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reduced. However, hard clinical outcomes such as the cardiovascular events that were
the primary outcome measure were not significantly reduced.
11.1.4 Lay perspectives
Whilst the e-Nudge trial was running, I began investigating some of the qualitative
issues including the attitudes of lay people towards risk assessment. This work is
included only to provide context for the main research question and as a pointer to
future research directions. The interview transcripts reported in the Appendix provided
evidence of a range of opinion over the value of primary cardiovascular risk reduction.
Whilst the overall feeling was very positive, some of the participants were less
enthusiastic when the practical implications were discussed. This study was very
limited and served only to provide me with some insights into the value of including
qualitative work as part of a clinical trial.
11.1.5 Contextual basis for CVD risk estimation
A further insight gained through this research relates to the shift in UK health policy
towards a broader understanding and concept of cardiovascular risk. This process began
with the focus in the 1970s on a small number of independent CVD risk factors, and in
particular on the probably causative, and certainly modifiable factors. The need to
develop effective preventive interventions (including drug therapy and lifestyle change)
required the identification of causative factors, as it would only be by modifying these
that CVD risk could be reduced. But interestingly, the emphasis has since shifted
towards the identification of risk on the basis of all relevant factors, including those
associated with but not necessarily causally linked with CVD outcomes. Overlapping
(i.e. non-independent) risk factors are now considered important markers in modern
algorithms, such as ethnicity, family history, and social deprivation. This approach has
resulted from the finding that preventive interventions tend to produce a fairly
consistent proportional reduction in absolute risk. If everybody’s absolute risk is
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reduced by a quarter by an intervention, those most likely to benefit are those with
greatest initial absolute risk, even when this risk is estimated using non-modifiable
factors. This contextual approach supports a more complex basis for defining risk, and
the use of algorithms that utilise factors that are at least partially redundant (in a
statistical sense) to define the at risk population. This conclusion is fundamental to
recent changes in health policy in this clinical area.
11.1.6 Responsibility to act on identifiable at risk groups
In Chapter 3 I discussed the responsibility felt by care givers and the priority given by
policy makers created simply by the ability to identify at risk individuals, particularly in
life threatening scenarios. The ‘Rule of Rescue’ holds (rightly or wrongly) that
identifiable individuals should take priority over those whose needs may be equal but
who are not identifiable, or at least not currently identified. This approach is not
generally considered valid by ethicists, but nevertheless influences policy makers and
clinicians on a more intuitive level. This issue arose in a number of ways during the
process of the e-Nudge trial.
First of all, the Ethics Committee required reassurance that it was ethical to
withhold the potential benefits of identifying raised CVD risk in the control arm.
Control patients were being identified as frequently as intervention patients (at least
initially), and yet no flagging mechanisms would be triggered. The committee were
reassured that the trial’s control arm would continue to benefit from ‘usual care’ i.e.
that the practice teams could continue to assess and address CVD risk in these people as
they had done in the past. They had access to the same range of risk factor data. I was
simply trialling the additional effect of the e-Nudge software. But an interesting
dilemma had been created by applying an algorithmic process to the data, a dilemma
that had not apparently arisen beforehand, even though all of the data existed. The
patterns were already present in the data but couldn’t easily be perceived by human
clinicians (2). Did this relinquish the responsibility of clinicians to respond to them?
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One might take the view that the e-Nudge is, as discussed below, a pattern recognition
tool of significantly greater complexity than the majority of search protocols in
common use (as it requires a weighted computation of data inputs), but it is likely that
in the foreseeable future such approaches will become commonplace.
This raises the question over whether the complexity of the search algorithm
determines any resulting responsibility. The identification of patients at risk of CVD
using the Framingham algorithm was a sufficiently complex approach algorithmically
that it represented a significant departure from ‘usual care’, and as its utility had not
been proven, it justified trialling. However, when the baseline data demonstrated that a
significant group with possible undiagnosed diabetes was identifiable through a
relatively simple search technique (comparable in complexity with many of the
everyday searches undertaken in general practice), it was not considered ethical (by
myself nor by EMIS) to identify such individuals in the control arm without taking
action. The QRESEARCH project that followed this finding used an even simpler
search protocol (3), detecting a still more significant number of individuals. In the press
coverage that followed this finding, I emphasised the simplicity of the search technique
that we had shown could uncover such widespread unmet health need. It was this
simplicity that made the discovery newsworthy, and that then entailed a responsibility
for practice teams to correct this apparent shortfall in care. As time goes by, more
complex algorithms are becoming available to identify similar at risk groups, including
the recently published ‘QDScore’ for future diabetes risk (4). This algorithm identifies
those at risk of future incident diabetes rather than prevalent undiagnosed diabetes, and
does not therefore hold the same ethical requirement for early action (although it could
be argued that the risk factor distributions of these categories overlap strongly).
However, it seems likely that in future, health care providers taking responsibility for
large electronic databases may feel responsible also for acting on the algorithmically
accessible patterns within them.
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In May 2009 I was invited to attend an EPSRC/MRC funded workshop entitled
‘Grand Challenges in Information Driven Health: An innovative multidisciplinary
patient-centric early detection care model’ organised by Cardiff School of Computer
Science and Cardiff School of Medicine. Its aim was “to define a research agenda
capable of delivering the technology, informatics and service model necessary to
provide the best community-based care for patients with chronic conditions in the
future.” Without anticipating the published report (still in preparation) from this event,
one issue arose that concerned our general responsibility for recognising patterns in
health data, data that might be largely owned and kept by the patient, given the
development of patient held records. A concern was shared that responsibility for acting
on such patterns might in future exist whether or not we had actually utilised the
necessary programme to identify them. At an early meeting with a practice that I
recruited for the e-Nudge trial, one general practitioner raised the related question of his
clinical duty to respond to the intervention patient alert messages, simply because the
patients (already potentially identifiable using existing data) had become actually
identified. It occurred to me that in a situation of increasingly adequate data, three
categories of pattern might exist: unidentifiable using currently conceived or available
algorithms; potentially identifiable (algorithm available but not actually executed); and
actually identified. Our responsibility to these groups is perhaps no longer confined, as
it may have been in the past, to the final one.
11.2 Potential for development of the e-Nudge approach to
other clinical areas
11.2.1 Algorithmic identifiction of at risk groups
The e-Nudge algorithm included the Framingham cardiovascular risk equation. Risk
factors were automatically extracted from electronic records and fed into this equation
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to yield a risk estimate as the output. This model of pattern recognition is more complex
than most other forms in current use. For the majority of such tasks in primary care,
searches are run to identify certain groups, subgroups of these groups, and perhaps
subgroups of these subgroups. For example: patients with diabetes; the subgroup with a
recent blood pressure measurement; then the subgroup with a recent blood pressure
measurement that is out of a defined target range. In other cases a number of different
(sometimes overlapping) groups or subgroups are identified. For example, those with
diabetes and either a blood pressure or a serum cholesterol that is out of target. Such
approaches require the construction of search protocols involving simple Boolean
AND/OR/NOT functions and the SHARED/EXCLUDE/INCLUDE rules built in to
general practice computer systems. These are also familiar to anyone used to searching
medical literature databases and other electronic resources. But to identify people at risk
of cardiovascular disease, the relevant data must not only be extracted but also then fed
into an algorithm typically involving a number of internal parameters including
regression co-efficients. During the development of the algorithm these parameters are
tuned to optimise the statistical fit between predicted and observed outcomes. Once
optimised, variation in the internal parameters is likely to reduce this fit unless a change
in the relationships between inputs and outcomes develops over time. This might occur
due to a change in population demographics, the clinical pattern of a disease, or the
interactions between risk predictors.
11.2.2 Identifying risk of other conditions
Cardiovascular disease prediction has, for reasons discussed in earlier chapters, lent
itself well to this more complex approach, but various other areas also show such
potential as the quality of primary care data improves. An example is the MDRD
(Modification of Diet in Renal Disease) algorithm for calculating estimated glomerular
filtration rate (e-GFR) (5). This was introduced as a software tool into practice systems
due to the requirement of the quality and outcomes framework for practices to identify
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those with chronic kidney disease (CKD) grades 3-5. Rather like the e-Nudge search
lists (available to practice teams for intervention patients) the MDRD lists are available
in EMIS and other systems to assist practitioners in creating CKD registers. But despite
the fact that general practice data are useful for this purpose (6), this tool is unable to
adequately define the CKD population without individualised adjustment of risk
assessment. It is able to identify likely cases on the basis of age, sex and serum
creatinine (all factors that are well supported by electronic data in primary care), but to
be confident of the e-GFR value other factors should be included that are less well
supported. These include black African ethnicity, which is still not reliably recorded in
general practice for many people. Extremes of muscle mass are also relevant and not
accounted for in the algorithm, which makes a generalisation about the relationship
between muscle mass and age.
Laboratory software used to estimate e-GFR does not necessarily contain
information on the patient’s sex, unlike the database of the general practice requesting
the test, but only their name on the request form. In reporting e-GFR, it may therefore
advise on adjustment of the MDRD estimate if the assumption it has made about the
gender of the patient is incorrect. This is a further example in which an algorithmic
computation is made on the basis of incomplete or uncertain data, where the missing
‘value’ (in this case gender) is not known with sufficient confidence to produce a
definite estimate, and may require clarification by a practitioner receiving the report. In
addition, a clinician might consider whether the serum creatinine measurements on
which the e-GFR values have been derived were typical for the patient and likely to
remain so. It is recommended that two abnormal values should be used, spaced at least
three months apart as a basis for inclusion on the CKD register. However, the particular
circumstances of the individual patient may determine whether such inclusion is
appropriate, circumstances that are only evident through examination of the patient
record by a human clinician. CKD registers cannot be automatically created solely by
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practice based software, and the same issue applies to ‘At risk of CVD’ registers. This
is an important conclusion of this thesis.
Looking to the future, risk of malignancy, osteoporosis, hospital admission, and
mental health problems are all possibilities for the automated (but provisional) creation
of ‘at risk’ registers, based on electronic data but probably requiring human
interpretation. In these examples the relevant risk factors are either less well known or
less well recorded than those for CVD risk. However the increasingly adequate
recording of outcome data in general practice (and other primary care sources such as
Primary Care Trust) databases may provide a basis for the future targeting of at risk
individuals in this setting.
11.3 Towards a nationwide adaptive prediction tool for
cardiovascular disease prevention
My original paper co-authored with Lucila Ohno-Machado (7) discussed the future
possibility of a nationwide adaptive prediction tool for cardiovascular disease
prevention. This model became a personal benchmark for the progress of my research
to date. Through such a tool changes in the relationships between risk predictors, their
interactions, and the relevant outcomes would be detected automatically and fed back to
primary care practitioners to tailor risk reduction strategies adaptively in response to
evolving population demography and risk patterns. Other advantages that we identified
included a wider potential range of risk factors than the traditional ones, and the use of
more complex algorithms capable of detecting interactions and imputing missing data
more effectively. The e-Nudge project attempted to investigate and establish a major
element of this approach, the application of a risk algorithm to ‘live’ primary care data
linked to screen alert messages to assist in the recognition of at risk individuals and to
improve risk factor data quality during routine care through feedback to practitioners.
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A further element of this model was that locally collected information on such
risk factors could be fed into a nationwide data collection system to develop a UK
based cardiovascular risk algorithm tailored to local patterns. This element was later
achieved by the QRISK team led by Julia Hippisley-Cox (8, 9). QRISK2 includes major
risk factors not included in the Framingham equation such as body mass index, social
deprivation, ethnicity, family history of cardiovascular disease, atrial fibrillation and
rheumatoid arthritis. The QRISK project enabled routinely collected UK data to assist
in the tailoring of cardiovascular risk predictions to the UK population.
One result of both the e-Nudge and the QRISK projects was the development of
a ‘Primary CVD Prevention Toolkit’ installed in all EMIS systems across the UK in
March 2009 and described in Chapter 10. This provides for the identification of at risk
individuals (according to QRISK2) in practice databases. The QRISK2 algorithm has
the potential to be adjusted over time if changes in risk factor patterns are detected
through the QRESEARCH database. It is not yet linked to screen alert messages (as
cardiovascular risk assessment is currently only required for the QOF for newly
diagnosed patients with hypertension), but most of the elements anticipated by the
original paper (7) have now occurred. The next question is: what further work is
necessary to fulfil the vision of a nationwide adaptive prediction tool for cardiovascular
disease prevention, and how can this be achieved?
First of all, the EMIS Primary CVD Prevention Toolkit would need to influence
clinical care. This might require linkage to screen reminder messages, and is a practical
issue. To overcome it, incentives would probably be required to balance the negative
aspects of screen messages. Such incentives would translate either to clear, unequivocal
clinical need (such as that identified by the undiagnosed diabetes alerts), or financial
incentives through incorporation into the QOF. The ethical issues discussed in Chapter
3 would be relevant to policy development in this area. Switching on CVD prevention
toolkit alerts would immediately create a significant volume of screen messages that
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would need to be managed alongside all the other demands of everyday practice and
would not be universally welcomed by practitioners and patients.
The QRESEARCH database can not directly feed its findings back to practices.
Information flow occurs in one direction only, as this is a research facility and practice
and patient anonymity are essential for ethical reasons. If changes in the pattern of CVD
risk were to occur over time in the UK population (requiring adjustments to the QRISK
internal parameters) then this would require a further QRISK study to derive and
validate an improved algorithm. This algorithm would then need to be installed in
practices through a patch transfer from EMIS or other software provider. This could in
principle be done quite frequently, although it is a time and resource consuming
process. However, my (and Lucila Ohno-Machado’s) original idea was that data
processing would be a distributed phenomenon rather than one occurring in a central
repository. It would be a continuous, automated process rather than one depending on a
series of retrospective analyses as in QRISK and QRISK2. Parallel processing is the
underlying paradigm of neural networks (as discussed in Chapter 2) and is the assumed
basis for human cognitive function. Local adaptive processing of cardiovascular risk
factor data in multiple practices (whilst guided by an algorithm common to all of them)
was the basis for the e-Nudge intervention. A further (relatively small) step would be to
allow the automated tailoring of the algorithm itself to local patterns in the data.
A future ‘adaptive prediction tool’ would provide this feedback through
ongoing ‘learning’ of the risk algorithm over time. This process would be continuous
rather than intermittent. Changes in the internal parameters of the algorithm would
occur without the need for in-depth analysis of past cohort outcomes by human
investigators. This thesis suggests that such ‘learning’ (i.e. the adaptive tuning of
algorithm parameters) could only inform ‘best guess’ identification of the ‘at risk’
population (due to data quality and other issues). However at the practice level this
might still improve targeting compared with an approach based on national cohort study
findings applied to current data. This would allow the tailoring of risk prediction to
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regional or local populations. Statistical power requirements would limit the population
size for such adaptation, but the volume of data present even at the primary care trust
(PCT) level, and certainly at the strategic health authority level is far greater than that in
the Framingham heart study. The potential need for such regional tailoring within the
UK is suggested by the recent derivation of ASSIGN, an algorithm derived from a
purely Scottish population cohort (10) and recommended by the Scottish Intercollegiate
Guidelines Network for Scotland (11).
Moving on to how such a system might be realised in practice, obstacles
include the unidirectional flow of information from practices to research databases, and
the need for retrospectively identified historical cohort populations on which to carry
out prospective observational outcome studies. EMIS-Web is a recently developed web-
based platform supporting UK electronic health records in an increasing proportion of
EMIS practices. Practices connected to EMIS-Web are provided with on-line back up
of data transferred in real time to two secure servers hosted by EMIS in Leeds. Unlike
QRESEARCH, this information is held for clinical rather than research reasons and
therefore includes all patient identifiers. For this reason, feedback of algorithmically
determined patterns using all available data (in the form of lists of at risk patients) to
practices would be permissible as it would not require the analysis of data by a human
researcher. The information would be contained within the NHS and regulated by the
governance framework of clinical care. The originally proposed use of the Newchurch
system to provide feed back to e-Nudge trial practices remotely (described in Chapter
5), whilst not in the end needed for the trial, was in a sense a ‘test case’ of this principle
and was approved by the Local Research Ethics Committee. Demonstrating the
effectiveness of such a system at reducing cardiovascular risk (or risk of other
conditions) would require a randomised controlled trial on a nationwide level following
the development of the adaptive risk algorithm, combining distributed pattern
recognition with feed back mechanisms (including screen reminder messages) delivered
at the point of care. It would require a programme of research involving clinicians,
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practice administrators, computer scientists, information technology technicians, and
industrial partners. This is a potential future direction for the research described in this
thesis.
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The Sheffield table survey 1997
(adapted from Ohno-Machado and Holt 2004*)
The Sheffield tables were published in 1996, and consist of rows and columns of cells,
each cell representing a combination of risk factor values (age, smoking status, diabetes
status, hypertension status, and LVH status). Separate tables are given for men and
women. Each cell contains a cholesterol value at which the combination of risk factors
would produce a risk of developing coronary heart disease (CHD) of >30% in the next
10 years. The cholesterol values were obtained using the Framingham algorithm for
calculating CHD risk.
These tables provided a framework for searching a practice population to
identify the most appropriate candidates for cholesterol measurement. In 1997 a series
of searches (named Sheffield 1-13) were carried out for this purpose on a North
Yorkshire population (registered with the Danby Practice). All cells in the Sheffield
tables that contained any cholesterol value were used to define the search protocols.
Because LVH status was frequently unknown or unrecorded, this risk factor was not
included in this survey.
Search Sex Hypertension Smoking Diabetes Age (years) No. identified
Sheffield 1 Male Y Y Y 30-70 0
Sheffield 2 Male Y Y N 34-70 12
Sheffield 3 Male Y N Y 36-70 3
Sheffield 4 Male Y N N 40-70 42
Sheffield 5 Male N Y Y 48-70 1
Sheffield 6 Male N Y N 54-70 29
Sheffield 7 Male N N Y 58-70 3
Sheffield 8 Male N N N 64-70 47
Sheffield 9 Female Y Y Y 36-70 1
Sheffield 10 Female Y N Y 40-70 3
Sheffield 11 Female Y Y N 42-70 6
Sheffield 12 Female Y N N 50-70 41
Sheffield 13 Female N Y Y 52-70 1
Y = Yes, risk factor present
N = No, risk factor absent
As a result, a total of 189 patients were identified out of a population of 2137
(8.8%) requiring cholesterol measurement. In some cases the cholesterol value would
already be known, and this survey’s results reflect the distribution of the risk factors in
the practice population and not the adequacy of the data. The individuals’ notes were
then tagged electronically and each patient subsequently invited in for a blood test.
Where it would then make a difference to treatment decisions, an ECG was arranged to
determine LVH status. The tables made it possible to determine in each individual case
whether or not the ECG result would actually affect treatment decisions over lipid
lowering therapy.
* Ohno-Machado L, Holt T. Complex pattern recognition in health data. Chapter in:
Complexity for Clinicians. Holt T (Ed.) Abingdon: Radcliffe Publishing, 2004.
SQL program for the Framingham CVD equation
drop function Calculate_CVD_10Year_Risk
GO
create function Calculate_CVD_10Year_Risk (@Age tinyint, @Sex bit, @SystolicBP float,
@DiastolicBP float, @TotalCholesterol float, @HDLCholesterol float, @Smoker bit,
@Diabetes bit, @LVH bit)
returns float
as
begin
declare @aa float, @ab float, @ac float, @ad float, @ae float, @af float, @ag float,
@ah float, @ai float, @aj float, @ak float, @al float, @am float, @an float, @ao float, @da
float, @db float, @dc float, @dd float, @de float, @df float, @dg float, @dh float, @di float,
@dj float, @dk float, @dl float, @dm float, @dn float, @dp float,
@lnAge float, @lnDiastolicBP float, @lnSystolicBP float, @ChlRatio float,
@lnChlRatio float, @lnTime float,
@u float, @mu float, @ro float, @risk float
-- Rules
--
-- Sex (0) is Male, Sex(1) is Female
-- Smoker (0) is a Non-Smoker, Smoker (1) is a Smoker
-- Diabetes (0) is No Diabetes, Diabetes (1) is a Diabetic
-- LVH (0) is No LVH, LVH (1) is LVH
-- Basic validation
-- Blood Pressure
if @SystolicBP < @DiastolicBP
-- Systolic lower than Diastolic
return (null)
-- Cholesterol
if @HDLCholesterol > @TotalCholesterol
-- HDL more than Total Cholesterol
return (null)
-- Validation complete
-- Set constants for CVD
set @aa = 0.6536
set @ab=-0.2402
set @ac=18.8144
set @ad=-1.2146
set @ae=-1.8443
set @af=0
set @ag=0.3668
set @ah=0
set @ai=-1.4032
set @aj=-0.3899
set @ak=-0.5390
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set @al=-0.3036
set @am=-0.1697
set @an=-0.3362
set @ao=0
set @da=0.6761
set @db=-0.2421
set @dc=17.5392
set @dd=-0.8019
set @de=-2.1231
set @df=0
set @dg=0.2584
set @dh=0
set @di=-1.0117
set @dj=-0.3900
set @dk=-0.5365
set @dl=-0.3575
set @dm=-0.1661
set @dn=-0.3847
set @dp=0
-- Initial calculations
set @ChlRatio = @TotalCholesterol/@HDLCholesterol
set @lnAge = log(@Age)
set @lnDiastolicBP = log(@DiastolicBP)
set @lnSystolicBP = log(@SystolicBP)
set @lnChlRatio = log(@ChlRatio)
set @lnTime = log(10)
-- Secondary calculations
set @u = @ac + (@ad * @Sex) + (@ae * @lnAge) + (@af * @lnAge * @lnAge) +
(@ag * @Sex * @lnAge) + (@ah * @Sex * @lnAge * @lnAge) + (@ai * @lnSystolicBP)+
(@aj * @Smoker) + (@ak * @lnChlRatio) + (@al * @Diabetes) + (@am * @Diabetes *
@Sex) + (@an * @LVH)
if @Sex = 0
set @mu = @u + (@ao * @LVH)
else
set @mu = @u
set @ro = exp(@aa + (@ab * @mu))
-- Calculate result
set @risk = 1 - exp(-1 * exp((@lnTime - @mu)/@ro))
return (@risk)
end
GO
VERSION 5 14.2.06
21.2.06
Dear Dr ……… and partners,
The e-Nudge Trial
We are writing to invite you to take part in a new research project involving the University of
Warwick and South Warwickshire PCT.
In outline, the study will involve alert messages and repeated computer searches to
identify individuals at high cardiovascular risk, particularly those who have modifiable
risk factors such as raised blood pressure or cholesterol levels. We will also be identifying
patients with undiagnosed diabetes based on past raised blood glucose readings. Further
information is included in the enclosed information sheet.
The trial will investigate whether the repeated flagging up of high risk patients to practice
teams reduces the incidence of cardiovascular events (such as strokes, myocardial infarction,
or new diagnoses of angina), the number of high risk patients in the population, and the
number of patients with undiagnosed diabetes.
Advantages to your practice in taking part in this study include:
1. Patients at high cardiovascular risk will be flagged up automatically, helping you
treat them more effectively.
2. Patients whose hypertension is only evident in the light of their overall cardiovascular
risk will be identified, improving the quality of your hypertension registers.
3. Patients with undiagnosed diabetes will also be identified.
4. In order to accurately measure cardiovascular event rates, we will need to ensure that
such events are not double counted (as may happen if two entries are made for the
same event), or unrecorded (as may happen in the case of a sudden death). We are
therefore offering to carry out these data quality improvement activities on your
behalf.
All local practices running EMIS LV software will have the opportunity to take part. The
searches will be run every eight weeks for two years, and the information will be fed back to
each practice through the automatic creation of alert messages. This project is designed under
strict confidentiality guidelines. No patient identifiable information will leave the NHS.
If you are willing to take part, or would simply like some more information please
express an interest by returning the attached sheet in the enclosed S.A.E. We will then
arrange to contact you personally to provide more details.
Yours sincerely,
Dr Tim Holt FRCGP Professor Margaret Thorogood PhD FFPH
Clinical Lecturer Chair of Epidemiology
VERSION 5 14.2.06
I am interested in taking part in the e-Nudge Trial and would like further
information
Practice name: ……………………………………………………….
Practice contact:………………………………………………………
Please return this slip to the research team in the enclosed S.A.E to
Dr Tim Holt
Centre for Primary Health Care Studies
Warwick Medical School
Gibbet Hill Rd
Coventry CV4 7AL
The e-Nudge trial: letter of agreement
Name of Practice:…………………………………………………………………….
Name of practice contact (may be Practice
Manager or administrative staff member)……………………………………………..
Email address of practice contact:……………………………………………………
This letter of agreement must be signed below by a GP principal on behalf of the practice,
and by a member of the Research team.
I have read the ‘Information for Participating Practices’ leaflet and consent to the
practice taking part in the e-Nudge Trial. I understand that:
 Software will be installed by EMIS for the trial, to create alert messages for high
cardiovascular risk patients, at no cost to the practice
 The practice will receive lists of high risk patients every eight weeks for two
years
 A study-funded Research Nurse may need to perform data quality improvement
activities in liaison with the practice
 The data downloaded for analysis will be entirely anonymous, and used only for
the purposes of the study
 Practices will not be individually identified in any report or publication
 The practice may withdraw from the trial at any time without giving a reason
Signed for the practice (must be a GP principal):………………………………………
Name:………………………………………………………….......................................
Date:…………………………………………………………………………………….
Signed (for the research team):…………………………………………………………
Name:…………………………………………………………………………………...
Date……………………………………………………………………………………..
Please return this form in the enclosed SAE to: Dr Tim Holt,
Clinical Lecturer, Centre for Primary Health Care Studies,
University of Warwick, Coventry CV4 7AL. Once the form has
been signed by the research team you will be sent a copy for
your records.
Using the e-Nudge
A brief guide for participating practices
Dr Tim Holt
Centre for Primary Health Care Studies
Health Sciences Research Institute
Warwick Medical School
Gibbet Hill Rd
Coventry CV4 7AL
tim.holt@warwick.ac.uk
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Using the e-Nudge
This guide should help you to deal with any problems encountered whilst using the e-Nudge.
The software has been designed to be as user-friendly as possible, but there are one or two
questions you may have that are answered below.
What the e-Nudge is
The e-Nudge is a system of feedback through which patients at high risk of cardiovascular
disease (CVD) are “flagged up” to the practice team. This happens in two ways: through the
creation of alert messages when the notes of such patients are opened, and through a system
of searches run every eight weeks.
What the e-Nudge is not
The e-Nudge assists in the identification of high risk individuals. It does not give specific risk
values, but it does identify patients who are very likely to have a high score. It never indicates
that a patient is definitely at low risk, as this is not possible with current general practice data.
It is not intended to replace clinical judgement.
-1-
Frequently Asked Questions (FAQs)
How accurate is the e-Nudge?
We have designed the software to make the best possible use of coded information in general
practice databases. However, this information is bound to have limitations, and we have erred
on the side of under-estimating risk in order that we do not incorrectly label a patient as high
risk. The threshold used is 20% cardiovascular (rather than coronary) risk over 10 years, as is
currently recommended.
This means that if a patient is flagged up as high risk, it is very likely that they are
indeed at high risk, but if they are not identified, they are not necessarily at low risk.
If you fail to see an alert for a patient you expect to be at high risk, this might be because:
 They may be a ‘control’ patient, who will not be flagged up in this trial (see below for
more). Control patients should continue to receive usual care, including any means of
calculating cardiovascular risk that you currently use.
 Their risk may have been underestimated because it is based on their most recent
cholesterol or blood pressure values, rather than the values before treatment. If in
doubt, use whatever means of calculating cardiovascular risk that you currently use.
 They may be at high risk due to factors not included in the risk equation, such as
family history of cardiovascular disease, ethnicity, central obesity, or impaired
glucose tolerance.
What are the ‘six groups’ that the e-Nudge identifies?
The e-Nudge is designed to identify six different groups of patients from within the over-50s
in your practice. The first four of these are:
Group 1: Those with existing CVD or diabetes, whose blood pressure or cholesterol
is out of target for the nGMS contract. As this is already standard practice in the
NHS, the control patients will continue to receive this alert system for this particular
group.
Group 2: Those who do not have CVD or diabetes, and are under 75yrs, who do not
have sufficient information to perform a Framingham risk estimate, but who would be
at high risk if “assumed” values were inserted for the missing data.
Group 3: Those under 75 who do have sufficient information for a risk estimate and
who appear to be at high risk of CVD.
Group 4: Those aged 75 years or over (too old for a Framingham calculation) whose
last three consecutive blood pressure readings were all out of the range <160/100
mmHg.
Two further groups are identified, largely to support the quality of the practice’s Diabetes
register (recognising that type 2 diabetes may be under-diagnosed):
Group 5: Those with possible undiagnosed diabetes, based on at least one past raised
blood glucose level > 11.1 mmol/L, but no diagnosis of diabetes and no subsequent
non-diabetic fasting level or Glucose Tolerance Test appropriately coded.
Group 6: Patients with cardiovascular disease (on the CHD or Stroke/TIA registers)
but not diabetes, who do not have a blood glucose level recorded in the past 3 years.
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How is risk estimated?
Patients in Group 1 are identified in the usual way, using the practice’s disease register to
identify those with CHD, Stroke/TIA, or Diabetes. For primary prevention patients (who do
not already have cardiovascular disease) less than 75 years old, the e-Nudge estimates risk by
extracting the most recent values of the Framingham variables and performing a risk
calculation using the Framingham cardiovascular risk algorithm. In the case of systolic blood
pressure, an average of recent values is taken where available. For Group 3 alerts, the
assumptions used by the software are stated, so that you may check they are correct if there is
any doubt. For instance, smoking status is not always clear or up to date in a patient’s record,
so you might like to check that the patient is still a smoker if this has been assumed.
What should I do if an ‘e-Nudge’ alert appears on the screen?
This is up to you and depends on your clinical judgement. You are not obliged to do anything.
The message can be cleared by simply hitting the ‘Return’ key, as for the usual nGMS alerts.
After I have entered new data in a patient’s record, will the e-Nudge alert change
immediately?
No. Any action taken in response to the e-Nudge will take up to 24 hrs to be ‘noticed’ by the
software, as the information that the software uses is updated using a search each night on the
practice database.
What should I do about the eight-weekly search lists?
It is up to you what you do with the eight-weekly lists. The lists are intended to identify all
the patients in the practice who would get an ‘alert’ message if their notes were opened on the
day the search is run. Of course, many of these patients may not present to the practice, and it
is up to you whether you contact any of them about this.
Why are the patients ‘randomised’?
This is a randomised controlled trial. The practice population is divided randomly into
‘control’ and ‘intervention’ patients using an electronic technique. The control patients will
simply receive the usual care currently in place in the practice, including any means you may
be employing to identify and control their cardiovascular risk. The intervention patients will
be subjected to the e-Nudge, which is the software tool programmed into your computer
system for the trial. Over the duration of the trial we will be examining whether the e-Nudge
leads to improved control of risk factors and reduced incidence of cardiovascular events such
as heart attacks and strokes in the intervention patients compared with the control patients.
Why have the individual patients not been consented?
This trial has been approved by the Warwickshire Local Research Ethics Committee. The
committee agreed that the trial’s participants are the practitioners involved in caring for the
patients, and not the patients themselves. The control population will continue to receive their
usual care during the trial. The benefits of e-Nudge alerts have not yet been demonstrated in a
primary care based controlled trial, so this randomisation is necessary.
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What information is given to patients about this trial?
A poster has been provided by the research team to display in the waiting area if the practice
wished to use it. Further copies can be supplied if required. The poster explains that the
practice is taking part in a research trial, and provides a contact number for more information
if needed. If any patients want to know more about the study, any of the research team listed
at the bottom of this document will be happy to talk to them.
An alert message mentioned that ‘diabetes status needs clarifying.’ What does this
mean?
The e-Nudge software looks for possible high risk patients who do not have sufficient
information recorded to perform a risk estimate. If the patient would get a high Framingham
risk estimate using a positive input for diabetes status, and there is no blood glucose
measurement on record in the past three years, then this patient would be flagged up asking
for diabetes status to be clarified. The software will never perform a Framingham calculation
on someone who is known to have diabetes as this is no longer recommended practice. The e-
Nudge identifies patients likely to benefit from having their diabetes status clarifying – those
who would get a high Framingham risk estimate if they did have diabetes and who haven’t
been tested recently. To clarify diabetes status in this trial for such patients, all that is needed
is a blood glucose measurement of any kind (random or fasting). The method chosen is up to
the clinician.
An alert message stated that the patient ‘may have undiagnosed diabetes.’ What should
I do?
This means that the patient is not on the diabetes register, but has at least one recorded blood
glucose measurement > 11.1 mmol/L in the record. The patient may have had further fasting
glucose levels that are < 6.9 mmol/L recorded in the system. However, fasting measurements
are often not coded properly due to the way results are returned from the laboratory. In such a
patient, all that is needed is to re-insert the fasting level, with the date it was measured, using
the Read Code 44g1 and the alert will stop appearing
If a fasting level has not been carried out, then this could be arranged (if you feel it is
necessary) and this code applied manually when the result is obtained. Other codes that can
stop the alerts from appearing are ‘Oral Glucose Tolerance Test’ (Read code 44V1) or
‘Diabetes resolved’ (Read codes 21263 or 212H).
What should I do if an alert keeps appearing, even though I’ve decided that I am not
going to do anything about the patient’s risk?
It may be inappropriate for clinical reasons to address a person’s cardiovascular risk. Like the
GMS alerts, the e-Nudge alerts will continue to appear, but you can just clear them by
pressing the ‘Return’ key.
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Contact details for the research team
If you or your patients have any further questions or experience any problems during the
study, please contact one of the research team listed below.
Dr Tim Holt Email: tim.holt@warwick.ac.uk
Clinical Lecturer Tel: 02476 574898 Mobile: 07967 757471
Fax:: 02476 572950
Professor Margaret Thorogood Email: Margaret.thorogood@warwick.ac.uk
Chair of Epidemiology Tel: 02476 574509
Dr Frances Griffiths Email: f.e.griffiths@warwick.ac.uk
Senior Clinical Lecturer Tel: 02476 522534
Health Sciences Research Institute
Warwick Medical School
Gibbet Hill Rd,
Coventry CV4 7AL
Alternatively, you could contact the Research Office and speak to Mrs Krysia Saul (email:
krysia.saul@warwick.ac.uk) or tel: 02476 573163.
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e-Nudge lists: Eight weekly reminder
Dear colleague,
This is your eight-weekly reminder that the e-Nudge lists are available. Please acknowledge
receipt of this email by simply ‘replying to sender.’
The lists can be accessed any time as follows:
Main Menu
ST – Search and Statistics
B – Patient searches
S – Search results
Scroll down to find the ‘e-Nudge intervention populations’ and press Return.
To remind you, there are six groups identified:
Group 1: Patients with cardiovascular disease (CVD) or diabetes, whose blood pressure or
cholesterol is out of target for the GMS contract.
Group 2: Patients without CVD or diabetes, who do not have sufficient information for a
Framingham risk estimate, but who would be at high risk if “assumed” values were inserted
for the missing information.
Group 3: Patients under 75 who do have sufficient information for a risk estimate and who
appear to be at high risk of CVD.
Group 4: Patients over 75 years (too old for a risk calculation) whose last three blood
pressure readings were all out of the range <160/100 mmHg.
(Group 5: Patients with possible undiagnosed diabetes - this group has been withdrawn from
the trial as of November 2006 as new EMIS software will be performing a very similar function
on all patients in the practice.)
Group 6: Patients with cardiovascular disease but not diabetes, who do not have a blood
glucose level recorded in the past 3 years.
If you are unclear about this then please refer to the User Guide, or contact me (contact
details below).
Best wishes,
Tim Holt
The e-Nudge Trial – Data collection for the DMC
Introduction
These notes describe a protocol for cleansing and extraction of data for the e-Nudge Trial
Data Monitoring Committee.
The e-Nudge Trial tests the effectiveness of a software tool (e-Nudge) that identifies (and
regularly updates) lists of patients at risk of cardiovascular disease, and flags them up to the
practice teams. It operates only on those over-50 years, and randomises the population into
‘control’ and ‘intervention’ patients. Only the intervention patients are alerted. The control
patients continue to get ‘usual care.’
The Data Monitoring Committee needs to examine the difference in the rate of cardiovascular
events in the control and intervention arms. If it were greater than 20%, the trial would need
to be stopped.
A cardiovascular event is defined as any of the following:
A new diagnosis of ischaemic heart disease
A new diagnosis of cerebrovascular disease
A myocardial infarction (patient may already be known to have ischaemic heart disease)
A stroke (patient may already have cerebrovascular disease eg past stroke or TIA)
A Transient Ischaemic Attack (TIA) (patient may already have cerebrovascular disease)
Sudden death from cardiovascular disease
An entry of ‘Angina’ in someone who is already known to have IHD is not a new event
unless it is associated with admission for a coronary artery procedure e.g. angioplasty.
However it is a new event if it occurs in someone who did not already have diagnosed IHD.
Sudden cardiovascular deaths are not always recorded electronically, but we decided that as it
is usual practice to make such a record, we will assume for this exercise that the searches will
pick up the majority of these events.
Constructing the searches
The searches should identify patients who have had an event during the first 12 months of
participation in the study. This date range needs to be applied to the search protocol as below.
From the EMIS Main Menu:
ST Search and Statistics
B Patient searches
A Add a new search
Search population: All patients in the database (including those who have died or left
the practice)
Add a feature: Age - Upper limit 120 years, lower limit 50 years
Add a feature: G3 Ischaemic Heart Disease (Add date range)
Include all children codes including Acute Myocardial
Infarction G30
Add a feature: G6 Cerebrovascular disease (Add date range)
Include all children codes
Press Return when complete, and name the search, mentioning ‘e-Nudge’ in the name, and
filing it in the ‘One off searches’ folder.
Run the search
Access the search results by ‘View to Screen,’ to produce a list of names and EMIS numbers.
Print the list out (and make sure the print out is kept securely in the practice when the exercise
is finished).
For each patient on the list, do the following in this order:
1. Check date of registration of the patient with the practice
2. Access the Medical Record to examine and count each event
3. Record the last digit of the NHS Number
The date of registration with the practice is noted in the Registration Status module (RS
from the Main Menu).
If the date of registration is close to (eg within 4 months of) the date of commencing the trial
then it is important to confirm that the event was a true event occurring at that time, rather
than an entry referring to a past event entered when the patient was first seen at the practice
before the past notes had arrived, as may happen during a New Registration Check.
To access the Medical Record:
From the EMIS Main Menu:
MR Medical Record
X All Non-Values
O Codes on/off
This reveals the codes of all the entries. Scroll down to identify the date range of interest, and
find the cardiovascular event codes (which will begin with G).
Then look into the Consultation record (press C from the Medical Record screen) and scroll
through the 12 month date interval to check the events. Record how many new events
occurred during this time for each patient. In most cases there will probably be only one.
Note: there may be some events in the Consultation record that are not in the ‘All Non-
Values’ list, and vice versa.
Finally, access the Registration Details (RD) to find the NHS number, and note the last digit.
The lists of patients identified should be left in a secure place in the practice, so that they
could be retrieved later if needed.
The only information to be removed from the practice is:
Name or site number of practice
Number of patients identified
Number of events for each patient
Last digit of NHS number for each event
Paper title (First author and year)
Reviewer
Country
Subjects (describe)
Setting
Unit of randomisation and
randomisation method
Describe intervention
Describe control condition
Outcome measure time
Outcome measures (type)
Were any outcome measures
quality checked?
Rate of follow-up
Number of subjects randomised
Number of subjects in final
analysis
First outcome measure (describe):
Control Intervention 1 Intervention 2 Intervention 3
Baseline
numerator and
denominator
(if given)
Outcome
numerator and
denominator
Second outcome measure (describe):
Control Intervention 1 Intervention 2 Intervention 3
Baseline
numerator and
denominator
(if given)
Outcome
numerator and
denominator
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Adequate sequence generation?
Incomplete outcome data addressed?
Free of selective reporting?
Free of unit of analysis errors?
0% 25% 50% 75% 100%
Yes (low risk of bias) Unclear No (high risk of bias)
Risk of bias tables for systematic review (Chapter 4)
Letter of invitation from practices to patients, Work package 2, Version 1: 1.9.06
Practice’s headed paper
Name
Address
Dear ………,
Our practice is taking part in a research trial based at the University of Warwick. The
research is about the prevention of heart disease and strokes using computers in the
practice. The University researchers are interested to know what patients think about
how these conditions should be prevented, and they would like to interview you as
part of this project.
We are enclosing an Information Leaflet about the study, which you should read
before deciding. It gives details about the study, and who to contact if you need
further information.
If you agree to take part, please complete the slip below and return it to the University
in the FREEPOST envelope enclosed. The research team will then get in touch with
you to arrange a date and time to meet up for an interview.
There is no obligation to take part in this study. If you prefer not to take part
then this will not affect your medical care in any way.
Yours sincerely
The practice
-------------------------------------------------------------------------------------------------------
I am interested in taking part in the research study
I would like further information before deciding
My name is:………………………………………
Telephone number:……………………………….
Or Email address:………………………………..
Signed……………………………… Date……………………………...
Please send in the FREEPOST envelope to: Dr Tim Holt, Health Sciences Research
Institute, Warwick Medical School, Gibbet Hill Rd, Coventry CV4 7AL.
Patient information for work package 2, version 1: 9.1.07
PATIENT INFORMATION SHEET
Patients’ views of the use of information technology in reducing the risk
of cardiovascular disease
You are being invited to take part in a research study. Before you decide, it is important for
you to understand why the research is being done and what it will involve. Please take time
to read the following information carefully. Talk to others about the study if you wish. Ask us if
there is anything that is not clear or if you would like more information. Take time to decide
whether or not you wish to take part.
What is the purpose of the study?
Preventing heart attacks and strokes (‘cardiovascular disease’) is an important part of the
work of a general practice. For some people, changing their lifestyle or taking medication to
reduce their risk is important, whilst for others it is much less so. We are interested to find out
more about patients’ attitudes towards this, and also whether they feel computers can help
their doctors to identify those at highest risk.
Why have I been chosen?
Your practice is taking part in a research trial that is testing a software tool for identifying
patients at risk of heart disease and stroke. As part of this research it is important for us to
understand the attitudes of patients in the practice. Your name has been selected randomly
from those over 50 years old in the practice. This invitation to participate does not mean that
you have been identified as high risk.
Do I have to take part?
No. You are perfectly entitled to decline the invitation to participate, or to withdraw from the
study at any time without giving a reason. If you do, you will be asked to sign a consent form.
You are still free to withdraw at any time and without giving a reason. A decision to withdraw
at any time, or a decision not to take part, will not affect the standard of care you receive.
What will happen to me if I take part?
If you agree to take part, you will be contacted by the research team either by telephone, or
by email, whichever you prefer, to arrange a time and place for the interview that suits you.
This could be in your own home, at the University of Warwick, or at another location if you
prefer. We would pay your travel expenses if it is not in your own home. If you are happy to
proceed you will be asked to sign a consent form. The researcher will then ask you some
questions, and encourage you to talk about your attitudes towards avoiding heart disease and
strokes. The interview will last approximately one hour and will be audio recorded. The
interview will be ‘transcribed.’ All the personal identification will be removed during
transcription. After the interview you can still withdraw your consent.
What are the possible advantages, disadvantages or risks of taking part?
We cannot promise the study will help you but the information we get might help improve the
treatment of people with cardiovascular disease. We do not believe there are any significant
risks in taking part. Whether or not you decide to take part will not affect your medical
treatment in any way.
What if there is a problem?
If you are harmed by taking part in this research project, there are no special compensation
arrangements. If you are harmed due to someone’s negligence, then you may have grounds
for a legal action but you may have to pay for it. Regardless of this, if you wish to complain,
or have any concerns about any aspect of the way you have been approached or treated
during the course of this study, complaints procedures will be maintained for which the Chief
Investigator takes responsibility. Any complaint about the way you have been dealt with
during the study or any possible harm you might suffer will be addressed. Please contact:
Patient information for work package 2, version 1: 9.1.07
Professor Yvonne Carter
Dean
Warwick Medical School
Gibbet Hill Rd
Coventry CV4 7AL
Telephone: 02476 574509
Will my taking part in the study be kept confidential?
Yes. All the information about your participation in this study will be kept confidential to the
research team.
Contact Details:
The research team are:
Dr Tim Holt, Clinical Lecturer
Professor Margaret Thorogood, Professor of Epidemiology
Dr Frances Griffiths, Senior Clinical Lecturer
Health Sciences Research Institute
Warwick Medical School
Gibbet Hill Rd
Coventry CV4 7AL
and Dr Stephen Munday
Director of Public Health
South Warwickshire Primary Care Trust
For further information about the study, please contact:
Dr Tim Holt
Warwick Medical School
Gibbet Hill Rd
Coventry CV4 7AL
Telephone: 02476 574898 or 02476 572950
What will happen to the results of the research study?
The information we gather during the interviews will be analysed, and the results will be
published in medical journals and through conference presentations. You will not be identified
in any of these reports, articles or presentations.
Who is organising and funding the research?
This study is sponsored by the University of Warwick, and funded through a Department of
Health PhD studentship. The research team receives no payments for including you in the
research project.
Who has reviewed the study?
This study was given a favourable ethical opinion by the Warwickshire Local Research Ethics
Committee.
Thank you for taking the time to read this sheet, and for considering taking part in this
study.
Patient consent form for interview, Work package 2, Version 2: 9.1.07
PATIENT CONSENT FORM
Title of project: Patients’ views on the use of information technology in
reducing the risk of cardiovascular disease
Researcher: Dr Tim Holt
Please initial box
1. I agree to being interviewed as part of the research study
“Patients’ views of the use of information technology in
reducing the risk of cardiovascular disease.”
2. I understand that the interviews will be audiotaped
3. I have read the ‘Information for Patients’ leaflet.
4. I understand that the information recorded during the
interview will be anonymised and transcribed at the
University of Warwick.
5. I understand that the anonymised information will be
securely stored for a minimum of five years and used only
for teaching and research.
6. I understand that I can withdraw my consent and stop the
interview at any time.
Name of participant:……………………………...
Signed:……………………………. Date………………………………..
Name of researcher taking consent:……………………………………..
Signed……………………………… Date….…………………………….
Interviews with members of the public 
The following pages describe a series of in-depth interviews with members of the 
public that I undertook as part of a process evaluation in support of the e-Nudge trial. 
Ethical approval for this study was gained from Warwickshire Local Research Ethics 
Committee. 
  
Selection of patients 
I recruited a practice in Stratford upon Avon that was taking part in the e-Nudge trial, to 
provide access to individuals to invite for interview. I visited the practice and asked the 
manager to print out the computer record numbers of individuals in three different age 
categories (50-65, 65-75, and over 75). I then randomly selected a sample of 30 record 
numbers (ten from each age band). The GPs then checked the records of all 30 and 
excluded three. The final list of 27 patients were invited by the practice by letter on 
practice headed paper with a tear off slip suggesting that they contact me directly if 
interested. Nine responded, and of these eight were interviewed. In the ninth case a 
suitable arrangement could not be identified.  
I considered the option of recruiting people that had been identified on the e-
Nudge lists (e.g. those with raised CVD risk) as their opinions might be more relevant 
than those of the low CVD risk population. But I felt that it was important (as the 
interviewer who might have to explain this) that I could assure each participant that 
they had been identified at random, and that their invitation did not imply anything 
about their own CVD risk. This was an important part of reassuring them that I had not 
examined their records without their consent.  
Nine people responded, and in eight cases I was able to make a satisfactory 
arrangement to meet up. I spoke to the ninth individual by phone but he did not 
subsequently get back to me as agreed, so after failing to contact him again I did not 
continue. The interviews were conducted at a venue of the interviewee‟s choice, which 
was the individual‟s home in all but one case (the preliminary pilot interview that 
occurred at the University of Warwick). The Patient information sheet and Patient 
consent form are also given in the Appendix. 
 
Topic guide 
The topic guide was as follows: 
 
 Patients‟ general perceptions of the value of prevention (rather than treatment) for 
cardiovascular disease 
 The perceived roles of lifestyle intervention, and of drug therapy in prevention 
 What, if any, is their individual experience of preventive therapy for cardiovascular 
disease? 
 How does this issue compare with other priorities in their life? 
 Whether they welcome the use of information technology to clarify their individual 
risk  
 Whether they feel this should be left largely to the health professional‟s clinical skill. 
 
Thematic analysis 
The interviews were audio-taped and sent to a professional secretarial service for 
transcription. I then examined the transcripts and highlighted each statement of 
particular relevance in the text with a marker pen. After examining the first two 
interviews I identified a number of themes and gave each a definition, according to its 
inferred meaning, using a basic thematic analytical approach (1). Further interviews 
were then analysed and the same themes were highlighted. New themes were also 
recognised, leading to a re-examination of the previous transcripts to seek these 
previously unrecognised themes within them. In some cases the meaning of the 
statement was within the definition of an existing theme and did not require the creation 
of a new theme, but did require a broadening of its definition. 
At the end of this iterative process I had constructed a grid listing the themes 
and providing definitions, any variation in usage or meaning, and examples. This is 
given in Table 1. 
 
 Theme label 
 
Definition and variation in inferred usage 
 
 
Examples from transcripts (patient number in 
brackets) 
 
 
Lifestyle 
 
 
Lifestyle factors (not requiring any measurement by 
the medical profession) mentioned as relevant to 
cardiovascular risk, e.g. diet, exercise, weight. 
“We try to eat sensibly as much as we can and we do 
take quite a lot of exercise.” (4) 
“..he [father] was very careful about his diet. He 
wouldn‟t have any fat or anything. And so he 
slimmed himself right down.” (7) 
 
Genes 
 
Genes mentioned as relevant to cardiovascular risk. 
Familial factors including non-genetically determined 
behaviours clustering within families included. 
“I come from a thin family..” (5) 
“..its in your genes I suppose.” (7) 
 
Other risk factors  
 
Cholesterol, blood pressure and other factors that 
usually require the medical profession to measure are 
relevant to cardiovascular risk 
“…but if there was evidence that that [future blood 
clot] is possible because obviously my cholesterol is 
high or whatever…” (8) 
 
Social factors  
Respondent mentions other, social factors possibly 
relevant to CVD risk, such as environmental exposure 
to fumes, stress, etc 
“..emissions from power plants and incinerators..” 
“Because he [father] had an office job…he had early 
retirement.” (7) 
 
 
Choice 
 
Individuals should be allowed to choose the extent to 
which they accept lifestyle advice, drug therapy, or 
risk assessment.  
“At the end of the day it‟s their choice and they know 
darn well that if they carry on smoking they‟re 
possibly at higher risk of dying before someone who 
doesn‟t smoke.” (3) 
“But if you invited people, and they had a choice of 
whether to come in or not, it would be their decision 
wouldn‟t it?” (4) 
 
 
Personal responsibility 
 
Individuals have a responsibility to look after their 
own health (usually this means through lifestyle). 
Extended to include the responsibility of parents to 
establish healthy lifestyle patterns in children 
“On obesity that is completely up to you, if you are 
obese the only way is obviously food, drinks, 
whatever the case may be, so that is up to you.” (8) 
“It‟s difficult to know about diet, what causes it, 
whether it‟s the home life which should be changed, 
what the parents feed their children on, what the 
children eat.” (6)   
   
  
 
Health service  
responsibility 
 
 
 
Health care providers have a responsibility (either to  
individuals or to society) to address the problem of 
CVD prevention 
 
 
 
“It‟s the medical professions [responsibility] to sort of 
suggest that they stop smoking or they cut down or  
   get slimmer” (6) 
“I feel that not enough effort is put into it [into 
prevention by the medical profession], and, as I said, 
I find it very disappointing.” (8) 
 
 
Positive about prevention 
 
Respondent feels positive about the preventive 
approach, but it was not compared specifically with a 
treatment/curative approach 
“Anything you can do to predict that there is a 
potential problem coming up I‟m in favour of, 
because you can then start doing something to avoid 
that problem…I‟m 100% behind it” (1) 
“I suppose if I can I‟d rather prevent something” (3) 
 
 
 
Negative about 
prevention 
 
 
 
 
Without necessarily comparing it to „cure,‟ the 
respondent makes a negative comment about the 
preventive approach in general. 
“Well I don‟t think that‟s essential, definitely don‟t.” 
(2) 
“..you see they don‟t give people with cancer all the 
treatment they should want … and I think that they‟ve 
already got it and I don‟t see why money should be 
spent on people who don‟t change their lifestyle, … 
as against the people who are ill. Seriously ill.” (6) 
“..supposing someone examines me and everything is 
in perfect order and there is no history of whatever, 
why should I take I suppose aspirins to thin the 
blood..” (8) 
 
 
 
Prevention is better than 
cure 
 
 
A preventive approach (health service or individual) is 
preferable to an approach based on treating or curing 
established conditions. 
“Oh I‟d rather, preventative is much better than cure 
isn‟t it,” (2) 
“Because in the end, its better to prevent things 
happening than cure them when they have happened.” 
(4) 
“It might be worth spending a lot of money on a lot of  
  
people, to prevent even one person having that 
[quadruple bypass] in terms of cost.” (5) 
“Alright you can treat or try to cure it as much as you 
can, but prevention I think is much better..” (8) 
 
Element of chance 
Unpredictable factors are involved in determining 
cardiovascular disease outcomes 
“I suppose nobody knows really when one‟s [heart 
attack] going to strike.” (3) 
“Its in the lap of the gods isn‟t it” (6) 
 
 
Medical authority 
 
The medical profession is more influential than lay 
sources in advising or managing cardiovascular risk, 
either through its professional status or its ability to 
offer personalised rather then population level advice 
or treatments.  
“So I feel I‟m in his hands really [the doctor‟s], and if 
he suggests something I go ahead with it.” (4) 
“Oh, I certainly wouldn‟t allow somebody who‟s not 
from a medical background to influence me like that.” 
(2) 
“I think people are far more likely to take notice of 
their doctor than a programme on the telly.” (6) 
 
Lay sources 
Information or advice originating from lay (non-health 
professional) sources mentioned in either a positive or 
negative light 
“…if you read the paper every day, magazines, its 
there all the time, about diet…” (5) 
 
Preventive drug therapy 
less preferable 
 
Preventive drug therapy is less preferable than 
lifestyle change in reducing cardiovascular risk 
“Well if you say to them „stop smoking‟ and they 
don‟t….Well I don‟t think you should give them any 
drugs then.” (7) 
“And if that wasn‟t possible for whatever reason, then 
obviously I would resort to tablets…” (8) 
 
 
Other serious disease 
 
Other diseases (such as cancer or dementia) compared 
with cardiovascular disease as a serious health 
concern 
“I think I would worry more about losing my mental 
ability.” (6) 
“My mother died of breast cancer, alright I went to 
the doctor and asked what my chances were and if 
anything could be done.” (6) 
 
Silent disease 
Disease may be established at an asymptomatic stage, 
at which point it might be amenable to preventive 
therapy.  
“I don‟t really know if there is something wrong with 
me or not….” (8) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
T 
 
 
 
 
 
 
 
 
 
Table 1: Recurring themes in the in-depth interviews with members of the public. 
 
 
 
 
Adequacy of records 
 
Respondent aware that information in practice records 
might help to predict CVD risk, whether or not they  
can comment on their adequacy. 
 
“If that doesn‟t give them enough information for 
them…to work out whether I‟m prone to whatever, I  
think it‟s a very poor show basically.” (8) 
 
Stigma inappropriate 
Any stigma attached to the label „At risk of CVD‟ 
(e.g. effect of the label on self image or life insurance 
risk, etc) is inappropriate or unfair 
“..the insurance company would have to accept that 
somebody with a 20% risk of heart disease, is not 
somebody that they shouldn‟t cover.” (5) 
 
Stigma appropriate  
 
Stigma attached to the label „At risk of CVD‟ is a 
relevant and understandable concern 
“..you wouldn‟t want to be turned down for 
insurance, would you?” (4) 
“You know, its putting a stigma on people, isn‟t it” 
[referring to insurance implications] (6) 
 
 
Age factors 
 
Use of a person‟s age (rightly or wrongly) to influence 
the management of their CVD risk, or more generally 
the relevance of age to the whole process of CVD 
prevention. 
“I certainly take more notice now I‟m my age 60, just 
over 60.” (3) 
“I‟m 67 at the moment, when I‟m 77 I‟ll probably 
have a different attitude to it.” (5) 
“I would be grateful for any help because at my age I 
think I‟m on borrowed time now myself.” (7) 
 
Side effects 
 
Side effects of medication are discussed as a possible 
negative aspect of prevention. 
 
“..there‟s always a side effect of some kind with any 
drug.” (4) 
 
 Interviewee number 
Theme label 1 2 3 4 5 6 7 8 
Lifestyle 
 
6 3 4 3 1 6 8 2 
Genes 
 
4  2 3 3 1 2 1 
Other risk factors  
 
3 1 1 1 1 1  2 
Social factors  
 
1 1   1  1  
Choice 
 
  4 1 2 3  4 
Personal 
responsibility 
2 1 3   4  5 
Health service 
responsibility 
1 1    1  5 
Positive about 
prevention 
2 4 7 5 4 5 4 1 
Negative about 
prevention 
 4    1   
Prevention is 
better than cure 
1 1 2 1 3   1 
Element of chance 
 
  1 1  1 2 1 
Medical authority 
 
2 5 2 2 3 3 2 1 
Lay sources 
 
    5    
Preventive drug 
therapy less 
preferable 
 3  1  3 2 6 
Other serious 
disease 
  1  1 4  2 
Silent disease 
 
   1    1 
Adequacy of 
records 
3 1 4 1 5 1 1 1 
Stigma 
inappropriate 
3  3 1 2 1  1 
Stigma appropriate  
 
1  1 3 1 1  1 
Age factors 
 
1  3  2 1 1 2 
Side effects 
 
  1 1 1  1  
 
 
Table 2: Frequency of recurring themes in the eight interviews with members of the 
public. 
 
 
 
 
 
Emergent themes 
The recurring themes were generally expected and the Topic guide was designed to 
explore these areas, although I took care to ensure that they arose spontaneously. An 
interesting outcome was that an individual might display conflicting views during the 
same interview.  
A number of other themes and issues emerged from the data and were less 
expected: 
1. Value of bypassing the medical profession for information or advice, e.g. 
through the Internet. This was suggested by the first interviewee, and also by the fifth.  
2. The value of receiving written confirmation of risk. “There‟s nothing like a 
written warning, verbal warnings don‟t count.” This was stated by the first interviewee, 
to support the systematic (rather than opportunistic) approach that would involve 
invitations to attend for clarification of risk. 
3. The same interviewee was also concerned about the risk algorithm and it 
adequacy, rather than just the adequacy of electronic information to support it. 
4. Two interviewees (2 and 7) felt that a preventive approach would indicate 
that the practice cared about or was interested in them, as they would be going out of 
their way to safeguard their future health. 
5. Perceived vulnerability, whilst not used explicitly as a term, was a concept 
brought up by at least two interviewees (3 and 7), who recognised that people vary in 
their own self-perceived resilience to lifestyle factors and to the less predictable 
elements of CVD risk. 
6. Interviewees 3, 4 and 8 mentioned governmental resource implications of 
CVD risk reduction, i.e. the costs of preventive health care.  
7. A „Big Brother‟ reference by interviewee 2 was similar to a comment by 
interviewee 5 about the authorities forcing people to change their lifestyle. 
8. Finally, a preference for sudden death (over lingering dependence) was 
expressed by two interviewees:  “So I‟d rather go out like a candle than be bloody 
lingering for a couple of years” (Interviewee No 7). The other one was a comment that I 
noted by hand after the audiotape recorder had been switched off: “The best solution 
would be to wait until you get the Alzheimer‟s disease, and then have the heart attack!” 
(Interviewee No 8). I had not included this area in the Topic guide, and so did not feel 
that I had ethical approval to explore what was probably a very emotive issue 
particularly in the older age groups.  
 
Summary of the analysis 
Having analysed the interview transcripts, I arrived at the following conclusions over 
the opinions and beliefs of the participants: 
 
 The participants generally believed CVD prevention to be an important and 
valuable area of health care.  
 Lifestyle issues (such as diet and exercise) were given as examples of CVD 
risk factors rather than those that the medical profession might identify as priorities, 
such as blood pressure, blood glucose, and cholesterol.  
 The interviewees generally considered that attention to lifestyle factors (and 
not just those amenable to drug therapy) was within the remit and responsibility of the 
medical profession. They generally felt that lifestyle factors should be addressed before 
considering drug therapy. 
 Regarding electronic data, there was little awareness of what exactly is 
recorded and the importance of the distinction between electronic data and free text data 
when it comes to identifying at risk individuals. 
 Most interviewees thought that identifiable individuals at risk of CVD should 
be made aware and should be helped to take action over it. Electronic means of 
assisting with identification were generally welcome. 
 Potentially negative aspects of CVD prevention arose during several of the 
interviews. Side effects of medication were mentioned by four interviewees, in two 
cases without me raising the issue. The potential problems of „labelling‟ individuals at 
risk were recognised, but generally only when I raised them. This issue was not actually 
included in the Topic guide but arose during the interviews. This was related to the 
phenomenon of „turning people into patients‟ discussed in Chapter 3, and I was a little 
surprised that it did not provoke more spontaneous comment than it in fact did. 
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A nationwide adaptive prediction tool for
coronary heart disease prevention
Tim A Holt and Lucila Ohno-Machado
Introduction 
THE National Service Framework (NSF) for coronaryheart disease1 recommends that patients with a greater
than 30% risk of developing coronary heart disease in the
following 10 years should be treated with a similar priority to
those with established disease. Identifying such patients,
who lack cardiovascular symptoms, presents a challenge
for primary care teams, and the NSF stresses the need for
a systematic rather than opportunistic service model, using
electronic disease registers and standardised Read codes.
There have been doubts about the quality and reliability of
data collected in primary care ever since the development
of large computer databases during the 1980s,2 but where
coding can be standardised, the ability of existing software,
such as MIQUEST, to extract the data anonymously from
practice databases provides the opportunity for a nationwide
data collection system. Such standardisation is becoming
an important means through which the goals of the NSF
can be achieved.3 Patterns of cardiovascular risk among the
United Kingdom (UK) population may vary in this century, as
they did in the last, through changes in demography,
lifestyle patterns, social conditions, modification of risk
factors, and through genetic exchange with populations
not adequately represented in the Framingham study,4 the
data source on which current predictions are based. In this
paper we discuss how an adaptive model might facilitate
the identification of high-risk patients, progressively
improve data quality, and ultimately adapt to the needs of
individuals in a situation of changing coronary heart disease
risk. 
Adaptive predictive models 
Adaptive predictive models are capable of ‘learning’ to clas-
sify cases according to patterns. They use existing data and
classification ‘gold standards’ to construct a model that can
predict to which class a new case belongs. They include
algorithms, such as logistic regression, which was the basis
for the Framingham algorithm, as well as more complex
models, such as neural networks,5 support vector
machines,6 and classification and regression trees.7 Neural
networks, which are widely used in industry for pattern
recognition and quality control, comprise input and output
layers of processing units, between which hidden layers
modify the transmission of information by attributing
‘weights’ to the various patterns of incoming data.
Successful pattern recognition is reinforced through an
increase in the weight attributed to the relevant input pattern.
This is done initially by ‘training’ the network using an existing
database, and then (if necessary) allowing the relative
accuracy of future predictions to adjust the weighting
mechanism in the hidden layers (Box 1).
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SUMMARY
Standardised electronic recording of cardiovascular risk factor
data collected during primary care delivery could be used to 
create a new strategy, using an adaptive prediction model, for
targeting primary prevention interventions at high-risk
individuals. In the short term, this should progressively improve
data quality and allow risk modification to be monitored at the
population level.  In the long term, feedback of data on
cardiovascular disease development might enable the model to
tailor the recommended interventions more appropriately to the
needs of the individual and to adapt to future changes in risk
patterns. Ultimately, the inclusion of additional cardiovascular
risk factors might enable a richer, more realistic picture of
cardiovascular risk profiles to be uncovered. This model may
have wider uses in both research and practice, and provides a
further incentive for the standardisation of record keeping in
primary care.
Keywords: primary prevention; number needed to screen;
coronary heart disease; adaptive learning.
Baxt has described a neural network model used to interpret
patterns of symptoms, clinical signs, and electrocardiograph
findings in 356 patients presenting with acute chest pain
to a hospital emergency department, 120 of whom were
subsequently found to have myocardial infarction.8 Twenty
input variables for each patient were fed in to the network,
which was trained using the data from half the patients and
then tested on the other half. The training and testing was
then repeated using the opposite halves of the sample. The
network was able to recognise the patients with myocardial
infarction with greater success than either physicians or
previous computer-based strategies. By recognising the
significance of combinations of minor variables, it performed
well even in the absence of electrocardiographic signs of
infarction. A neural network model has also been used
successfully to assess cardiovascular risk using a number of
different lipids as input variables.9
If data collected during the process of care is used to
build an adaptive prediction tool, it will be more likely that
the model will perform well in classifying new cases. Data
collected in more controlled environments may be more
adequate to characterise risk factors and classify new cases
in a similar population than to classify new cases in a different
population. The Framingham algorithm has been validated
in northern Europeans,10 but may not remain valid indefi-
nitely, and is not universally applicable to all ethnic groups
without recalibration.11 
One of the strengths of collecting electronic data during
the process of care is that large sets of data can be collected
in a relatively short time. Taking advantage of this to construct
adaptive models that will be used in a similar population is
very important. Another benefit is that different models can
be constructed in which only certain variables need to have
corresponding values. For example, in the electronic imple-
mentations of the Framingham algorithm suggested by the
NSF,12 the software will not produce a risk estimate unless all
the variables have corresponding values. If the value for HDL
cholesterol is unknown, for example, the algorithm either
assumes an estimated value or it will not run. Adaptive pre-
dictive models built with a subset of the variables could be
used in these cases. This ability makes such models useful
in the presence of incomplete data, and would become
important if additional risk variables were to be included in
the calculation in the future.
Current primary prevention strategies
‘Ten-year risk’ is currently assessed using the Framingham
algorithm and the individual patient’s risk variables (Box 2).
These variables were selected for the Framingham study
because they are ‘objective and strongly and independently
related to CHD’.13 Other factors known to affect risk include
the patient’s ethnic group, exercise level, alcohol consump-
tion, other dietary variables, family history, body mass index,
and waist-to-hip ratio. The exclusion of these factors limits
the accuracy of the Framingham calculation, but in an indi-
vidual’s case can be used to modify risk estimations at the
discretion of the clinician.14 How much to adjust remains an
open issue.
The NSF recommends that patients known to have
hypertension and/or diabetes are selected first for risk
assessment.1 Such patients are at higher risk than the gen-
eral population, and the ‘number needed to screen’ to find
an individual with more than a 30% 10-year risk is therefore
reduced through this strategy. However, those at highest risk
tend to be the older patients in all risk factor groups, and the
effect of age may outweigh the other major factors. In the
age group 35–39 years, the number needed to screen is
greater than 1,000 for both men and women, but only 10 for
men and 75 for women aged between 60 and 64 years.15
Eighty-five per cent of the population’s avoidable cardiovas-
cular disease is to be found in the 16% who are over 65
years old.16 Clinical intuition is not a sufficient means of
reducing the number needed to screen, and subjective
estimates of individual risk by general practitioners or practice
nurses are inferior to computer-assisted risk calculations.17
A new targeting strategy
Candidates for primary prevention screening could be iden-
tified electronically by roughly estimating the 10-year risk on
all patients in the practice, based on the most recent values
of the existing coded risk variables, or, in the case of systolic
blood pressure, an average of the last two measurements —
this is the mechanism used by the current EMIS system to
calculate the risk of individual patients. Those patients on
treatment for hypertension or hyperlipidaemia would need to
be identified with a lower threshold, because they will have
a higher risk when assessed using pretreatment levels.
Existing computer software in primary care can make such
a distinction electronically. While the Framingham algorithm
is designed to predict outcomes using pretreatment blood
pressure and lipid levels, the same algorithm might be used
as a starting point for assessing modified risk and then
adjusted according to outcomes using the adaptive prediction
model. This would provide essential information on the
impact of treatment on risk which is not available from the
Framingham study.
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A neural network might be used as a quality control device in 
a plate factory. The inputs would include features of the plate,
such as its thickness, reflectivity and shape, and the output
would be a prediction of how easily it might break. 
The relative success of the predictions (determined by the rate
of plate breakage) could be allowed to modify the weights
given to the appropriate input patterns, so that the network
effectively ‘learns’ from experience, and can adapt its
predictions over time to consistent changes in the environment
to which the plates are exposed.
Box 1. An example of a neural network.
 Age 
 Sex
 Smoking status 
 Systolic blood pressure 
 Total serum cholesterol level 
 Serum HDL cholesterol level 
 Presence or absence of diabetes 
 Presence or absence of left ventricular hypertrophy
Box 2. The Framingham input variables.
In this way, the computer could, through regular searches,
identify patients who were actually or potentially drifting into
the greater-than-30% range. The practice could then be
informed, perhaps on a 3-monthly basis, of all such patients,
who would be identified anonymously using electronic
record numbers and listed in order of suspected risk. The
interval could be adjusted according to available time and
resources.
So far, this process could all be carried out at practice
level without the need for extraction of data by an external
agency, but the pooling of data nationally would have one
further potential benefit: adaptive learning of the prediction
algorithm. The healthcare system in the UK, as opposed to
the United States, is equipped to quickly build predictive
models from data collected in the process of care, including
models that take into account regional differences in terms
of patient population and practice variation.
Adaptive learning
Linking practices by pooling extracted data would, in principle,
enable the adaptive prediction model to adjust its internal
parameters in response to observed outcomes (namely, the
development of coronary heart disease and stroke). This
‘reprogramming’ is possible because the same database that
provides the values of the Framingham variables also contains
the dates when each patient who later developed coronary
heart disease was diagnosed. The ability of existing comput-
er software to examine data retrospectively on the timing of
coronary heart disease onset has already been demon-
strated.18 In principle, therefore, all the information needed to
retrain the model is present within the system (Figure 1).
An example of where such modification might occur
concerns the predictive values of systolic and diastolic
blood pressures, and pulse pressure in relation to age.
There is recently published evidence from the Framingham
study that diastolic blood pressure is a more reliable predictor
of future cardiovascular outcomes in younger patients
compared with older ones, in whom systolic pressure is
more reliable.19 Above a certain age, pulse pressure may
then become the best predictor. An adaptive predictive
model would eventually produce the best prediction it could
for each age group when exposed to enough data over
extended time periods, recognising that the weights appro-
priate for the systolic and diastolic blood pressure values
would be partly dependent on the value of the age variable. 
Advantages of an adaptive prediction tool
built with primary care data
The targeting of individuals for risk assessment would be
improved by using expected overall risk as the basis for
patient selection, rather than a diagnosis of diabetes or
hypertension. The electronic retrieval of any of the other
variables, the most important of which is age, would assist
in reducing the number needed to screen.
Patients who are not diagnosed with hypertension but
who have raised blood pressure measurements, and who
represent a significant case volume,20 would be included in
the screening process because they would be identified by
their blood pressure values, and not on the basis of inclusion
in the hypertension disease register.
Where data are missing, a different predictive model could
be used (although data should become increasingly complete
over time within the higher risk groups).
By measuring risk using the most recent input variable
values, the model can monitor the adequacy of risk modifica-
tion in a practice population, making it amenable to audit.
Decisions about treatment can still be based on pretreatment
blood pressure and lipid levels, as recommended in the
NSF.
The cyclical nature of the process, like the traditional audit
cycle, means that improvements are progressive, and
patients moving into the high-risk category over time can be
recognised. High-risk patients are a dynamic subgroup that
is constantly revising its membership. This dynamism needs
to be reflected through a targeting policy that is ongoing
rather than a ‘once-only’ exercise.
Those patients at high risk, whose blood pressure defies
reduction to target levels through drug treatment can,
nevertheless, have their overall risk reduced by the use of 
combined approaches. This process is facilitated through
the monitoring of modified rather than pretreatment risk.
Discussion
The targeting phase of this model has no minimum quality
requirement other than an electronic age and sex register,
but the adjustment of the algorithm would only be appropriate
if data quality were maintained at a high level, creating
numerous difficulties. In particular, the measurement of
blood pressure would need to be carried out by adequately
trained staff, in line with recommended practice.21 Blood
pressure measurements taken by primary care clinicians in
busy surgeries, and on patients who may be unwell at the
time, may differ from those gathered in the less pressured
conditions of a prospective cohort study. Coded outcome
measures would need to include all cardiovascular events,
including sudden cardiovascular deaths, while morbidity
registers for coronary heart disease in general practice are
currently of variable quality.22 Recorded dates of the onset of
cardiovascular disease may be delayed following presentation
while investigations are undertaken to confirm the diagnosis.
Other influences might also undermine the model’s validity;
for example, financial incentives based on achievement of
blood pressure targets rather than on the quality of data
recording. Patients moving from one practice to another
would need to be identifiable in order to match predictions
with outcomes, and might be lost in the process. This
problem of ‘data censoring’23 can be accounted for in some
of the statistical models proposed above, in order that the
information is still useful even if incomplete, but it will remain
an issue. 
It is therefore likely that some of the participating practices
across the UK, with a commitment to maintaining high-quality
data and accurate, up-to-date disease registers for both
coronary heart disease and diabetes, would need to be
identified (Box 3) in order to minimise these obstacles. It
might be hoped that the usefulness of the tool would motivate
participants to enter high-quality data. The sheer quantity
of information available, which would soon exceed any
past cohort study, might address questions previously
unanswerable owing to inadequate sample sizes. Other
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factors known to influence risk could be included, and the
minor variables might become more important when present
in certain combinations, as seen in the example from Baxt
discussed above.8 Such combinations might occur rarely,
even in a large cohort study population, and their predictive
value may therefore escape recognition. In principle, the
model could use any relevant factor that is recordable
electronically, including the use of drugs such as aspirin,
angiotensin-converting enzyme (ACE) inhibitors, and
beta-blockers, as well as the known missing factors dis-
cussed above. 
The adaptive prediction model would need to be poised to
respond to changing patterns with an appropriate sensitivity,
in order that only statistically significant trends are allowed
to lead to modification of the algorithm. It might be expected
that an adjustment in the algorithm would occur initially as a
result of risk differences between the original Framingham
cohort and the current UK population. Thereafter, more
gradual changes might be seen as an adaptation to demo-
graphic and genetic changes in the UK population. 
The model could only be as ‘smart’ as the data allowed,
and unless given information on ethnicity (which is not
routinely recorded electronically), it could not allow for the
known differences in risk between different ethnic groups.
In practice, however, human involvement, which is of
course invaluable to the process of communicating risk and
advising on lifestyle modification and treatment to individual
patients, would still, under this proposed strategy, allow this
and other missing factors to be taken into account when
planning treatment, as recommended under the current
policy. Coronary heart disease prevention is a challenging
area of primary care. This model can only assist in certain
stages of a complex process, but might enable resources
to be targeted more effectively, advice to become more
sensitively tailored to the individual, and in the process
generate information for research through a novel mechanism
involving practising clinicians in the natural environment of
everyday care.
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Figure 1. A nationwide adaptive prediction model for coronary heart disease (CHD) prevention. The development of new CHD cases in the
population is detected by scanning the CHD register during each cycle. These outcomes are then allowed to modify the prediction algorithm,
if necessary, by comparing past risk factor patterns with outcomes in both CHD and non-CHD cases.
Model receives input data
(most recent Framingham
variable values)
Non-CHD patients
Model detects
development of CHD in
previously assessed 
patients
Model executes
prediction algorithm
New CHD cases
Model reviews data on all
patients and scans the 
CHD registers
Model identifies
currently high-risk
individuals as output
Practices invite in
patients selected by
the model
Clarify/update data
Identify pretreatment blood
pressure levels
Check fasting lipids
Calculate risk, make
treatment decisions
 Routine electronic recording of all the
Framingham input variables
 Separate electronic disease registers for type 1
and type 2 diabetes
 A coronary heart disease register with accurate
dates of onset 
 Blood pressure measurements carried out by
adequately trained personnel
 A policy of testing for diabetes in patients
undergoing cholesterol estimation
 Electronic recording of anti-hypertensive
and lipid-lowering medication use 
 Coded recording of deaths from cardiovascular disease
Box 3. Minimum data quality standards for participating practices.
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Coronary heart disease prevention is an obvious example
where a framework for standardised electronic recording
has been specified in the NSF, and a prediction algorithm
is already in widespread use. Other potential applications
include the assessment of predictive values for primary care
symptom complexes24 and the prognosis of malignant
disease in individual patients.25 
Conclusion
The development of computerised disease registers and the
electronic recording of values for cardiovascular risk factor
variables open up the possibility of a nationwide adaptive
prediction tool, which would be capable of pooling data
from a large number of participating practices committed to
high-quality data recording. Such a model would function
as a pattern recognition device, identifying candidates for
coronary heart disease risk assessment and allowing risk
control to be monitored at the population level. 
In principle, the model could improve the accuracy of
predictions currently made through the Framingham algorithm
over time, by responding to significant trends in the patterns
of coronary heart disease risk in the UK as they develop
during the 21st century. Where data quality allows, the same
method could be applied to other areas of clinical care, and
may help to bridge the gap between research and practice.
This provides a further stimulus for the integration and stan-
dardisation of electronic record keeping in primary care.
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Sirs—In the April issue of the International Journal of
Epidemiology, Hans-Werner Hense provides a comprehensive
treatise on the current state of cardiovascular risk assessments.1
He highlights the problems with using risk scores derived from
epidemiological data to target preventive treatment at highest
risk individuals. His comments add to the growing literature
recognizing that the risk assessment methods used in current
treatment guidelines do not provide an accurate assessment
of an individual’s true risk.2,3 Hense identifies some of these
potential sources of inaccuracy: the variation of cardiovascular
risk between populations, using predictions based on
assessment of risk factors at one occasion only, the confusing
variety of endpoints used in different risk scoring methods,
and the ‘contamination’ of risk predictions by risk-reducing
treatments such as blood pressure lowering drugs. Hense also
highlights the important, but often unrecognized, implications
of basing treatment on different thresholds of risk. For example,
when the threshold is 30% 10-year risk of coronary heart
disease, around 84% of the disease events may occur in the ‘low
risk’ group—people who might potentially be reassured by the
decision that treatment was not indicated for their level of risk.
When the threshold is 15%, this false negative rate falls to
25%, but the number identified as being at high risk yet do not
have a cardiac event rises from 6% to 45%.2 Hense is right to
say that this information is implicit in the particular thresholds
that are chosen, but unfortunately guideline authors or
practising clinicians are rarely so explicit. Clinicians might
wrongly assume that population screening to identify high risk
individuals is supported by evidence of effectiveness and meets
the basic requirements of a screening test.4
As well as listing the problems with cardiovascular risk
assessment, Hense offers some solutions. These include the
re-calibration of risk functions to regional event rates, and the
pooling of cohort studies to limit the influence of regression
dilution bias. He identifies the approach adopted by the SCORE
(Systemic Coronary Risk Evaluation) investigators of pooling
data from 12 European cohorts, and providing risk assessment
charts for high and low risk countries.5 Unfortunately, the
SCORE approach is limited by the use of cardiovascular death as
its endpoint and it does not have an indicator variable taking
into account treatment effects. The SCORE project represents an
impressive collaboration that will have entailed a considerable
amount of work to obtain, clean, and pool such a diverse collection
of datasets. However, it is not certain that the advantages over the
available Framingham scores are sufficient to have justified such
effort. A simpler approach might have been to use the published
Framingham score that adjusts for hypertension treatment effects,
and re-calibrate it for different regions within Europe using
a method previously described.6,7 Additionally, the SCORE
algorithm in its current form cannot be used in many inner city
family practices where the majority of the patients live in areas of
students in public and private schools was 18.3% and 8.1%,
respectively—perhaps because of improved information dissemi-
nation and greater stress on health education in private schools
compared with public schools. In all, 62% of adolescents reported
their reason for smoking as enjoyment, while 18% claimed to
have been influenced by advertisements to begin smoking.
The majority of students (61.3%) were smoking with their friends.
In this study adolescents also reported family tobacco use: father
19.8%, mother 27.8%, brother 21.0%, and uncle 27.1%. Multiple
logistic regression analysis of factors associated with smoking
revealed that after adjustment for age, ethnicity, and place of
residence, students in public schools were more likely to be
smokers compared with those in private schools (adjusted odds
ratio [OR] = 1.6; 95% CI: 1.0, 2.7). Adolescents were more likely
to be smokers if their peers were smokers (adjusted OR = 6.2;
95% CI: 3.91, 9.9). Boys who spent most of their leisure time
outside their homes were more prone to smoke cigarettes (adjusted
OR = 3.9; 95% CI: 1.2, 13.2) as were those who had a smoker
in the family (adjusted OR = 1.7; 95% CI; 1.1, 2.8). During
adolescence, tobacco use by peers may create a positive image
of smoking and create easy access to cigarettes, especially in
developing countries where there are no restrictive laws on the
sale of cigarette to minors. The findings presented in this study
are consistent with other studies conducted on adolescent
smoking behaviour, which showed that parents, siblings, and
peers are powerful influences for adolescent smoking.5 Smoking
is usually initiated during adolescence and being amenable to
behaviour modification it should become a public health priority
to educate adolescents and parents regarding hazards of smoking
in Pakistan and other developing countries.
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socio-economic deprivation or are from black and minority ethnic
groups. Consequently, the SCORE approach only represents a
minor tweaking of the ‘one size fits all’ approach.
To improve the discrimination of risk scores, we need a better
understanding of the cardiovascular disease process and Hense
suggests including new biochemical and other variables to identify
sub-clinical disease. Although the predictive accuracy may
be improved, the inclusion of additional variables requiring
specialized equipment will cause the acceptability and clinical
application of the risk assessment tool to suffer. Collection of basic
risk factor information such as high-density lipoprotein cholesterol
by primary care teams is at best inconsistent, so inclusion of these
‘new’ risk factors in a clinically valid risk score may not improve
population screening in the short or medium term.8
It is unlikely that risk scores derived from cohort studies
designed primarily to investigate aetiological rather than
prognostic factors related to cardiovascular disease will ever be
sufficiently flexible to fully take into account the issues of
generalizability, measurement error, treatment effects, and
temporal changes in disease incidence. Increasingly large vol-
umes of data related to cardiovascular disease are now routinely
collected in standardized form from primary care as a way
of monitoring the performance and quality of primary care
practitioners. Information technology systems are now sufficiently
sophisticated for data held at the practice level to be remotely
accessed and analysed by a central system. Risk factor and
outcome information collected on millions of individuals will
provide an extremely powerful resource for developing risk
prediction models. If details of ethnicity were collected, this would
remove the problem of a shortage of relevant incidence data
within European countries. New, adaptable statistical approaches
are required, such as neural networks that are able to modify their
predictions or ‘learn’ from new risk factor and outcome infor-
mation from these routine data sources.9
There is no doubt that using a multi-factorial score to guide
the clinician in targeting preventive treatment is preferable to
managing patients on the basis of arbitrary levels of single risk
factors. The use of various risk scoring methods can play an
important part in educating the clinician and the patient about
the contribution that lifestyle and physiological measures make
to overall risk, and also help with understanding the benefits
of preventive intervention. However, the development of more
accurate and practical risk scoring methods that are relevant to
primary care teams has stalled. A single risk assessment method,
such as the Framingham coronary risk score, that is not tailored
to the individual situation of the patient, does not provide
patients and their doctors with sufficiently accurate information
to make major treatment decisions. The pooling of many similar
cohort studies to derive a score adapted to national levels
of cardiovascular disease offers only a limited advance. Much
greater imagination is required to make the most of the huge
volumes of regularly updated information on cardiovascular
disease that is routinely collected in primary care. The data
could be used to devise locally adaptable risk assessment
methods that automatically calculate an individual’s risk from
the available data. Doctors and nurses perform risk assessments
with only moderate accuracy,7 so this automation would take
the process of performing the risk assessment from the time-
limited doctor’s consultation and allow the creation of a register
of high risk patients. The seamless integration with the
consultation, of a continually updated risk score derived from
patients in primary care, would overcome the major deficiency
of even the most accurate risk scoring tool—that is of being used
incorrectly or not being used at all.
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Introduction
A number of recent directives point towards database
integration as the way forward for health informatics
in the National Health Service (NHS), including Infor-
mation forHealth andDelivering 21st Century IT Support
for the NHS: national strategic programme.1,2 Signiﬁcant
barriers remain, however, particularly at the interface
between health and social care.3 These include not only
issues of conﬁdentiality and patient consent, in the con-
text of the 1997 Caldicott Review and the 1998 Data
Protection Act, but also those of data quality and
software compatibility.4–6 Potential beneﬁts of data-
base integration include access to clinical records,
investigation results, and allergy and medication his-
tories by clinicians dealingwith patients ‘out of hours’;
electronic linkage between primary and secondary
care units; the detection of population-level changes
in morbidity patterns, including infectious diseases;
improved communication between professionals using
the databases; and, increasingly, the use of such data
for research.
Twenty-four-hour emergency access to medical
records is one of the deﬁned objectives of Information
for Health, to be achieved by 2005. Because these
records are traditionally held in general practice (GP)
premises, and such premises are no longer the usual
point of delivery of out-of-hours care, this objective
unavoidably requires external access to practice-held
records. The move towards increased access and
ABSTRACT
The NHS Care Records Service (CRS) is a major
goal of the National Health Service (NHS) Mod-
ernisation Programme. It will provide for 24-hour
access by clinicians to electronic patient records and
the integration of information from previously
separate databases, reducing the ‘seams’ between
primary and secondary care, between out-of-hours
and ordinary working hours, and ultimately between
health and social care. Such integration is likely
to aﬀect not only individual patient care, but also
public health including disease surveillance, and
the monitoring of clinical activities including the
achievement of clinical governance targets. The
potential beneﬁts for patients, practitioners and
managers are numerous. However, the process raises
issues over conﬁdentiality, data protection and data
quality. During 2003 a project was undertaken in
SouthWarwickshire to develop anNHSCRSwidely
available to primary care clinicians in the region.
This was part of a wider initiative funded by the
NHS Connecting for Health (NHS CfH). Twenty-
six out of 36 local practices took part, providing a
combined database of 181 961 clinical records. All
but one of the original objectives was achieved.
Lessons were learned which could usefully inform
the development of the CRS more generally in the
NHS.
Keywords: care records service, information
storage and retrieval, medical records systems –
computerised, interoperability
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information ﬂow may be contrasted with the ‘need to
know’ principle that is central to the Caldicott Re-
view.4 For an integrated database system to satisfy
both guidelines, clearly deﬁned protocols governing
rights of access are required. One of the successes of
the project we describe was the achievement of this
outcome. The project objectives are shown in Box 1.
The South Warwickshire
Demonstrator Project
South Warwickshire Primary Care Trust (PCT) is situ-
ated in the West Midlands, south of Coventry and
Birmingham, serving a population of 249 000. A district
general hospital at Warwick provides the majority of
secondary care services. Within primary care there are
36 general practices and approximately 142 general
practitioners. At the time of this project all the practices
were computerised to varying degrees and the major-
ity had links to hospital databases for transmission of
laboratory data. In addition to general practices, GP
hospital facilities, physiotherapy units andNHSAcute
Trust community clinics took part in this project.
The global information technology (IT) company
IBM and Newchurch (a United Kingdom [UK]-based
private health informatics company that specialises in
primary care database management) were contracted
to manage the project in collaboration with local stake-
holders.7 Newchurch were responsible for the pro-
tection of data held in a central repository located at
Teddington, Greater London. Every 24 hours the
repository was updated by downloads from the source
systems. Data quality was improved by cleansing and
standardising the coding. This information was ac-
cessible to authorised users over the NHSnet, and
access to the repository occurred both through ﬁxed-
line NHS connections and mobile devices. The user
interface, the ‘Primary Care Information Solution’
(PCIS), was available at 320 access points at general
practice surgeries, hospital Accident&Emergency (A&E)
departments, GP hospital wards and community-based
clinics. Each user accessing the system was allocated a
security level. ‘Sensitive’ or ‘conﬁdential’ information
was identiﬁed and the user’s security level determined
how much information was accessible to that user.
Whilst the project was established on the basis of
‘implied consent’ (patients aware of the project
through publicity and unhappy about it could with-
hold their records, but otherwise would be included),
access only actually occurredwith the patients’ expressed
consent at the point of care. For instance, a patient
seen in the A&E department would be asked to
consent to access to their general practice records by
A&E staﬀ. This process could be overridden if the
patient was too unwell to discuss it, but otherwise
ensured that a patient unaware of the project could
dissent to access if theywished. Staﬀundergoing training
in the use of the system were made aware of the audit
trail facility which records every instance of access,
including the user’s identiﬁer.
Software compatibility
In addition to conﬁdentiality issues, a further obstacle
to database integration is the diversity of software
providers in primary and secondary care. To overcome
this problem, a wider system capable of incorporating
a number of software providers was required. The
Health Care Interoperability Forum (HCIF) exists to
promote information ﬂow and the operability of alter-
native software in the shared NHS environment.8 The
HCIF is a UK-based commercial co-operative that
subscribes to Health Level 7 (HL7), an international
body ‘providing standards for the exchange, manage-
ment and integration of data that support clinical
patient care and the management, delivery and evalu-
ation of healthcare services’.9 The UK component,
HL7UK, provides the currently accepted guidance on
interoperability within theNHS. The software systems
involved included: from general practice: EMIS, Vision
and Torex (now iSOFT) GP systems; from the PCT:
CISS (Community Services) and CPA (Mental Health)
Systems; and fromWarwick Hospital: Torex PAS and
Anglia Reporting Systems. Data ﬂow between diﬀer-
ent web-based units was facilitated through the use of
extensible mark-up language (XML). XML is a more
ﬂexible language than hyper text mark-up language
(HTML) but is simpler to program and more usable
than standard generalised mark-up language (SGML).
The use of XML in this project was an important
means of achieving interoperability.10
This project, funded by theNHSProgramme for IT,
was one of a number of similar initiatives, including
Electronic Record Development and Implementation
Programmes (ERDIPs).11,12 The collation of informa-
tion on the same individual fromdiﬀerent sources was
madepossibleby theuseof aMasterPatient Index (MPI).
Box 1 Project objectives
. To create a working model of rapid primary
care record integration for South Warwick-
shire Primary Care Trust.
. Where applications cannot be demonstrated
within the schedule, to complete the design
and planning to illustrate what can be done
and how.
. To explore the implications and beneﬁts in
process and technical terms of using the Dem-
onstrator and of hosting GP software systems.
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The Master Patient Index
TheMPI is based on patients’ NHS numbers, allowing
‘registration’ to occur above the practice level. The
current system of practice-based registration (in which
patients registering with a new practice automatically
trigger the cancellation of their previous registration)
ensures that they can no longer be registered in more
than one general practice. This contrasts with other
medical registers (such as hospital laboratory data-
bases) where it is not as easy to ensure that the same
patient won’t be counted twice. The same MPI prin-
ciple has been used in Canada, where the Integrated
Health Research Network database collates informa-
tion across Quebec, serving an integrated system of
care between hospital and community services.13 In the
MPI used in this project, NHS numbers were aligned
with PCT-held patient demographics and Warwick
Hospital casenote (‘UR’) numbers, in order that both
hospital and community data could be integrated
without duplication. The prime identiﬁer for all
patients was their NHS number.
Outcomes of the project
Box 2 lists themain outcomes following completion of
the project in September 2003, and Box 3 shows more
recent data on usage of the system. The majority (26/
36: 72%) of general practices in the areawerewilling to
take part. A small number (2/36: 5%) were unhappy
about the conﬁdentiality issues, whilst eight practices
did not respond to the invitation to participate. This
represents approximately 181 961 patients from a pos-
sible total of 249 000, or 73% of the PCT’s active
patient list. The participating practices, as well as
other healthcare facilities in the area, hosted a total
of 320 instances of Newchurch’s PCIS, a standard user
interface. Three hundred NHS staﬀ attended training
sessions, and a total of 498 user identiﬁers (at varying
levels of access) were issued. This led to an integration
of a wide range of information sources across primary
and secondary health care, and mental health. The
most recent Department of Health guideline, Conﬁ-
dentiality: NHS Code of Practice was not published
until the end of July 2003, but this project was oper-
ated in accordance with guidelines available at the
time and was compatible with this document.14 The
total cost of the project was £1 477 417, falling within
the £1.5 million budget available. The software was
originally designed to update the central repository
every 30 minutes, but for the duration of the project it
was not possible to improve on the 24-hour cycle
achieved. It is hoped that the cycle might be shortened
through further work in the future in order to move
the operation closer to ‘real time’.
Lessons learned
The following issues arose during this project, and are
discussed in more detail in the End Project Report:15
1 A CRS based on GP records is possible to implement
and can lead to improved patient care. The project
was delivered within the anticipated time-scale and
the overall budget. Examples of comments from
system users are given in Box 4.
2 IT needs integration with change management for
rapid adoption. The project suﬀered from a lack of
Box 2 Outcomes of the CRS Demonstrator
Project
. 26 out of 36 practices daily contributed data to
a centrally hosted CRS repository. This rep-
resents approximately 181 961 patients from a
total list of 249 000, or 73% of the PCT’s active
patient list
. 498 user identiﬁers issued and 300 staﬀ attended
formal PCIS training sessions
. Integration with CISS (Community Health),
CPA (MentalHealth), Pathology andRadiology,
providing awide range of patient data available
to authorised users
. The creation of a security model, accommo-
dating PCT and practice positions on conﬁ-
dentiality and consent within available national
guidance
. Agreed security proﬁles for diﬀerent categories
of users of the central system (GPs, practice
staﬀ, out of hours, A&E, mental health pro-
fessionals, non-mental health clinicians)
. System conﬁgured to meet the needs of pri-
mary health community and participating
acute trust groups
. The ability to view radiology and pathology
results associated with the patient record
Box 3 Usage of the system
. There are 320 instances of the PCIS at general
practices, community health oﬃces, GPwards,
physiotherapy, the A&E department ofWarwick
Hospital, and other centres.
. Between January and July 2005, there were
approximately 7200 log-ins to PCIS from
practices, non-practice users and the PCT.
Approximately 25% of activity arises from
A&E departments in the region.
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incentives beyond the perceived utility of the end
result, and receptiveness was variable. Participation
was voluntary, and as the facility was not under-
pinned by a speciﬁc change management pro-
gramme, the CRS was seen by some as an IT
initiative rather than a wider modernisation op-
portunity. Most activities in the project required
negotiation with clinicians for access to services,
and this inevitably took a lower priority to clinical
care.
3 Conﬁdentiality and consent issues. Lacking precedents
on which to base speciﬁc conﬁdentiality guidelines,
the model was developed through extensive dis-
cussions between the project board, patient rep-
resentatives, PCT Caldicott Guardians and practices.
This process took longer than expected, but was felt
to be crucial to the project. The need for detailed
negotiation must be accounted for in planning and
scheduling similar projects elsewhere. A nationally
agreed ethical framework for such projects would
assist considerably, but there will always be local
issues and obstacles to negotiate.
4 New communications strategies are needed. Apart
from the PCT board, a number of local stakeholder
groups received formal presentations, including
the Acute Trust Board, the Medical, Nursing and
Allied Health Professionals Committees, the Shadow
Patient Council and the Community Health Coun-
cil. Progress on the project and its outcomes were
also communicated through PCT newsletters,
and through direct communications from the GP
‘champion’ and the PCT IM&T manager to local
practitioners and users. However, a future com-
munication strategy could be more tailored to the
needs of disparate users from diﬀerent backgrounds,
to avoid the information overload that can easily
result in the ‘default delete’ option when presented
with promotional material.
5 An integrated environment introduces complexity.
The project identiﬁed the need for a Representative
User Forum to advise on the delivery of the project
and prioritise any enhancements. Such a forumwas
initially involved in the early stages but tended later
to fragment so that advice was gained from indi-
viduals rather than the forum itself thereafter. There
were problems integrating certain hospital casenote
(‘UR’) numbers with NHS numbers, and the more
widespread use of NHS numbers would have sim-
pliﬁed integration. The system was operated through
the NHSnet and was therefore dependent on its
performance. During August 2003 the MSBlast
virus, which caused extensive damage to web-based
systems generally, resulted in a failure of retrieval of
data to the central repository for eight days, requir-
ing a catch-up period. Future developments of the
CRS will require attention to this issue of vulner-
ability at the system level.
6 Don’t call it a ‘Demonstrator’. This term tended to
portray an experimental rather than ongoing status
for the project, which meant that some individuals
were unclear how much it justiﬁed their time.
Extension of funding has enabled the system to
remain in operation following the end of the
project.
7 Strategic health authorities, PCTs, GPs and suppliers
can work together to achieve a CRS. The project
beneﬁted from excellent relationships between all
the parties concerned, who shared common aims
and objectives. The CRS both requires and builds
on such relationships through its integrated struc-
ture.
Discussion: the future
The technical success of this project in providing a
shared software environment for the NHS Care Rec-
ords Service at the PCT level was clearly demonstrated.
In the process, a number of issues relevant to the
ongoing national integration of NHS databases were
identiﬁed.
Obstacles to integration include technical issues
such as software compatibility and standardisation
of record keeping.16 Huston emphasises that infor-
mation technology itself will not solve the problem of
Box 4 Examples of user feedback
‘With the PCIS we were able to obtain infor-
mation on the drugs that the patient took regu-
larly, giving us the knowledge of what a patient’s
drug history was.’
‘An elderly lady came to A&E in an ambulance
from a nursing home without a nurse in attend-
ance.When the doctor started to take the history,
it was evident that she was unable to recall her
past medical history. PCIS enabled us to get this,
which then enabled us to deliver appropriate
nursing care.’
‘The patient had an ECG taken which showed an
arrhythmia; we needed to establish whether this
was new or old. By accessing the PCIS we were
informed that it was old and therefore prevented
a hospital admission.’
‘The PCIS enables us to establish what a patient’s
tetanus status is.’
‘The patient said that the morning pills she took
were white, and the evening pills were pink; PCIS
provided us with the information to establish the
names of the drugs she was taking.’
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poor record keeping, and recommends that clinicians
rather thanmanagers should lead theprocessof standard
setting.17 Data quality is also a potential problem.
Ideally, universal patient identiﬁers are required for
optimal record linkage, and inaccuracies in patient
records might in theory be ampliﬁed by database
integration.18,19 Methods of measuring data quality
are known, but patients may remain concerned unless
ownership of information is clear and strictly con-
trolled, so that the beneﬁts of information sharing can
occur without loss of conﬁdentiality.20,21 In a quali-
tative practice-based study,Ward and Innes have shown
that whilst patients expect their doctors to limit access
to their records appropriately, they also expect them
to make relevant information quickly available across
the health service where needed.22 This is a diﬃcult
but important balance to strike.
This project was undertaken within a ﬁxed time-
scale and budget, but the facility remains in use and
could be extended in future as the NHS undergoes
further modernisation. Access to the system from
secondary care (other than GP wards) was limited to
A&E, but PCIS units could in principle be set up in
hospital outpatient departments as well as inpatient
wards, intensive care units or theatre recovery. The
system may also be used to support the development
of GPs with Special Interests (GPSIs), as this role
expands in future years. The Master Patient Index,
which allows PCT-level registration to occur, could be
used to provide more adequate registers for speciﬁc
clinical conditions. These not only include diagnostic
groups (such as diabetes, for the targeting of patients
for interventions such as community retinal photog-
raphy), but also those with diﬀerent conditions but
sharing similar or overlapping needs. An example of
this is the ‘ELDIT’ study (Epidemiology of Liver Disease
In Tayside), which used the same principle of database
integration, including biochemistry, immunology and
virology laboratory sources.23 Diagnostic algorithms
have been applied to this combined database to classify
individual cases, recognising patterns through col-
lation of information from multiple sources. In ad-
dition to established conditions, data from previously
isolated sources might facilitate the identiﬁcation of
patients at risk of certain conditions, where risk factor
proﬁles are complex. These might include children at
risk of abuse, or the identiﬁcation of patients likely to
require hospital admission in the near future, an area
currently under investigation by the King’s Fund.24
The latter two groups might particularly beneﬁt from
the inclusion of social services data, not included in
this South Warwickshire project but a potentially
valuable source for inclusion in the future. Simi-
larly, the inclusion of dentists’ and opticians’ re-
ports might further amplify the potential of the
model for inter-professional communication to
the beneﬁt of patients.
Limitations and future research
needs
This case study has described the establishment of a
local Care Record Service in SouthWarwickshire. The
beneﬁts of this service have not yet been formally
researched following the project’s completion, but
during its creation the same sorts of issues and obstacles
to implementation found elsewhere were identiﬁed.25
To justify the costs of such systems, added value above
existing facilities to both patients and clinicians need
to be demonstrated.26 In a series of case studies and in-
depth interviews across four acute NHS trusts, Hendy
et al have uncovered the ‘sociocultural’ as well as
logistic challenges of such integration, particularly
within the time-scales initially proposed by NHS Con-
necting forHealth.27 ThisDemonstrator Project needs
to be similarly researched through a more extensive
evaluation of the system’s usage, exploring not only
the technical and logistic barriers to its ongoing
delivery, but also the qualitative issues of acceptability
and perceived beneﬁt from the perspectives of patients
and practitioners.
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Abstract
Background: Cardiovascular disease (including coronary heart disease and stroke) is a major
cause of death and disability in the United Kingdom, and is to a large extent preventable, by lifestyle
modification and drug therapy. The recent standardisation of electronic codes for cardiovascular
risk variables through the United Kingdom's new General Practice contract provides an
opportunity for the application of risk algorithms to identify high risk individuals. This randomised
controlled trial will test the benefits of an automated system of alert messages and practice
searches to identify those at highest risk of cardiovascular disease in primary care databases.
Design: Patients over 50 years old in practice databases will be randomised to the intervention
group that will receive the alert messages and searches, and a control group who will continue to
receive usual care. In addition to those at high estimated risk, potentially high risk patients will be
identified who have insufficient data to allow a risk estimate to be made. Further groups identified
will be those with possible undiagnosed diabetes, based either on elevated past recorded blood
glucose measurements, or an absence of recent blood glucose measurement in those with
established cardiovascular disease.
Outcome measures: The intervention will be applied for two years, and outcome data will be
collected for a further year. The primary outcome measure will be the annual rate of cardiovascular
events in the intervention and control arms of the study. Secondary measures include the
proportion of patients at high estimated cardiovascular risk, the proportion of patients with missing
data for a risk estimate, and the proportion with undefined diabetes status at the end of the trial.
Background
Primary research question
Can an automated system of electronic feedback (e-
Nudge) reduce the incidence of cardiovascular events in
high risk patients in general practice, compared to "usual
care"?
Background
A major focus of chronic disease management is the pre-
vention of cardiovascular disease (CVD). An important
development occurred in UK primary care in April 2004,
with the introduction of the "new General Medical Serv-
ices Contract" (nGMS) [1]. This involved the establish-
ment of registers for a number of conditions relevant to
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tronic record keeping has made the data potentially useful
for research [2]. The Quality and Outcomes Framework
(QOF) of the nGMS specifies targets for blood pressure,
serum cholesterol levels, and smoking cessation advice for
patients with hypertension, diabetes, or established CVD.
Whilst not included in the QOF, the Coronary Heart Dis-
ease (CHD) National Service Framework (NSF) [3] also
recommends the systematic identification of patients at
high risk of CHD but who are not yet displaying any
symptoms.
For many patients, the need for preventive treatment is
clear, for example through a diagnosis of CVD or diabetes,
but for others, the overall cardiovascular risk should be
taken into account when determining the need for treat-
ment of hypertension or hypercholesterolaemia. This
strategy is strongly supported by the recently published
Joint British Societies guidelines on prevention of CVD in
clinical practice [4]. This project will assess the effective-
ness of targeting patients who are the most likely to bene-
fit from risk factor modification on the basis of their
absolute risk of cardiovascular events.
Changing clinical behaviour through electronic reminders
Despite increasing use of electronic reminders and alert
messages, there are relatively few controlled trials that
demonstrate their ability to modify clinical behaviour,
and none so far carried out in the UK under the new Gen-
eral Practice contract. Published literature is largely con-
cerned with the following uses of these tools:
• to increase physician or nurse adherence to guidelines
on best practice in the clinical environment [5], including
the use of drug therapy [6]
• to increase the uptake of vaccinations [7-11]
• to promote other preventive health care activities, by
triggering opportunistic interventions including screening
[12], monitoring [13,14], diagnostic tests [15], and life-
style counselling [16,17]
• to increase the cost-effectiveness of health care, by avoid-
ing duplication, facilitating communication between
members of the health care team [18], and reducing the
need for recall of patients through increased use of oppor-
tunistic activities during consultations
Of these, the most successful area is vaccination uptake,
where a number of studies have demonstrated benefit [7-
10], and in the avoidance of prescribing errors, where
alerts have been shown to be effective in decreasing the
ordering and administration of contraindicated drugs, for
instance due to renal insufficiency [19].
Results in other areas have been mixed [20], and may
depend on the response of the clinician to the alert mes-
sage, which must therefore be appropriately designed
[21]. In a United States outpatient clinic setting, Tierney et
al [22] tested the effects of a system of electronic 'sugges-
tions' for cardiac care patients through a randomised con-
trolled trial, and failed to demonstrate any control-
intervention differences in quality of life, medication
compliance, health care utilisation, costs, or satisfaction
with care. The intervention had no effect on physicians'
adherence to the care suggestions. However in Italy, elec-
tronic reminders have been shown to be effective in mod-
ifying prescribing behaviour. Filippi et al [23] investigated
the effects of computerised reminders plus a letter describ-
ing the beneficial effects of anti-platelet therapy (interven-
tion group) with the letter alone (controls) among 300
Italian general practitioners randomised to each group.
The number of treated patients was significantly raised in
the patients of the intervention group (OR 1.99, 95% CI
1.79 – 2.22).
In Scotland, the CARDIA (Computerised Automated Risk
Detection Intervention and Advice) program [24] serves
practices throughout Angus using a similar system of data-
base integration as that proposed in this e-Nudge study.
CARDIA interrogates the electronic health record (EHR),
which uses information from both primary and secondary
care sources. CARDIA targets resources by examining the
practices' EHRs, identifying patients with existing cardio-
vascular disease (or those at high risk of it based on a
Framingham calculation), and assesses the adequacy of
care (e.g. drug therapy) in individual patients. However
the effectiveness of this program has not been formally
tested in a clinical trial.
In secondary care, Lilford et al [25] have described (but
not evaluated) a system of electronic reminders for use in
the antenatal clinic. This system supplies action sugges-
tions during the antenatal booking interview, as a comple-
ment to individual clinical judgement. Eighty-two
different suggestions were included in the software, and
on average 1.5 of these were generated in an individual
history. The authors emphasise the potential for such sys-
tems to be adapted to the resources and preferences of dif-
ferent hospitals.
Controlled studies similar to the e-Nudge trial
One randomised controlled trial in primary care [26] has
assessed the effectiveness of electronic feedback using off-
line data analysis followed by a flag in the electronic
health record. Randomisation was at the health profes-
sional level. The outcome was the proportion of patients
under the care of each professional still eligible for an alert
a month later. This design is in some ways similar to this
e-Nudge trial, and the result was positive, but it took placePage 2 of 13
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with follow-up one month later. In secondary care, the
effectiveness of a similar intervention aimed at clinicians
caring for hospital inpatients at risk of deep vein throm-
bosis (DVT) was more dramatically demonstrated [27]. In
this case randomisation was at the individual patient level
and the outcome was the actual development of DVT. The
intervention group patients were found to have a 40%
reduced rate of thrombosis compared with controls. A
similarly-designed study of electronic reminders for the
improved care of patients with HIV infection achieved a
significant reduction in hospitalisation in the interven-
tion group [28].
Mitchell et al [29] used information extracted from Scot-
tish general practices to target care towards those aged 65–
79 years most in need of intervention for their blood pres-
sure. Information was extracted annually, and 54 practices
were cluster-randomised into three groups: those receiv-
ing feedback of information identifying patients with
uncontrolled blood pressure, those receiving the same
feedback but including patients' estimated absolute cardi-
ovascular risk, and control practices receiving no feed-
back. Whilst reductions in the proportion of patients with
controlled blood pressure were seen, the results were com-
promised by difficulties in stratification according to prac-
tice characteristics (resulting in an excess of controls that
were training practices, and having a hypertension recall
system).
Evidence published to date suggests that the benefits of
electronic reminders are context-dependent, relying not
only on the area of care involved, but also on organisa-
tional parameters, clinical targets, and medicolegal impli-
cations. A Veterans Health Administration study [30]
demonstrated significant variation in the implementation
of electronic reminders including their greater use for con-
ditions associated with performance measures. Agarwal et
al [31], in a study of 15 different computerised reminders
found that while overall adherence was high, there is sig-
nificant variation by clinic, individual clinician and indi-
vidual reminder. For instance, the hepatitis C risk
assessment reminder was found to have the highest over-
all adherence rate (95.9%) and the tobacco use cessation
had the lowest adherence rate (62.9%). Dickey et al [32]
have reviewed the literature on a range of office based
tools for improving behavioural change counselling in
primary care. This included all types of tool, including
electronic reminders. They found that no one type of tool
or method of teamwork was consistently more effective
than another, and identified the need for more high qual-
ity research, particularly in the area of health risk assess-
ment and electronic reminder systems.
There is therefore mixed evidence supporting the effective-
ness of electronic reminders and a need to confirm their
ability to modify clinical behaviour in the particular con-
text of UK primary care under the new GMS Contract.
Overview of study design
This is a randomised controlled trial to test the effect of an
automated electronic feedback system on CVD prevention
in general practice. The practice populations over the age
of 50 years will be randomised into two groups: "interven-
tion" and "control". Intervention patients currently
belonging to one of the high risk search groups described
below will have alert messages appear on the screen when
their electronic notes are opened. We will also apply an
electronic search protocol every eight weeks to both
groups throughout the study, to produce continually
updated lists of potentially high risk patients for cardio-
vascular events. For the intervention group the patients on
these lists will be revealed to the practice. The clinical soft-
ware company EMIS, who serve the majority of practices
in Warwickshire and Coventry, have programmed their
software to produce the alerts and the eight-weekly lists
for intervention patients. This "intervention" involves the
feedback to practice teams to identify patients who are
currently at high estimated risk, patients whose data is
incomplete (who may benefit from updated measure-
ments of cholesterol, blood glucose, blood pressure or
recording of smoking status) and those who may have
undiagnosed diabetes, through the alert messages and the
eight-weekly lists. The control group will receive the usual
care provided under the nGMS contract. No information
will be withheld from the clinicians regarding control
patients, the only difference will be the absence of
reminders to draw their attention to the information. The
practice teams themselves will decide on any changes in
treatment in consultation with individual patients in both
arms of the study, allowing care to remain tailored at the
clinician-patient level. Outcomes will include the number
of cardiovascular events and the number of high risk
patients in the two populations (defined by inclusion on
the eight-weekly search results). The design of the search
protocol and the justification for the thresholds are
described in the appendix.
Methods
Recruitment
Up to twenty-six general practices in Coventry and War-
wickshire who use EMIS LV software will be invited to par-
ticipate in the trial. Dr Tim Holt will visit each practice to
explain the trial and gain written consent from the general
practitioners.
Randomisation
Participating practice patients over 50 years of age will be
randomised into two groups – "intervention" and "con-Page 3 of 13
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groups throughout the study using an electronic tech-
nique that is concealed to all researchers and practitioners
involved. This process will occur electronically during
each search, so that those who join the practice during the
study will be randomised automatically as soon as they
are first provided with electronic notes as a fully registered
patient. Temporary residents are not included in the
study.
Applying the search strategy
Alerts will be created automatically using patient informa-
tion that is updated in real time and the search protocol
described in Figures 1, 2, 3. For the eight-weekly lists we
will apply the same search protocol to the databases of
participating practices. This will produce lists for each
practice of the high modifiable risk patients in the inter-
vention arm of the study on the day of the search. The
groups identified can be summarised as:
GROUP 1: Patients of all ages with existing cardiovascular
disease or diabetes, whose blood pressure or cholesterol
level is outside the QOF target range at the last estimation,
or no "in date" level is recorded.
GROUP 2: Patients who are not known to have cardiovas-
cular disease or diabetes, are under 75 yrs old, and whose
risk profile is incomplete – more information is required
to perform a risk estimate – but whose cardiovascular risk
would be greater than 20% if the "assumed" values of the
missing factors are used (see definition in appendix).
GROUP 3: Patients who are not known to have cardiovas-
cular disease or diabetes, are under 75 yrs old, and whose
most recent risk variable values indicate that their risk
level is raised.
GROUP 4: Patients who are not known to have cardiovas-
cular disease or diabetes, are greater than 75 yrs old and
who have persistently elevated blood pressure based on
the three most recent consecutive readings.
GROUP 5: Patients with possible undiagnosed diabetes
on the basis of at least one previous high blood glucose
record.
GROUP 6: Patients with CVD but not diabetes, who have
not had a blood glucose measurement in the past three
years.
Information on the "intervention" patients identified at
each search is revealed to the practices. Information on
the control patients including the number identified will
be saved but no action will be triggered (Figure 4).
Intervention – the "e-Nudge"
The e-Nudge is an automated feedback system that exam-
ines information already contained in practice databases
to help practice teams target preventive interventions
towards the individuals most likely to benefit. At the same
time, the e-Nudge identifies clinically important missing
risk variable values and patients with possible undiag-
nosed diabetes. Designed to run as a series of updated
alert messages and searches that use most recent risk vari-
able values, it is able to track practice populations over
time as patients enter and leave the area, grow older, and
enter practice disease registers, such as those for diabetes,
CHD, or stroke. It recognises that risk profiles are
dynamic, and that "one-off" estimates of risk in individu-
als are liable to become outdated [33].
The alert messages will arise automatically through EMIS
software when a high risk patient's notes are opened, and
are continuously updated in real time. To identify patients
who may not present to the practice, electronic searches
will be undertaken every eight weeks. The purpose of both
alerts and the lists is to trigger awareness of individual
patients' risk within the practice team, and not to dictate
specific treatments. The "e-Nudge" is therefore simply the
feedback of this information. The resulting action is at the
discretion of the practice team, and can be tailored both
to the time available, and to the needs and preferences of
the individual patient in the context of the clinician's
broader knowledge of co-morbidity, current medication,
and past response to treatment. The practice teams will
have the following notifications for intervention patients
identified in the searches.
1 The eight-weekly search result is presented to a nom-
inated member of the primary care team under the six
group headings.
2 Alert messages are displayed automatically on the com-
puter screen each time the patients' electronic notes are
opened. These are triggered for those identified in any of
the groups:
• Group 1 patients: This CHD/Stroke/Diabetes (state
which) patient's (BP) or (serum cholesterol) level (specify
which) is out of the target range.
• Group 2 patients: This patient may be at high cardiovas-
cular risk, but values for the following risk variables were
either missing or out of date: (specify which variables).
• Group 3 patients: This patient's estimated cardiovascular
risk may be elevated, based on the most recent risk variable
values.(State assumptions made)Page 4 of 13
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ently elevated based on three consecutive values.
• Group 5 patients: This patient may have undiagnosed dia-
betes, based on a previous raised blood glucose level ≥ 11.1
mmol/L.
Search algorithm to identify those most likely to benefit from cardiovascular prevention based on recent risk variable valuesFigure 1
Search algorithm to identify those most likely to benefit from cardiovascular prevention based on recent risk variable values. 
Definitions for terms in inverted commas are given in the appendix along with justification of thresholds and search protocol.
Total population over 50 yrs 
On CHD, Stroke or Diabetes registers? 
Yes        No 
If most recent systolic BP > 150 mmHg 
(>145 if patient has diabetes)                 Less than 75 years old? 
or     
most recent diastolic BP > 90 mmHg                              No 
(>85 mmHg if patient has diabetes)     
or            
most recent cholesterol > 5.0 mmol/L     Yes                       Are all of the     
or                    last three BPs 
BP or cholesterol value not recorded in                     >160 (systolic) 
the past fifteen months                                     or >100(diastolic) 
                                           (where available) 
     
GROUP 1    Does the record                        
     contain “in date”       
            information on all the                
                   “Framingham variables”?             No
              Yes   
          
         No      Yes              GROUP 4
Inserting “assumed” values                                Estimated 10 yr CVD risk >20%
for the missing variables,                      based on most recent values? 
would the 10 year CVD risk be >20%? 
     Yes       No      Yes      No 
GROUP 2      GROUP 3 Page 5 of 13
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has no recorded blood glucose measurement in the past
three years.
Control condition
Control patients at high estimated risk will be identified
but the practice teams will not be provided with these
extra reminders, although the team will have access to all
the clinical information used to assess risk status. Control
patients will continue to receive the usual care provided
by current general practice under the nGMS contract.
Some practices have started to use alerts for CVD or Dia-
betes patients who are out of the nGMS blood pressure
and cholesterol targets since this study was conceived.
Where this is now 'usual care,' this part of the intervention
(Group 1 alerts) will not be withheld from the control
patients, but the rest of the e-Nudge (including identifica-
tion on the eight-weekly searches) will be. The standard of
care is high in the study locality [South Warwickshire Pri-
mary Care Trust, QOF data on file], providing a suitable
environment to test the e-Nudge. If the study shows a pos-
itive effect, this will demonstrate that even good care can
be improved, and it is anticipated that the tool will be
even more effective in environments where care is of a
lower standard.
Ethical approval
The trial has been developed in accordance with the Dec-
laration of Helsinki, and approved by Warwickshire Local
Research Ethics Committee (Ref: 05/Q2803/85).
Outcome analysis
The searches and alerts will continue for a period of two
years, at the end of which the data will be examined. We
will continue to collect and analyse data on the primary
and secondary outcomes of the study for a further year
after this. Outcomes will be measured using searches on
practice databases. Analysis will be undertaken on an
"Intention To Treat" basis within practices. Practices that
withdraw will have their data censored from the date of
withdrawal from the trial.
Primary outcome
Difference in the annual incidence rate of cardiovascular
events (see definition in the appendix) in the intervention
and control populations during the two years of the study,
Identification of Group 5Figure 2
Identification of Group 5.
Total population over 50 yrs 
On Diabetes register? 
No
Is there a random blood 
glucose value > 11.1mmol/L?, 
without a subsequent FBG < 6.9 
or  OGTT code 
   Yes    
               Yes            
                          No 
          GROUP 5Page 6 of 13
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intervention.
Secondary outcomes
• Difference in the proportion of high risk patients
(Groups 1, 3 and 4) identified in the control and interven-
tion populations averaged over the last three searches in
the two year intervention period, and in the third year fol-
lowing the end of the intervention.
• Difference in the proportion of patients in each popula-
tion identified with missing data (Groups 2 and 6) aver-
aged over the last three searches in the two year
intervention period, and in the third year following the
end of the intervention.
• Difference in the proportion of patients with undefined
diabetes status (i.e. raised blood glucose levels with no
diagnosis of diabetes and no FBG or OGTT results to con-
firm status) (Group 5) in the intervention and control
populations averaged over the last three searches in the
two year intervention period, and in the third year follow-
ing the end of the intervention.
Statistical analysis
Analysis of the data will be carried out in STATA. The prin-
ciple analyses will be on an intention-to-treat basis and
will be performed using the CONSORT guidelines (2001)
[34].
Data monitoring committee
Outcomes will be assessed annually during the study by
an independent data monitoring committee, who will
inform the trial investigators if the trial should terminate
early on ethical grounds due to a 20% difference in mor-
tality or morbidity between the intervention and control
groups.
Data quality assurance measures
We will examine the cause of death of every patient in the
practices over age 50 years who dies during the study, to
ensure that all cardiovascular deaths are recorded appro-
priately in searchable form prior to outcome data extrac-
tion. Any patient recorded as having more than one
cardiovascular event during the study will have their clin-
ical record examined, to identify patients who have had
the same event recorded twice (which may happen when
a consultation for a stroke, TIA or myocardial infarction is
mistakenly labelled as a "new episode" rather than a
"review"). This process will be carried out both on con-
trols and intervention patients. In addition, we will exam-
ine the notes of any patient who has a record of an event
dated within 4 months of registration with a practice, in
case this event occurred in the past but was incorrectly
dated when the patient registered.
Sample size calculation
Event rates
Our study defines a cardiovascular event as a new diagno-
sis of CVD, a new myocardial infarction, a new stroke, a
new transient ischaemic attack, or sudden death from
CVD. A new stroke in someone with a previous stroke will
Identification of Group 6Figure 3
Identification of Group 6.
Total population over 50 yrs 
On CHD or Stroke/TIA register? 
  No       Yes 
Is there a blood glucose measurement 
in the record in the past 3 years? 
Yes     No 
GROUP 6 
Eight-weekly searches on practice databasesFi ure 4
Eight-weekly searches on practice databases.
Randomisation
Control patients                     Intervention patients 
SEARCH
    High risk control       High risk intervention 
             patients        patients 
 Record made of search result 
with date, but no      Lists presented 
              further action                   to practice teams 
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patient previously diagnosed with angina will be recorded
as a new event, but a new onset of angina in a patient who
already had a diagnosis of acute myocardial infarction
might not be recorded as a new diagnosis, as the patient
will already be on the CHD register.
The British Heart Foundation [35] has compiled an esti-
mate of the number of cardiac events in the UK popula-
tion in 2002 from several available data sources. The
number of myocardial infarctions (all ages) was estimated
to be 268,000, while the number of new cases of angina
(all ages) was estimated to be 338,000
The UK population was 59,321,700 in 2002 [Sources:
Office for National Statistics, General Register Office for
Scotland, Northern Ireland Statistics and Research
Agency], so estimated incidence rates for coronary heart dis-
ease are
Incidence of myocardial infarction 451.77 per 100,000
Incidence of new case of angina 569.77 per 100,000
For cerebrovascular disease, the OXVASC study [36] pro-
vides a local source of information drawn from an
Oxfordshire population. The incidence rates were:
Incidence of stroke 187 per 100,000
Incidence of TIA 51 per 100,000
Therefore
Incidence of all cardiovascular events 1260 per 100,000
Clinical significance
We aim to demonstrate at least a 10% reduction in the car-
diovascular event rate. This means that for a positive out-
come, the event rate in the intervention population must
be ≤90% of the event rate in the control population. We
therefore estimated the necessary sample size for this
reduction to be detected at the 5% level with 80% power.
Estimating population size needed
A Poisson distribution model is appropriate for events
that are rare on an individual level, occurring randomly
and independently at a constant rate in a population [37].
Assuming a Poisson distribution, the formula for the sam-
ple size is:
where:
λ0 = the expected incidence of cardiovascular events (i.e.
1260/100,000)
δ = new incidence in the intervention group
z1-α = standardised normal distribution value based on
0.05 significance level
z1-β = standardised normal distribution values for 80%
power
N = total number of patients required in the study
Nw = total number of patients required in the study + 10%
to account for practice withdrawal
For 80% power and 0.05 significance level (2-tailed) [38]
(see Table 1):
The practice population required to detect both statisti-
cally and clinically significant changes in the cardiovascu-
lar event rate is therefore estimated to be approximately
70,000, the combined list size of all age groups in partici-
pating practices.
Discussion
We have described the protocol of our trial of an elec-
tronic reminder system (the e-Nudge) that aims to change
general practitioners' behaviour with respect to patients at
risk of CVD. The trial will use routinely collected elec-
tronic data to repeatedly flag up high-risk patients and
will measure the outcomes in terms of cardiovascular
event rates and the risk profile of the over-50 year popula-
tion. Electronic alert messages are now commonly used in
the increasingly integrated software environment of UK
primary care, but the evidence to support them is incon-
clusive. This trial will attempt to provide a more robust
evidence base for the use of such tools for preventive care
in UK general practice.
N
z z
=
+ +
− −
[ ( )]1 0 1 0
2
2
α βλ λ δ
δ
Table 1: 
Reduction in incidence (%) z1-α z1-β λ0 δ N Nw
10 1.96 0.8416 0.0126 0.001260 64133.46 70546.80Page 8 of 13
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project included those of data quality and software inter-
operability. Because the coding of clinical data under the
nGMS is linked to remunerative targets, a widespread
standardisation of Read coding has occurred since 2004 in
areas of care related to chronic disease management.
Without this development it is doubtful that a trial of this
design could be conducted. Despite this, the use of alter-
native codes within the nGMS contract for data such as
blood glucose values made the programming of the search
algorithm challenging, particularly as more than one hos-
pital laboratory (which generate these data for practices
through electronic links) are involved in the study area.
The identification of individual patients' smoking status
was designed with current recording practice in mind, and
this area of the program was the least secure in terms of
accuracy, as it is not always possible to determine from
electronic records exactly how long ago an ex-smoker
quitted. Participating clinicians are made aware of the
limitations of this part of the program so that adjustments
can be made based on a knowledge of the patient's actual
smoking history.
The e-Nudge Trial is an example of a new model of pri-
mary care research. It involves the flow of information out
of the databases of participating practices to the practising
teams, to then influence clinical behaviour and future
data patterns. The search techniques involved include not
only the identification of patients according to the pres-
ence in their notes of coded data, but a computation (using
in this case the Framingham CVD algorithm) to define a
more complex decision boundary between the high risk
and low risk patients in a live database. This approach has
become necessary in the light of the most recent guide-
lines on the prevention of cardiovascular disease [4],
which explicitly support the definition of the hypertensive
and hyperlipidaemic populations according to overall car-
diovascular risk, estimated using both risk algorithms and
other information known to the clinician. Such algo-
rithms might lend themselves to future adaptation, by
broadening the range of input risk variables, the use of
alternative statistical models for the classification of high
risk groups, and tailoring to regional populations [33].
The appendices describe the evidence behind the choices
made in designing the study including thresholds,
assumed values, and definitions.
Appendices
1. Justification for the thresholds and search protocols
used in the study
a) Age group
b) The high CVD risk group (Group 3)
2. Identifying patients with undiagnosed diabetes
3. Screening for type 2 diabetes in populations at risk of
CVD
4. Search groups 1, 3 and 4
5. Definitions:
a) "In date"
b) "Framingham variables"
c) "Assumed values"
d) "Cardiovascular event"
1. Justification for the thresholds and search protocols used 
in the study
a) Age group
We decided to include in the searches only those patients
over 50 yrs, as the prevalence of cardiovascular disease
begins to climb steeply at this age [35]. As the main out-
come involves a comparison of the effect of the interven-
tion on event rates, this will avoid the dilution of each
denominator population by low risk patients.
b) The high CVD risk group (Group 3)
The group at high risk of CVD (but who do not already
have CHD, Stroke/TIA, or Diabetes) is defined not by a
simple combination of diagnostic categories, but as the
output of a risk prediction algorithm. The Framingham
study data [39] is currently the best available source for
patients without CVD under 75 years, and is recom-
mended in the CHD NSF [3] and the 2004 British Hyper-
tension Society Guidelines [40], despite some concern
over its applicability to the UK population [41]. We will
be using the most recent values as inputs for this algorithm.
Whilst the recommended approach is to use values prior
to treatment with antihypertensive or lipid lowering ther-
apy, our approach is similar to that applied to individuals
in existing prediction tools [42,43] that can compare "pre-
treatment" with "post-treatment" risk, to emphasise the
impact on risk of intervention such as drug therapy and
lifestyle modification. We are therefore making no dis-
tinction between the estimated risk levels of two patients
with identical risk profiles including blood pressure, one
of whom is on antihypertensive treatment and the other is
not. In fact the treated patient, whilst having a signifi-
cantly lower cardiovascular risk than before commencing
therapy, still has a higher risk (not recognised by our
search protocol) than the otherwise similar patient with
the same blood pressure not requiring therapy. Despite
this limitation, this approach is currently the most effec-
tive means of utilising primary care data (where "pre-Page 9 of 13
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identifiable), and is very much in keeping with the moni-
toring process of the QOF, which measures performance
according to the most recent values of variables such as
blood pressure or serum cholesterol.
2. Identifying patients with undiagnosed diabetes
The application of these searches provides an opportunity
to identify patients who may have undiagnosed diabetes.
Such searches have been shown to include patients absent
from diabetes registers with blood glucose measurements
above the usual diagnostic threshold of 11.1 mmol/L. For
instance, the Diabetes Audit and Research in Tayside Scot-
land (DARTS) study [44] identified 701 patients with iso-
lated hyperglycaemia in a number of primary and
secondary care registers, from a population of 391 274.
This figure was 9.2% of the 7596 identified with diabetes.
Whilst such patients (particularly if asymptomatic)
require further investigation to clarify their diabetes status
[45], a number may benefit through earlier detection and
treatment if diabetes is confirmed. During pilot work in
one local practice, a search identified the following (see
Table 2):
Of these six:
1. Four patients had undiagnosed type 2 diabetes later
confirmed by fasting blood glucose measurements.
2. One patient had impaired fasting glycaemia (FBG 6.9
mmol/L) and is awaiting further investigation with OGTT
to exclude diabetes.
3. One patient had probable steroid induced hyperglycae-
mia and has had a normal blood glucose value recorded
since stopping the steroids.
We are therefore including as part of the regular searches
a query to identify such patients, who may have undiag-
nosed diabetes based on previous raised measurements.
Such patients identified in this study will need to have a
subsequent non-diabetic fasting blood glucose level (≤6.9
mmol/L) or Oral Glucose Tolerance Test in order that
future searches classify them as not having diabetes (see
also appendix 5 below). Some of these patients in whom
diabetes appears to be refuted by fasting measurements
may go on to have further abnormal plasma glucose lev-
els, in which case they will again be identified as possible
cases (Group 5) until a further normal fasting glucose
level is obtained, or a diagnosis of diabetes is made.
3. Screening for type 2 diabetes in populations at risk of 
CVD
Diabetes UK has issued a position statement on the early
identification of people with type 2 diabetes [46]. Among
other groups, this document identifies people with ischae-
mic heart disease, cerebrovascular disease, peripheral vas-
cular disease or hypertension as high risk groups justifying
screening, with a screening interval of three years. How-
ever a reliable and practical screening test has not been
established. Whilst fasting plasma glucose estimation is
significantly more specific than random plasma glucose
estimation, it is less practical. In addition to the detection
of possibly undiagnosed patients described above, we
have therefore designed the study to encourage blood glu-
cose testing at least every three years in groups who either
have, or who are at high risk of CVD. These tests can be
carried out during the routine blood checks that patients
receive for monitoring of lipid lowering or anti-hyperten-
sive therapies. Therefore negative diabetes status will only
be assumed if the patient is not on the Diabetes register
and a normal plasma glucose level (random or fasting) is
present in the record within the three years prior to the
search. We will be allowing the follow up of patients with
borderline plasma glucose levels to remain at the discre-
tion of the practices. (The recently published Joint British
Societies guidelines on prevention of cardiovascular dis-
ease in clinical practice (JBS 2), clarifies currently recom-
mended practice in this area for the first time [4].) This
study may be able to determine whether this approach is
useful as a means of detecting type 2 diabetes earlier in
these groups, given its practicality and low cost. Practices
are at liberty to use more specific screening tests on any
individual whom they feel justifies it.
4. Search groups 1, 3 and 4
The Group 1 patients are identified on the basis of thresh-
olds used as audit targets in the nGMS contract for second-
ary prevention. Whilst these treatment targets are
essentially arbitrary [47], they have been selected through
extensive discussions between the Department of Health
and expert advisory bodies. Following advice in the
National Service Framework for Diabetes [48] and sup-
ported by the 2004 BHS guidelines [40] and JBS 2 [4], the
nGMS QOF recommends that patients with diabetes are
treated as if they already have cardiovascular disease in
terms of cholesterol and blood pressure control. The latter
in fact requires tighter target levels than for patients with
CVD alone. For this reason they will similarly be regarded
as secondary prevention patients in this study.
For primary prevention (Group 3 and Group 4), the Brit-
ish Hypertension Society Guidelines (2004) recommend
Table 2: 
Currently registered patients: 12,245
Plasma glucose on record ≥ 11.1 mmol/L but no 
diagnosis of diabetes
6Page 10 of 13
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≥20% as a threshold for treatment of grade I hypertension
with antihypertensive drugs, or lipid lowering therapy in
all groups at this risk level up to the age of 80 yrs [40].
However, the Framingham algorithm is not designed to
be used in patients over 75 years of age, and the CHD NSF
[3] recommends that the systematic identification of new
primary prevention candidates (particularly for lipid low-
ering therapy) should stop at age 74 years. However, older
hypertensive patients benefit from blood pressure reduc-
tion and the identification of patients with grade II hyper-
tension or higher, based on serially elevated blood
pressure measurements can therefore be justified above
this age limit. Whilst it might be justifiable to reduce this
threshold (for instance to identify older patients with
grade I rather than grade II hypertension), this would
involve identifying potentially large numbers of patients
whose need for treatment was not as clear, adding consid-
erably to the workload involved.
5. Definitions
5a "In date" means:
1. A blood pressure reading within the last fifteen months
for patients who have CHD/Stroke/TIA or Diabetes, oth-
erwise three years.
2. A blood glucose level within the last three years (for
those without diabetes).
3. A cholesterol level in the last fifteen months for CHD,
Stroke/TIA or Diabetes patients, and three years for non-
CHD/Stroke/TIA, non-Diabetes patients (applies to possi-
ble Group 2 patients, see next section).
5b "Framingham variables", in this study means:
1. Age
2. Sex
3. Smoking status (considered positive if record of smok-
ing tobacco at last use of this Read code group, however
long ago). A previously recorded smoker who has stopped
will be considered a non-smoker only if 1 year has elapsed
since quitting. Therefore a "smoker" is anyone who has
smoked tobacco regularly in the past 1 year.
4. Systolic blood pressure – average of last three "in date"
values if available. If there are fewer measurements avail-
able, then the average of these is taken.
5. Total serum cholesterol at most recent measurement, if
"in date"
6. Serum HDL cholesterol – as for total cholesterol
7. Left Ventricular Hypertrophy status – assume negative
unless there is any positive electronic record of LVH.
8. Diabetes status, according to whether or not the patient
is on the Diabetes register. However, as discussed above,
this depends on the quality of such registers. If a primary
prevention patient less than 75 yrs does not have a diag-
nosis of diabetes, but there is no blood glucose level "in
date" (i.e. in the past three years), then the risk algorithm
will base the risk calculation on an assumption of positive
Diabetes status, and if the risk level is then high, the prac-
tice will be notified with this assumption stated, as a
Group 2 Alert message. If a patient (this time including
those above 75 yrs) is not on the Diabetes register but
there is a record of a blood glucose level greater than or
equal to 11.1 mmol/L, then the practices will be notified
for clarification, regardless of the patient's CHD/Stroke
status or calculated risk level as a Group 5 patient. The
matter can be clarified by the practice teams if they wish,
by organising a Fasting Blood Glucose (FBG) or Oral Glu-
cose Tolerance Test (OGTT). A FBG ≤6.9 mmol/L or OGTT
code following (at a later date to) the high random blood
glucose level will mean that the patient is no longer in
Group 5 (but may re-enter it if further raised blood glu-
cose levels occur). The FBG or OGTT must be clearly
recorded electronically by the practices using appropriate
codes (to distinguish fasting values from random blood
glucose values), or the patient will continue to be flagged
up in subsequent searches. If, despite a normal FBG result
or OGTT, a further raised random value subsequently
occurs (≥ 11.1 mmol/L) then once again the program will
question whether or not the patient has diabetes by
including them in Group 5, until a further FBG ≤ 6.9 or
OGTT code is recorded, or the patient is diagnosed and
added to the Diabetes register.
5c "Assumed values" for the missing variables means:
1. For systolic blood pressure: Male 135 mmHg, Female
132 mmHg
2. For total serum cholesterol: Male 5.7 mmol/L, Female
6.2 mmol/L
3. For HDL cholesterol: Male 1.4 mmol/L, Female 1.7
mmol/L
4. For diabetes: positive status.
5. For smoking status: non-smoker.
These blood pressure and cholesterol thresholds are the
approximate median or mean values in the 50–74 yearPage 11 of 13
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[49].
5d A "cardiovascular event" is defined as:
1. A new diagnosis of cardiovascular disease (i.e. entry
onto the CHD or Stroke/TIA registers)
2. A new stroke or transient ischaemic attack (TIA)
(whether or not already on the Stroke register)
3. A new myocardial infarction (whether or not already on
the CHD register).
4. Sudden death from cardiovascular disease.
Abbreviations
CVD Cardiovascular disease
CHD Coronary heart disease
TIA Transient ischaemic attack
DVT Deep vein thrombosis
nGMS The new General Medical Services contract in UK
primary care
QOF Quality and Outcomes Framework of the nGMS
BHS British Hypertension Society
JBS 2 The second report of the Joint British Societies on
the prevention of cardiovascular disease in clinical prac-
tice
EHR Electronic health record
FBG Fasting blood glucose
OGTT Oral glucose tolerance test
LVH Left ventricular hypertrophy
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INTRODUCTION
Current UK guidelines recommend that individuals
at ≥20% risk of cardiovascular disease over the
next 10 years should be identified for primary
prevention interventions,1–3 including lipid-lowering
therapy. However, such activity is not
commissioned through the Quality and Outcomes
Framework (QOF),4 and practice teams must
balance the resource implications against other
priorities, including the care of those with
established cardiovascular disease.
The identification of individuals at risk is assisted
by the ‘e-Nudge’ software tool, developed by the
current research team and programmed by EMIS, to
identify individuals likely to justify either intervention
or further assessment of cardiovascular risk. The
e-Nudge tool is an automated system of continually
updated searches and screen alerts currently under
trial. Its name reflects the role of the software to act
as a subtle prompt in consultations to support
cardiovascular disease prevention during routine
care. The aim of the current survey was to compare
the proportions of individuals identified in different
risk categories, and discuss the implications for
routine practice.
In addition to the practical challenge of fitting risk
assessments into busy practice, there is concern
over identifying cardiovascular risk in older
individuals that may be attributable largely to non-
modifiable factors.5,6 This study reports the
proportion of the population aged 50 years and
over identified, using the e-Nudge algorithm, as at
≥20% risk, the proportion who may be at risk but
have missing risk factor information, and the
proportion with diagnosed cardiovascular disease
or diabetes who have at least one modifiable risk
factor outside of the audit target of the QOF.
METHOD
The e-Nudge tool identifies several groups of
patients based on clinical variables and the
availability of risk-factor information in the practice
database. It also identifies individuals with
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insufficient recorded information for a risk estimate.
For those with sufficient data and no diagnosis of
cardiovascular disease or diabetes, it estimates
cardiovascular risk using the Framingham
cardiovascular disease equation.7 Details of its
structure are published elsewhere.8
It takes into account an average of up to three
systolic blood-pressure values in the past 3 years,
and the most recent total and high-density
lipoprotein cholesterol levels. Where information is
missing, dummy values are inserted to calculate a
potential risk score. When smoking status is
unknown, the patient is assumed to be a non-
smoker. Where blood-pressure or cholesterol
values are missing, the algorithm uses median
values of the 50–74-year-old group from the Health
Survey for England 2003.9
As glucose testing is important in cardiovascular
risk assessment, the e-Nudge tool assumes a
positive diabetes status for those aged 50–74 years
who are not on the diabetes register and have had
no blood–glucose measurement in the past 3 years,
and calculates the Framingham cardiovascular
disease risk. If this is ≥20%, the individual is
identified as being in the group requiring further
data collection. This information helps to target
those most likely to benefit from testing for
diabetes. The Framingham equation was not
applied to those with known diabetes or
cardiovascular disease, but in these groups it
identifies those outside the QOF audit targets for
blood pressure and/or total cholesterol level.
The e-Nudge software was installed in 19
general practices in north and south Warwickshire,
Coventry, and Rugby as part of a randomised
controlled trial of it.8 After installation, baseline data
on the proportion of the population identified in the
various categories were extracted to provide the
data for this survey. These provide information on
the levels of data available to support a programme
of primary cardiovascular disease prevention and
the likely workload implications for general
practice. For the primary prevention group, all
individuals above the risk threshold of ≥20% are
flagged up, with no stratification of risk above this
level. The age of the patient is known to the
clinician during the consultation but there is no
breakdown by age of identified individuals in this
survey.
RESULTS
The 19 practices had a total list size of
approximately 121 000, with 36 546 patients aged
≥50 years. Median list size was 5200 (ranging
between <2000 and >12 000). Age structure
closely matched that of the UK population and all
quartiles of the English Index of Multiple
Deprivation were represented. Based on the Super
Output Areas of the practice postcodes, the
coronary heart disease standardised mortality
ratios ranged from 74 to 110.
Altogether, 5.9% of the population aged
≥50 years were identified as aged 50–74 years and
with ≥20% cardiovascular disease risk based on
existing data; 26.4% were aged 50–74 years and
possibly at risk, but some risk-factor information
was missing, and 9.2% aged over 50 years (no
upper age limit) were already diagnosed with
cardiovascular disease or with diabetes, but had a
total serum cholesterol or blood-pressure
measurement out of the QOF audit target range for
the relevant group (Table 1). Some patients
identified were already on treatment for at least one
risk factor but remained at ≥20% estimated risk,
with the potential in some cases to benefit from
further risk reduction.
DISCUSSION
Summary of main findings
This study demonstrates that primary care data
may be combined with practice-based software to
identify individuals at risk of cardiovascular disease.
Around 6% of the population aged ≥50 years and
<75 years, appears to be at raised risk (≥20%)
TA Holt, M Thorogood, F Griffiths, et al
How this fits in
Despite recent improvements in the recording of cardiovascular risk factor
data in primary care, for every individual with complete risk factor
information, there are perhaps four or five in the practice who would require
further data collection. They are also outnumbered by individuals with
established cardiovascular disease whose risk factors are both uncontrolled
and modifiable.
Proportion of population
Group definition Number identified aged ≥50 years (%)
Patients aged 50–74 years at ≥20% 2152 5.9
cardiovascular risk based on existing data
Patients aged 50–74 years with missing 9657 26.4
risk factor information who would be at
≥20% risk when assumed values are
inserted (see Method)
Patients aged ≥50 years with known 3346 9.2
cardiovascular disease or diabetes whose
blood pressure or cholesterol level was
not in target in the past 15 months (Quality
and Outcomes Framework audit target)
aTotal number of patients = 36 546
Table 1. Numbers and proportions of patients identified in
each risk category (aggregated data from all 19 practices).
Original Papers
based on existing data. In some cases, raised risk
was only apparent when a number of factors were
combined, demonstrating the potential for the
software to assist practitioners in determining
actual risk (Box 1, Case 1).
Strengths and limitations of the study
This survey involved a range of practices from
urban, suburban, and rural environments, and used
‘live’ data collected during routine practice.
However, there are a number of problems with this
approach: pre-treatment values of blood pressure
and lipids are not always available, and e-Nudge
uses the most recent values; risk may be
underestimated in some cases as the Framingham
risk equation, on which the e-Nudge is based,
should ideally use pre-treatment values; as a case-
finding tool, this limitation increases its specificity at
the expense of some sensitivity.
The e-Nudge tool is designed to assist practice
teams that may then assess individual risk based
on the broader context, including risk factors such
as ethnicity, obesity, waist circumference, family
history, and deprivation. An age cut-off of 50 years
was chosen for the e-Nudge randomised
controlled trial,7 as the outcomes will include
cardiovascular events that are more common
above this age; this threshold was used in the
current survey. If patients aged 40–49 years, who
are at lower overall risk, were included, the number
of patients requiring intervention would increase,
although the proportion of the population that was
identified would fall.
Unknown diabetes status accounts for the
relatively high number of people that were
identified with no recent glucose value on record
but who would get a high Framingham risk score
if a positive input was assumed for their
diabetes status. This is a pragmatic manoeuvre to
avoid identifying the entire population of those
aged ≥50 years who have no recent blood–glucose
level on record, many of whom will be at low
estimated risk. This compromise allows a user of e-
Nudge to identify the patients most likely (from a
cardiovascular disease risk-profiling perspective)
to benefit from blood glucose testing. The use of
‘assumed’ values for missing data is a common
technique but may have a significant detrimental
effect on the effectiveness of a screening
programme.10
There are also problems with basing risk
calculations on single risk-factor values. Although
e-Nudge uses an average of up to three systolic
blood-pressure measurements, it uses only
single values for cholesterol levels (as commonly
occurs in clinical practice). At the 20% threshold,
95% confidence intervals for cholesterol values may
produce a range of risk estimates from 14%
to 26%.11
Comparison with existing literature
Studies using cardiovascular disease risk
algorithms applied to primary care data include
those of Muir et al,12 Mitchell et al,13 and Marshall.14
However, all of these studies used data collected
before the introduction of the QOF, which led to a
widespread standardisation of electronic coding of
cardiovascular risk factors. More recently, a new
cardiovascular risk algorithm (QRISK) has been
developed based on this approach.15 This study by
Hippisley-Cox et al found that 13% of the 35–74-
year-old age group would be at ≥20% risk
according to the Framingham algorithm. This is a
higher figure than the 6% found in the present
study, mainly because the QRISK figure (using a
different denominator population) includes those
patients with substituted values for missing risk-
factor data. The figure in the present study for the
‘incomplete data but potentially at risk’ group
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 Case 1
• A 50-year-old male
• Smoker
• Average of recent systolic blood pressures = 140 mmHg
• Total cholesterol = 4.6 mmol/l
• High-density lipoprotein (HDL) cholesterol = 0.8 mmol/l
This person has modifiable risk factors: as well as help with stopping
smoking, his cholesterol ratio might be improved through drug therapy and
dietary advice. However, he might be difficult to spot as ‘at-risk of
cardiovascular disease’ without help from the software, as his blood
pressure and total cholesterol are not particularly high.
 Case 2
• A 74-year-old male
• Non-smoker
• Average of recent systolic blood pressures = 145 mmHg
• Total cholesterol = 5.2 mmol/l
• HDL cholesterol = 1.3 mmol/l
It will be more difficult to modify this patient’s risk, as his age is a significant
factor. However, his blood pressure might justify treatment under current
guidelines if it remains in the range 140–159 mmHg, and his lipid profile
might also be further improved.
Either of these people might benefit from modification of the other factors
not included in the risk algorithm, such as physical activity, weight, and waist
circumference. Both justify low-dose aspirin therapy.
Box 1. Vignettes of patients at risk of cardiovascular disease.
(26.4%) is higher because of the ‘uncertain
diabetes status’ described above.
Implications for future research and
clinical practice
Current guidelines recommend that those with a
≥20% 10-year risk of cardiovascular disease should
be treated and followed up with a similar priority to
those with established disease.2 For every
individual with complete risk-factor information,
there are perhaps four or five in the practice who
would require further data collection. This additional
investigation implies a considerable resource
commitment, although risk stratification might
optimise this process.14
Individuals identified include those whose risk is
difficult to modify (Box 1, Case 2). At the same time,
secondary prevention patients with uncontrolled
but more clearly modifiable risk factors are also
easy to identify. Such patients are already labelled
with a significant medical problem and are usually
already used to taking drug therapy. It is hoped that
the current randomised controlled trial of the e-
Nudge software8 will provide further evidence on
British Journal of General Practice, July 2008498
the feasibility of primary cardiovascular disease
prevention as part of routine care in UK general
practice.
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ABSTRACT
Background
Around 1% of the UK population has diabetes that is
either undiagnosed or unrecorded on practice disease
registers.
Aim
To estimate the number of people in UK primary care
databases with biochemical evidence of undiagnosed
diabetes. To develop simple practice-based search
techniques to support early recognition of diabetes.
Design of study
Cross-sectional survey of 3 630 296 electronic records.
Setting
Four hundred and eighty UK practices contributing to
the QRESEARCH database.
Method
Electronic searches to identify people with no diabetes
diagnosis in one of two categories (A and B), using the
most recently recorded blood glucose measurement:
random blood glucose level ≥11.1 mmol/l or fasting
blood glucose level ≥7.0 mmol/l (A); either a random or
a fasting blood glucose level ≥7.0 mmol/l (B). An
additional outcome measure was the proportion of the
population with at least one blood glucose
measurement in the record.
Results
The number (percentage) identified in category A was
3758 (0.10% of the total population); the number in
category B was 32 785 (0.90%). Projected to a practice
of 7000 patients, around eight patients have
biochemical evidence of undiagnosed diabetes, and 68
have results suggesting the need for further follow-up.
One-third of people aged over 40 years without
diabetes have a blood glucose measurement in the
past 2 years in their record.
Conclusion
People with possible undiagnosed diabetes are readily
identifiable in UK primary care databases through
electronic searches using blood glucose data. People
with borderline levels, who may benefit from
interventions to reduce their risk of progression to
diabetes, can also be identified using practice-based
software.
Keywords
blood; clinical informatics; diabetes; diagnosis;
glucose; screening.
INTRODUCTION
The global rise in diabetes prevalence poses major
challenges for healthcare providers.1 Symptoms of
type 2 diabetes develop insidiously, so that a
significant proportion of patients are undiagnosed,
even in countries with a well-developed healthcare
infrastructure. Up to 1% of the population of England
is thought to have undiagnosed or unrecorded
diabetes,2 and is not receiving access to well-
organised systematic care and follow-up.3 In addition,
people with impaired glucose regulation are likely to
be excluded from the structured follow-up offered to
those with diabetes,4 even though they benefit from
interventions to reduce the risk of progression to
diabetes,5–7 and to control cardiovascular risk.
Therefore, there is a good case for identifying
individuals with evidence of undiagnosed diabetes or
impaired glucose regulation.
General practice records might assist in the
identification of individuals most likely to have
undiagnosed diabetes, but this approach depends
largely on the availability of relevant, coded data. In a
recent study in the Netherlands, hypertension,
cardiovascular disease, and lipid metabolism
disorders were identified as the most useful risk
factors available in the electronic records.8 Family
history is an important factor but was not coded
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consistently and so could not be included. In a
community-based study in New Zealand, randomly
selected householders were invited for casual blood
glucose testing and risk assessment, followed by oral
glucose tolerance testing in selected cases.9 The
results suggested that glucose measurements
themselves are superior to traditional risk factors
alone as a means of identifying groups for formal
diabetes screening, particularly in Europeans. A
general practice-based targeting strategy based on
this principle but utilising existing blood glucose data
would depend on their availability in electronic
records, and this has not previously been measured in
current UK practice. The volume of such data is set to
rise following the guidelines of the Joint British
Societies, which recommend opportunistic blood
glucose measurement in everyone over 40 years
undergoing cardiovascular risk assessment.10
This study was undertaken to estimate the number
of people in the UK with biochemical evidence of
undiagnosed diabetes, and the number justifying
retesting to clarify their diabetes status, identifiable by
existing electronic blood glucose data in primary care.
The study was designed to test the utility of electronic
searches as a means of targeting this group, and to
measure the availability of blood glucose data to
support them. This approach has the advantage that
the existence of raised blood glucose measurements
in a patient’s record provides justification for further
testing that is independent of the argument for or
against population screening for diabetes.
METHOD
Study design
A population-based, cross-sectional survey using
version 11 of the UK QRESEARCH database was
undertaken.11 This database contains the anonymised
electronic healthcare records of over 9 million
patients ever registered with 499 general practices
throughout the UK. The information recorded on the
database includes patient demographics (year of
birth, sex, socioeconomic data derived from the UK
2001 census), characteristics (height, weight,
smoking status), symptoms (if coded electronically),
clinical diagnoses, consultations, referrals, prescribed
medication, and results of investigations.
Biochemistry results (including electronically-coded
blood glucose values) are available that are now
transmitted directly into the patients’ notes from the
local laboratory. The database has been validated by
comparing birth and death rates, consultation rates,
and prevalence and mortality rates with other data
sources including the General Household Survey12
and the General Practice Research Database.13
Practices were included in the analysis if they had
complete data transmission until at least 1 June 2006.
Patients were included if they were registered with the
practice on 1 June 2006.
Diagnostic definitions
The current diagnostic criteria for diabetes of the
World Health Organization (WHO) were used in this
study.14 A fasting plasma glucose level ≥7.0 mmol/l on
two occasions is diagnostic of diabetes in a patient
with no symptoms. In a clearly symptomatic patient,
a single raised random plasma glucose level of
≥11.1 mmol/l can be used to make the diagnosis.
Patient subsets and code groups
The following subsets of patients were identified
according to information in their electronic health
record (codes available from the authors):
• patients with a computer-recorded diagnosis of
diabetes;
• patients with a computer diagnosis of impaired
glucose tolerance or impaired fasting glycaemia;
• patients with at least one random glucose
measurement or one fasting glucose measurement;
and
• patients with computer-recorded evidence of a
normal glucose tolerance test.
Search strategies
Two alternative electronic search strategies were
applied, examining the most recent blood glucose
measurement available in the record. Both strategies
initially identified patients who do not have a
diagnosis of diabetes (or impaired glucose tolerance)
and have not had a diagnosis of diabetes excluded by
a normal glucose tolerance test, or as indicated by
the use of an appropriate Read code, as detailed in
the Results section.
Strategy A
Patients were included in the results if the most recent
blood glucose measurement was a fasting level
≥7.0 mmol/l or a random level of ≥11.1 mmol/l.
Strategy B
Patients were included in the results if the level
(fasting or random) of the most recent blood glucose
How this fits in
The availability of blood glucose data in UK general practice records offers a
new opportunity for identifying individuals requiring testing for diabetes. Most
practices have patients with biochemical evidence of undiagnosed diabetes,
who are identifiable by simple computer searches. As part of practice-based
software, these searches may allow such individuals to be identified and
followed up during routine care.
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measurement was ≥7.0 mmol/l.
The prevalence of each outcome was also
determined by 5-year age–sex band.
RESULTS
Study population and prevalence of diagnosed
diabetes
A total of 480 general practices met the inclusion
criteria for the study. There were 3.63 million patients
registered, of whom 50.43% were female, and 8.03%
were aged 75 years or over.
A total of 128 421 patients were identified with a
computer-recorded diagnosis of diabetes, giving an
overall prevalence of 3.54%. The median practice
prevalence of diabetes is 3.60%. Table 1 shows the
age–sex-specific prevalence rates for a diagnosis of
diabetes.
Exclusions from the target population
Of the 3.51 million people without a computer-
recorded diagnosis of diabetes, 0.27% were
excluded from the target population because of a
diagnosis of impaired glucose tolerance or impaired
fasting glycaemia, a code for ‘diabetes resolved’ (for
example, after pregnancy), or a code for ‘diabetes
excluded’. As shown in Figure 1, there were
3.49 million people in the target population for further
analysis.
Availability of blood glucose data
Overall, 1.05 million people (30% of the target
population) had at least one computer-recorded
blood glucose value, with considerable variation
between practices. This figure rises to two-thirds of
those aged 65 years or older. Some of these
measurements were taken over 10 years ago, but in
the past 2 years approximately half of all patients
aged over 65 years, one-third of those aged over
40 years, and one-fifth of the total population have
undergone blood glucose estimation. The proportion
of blood glucose measurements that were clearly
fasting was 15.9%. In 22.2% they were reported
using a random code, but in 62% of measurements it
was not clear from the code whether the sample was
fasting or random. For all cases that were not clearly
reported as fasting, it was assumed that the sample
was random, but some of these measurements may
have in fact been taken on fasting samples.
Primary outcomes
Using strategy A, 3800 patients were identified from
the target population whose last glucose
measurement was suggestive of diabetes (that is, a
random value of ≥11.1 mmol/l or a fasting value
≥7.0 mmol/l).
Of those identified, only 1.3% had diabetes
excluded on the basis of a subsequent normal oral
glucose tolerance test, leaving 3758 patients
requiring further investigation or follow-up.
Using strategy B, 33 057 people were identified
Diagnosis of
diabetes
n = 128 421
480 Practices
population
n = 3 630 296
No recorded diagnosis 
diabetes
n = 3 501 875
Diagnosis 
 IGT
n = 8005
Remaining
population
n = 3 492 312
Diabetes
resolved
n = 5
Diabetes 
excluded
n = 1553
Glucose not  
on
computer
n = 2 442 589
Glucose
on
computer
n = 1 049 453
Last measure
random
n = 833 320
Last measure
fasting
n = 216 133
Random
<7 mol/l
n = 802 760
Random
7–11 mol/l
n = 29 257
Random
>11 mol/l
n = 1303
Fasting
<7 mmol/l
n = 213 636
Fasting
≥7mmol/l
n = 2497
Figure 1. Number and
percentage of the study
population in each
diagnostic category.
Percentage of Percentage of
Prevalence study population study population
Age band, of diagnosed identified using identified using
Sex years diabetes per 100 Strategy A Strategy B
Female <15 0.15 0.00 0.03
15–24 0.40 0.01 0.17
25–44 1.01 0.04 0.56
45–64 4.05 0.11 0.99
65–74 9.91 0.22 1.84
≥75 10.39 0.34 3.57
Male <15 0.15 0.00 0.03
15–24 0.42 0.01 0.13
25–44 1.23 0.04 0.36
45–64 5.85 0.20 1.30
65–74 13.53 0.34 2.44
≥75 13.95 0.36 3.45
Total All ages 3.54 0.10 0.90
Table 1. Percentages of people with diagnosed diabetes and
those identified by strategies A and B in the study.
IGT = impaired glucose tolerance
where the most recent blood glucose value (random,
fasting, or non-specifically coded) was ≥7.0 mmol/l.
This figure fell to 32 785 once those with a normal
glucose tolerance test had been excluded. This
represents just under 1% of the entire study
population and approximately 3.5% of all patients
aged over 65 years.
Table 1 shows the age–sex breakdown of patients
identified using strategies A and B.
Time since last recording
Figure 2 shows the time periods since the abnormal
glucose measurement according to strategies A and
B. In some cases the last recorded value was
relatively recent, so the individual may still be in the
usual process of follow-up and no other action would
be required. The distributions indicate that this was
more likely to be the case for strategy A individuals,
whose results may be more obviously significant. But
in over one-third of the ‘A’ patients and half of the ‘B’
patients, the last recorded value was more than
1 year ago. In around one-fifth of the ‘A’ patients and
nearly one-third of the ‘B’ patients, it was in excess
of 2 years.
Variation between practices
Table 2 shows the mean, median, and interquartile
ranges of the numbers identified in the two categories
in the 480 practices, demonstrating a wide range of
values obtained. The majority of practices (440/480)
had at least one strategy A patient identified, and all
but one had at least one strategy B patient.
DISCUSSION
Summary of main findings
A significant proportion of the population has
undergone blood glucose measurement, and the use
of simple electronic searches allows us to identify
people requiring clarification of their glucose
tolerance. The numbers identified varied between
practices. The majority (440/480) of practice
databases include patients with evidence of
undiagnosed diabetes based on the most recent
blood glucose measurements (strategy A). Some of
these may be known to have diabetes but are not on
the practice diabetes register, and are therefore
unlikely to receive well-organised, systematic care
and follow-up. A proportion of the blood glucose
levels reported by laboratories using random or non-
specific codes may in fact have been taken from
fasting samples.
All but one of the 480 practices in this study’s
sample included people whose most recent blood
glucose level probably requires further follow-up
according to current guidelines (strategy B).10 This
would involve a review of symptoms suggestive of
diabetes, clarification over whether the sample was
fasting or random, and/or investigation with a fasting
glucose or oral glucose tolerance test.
Strengths and limitations of the study
This is a large population-based study utilising
routinely collected data from general practices all
over the UK. The age–sex structure of the study
population is similar to national estimates, although
the QRESEARCH population is slightly older. The
prevalence of diagnosed diabetes in this study
(3.54%) is very similar to the national prevalence for
all practices in England (QMAS prevalence for 2006
3.60%),15 suggesting QRESEARCH is likely to be
representative of practices for case ascertainment,
screening, diagnosis, and electronic recording of
diabetes. QRESEARCH uses data exclusively from
EMIS (Egton Medical Information Systems)
practices. EMIS provides clinical software to
approximately 59% of general practices in the UK.
The national recommended Read codes used to
transmit results to practices from hospital
laboratories are the same for EMIS and non-EMIS
practices.16 Through the cross-sectional design of
this study it was not possible to determine the
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Strategy A Strategy B
Mean number of patients per practice 8 68
Median number of patients per practice 5 57
Interquartile range 2–10 30–92
Maximum 67 344
Number of practices (out of 480) with no patients identified 40 1
Table 2. Variation in results among practices.
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Figure 2. Proportion of
blood glucose
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proportion of patients identified who were
subsequently diagnosed with diabetes or impaired
glucose regulation.
Comparison with existing literature
This is the first nationwide survey to investigate the
potential of practice-based searches for the detection
of undiagnosed diabetes. The Diabetes Audit and
Research in Tayside Scotland (DARTS) study
identified some individuals with isolated
hyperglycaemia in healthcare databases who were
not on diabetes registers.17 This study involved just
eight general practices, and took place in a small
region of Scotland in 1996, when the prevalence of
diabetes was significantly lower than today. It
predated the introduction of the Quality and
Outcomes Framework in 2004 (which promotes the
maintenance of electronic diabetes registers),3 the
widespread establishment of laboratory links for
electronic data transmission, and the JBS2 report,10
which established a policy for the follow-up of
borderline blood glucose levels and actively
encourages the testing of blood glucose in the over-
40-year population, through cardiovascular risk
assessments.
Implications for future research and clinical
practice
The proportions in these categories in which
diabetes or impaired glucose regulation is confirmed
on further testing will be investigated by the present
authors, using a sample from current primary care, to
clarify the usefulness of the software in the
identification of undiagnosed diabetes. Further
research is also planned to investigate the obstacles
to follow-up of borderline blood glucose levels.
These might include lack of clarity among
practitioners over diagnostic thresholds, failure of
laboratories to specify random or fasting results,
problems with practice follow-up systems, or lack of
patient concordance with invitations for retesting. It
can be concluded that there is considerable scope in
the UK for using electronic health records to identify
people for recall and further assessment, thereby
assisting in early detection of diabetes and impaired
glucose regulation. Since the completion of this
project, EMIS has introduced new software into all its
practices for flagging up individuals in the ‘A’ and ‘B’
categories, to assist in their identification and follow-
up during routine care.
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Abstract
An estimated 750,000 people in the UK have diabetes that iseither undiagnosed or unrecorded on diabetes registers.Opportunities are missed to prevent or delay
complications and reduce cardiovascular risk. This ‘missing
population’ problem has been addressed at various levels: raising
awareness among the public; targeted case finding in at-risk
groups; and lowering the threshold for investigation of suggestive
symptoms among clinicians. Cardiovascular risk assessments are
recommended in the UK for the over 40-year-old population and
include blood glucose measurements. To further support these
measures, this article discusses a recently reported technique for
identifying possible cases of undiagnosed diabetes using simple
searches on primary care databases, and
its implications for practice and future research.
Br J Diabetes Vasc Dis 2008; 8: 291–294
Key words:  diabetes, diagnosis, screening, glucose, blood
informatics
Introduction
Patients with diabetes are usually diagnosed several years after
the onset of hyperglycaemia1 and may already have microvascu-
lar and macrovascular complications.2 This adds to epide -
miological evidence3 of a substantial ‘missing population’,
estimated to be 750,000 individuals in the UK.4 These people are
not receiving appropriate care for a potentially disabling condi-
tion amenable to preventive measures. Some undiagnosed
patients have no symptoms. Intervention in such cases is
assumed to be beneficial, but controlled trial evidence of this
would be valuable and such a trial is underway.5 Other undiag-
nosed patients do have low grade symptoms likely to respond to
treatment, and this further supports the case for early detection.
Early detection strategies
Numerous approaches have been employed to promote early
detection. Public awareness raising campaigns include posters
to encourage individuals to come forward for testing, based on
classical risk factors such as ethnicity, family history, and central
obesity. Case finding in primary care has broadened this risk
profile to include other factors including anti-hypertensive med-
ication.6 Such strategies are limited not only by the lack of speci-
ficity of some of these predictors, but also by the availability of
the necessary data in general practice computer systems.7
The Joint British Societies’ Guidelines on the Prevention of
Cardiovascular Disease in Clinical Practice 2 (JBS2) report of
20058 recommended random blood glucose measurement as
part of cardiovascular risk assessments in the over 40-year-old
population. This is preferable to diabetes screening alone, due
to the overlap between diabetes and CVD. The report sug-
gested that random levels of 6.1 mmol/L or above should be
followed up with a fasting plasma glucose measurement, and
if necessary by a further fasting test or oral glucose tolerance
test until the glucose tolerance status is clarified. 
The e-Nudge trial
The ‘e-Nudge’ is a software tool developed in collaboration between
the University of Warwick and the clinical software company EMIS.
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It interrogates primary care data to identify patients at risk of CVD
and is currently under trial in 19 general practices in Coventry and
Warwickshire. The trial protocol9 describes six categories of patients
identified on the basis of estimated cardiovascular risk and on the
completeness of recorded risk factor data. Identified patients are
flagged up through screen alert messages and regularly updated
lists. One of the groups initially included people with possible undi-
agnosed diabetes based on raised blood glucose values (any level ≥
11.1 mmol/L with no subsequent normal fasting level < 7.0 mmol/L
or normal oral glucose tolerance test) and absence from the practice
diabetes register. Following installation of the software, the number
of patients in each group was measured before the software began
operating on a random half of the over 50-year-old population. The
baseline data have been published for the groups identified as at
raised estimated risk of CVD (≥ 20% over 10 years), those with pos-
sibly raised risk but incomplete information, and those with known
CVD but uncontrolled blood pressure or serum cholesterol.10 The
group involving possible undiagnosed diabetes identified 33 individ-
uals from a denominator population of 36,546 (0.09%). Whilst this
figure is small at the practice level, it amounts to significant numbers
in larger populations, and creates an opportunity to introduce a new
means of identifying undiagnosed cases.
The QRESEARCH survey
It was unclear whether this issue was a regional one (in Coventry and
Warwickshire) or typical of practices all over the UK. It was also
unknown from the e-Nudge data how recently the blood glucose
measurements were taken. Patients identified would include those
whose raised level had been measured the week before with follow-
up arranged in the near future, a situation requiring no additional
intervention. To answer these questions a new team applied to
Nottingham University’s QRESEARCH database (a large database
derived from the anonymised health records of over 9,000,000
patients) to run a similar (but modified) search on a much larger sam-
ple of EMIS practices across the UK. This survey was published earlier
in 2008,11 and involved 480 practices providing more than 3,600,000
electronic records. Two search strategies were applied to the popula-
tion (of all ages) not on the diabetes register and with no recent ‘nor-
mal glucose tolerance test’ code. The searches examined all blood
glucose measurements. These are generally taken on plasma samples
and the results transmitted electronically to the practices from the
hospital laboratory. Strategy A identified those whose most recent
value was in the diagnostic range for diabetes (≥ 7.0 mmol/L fasting
or ≥ 11.1 mmol/L random plasma glucose, or non-specifically coded).
Strategy B identified those whose most recent glucose value (using
any code) was 7.0 mmol/L or higher. For strategy A, a similar propor-
tion to the e-Nudge result (0.1%) was found, and for the more inclu-
sive strategy B, 0.9% of the population was identified.11
This survey suggested that patients with possible undiag-
nosed diabetes are identifiable in the majority of UK practices
using very simple search strategies on existing data. Of the 480
practices sampled, 440 contained at least one strategy A patient,
and all but one contained at least one strategy B patient. The sur-
vey also demonstrated that blood glucose has been measured
during the previous two years in a third of people over 40 years
old without a diagnosis of diabetes. Finally, the results confirmed
that the patients identified were not simply those with very recent
tests still in the process of active follow-up. In fact, a significant
proportion of patients (even in strategy A) had undergone the
blood glucose test that identified them more than a year ago.
Discussion
Extrapolating results to UK population
The QRESEARCH database has been validated against other epi-
demiological data sources and broadly represents the UK public
registered with general practice. Data on blood glucose measure-
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Table 1.  Estimation of patients in UK to be identified using strategy A and B (based on Office of National Statistics mid year population estimates for 2004)
Estimated UK Estimated numbers in Estimated numbers in
Gender Age band population UK using strategy A UK using strategy B
Female < 15 years 5,297,200 218 1,653
Female 15–24 years 3,787,000 425 6,580
Female 25–44 years 8,622,600 3,662 48,694
Female 45–64 years 7,368,000 8,434 73,112
Female 65–74 years 2,658,900 5,834 49,014
Female > 75 years 2,829,900 9,579 100,920
Male < 15 years 5,569,500 201 1,862
Male 15–24 years 3,933,300 421 5,307
Male 25–44 years 8,506,800 3,611 30,448
Male 45–64 years 7,170,400 13,982 92,992
Male 65–74 years 2,374,400 8,036 57,987
Male > 75 years 1,716,700 6,112 59,268
Total 59,835,000 60,516 527,838
ments are transmitted to EMIS practices in the same way as for
other software systems, using electronic links to local hospital lab-
oratories and recognised data transfer protocols. This suggests that
the findings are typical of practices throughout the UK and that
the results can be extrapolated to the UK population based on the
proportion of people in the respective age bands (table 1). This
indicates that in the UK there are 60,000 people with probable
undiagnosed diabetes who are readily identifiable based on 
information already within their general practice records. 
It also appears that 528,000 people are identifiable who
require follow-up of a blood glucose reading. In these cases the
likely outcome is less clear, but almost all would justify further
testing according to the JBS2 recommendations.8 Such patients
may turn out to have undiagnosed diabetes (particularly if the
initial result that identified them was obtained on a fasting
sample), or may have impaired glucose regulation, a modifiable
risk factor both for future incident diabetes and for CVD.
For either strategy, a proportion may be found to have nor-
mal glucose tolerance. Nevertheless, given the existence of a
raised blood glucose level (≥7.0 mmol/L) at the most recent
measurement in their records, it could be argued on both 
ethical and pragmatic grounds that these groups are a good
starting point in the quest for the missing population.
Implications for practice
At the outset of the QRESEARCH survey, EMIS committed to
address the issue through changes to their software system if signi-
ficant numbers were uncovered, as the QRESEARCH data are 
all anonymous and the patients detected cannot be identified 
individually. Soon after the initial data extraction, when the results
indicated high patient numbers, a new software module was
developed and installed in all EMIS practices nationally. In a similar
way to the e-Nudge, this module creates lists, updated every 24
hours, of identified ‘A’ and ‘B’ patients that can be accessed by pri-
mary care teams (figure 1). If a patient currently on one of the lists
presents to the practice and the electronic record is opened, a screen
alert message appears stating, ‘Rule out Diabetes – Latest Glucose
High’ (figure 2).
Meanwhile, the e-Nudge trial continues but with the undiag-
nosed diabetes group removed, due to the availability of this soft-
ware module, which is now part of routine care in nearly 60% of UK
practices. 
Implications for other software providers
The EMIS module is based on the same search strategy as that
described in the study report,11 allowing other software
providers both in the UK or abroad to develop similar tech-
niques. All that is required is an electronic diabetes register
and plasma glucose data searchable in the individual patients’
records.
Further research
The availability of blood glucose data identified in the QRE-
SEARCH project creates an opportunity for including this as a
predictor in a new algorithm for assessing diabetes risk. This
could usefully support the more traditional risk factors as a
means of targeted case finding to identify the missing population
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Figure 1. Screenshot of the EMIS system displaying strategy A individuals. The ‘Patients Included’ tab produces a drop
down list of patient names that can then be right-clicked to browse the medical record directly
Reproduced with kind permission from Egton Medical Information Systems Ltd.
with undiagnosed diabetes and to promote cardiovascular dis-
ease prevention. The model of data interrogation on cardiovas-
cular and diabetes risk factor data fed back to clinicians during
routine care lends itself to adaptation to emerging risk patterns
in the evolving software environment of primary care.
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Figure 2. Screen alert message appearing on opening the notes of a patient identified at risk of undiagnosed diabetes
Reproduced with kind permission from Egton Medical Information Systems Ltd.
Key messages
 Patients with probable undiagnosed diabetes are
readily identifiable using simple computer searches in
general practice
 Others are identifiable who justify follow-up of
borderline blood glucose levels
 New software installed into the majority of UK
practices flags up these groups as part of routine care
 This supports existing initiatives for identifying the
‘missing population’ with diabetes
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